WorldWideScience
 
 
1

Permanent /sup 125/I implants in head and neck cancer  

Energy Technology Data Exchange (ETDEWEB)

One hundred twenty-four patients were treated with advanced recurrent head and neck cancer for palliation with radioactive permanent Iodine-125 (/sup 125/I) implants. Complete regression occurred in 71% of the 118 lesions for which evaluation was possible and greater than 50% regression occurred in 18%; no meaningful regression occurred in 11%. Local recurrence of cancer was subsequently seen in 21% of the lesions which had regressed completely, in 55% of those which had regressed incompletely, and in 100% of those which had not regressed. The incidence of serious complications was 5.5%. Overall, in 64% of the instances the implanted lesions remained controlled until the patient's death, usually due to progression of cancer elsewhere in the body. It is concluded that permanent 125I implants offer useful palliation to the patient with recurrent head and neck cancer with a minimum of toxicity and inconvenience. Because of their low toxicity even after prior full-course external radiation therapy, the authors are currently investigating their use as planned adjunct to external radiation therapy and chemotherapy in the initial definitive management of patients with locally advanced head and neck cancer.

Vikram, B.; Hilaris, B.S.; Anderson, L.; Strong, E.W.

1983-04-01

2

Permanent 125I implants in head and neck cancer  

International Nuclear Information System (INIS)

One hundred twenty-four patients were treated with advanced recurrent head and neck cancer for palliation with radioactive permanent Iodine-125 (125I) implants. Complete regression occurred in 71% of the 118 lesions for which evaluation was possible and greater than 50% regression occurred in 18%; no meaningful regression occurred in 11%. Local recurrence of cancer was subsequently seen in 21% of the lesions which had regressed completely, in 55% of those which had regressed incompletely, and in 100% of those which had not regressed. The incidence of serious complications was 5.5%. Overall, in 64% of the instances the implanted lesions remained controlled until the patient's death, usually due to progression of cancer elsewhere in the body. It is concluded that permanent 125I implants offer useful palliation to the patient with recurrent head and neck cancer with a minimum of toxicity and inconvenience. Because of their low toxicity even after prior full-course external radiation therapy, the authors are currently investigating their use as planned adjunct to external radiation therapy and chemotherapy in the initial definitive management of patients with locally advanced head and neck cancer

1983-04-01

3

Loading technique comparison in permanent 125I prostate implants.  

UK PubMed Central (United Kingdom)

Treatment of prostate cancer utilizing iodine 125 (125I) interstitial seed implants has become an accepted and widely used modality. Numerous variations in 125I seed implant loading distribution techniques have developed as a result of the preferences of individual institutions implementing the modality. No particular universal standard is currently used for 1251 seed implants. A major concern with 125I seed implants is coverage of the prostate with the desired dose and the minimization of dose to the urethra. A variation of seed distribution per individual anatomy is desirable. Historically, brachytherapy relied on dosimetry systems, such as the Paris, Quimby, and Manchester systems to achieve the desired dose distribution. Use of various peripherally loaded 125I seed implant distributions to accommodate anatomic variations within the same institution prompted the interest of how the results compare to the Manchester system.

Williams BV; Horton J; Lawyer A; Chapman J

1999-01-01

4

Ten cases of metastatic cervical cancer with the treatment of permanent 125I seeds interstitial implants  

International Nuclear Information System (INIS)

[en] Objective: To investigate the clinical effect of permanent 125I seeds interstitial implants for metastatic cervical cancer. Methods: Under the guidance of the B-sonography, 125I seeds were implanted into the eleven cervical lymph nodes of ten patients who had been given tumor resection. The pain relief and tumor size were observed in regular follow-up after one-month treatment. Results: All the patients were followed up for 6-14 months,and the postoperative recovery was good with no complication. One month after the implantation, the pain symptom was alleviated entirely in two nodes and partly in nine nodes. The tumor size shrank in ten nodes while there was no change in one node after one month. Conclusion: Permanent 125I seeds interstitial implants for metastatic cervical cancer is a safe, minimally invasive and effective treatment. (authors)

2011-01-01

5

Optimization of permanent 125I prostate implants using fast simulated annealing  

International Nuclear Information System (INIS)

Purpose: Treatment planning of ultrasound-guided transperineal 125I permanent prostatic implants is a time-consuming task, due to the large number of seeds used and the very large number of possible source arrangements within the target volume. The goal of this work is to develop an algorithm based on fast simulated annealing allowing consistent and automatic dose distribution optimization in permanent 125I prostatic implants. Methods and Materials: Fast simulated annealing is used to optimize the dose distribution by finding the best seed distribution through the minimization of a cost function. The cost function includes constraints on the dose at the periphery of the planned target volume and on the dose uniformity within this volume. Adjustment between peripheral dose and the dose uniformity can be achieved by varying the weight factor in the cost function. Results: Fast simulated annealing algorithm finds very good seed distributions within 20,000 iterations. The computer time needed for the optimization of a typical permanent implant involving 60 seeds and 14 needles is approximately 15 min. An additional 5 min are necessary for isodose distribution computations and miscellaneous outputs. Conclusion: The use of fast simulated annealing allows for an efficient and rapid optimization of dose distribution. This algorithm is now routinely used at our institution in the clinical planning of 125I permanent transperineal prostate implants for early stage prostatic carcinoma.

1996-10-01

6

[Technique of intraoperative planning in prostatic brachytherapy with permanent implants of 125I or 103Pd].  

UK PubMed Central (United Kingdom)

OBJECTIVES: Prostatic brachytherapy with permanent 125I or 123Pd seeds implantation is a therapeutic option for organ-confined prostate cancer. We analyze the technique based on previous planning, our current intraoperative planning procedure and the reasons that moved us to introduce this change. METHODS: Changes in prostate volume and spatial localization observed between previous planning and intraoperative images, and possible difficulties for seed implantation due to pubic arch interference are some of the reasons that induce us to change technique. RESULTS: Before the operation, we calculate the prostatic volume by transrectal ultrasound; with this information we determine the total implant activity following Wu's nomogram, and per-seed activity; therefore, it is an individual process for each patient. We perform a peripheral implant, placing 75-80% of the seeds within the peripheral prostatic zone, generally through 12-15 needles, the rest of the seeds are placed in the central prostatic zone using a maximum of 3-4 needles in high volume prostates. The day of intervention, after positioning and catheter insertion, volumetry is re-checked. Ultrasound images (from base to apex every 5 mm) are transferred to the planner were a suitable seed distribution is determined. Implantation is then performed placing all needles unloaded, and then intraoperative post-planning to allow us to check implant precision is performed after cistoscopically check that there is no urethral or bladder penetration by any needle. We finish with the insertion of seeds into the prostate. Total time for the procedure is around 90 minutes. CONCLUSIONS: Intraoperative planning is an additional step for the treatment of prostate cancer with permanent seeds brachytherapy, which avoids the disadvantages of previous planning and improves tumor inclusion in the ideal irradiation dose area, which will translate into better local disease control.

Prada Gómez PJ; Juan Rijo G; Hevia Suarez M; Abascal García JM; Abascal García R

2002-12-01

7

Verification of air-kerma strength of 125I seed for permanent prostate implants in Japan  

International Nuclear Information System (INIS)

[en] To assure the physical quality of brachytherapy, we investigated the difference between measured and manufacturer's stated source strengths in a single model SourceTech Medical (STM) 1251 125I seed. A well-type ionization chamber with a single-seed holder was used to measure the source strength of 2412 125I seeds before implant in 34 patients. The air-kerma strength was 0.450 U for all cases. The mean source strength for each patient was measured and compared with the manufacturer's stated value. The deviation from the measured value was compared with the tolerance range of the American Association of Physicists in Medicine (AAPM) TG-56 report's recommendation. The measured source strength was higher than the manufacturer's stated value, with a median difference of 1% (range, -2% to 5%). Sixteen of the totals of 2412 seeds (0.7%) were more than 5% different from the manufacturer's stated value. The median standard deviation (SD) from the mean value was 2.2% (range, 1.1% to 2.5%) for all patients. This is the first report of a single-seed assay performed for the model STM1251 125I seed. In this study the manufacturer's stated strength agreed well with the measured value. Nevertheless, the advisability of performing a single-seed assay at every institution should be considered, by referring to the appropriate regulations; for example, those used in the United States. (author)

2009-01-01

8

Nursing care for elderly lung cancer patients treated with CT-guided permanent interstitial co-implantation of 125I seeds and slow-released fluorouracil  

International Nuclear Information System (INIS)

Objective: To investigate the specific measures and effect of the nursing care for elderly lung cancer patients who were receiving the treatment of CT-guided permanent interstitial co-implantation of 125I seeds and slow-released fluorouracil. Methods: Active care, including adequate preoperative preparation, proper support during operation and postoperative nursing,was carried out for fifty-three elderly patients with lung cancer during their treatment course of CT-guided permanent interstitial brachytherapy with co-implantation of 125I seeds and slow-released fluorouracil. Results: In order to ensure accurate puncture and the smooth particle implantation, the possible conditions which might happen after the procedure were informed to the patients before the surgery and useful advice was given to patients to guide their daily activities. All 53 patients showed no obvious fear before surgery and made good cooperation during the procedure, moreover, they well responded to the therapy and recovered pretty soon. Conclusion: CT-guided permanent interstitial co-implantation of 125I seeds and slow-released fluorouracil is a safe, minimally-invasive and newly-developed technique with reliable effect, which is especially suitable for aged patients. Active and adequate nursing care is essential during the whole therapeutic course. (authors)

2009-01-01

9

A Comparison of Acute and Chronic Toxicity for Men With Low-Risk Prostate Cancer Treated With Intensity-Modulated Radiation Therapy or 125I Permanent Implant  

International Nuclear Information System (INIS)

Purpose: To compare the toxicity and biochemical outcomes of intensity-modulated radiation therapy (IMRT) and 125I transperineal permanent prostate seed implant (125I) for patients with low-risk prostate cancer. Methods and Materials: Between 1998 and 2004, a total of 374 low-risk patients (prostate-specific antigen 125I patients). Median follow-up was 43 months for IMRT and 48 months for 125I. The IMRT prescription dose ranged from 74-78 Gy, and 125I prescription was 145 Gy. Acute and late gastrointestinal (GI) and genitourinary (GU) toxicity was recorded by using a modified Radiation Therapy Oncology Group scale. Freedom from biochemical failure was defined by using the Phoenix definition (prostate-specific antigen nadir + 2.0 ng/ml). Results: Patients treated by using IMRT were more likely to be older and have a higher baseline American Urological Association symptom index score, history of previous transurethral resection of the prostate, and larger prostate volumes. On multivariate analysis, IMRT was an independent predictor of lower acute and late Grade 2 or higher GU toxicity and late Grade 2 or higher GI toxicity. Three-year actuarial estimates of late Grade 2 or higher toxicity were 2.4% for GI and 3.5% for GU by using IMRT compared with 7.7% for GI and 19.2% for GU for 125I, respectively. Four-year actuarial estimates of freedom from biochemical failure were 99.5% for IMRT and 93.5% for 125I (p = 0.09). Conclusions: The IMRT and 125I produce similar outcomes, although IMRT appears to have less acute and late toxicity.

2008-06-01

10

Sector analysis of 125I permanent prostate brachytherapy provides a rapid and effective method of evaluating and comparing pre- and post-implant dosimetry.  

UK PubMed Central (United Kingdom)

PURPOSE: To evaluate a sector analysis program in the assessment and comparison of pre- and post-implant dosimetric parameters during the development of an (125)I permanent prostate brachytherapy service. METHODS AND MATERIALS: A total of 50 consecutive men being treated with permanent prostate brachytherapy had dose-volume analysis in 12 sectors of their pre-implant ultrasound (USpre) and post-implant CT (CTpost) studies. Individual sectors were created by dividing prostate into three equal lengths, namely base, midgland, and apex. Each of these volumes was then divided into four axial sectors. Dosimetric parameters were compared in adjoining sectors within each study and between studies. RESULTS: There were statistically significant differences between individual sectors on USpre and CTpost volumes with CTpost higher than USpre (p=0.001). Statistically significant differences were found in corresponding sectors on USpre and CTpost for all dosimetric parameters. The dosimetric parameters were significantly lower on CTpost in the anterior base and midgland (p=0.001) and significantly higher at the posterior apex and midgland (p=0.05). Dose homogeneity was demonstrated in adjoining sectors in all USpre and most adjoining sectors on CTpost. CONCLUSIONS: Sector analysis allows rapid assessment of USpre and CTpost dosimetry. It offers a scientific method of identifying areas of increased and reduced dosing on CTpost when compared with USpre, providing a learning tool to refine dosimetric analysis and highlight sectors where implant quality could be improved.

Mohamed Yoosuf AB; Workman G; O'Toole MM; Straney M; Verghis R; Napier E; Mitchell DM

2013-05-01

11

Application of 125I seed permanent plantation in osseous metastases  

International Nuclear Information System (INIS)

[en] Objective: To evaluate the value of 125I permanent plantation in treating osseous metastases. Methods: Twenty-two patients with osseous metastases were accepted radioactive seeds 125I permanent plantation. The curative effect was appraised according to the degree of ostalgia relieving and the changing of the radiology imaging in patients. Results: Accepted radioactive seeds 125I permanent plantation, relief of pain was obtained and the effective rate is 91% (20/22). However none of the patients showed severe side-effect. Among 32 lesions in 22 cases followed-up by CT in 2 months, 4 obtained CR, 18 obtained PR, 10 NC and 0 PD. The responsive rate was 68.7%. Conclusion: 125I permanent plantation procedure can be a safe and effective method in treating osseous metastases and obtaining good clinical effects with minimal damage and few complications. (authors)

2007-01-01

12

Implantation of 125I in prostatic cancer  

International Nuclear Information System (INIS)

A technique of interstitial irradiation of the prostate using a 125I ? source is described. Preliminary results with this treatment are reported and some apparent advantages and disadvantages of the method are discussed. This technique has been utilized only in selected patients with carcinoma of the prostate and a controlled study of comparable patients treated by alternative methods has not been carried out

1974-01-01

13

125I seed fixity after implantation in parotid region  

International Nuclear Information System (INIS)

[en] Objective: To observe the fixity of 125I seed after implantation in parotid region. Methods: Ten patients treated with 125I seed interstitial brachytherapy in parotid were randomly selected. Within one week after the treatment, two plane radiographs were taken by radiotherapy simulator and 125I seed was counted. All plane dosimetry analysis were performed by treatment planning system. The areas surrounded by 50%, 100% and 150% of prescription dose curve and dose equality index were calculated. Two months after the treatment, the same examination were repeated and were compared with t test. Results: The number of seeds was equal in two examination. There were no significant differences in two examinations either for the areas surrounded by 50%, 100% and 150% of prescription dose curve or for the dose equality index. Conclusions: The position of 125I seed after implantation in parotid region is quite fixable, which can ensure the curative effect. (authors)

2008-01-01

14

Use of 125I for interstitial implants  

International Nuclear Information System (INIS)

The use of iodine-125 seeds for the implant irradiation of malignant tumors was investigated in terms of efficacy and radiological safety. Studies over a 3-year period at the Memorial Hospital for Cancer and Allied Diseases in New York were supported by the Bureau of Radiological Health. The final report indicates that iodine-125 is a satisfactory substitute for the high energy gamma emitters used in interstitial irradiation. Tumor doses of 16,000 rads were tolerated without undesirable early side effects. Methods for routine calibration of seeds and determination of dose distribution within patients were developed. A theoretical value for the absorbed dose constant of iodine-125 was computed. Personnel monitoring of hospital staff and survey of patients with sources in situ showed a marked reduction in exposure from these sources. Disadvantages were noted in the difficulty of locating lost sources and need to shield patients after discharge

1975-01-01

15

Operation and permanent low activity 125I brachytherapy for recurrent high-grade astrocytomas  

International Nuclear Information System (INIS)

[en] Twenty-two adult patients with recurrent high grade astrocytomas [18 glioblastoma multiforme (GBM) and 4 anaplastic astrocytoma (AA) at time of implant] underwent therapy at the University of Washington from October 1991 through March 1995, with repeat craniotomy, maximal debulking of tumor, and placement of permanent low activity 125I seeds. Median age was 41 years and median Karnofsky performance status was 90. Median survival for the entire group was 65 weeks from the time of implant. For the subgroup of GBM patients, median survival was 64 weeks from the time of implant. One-year survival from the date of implant was 57% for the entire group and 59% for those with GBM. The site of first failure after implant was local (within 2 cm of the resection cavity) in 70%, distant (noncontiguous, beyond 2 cm) in 18% and concurrently local and distant in 12%. There was one case of symptomatic radiation injury that resolved with steroid therapy, and no patient required repeat craniotomy for parenchymal necrosis. For patients with recurrent GBM, treatment with resection and permanent low activity 125I brachytherapy yielded improved survival compared to an internal historical control group treated with resection and chemotherapy (p = 0.023). Craniotomy with maximal tumor debulking and placement of low activity 125I seeds yields encouraging results with minimal morbidity in patients with recurrent high-grade astrocytomas

1996-06-01

16

Intraoperative pterygo-palatine interstitial /sup 125/I seed implants  

Energy Technology Data Exchange (ETDEWEB)

Intra-operative /sup 125/I seed implants of the pterygo-palantine fossa and/or base skull region were performed in 15 patients at Stanford between 1976 and 1980. Local control was obtained in the implanted volume in 6 of the 10 previously untreated patients and in 4 of 5 of those who were treated with combined resection and seed implantation after local recurrences. The technique of base skull implantation, the low incidence of complications from this procedure and the dosimetric methods are discussed.

Goffinet, D.R. (Stanford Univ. School of Medicine, CA); Martinez, A.; Pooler, D.; Fee, W.; Levine, P.A.

1983-01-01

17

Intraoperative pterygo-palatine interstitial 125I seed implants  

International Nuclear Information System (INIS)

Intra-operative 125I seed implants of the pterygo-palantine fossa and/or base skull region were performed in 15 patients at Stanford between 1976 and 1980. Local control was obtained in the implanted volume in 6 of the 10 previously untreated patients and in 4 of 5 of those who were treated with combined resection and seed implantation after local recurrences. The technique of base skull implantation, the low incidence of complications from this procedure and the dosimetric methods are discussed

1983-01-01

18

Urethral dosimetry constraints in 125I permanent prostate brachytherapy used as boost to external radiotherapy  

International Nuclear Information System (INIS)

With 125I monotherapy in permanent brachytherapy implants, the recommendation is to deliver to the urethra less than 150% of the prescribed dose, 145 Gy, that is a limit of 217.5 Gy. However, there are not recommendations in the case of the brachytherapy boost. At our hospitals, permanent brachytherapy implants are used as a 108 Gy boost in intermediate risk patients with prostate carcinoma, which have undergone an external beam radiotherapy course ranging between 45 and 50.4 Gy. The purpose of this work is to present a simple radiobiologically-based analysis performed in order to obtain the urethral dose limit in permanent prostate brachytherapy boost. The linear-quadratic model has been used to determine the biologically effective dose, analysing the results for different dose/fraction, t1/2 and a/b values. Assuming 46 Gy delivered by external beam radiotherapy, it is found that a limit value of 145 Gy, corresponding to the isodose level of 135% of the prescribed dose, is adequate. The results for a ten patients sample are shown in order to illustrate the values that are obtained in clinical practice. In conclusion, we present the method employed to find the urethral dose limit in the case of the combination of external beam radiotherapy and permanent 125I seeds brachytherapy boost implants (Author).

2010-01-01

19

Sequential Comparison of Seed Loss and Prostate Dosimetry of Stranded Seeds With Loose Seeds in 125I Permanent Implant for Low-Risk Prostate Cancer  

International Nuclear Information System (INIS)

Purpose: To compare stranded seeds (SSs) with loose seeds (LSs) in terms of prostate edema, dosimetry, and seed loss after 125I brachytherapy. Methods and Materials: Two prospective cohorts of 20 men participated in an institutional review board-approved protocols to study postimplant prostate edema and its effect on dosimetry. The LS cohort underwent brachytherapy between September 2002 and July 2003 and the SS cohort between April 2006 and January 2007. Both cohorts were evaluated sequentially using computed tomography-magnetic resonance imaging fusion-based dosimetry on Days 0, 7, and 30. No hormonal therapy or supplemental beam radiotherapy was used. Results: Prostate edema was less in the SS cohort at all points (p = NS). On Day 0, all the prostate dosimetric factors were greater in the LS group than in the SS group (p = 0.003). However, by Days 7 and 30, the dosimetry was similar between the two cohorts. No seeds migrated to the lung in the SS cohort compared with a total of five seeds in 4 patients in the LS cohort. However, the overall seed loss was greater in the SS cohort (24 seeds in 6 patients; 1.1% of total vs. 0.6% for LSs), with most seeds lost through urine (22 seeds in 5 patients). Conclusion: Despite elimination of venous seed migration, greater seed loss was observed with SSs compared with LSs, with the primary site of loss being the urinary tract. Modification of the technique might be necessary to minimize this. Prostate dosimetry on Days 7 and 30 was similar between the SS and LS cohorts.

2009-01-01

20

Urinary morbidity with a modified peripheral loading technique of transperineal 125i prostate implantation  

International Nuclear Information System (INIS)

[en] Purpose: Analysis of urinary morbidity within the first 12 months following a modified peripheral loading technique for permanent transperineal transrectal ultrasound (TRUS) guided 125I prostate implantation and comparison of urinary morbidity with various clinical and implant parameters. Materials and Methods: Between October 1, 1996, and March 11, 1998, 87 patients with favorable, early stage prostate cancer were treated with permanent transperineal TRUS guided 125I prostate implantation. A peripheral loading technique was utilized for source placement with 75-80% source distribution in the periphery and 20-25% source distribution centrally. A mean total activity of 38 mCi of 125I was implanted (range, 19-66 mCi). The mean source activity was 0.43 mCi/source (range, 0.26-0.61 mCi/source) and the mean number of sources implanted was 88 (range, 56-134). The minimum prescribed dose to the prostate was 145 Gy. The median D90, V100, and V150 were 152 Gy (range, 104-211 Gy), 92% (range, 71-99%), and 61% (range, 11-89%), respectively. The median follow-up time was 19 months (range, 12-29 months). Urinary morbidity was scored at 3 weeks and then at 3-month intervals for the first 2 years using a modified Radiation Therapy Oncology Group (RTOG) grading system (scale 0-5). Results: Most patients developed at least minor urinary symptoms with frequency or nocturia being the most common. Overall, 79% (69/87) of patients experienced urinary morbidity with 21% (18/87) reporting no symptoms. The incidence of overall Grade 1 urinary morbidity was 37% (32/87); Grade 2 morbidity was 37% (32/87); and Grade 3 morbidity was 6% (5/87). There was no Grade 4 or 5 morbidity. The incidence of Grade 0 frequency/nocturia was 36% (31/87); Grade 1 was 33% (29/87); Grade 2 was 30% (26/87); and Grade 3 was 1% (1/87). Grade 0 dysuria was seen in 56% (49/87) of patients; 32% (28/87) had Grade 1; 10% (9/87) Grade 2; and 1% (1/87) Grade 3 dysuria. Most urinary symptoms started a few weeks after implantation and began to subside by 6 months. At 12 months, 22% (19/87) of patients had persistent urinary symptoms (78% Grade 0, 15% Grade 1, 3% Grade 2, and 3% Grade 3). The mean urethral point dose was 174 Gy (range, 99-315 Gy). The mean number of sources implanted correlated significantly with the likelihood of developing acute urinary morbidity (p 0.03). The total activity implanted also correlated with the morbidity outcome dysuria (p = 0.01) with a threshold seen at 37 mCi. Urethral point dose, source activity, intraoperative TRUS prostate volume, D90, V100, V150, patient age, pretreatment PSA, Gleason score, and T stage did not correlate with morbidity. Conclusions: Permanent transperineal TRUS guided 125I prostate implantation using a modified peripheral loading technique is associated with mild urinary morbidity that resolves in 78% of patients by 12 months. Grade 3 urinary morbidity was encountered in only 6% (5/87) of patients. Urinary morbidity may be related to the total number of sources implanted and/or the total activity implanted. Overall urinary morbidity was not correlated with urethral point dose, source activity, intraoperative TRUS prostate volume, D90, V100, V150, patient age, pretreatment PSA, Gleason score, and T stage. The low incidence of urinary morbidity may be a consequence of our modified peripheral loading technique and/or the selection of patients with good-to-excellent preimplant urological parameters. Longer follow-up is necessary to assess biochemical control rates and long-term morbidity

2000-05-01

 
 
 
 
21

Comparison of 3 different postimplant dosimetry methods following permanent 125I prostate seed brachytherapy.  

UK PubMed Central (United Kingdom)

Postimplant dosimetry (PID) after Iodine-125 ((125)I) implant of the prostate should offer a reliable qualitative assessment. So far, there is no consensus regarding the optimum PID method, though the latest literature is in favor of magnetic resonance imaging (MRI). This study aims to simultaneously compare 3 PID techniques: (1) MRI-computed tomography (CT) fusion; (2) ultrasound (US)-CT fusion; and (3) manual target delineation on CT. The study comprised 10 patients with prostate cancer. CT/MR scans with urinary catheters in place for PID were done either on day 0 or day 1 postimplantation. The main parameter evaluated and compared among methods was target D90. The results show that CT-based D90s are lower than US-CT D90s (median difference,-6.85%), whereas MR-CT PID gives higher D90 than US-CT PID (median difference, 4.25%). Manual contouring on CT images tends to overestimate the prostate volume compared with transrectal ultrasound (TRUS) (median difference, 23.33%), whereas on US images the target is overestimated compared with MR-based contouring (median difference, 13.25%). Although there are certain differences among the results given by various PID techniques, the differences are statistically insignificant for this small group of patients. Any dosimetric comparison between 2 PID techniques should also account for the limitations of each technique, to allow for an accurate quantification of data. Given that PID after permanent radioactive seed implant is mandatory for quality assurance, any imaging method-based PID (MR-CT, US-CT, and CT) available in a radiotherapy department can be indicative of the quality of the procedure.

Marcu LG; Gowda R

2013-01-01

22

Ejaculatory Function After Permanent 125I Prostate Brachytherapy for Localized Prostate Cancer  

International Nuclear Information System (INIS)

Purpose: Ejaculatory function is an underreported aspect of male sexuality in men treated for prostate cancer. We conducted the first detailed analysis of ejaculatory function in patients treated with permanent 125I prostate brachytherapy for localized prostate cancer. Patients and Methods: Of 270 sexually active men with localized prostate cancer treated with permanent 125I prostate brachytherapy, 241 (89%), with a mean age of 65 years (range, 43-80), responded to a mailed questionnaire derived from the Male Sexual Health Questionnaire regarding ejaculatory function. Five aspects of ejaculatory function were examined: frequency, volume, dry ejaculation, pleasure, and pain. Results: Of the 241 sexually active men, 81.3% had conserved ejaculatory function after prostate brachytherapy; however, the number of patients with rare/absent ejaculatory function was double the pretreatment number (p

2009-05-01

23

Evaluation of 125I seed implantation combined with arterial infusion chemotherapy in treating unresectable lung cancer  

International Nuclear Information System (INIS)

[en] Objective: To assess the therapeutic effect of CT-guided 125I seed implantation combined with arterial infusion chemotherapy in treating unresectable lung cancer. Methods: Thirty patients with unresectable non-small call lung cancer were randomly divided into two groups. Group A (study group,n = 14)was receiving arterial infusion chemotherapy one week before and one week after 125I seed implantation. Group B (control group, n = 16) was receiving 125I seed implantation only. Two months after 125I seed implantation, follow-up checkup with thoracic CT scanning was carried out in all patients. The response to treatment was evaluated in accordance with RECIST criteria and the accumulated survival rate was analyzed by means of Kaplan-Meier. Results: Scheduled treatment was completed in all 30 patients. Under CT-guidance, 552 125I seeds were implanted in the patients of group A, while 603 125I seeds were implanted in the patients of group B. Nine patients in group A received two times of arterial infusion chemotherapy. Follow-up CT examination showed that the case number of complete remission, partial remission,stabilized disease and progressive disease in group A was 0, 10, 4 and 0 respectively, with an overall response rate of 71.43%. The corresponding data in group B was 0, 10, 5 and 1 respectively, with an overall response rate of 62.5%. The difference in the response rate between two groups was of no statistical significance (P > 0.05). The one-year survival rate of group A and B was 78.6% and 62.5% respectively, the difference between the two groups was statistically significant (P 125I seed implantation combined with arterial infusion chemotherapy is an effective treatment for unresectable lung cancer, it can significantly prolong the patient's survival time. (authors)

2009-01-01

24

Evaluation of the dose distribution for prostate implants using various 125I and 103Pd sources  

International Nuclear Information System (INIS)

[en] Recently, several different models of 125I and 103Pd brachytherapy sources have been introduced in order to meet the increasing demand for prostate seed implants. These sources have different internal structures; hence, their TG-43 dosimetric parameters are not the same. In this study, the effects of the dosimetric differences among the sources on their clinical applications were evaluated. The quantitative and qualitative evaluations were performed by comparisons of dose distributions and dose volume histograms of prostate implants calculated for various designs of 125I and 103Pd sources. These comparisons were made for an identical implant scheme with the same number of seeds for each source. The results were compared with the Amersham model 6711 seed for 125I and the Theragenics model 200 seed for 103Pd using the same implant scheme.

2009-01-01

25

Replacing external beam irradiation with 125I seed implantation as brachytherapy for breast cancer  

International Nuclear Information System (INIS)

[en] Objective: To investigate the feasibility of replacing post-operative external irradiation with intraoperative interstitial implantation of 125I radioactive seeds in patients with breast cancer. Methods: Twenty-four patients underwent modified radical mastectomy for breast cancer, intraoperative interstitial implantation of 125I seed was carded out evenly over the whole operative field. No post-operative external irradiation was applied. Results: All patients were followed. To date, no locoregional recurrence was observed, nor was any complication related to the treatment. Conclusion: The primary result was satisfactory. More experience is required for definite conclusion. (authors)

2005-01-01

26

Clinical efficacy of CT-guided 125I seed implantation therapy for advanced pancreatic cancer  

International Nuclear Information System (INIS)

Objective: To discuss the clinical efficacy of CT-guided radioactive 125I seed implantation treatment for unresectable pancreatic cancer. Methods: Forty patients with inoperable pancreatic cancer were enrolled in this study, including 25 males and 15 females with an median age of 69 years (38-89 years). Treatment planning system (TPS) was used to reconstruct 3-dimensional images of pancreatic tumor and to define the quantity and distribution of 125I seeds. The radioactivity of 125I seeds was 0.5 - 0.8 mCi / seed. The seeds were implanted into pancreatic tumor under CT guidance at intervals of 1 cm and were kept away from vessels, pancreatic duct and other adjacent important organs. The tumor matched peripheral dose (MPD) was 60-140 Gy. The median amount of implanted 125I seeds was 36 (18-68) in number. CT scan was performed immediately after the procedure to check the quality of the seeds. In addition, 10 patients received concurrent chemotherapy with arterial infusion of gemcitabin and 5-fluororacil (5-Fu) for 3 to 4 therapeutic courses. Results: The median diameter of the tumors was 4.9 cm. The follow-up period was 2 to 28 months. After the treatment the refractory pain was significantly relieved (P 125I seed implantation is a safe, effective and minimally-invasive brachytherapy for unresectable pancreatic cancer with reliable short-term efficacy. It has an excellent anti-pain effect. The curative results can be further improved when chemotherapy is employed together. However, its long-term efficacy needs to be observed. (authors)

2009-01-01

27

Clinical efficacy of CT-guided 125I seed implantation therapy for advanced lung cancer  

International Nuclear Information System (INIS)

Objective: To investigate the safety and clinical efficacy of CT-guided radioactive 125I seed implantation treatment for advanced lung cancer. Methods: The clinical data of thirty cases with lung cancer, which was proved by puncture biopsy, histology or cytology, were retrospectively analyzed. The pathologic diagnoses included squamous cell carcinoma (n=13), adenocarcinoma (n=8) and metastatic lung cancer (n=9). Using treatment planning system (TPS) 3D images of the tumor were reconstructed, the number and the dose rate distribution of 125I seeds were calculated. The matched peripheral dose (MPD) of 125I seed implantation was 80-130 Gy. The median amount of implanted 125I seeds was 35 (8 - 83) in number. Results: Follow-up observation was made at 1, 3, 6 and 12 months after the treatment in all patients. The median survival time was 12 months (7-18 months). The cumulative survival rate at 6, 9 and 12 months was 100.0%, 80.0% and 23.3%, respectively. Follow-up CT images 12 months after the therapy showed that complete relief (CR) was seen in 9 cases, partial relief (PR) in 14 cases, no change (NC) in 4 cases and progression (PD) in 3 cases. The overall effective rate (CR + PR) of 1-month, 3- month, 6-month and 12-month was 83%, 80%, 80% and 77%, respectively. During following-up period, pneumothorax occurred in 3 cases and bloody sputum occurred in 7 cases. Conclusion: CT-guided radioactive 125I seed implantation treatment is a safe, effective and minimally-invasive treatment for lung cancer. (authors)

2009-01-01

28

Percutaneous vertebroplasty combined with interstitial implantation of 125I seeds in banna mini-pigs.  

UK PubMed Central (United Kingdom)

BACKGROUND: Although brachytherapy is one of the most effective ways to treat metastatic spinal tumor with little damage to surrounding healthy tissue, it may cause radiation myelopathy if an overdose occurs. Establishing a valuable animal model can help to find a method to overcome its complications. In the current study, we set up a banna mini-pig model to mimic percutaneous vertebroplasty with 125I seed implantation. METHODS: Percutaneous vertebroplasty (PVP) combined with interstitial implantation of 125I seeds, 125I seeds were transplanted into the vertebral body at the T13 level of the spine in banna mini-pigs. After raising them for up to eight months, the spinal cord and vertebral body were collected for pathological analysis. RESULTS: A potential animal model had been successfully established, no case of radiation myelopathy was found in any of the treated banna pigs, and no significant cellular impairment was noted by pathological analysis. CONCLUSIONS: It proves that PVP with 125I brachytherapy is an effective method to treat metastasis spinal tumor, and that the banna mini-pig can be a suitable model to investigate the mechanism of brachytherapy complications.

Yang Z; Zhang Y; Xu D; Maccauro G; Rossi B; Jiang H; Wang J; Sun H; Xu L; Chen Y; Liu X

2013-01-01

29

125I seed implant brachytherapy for the treatment of parotid gland cancers in children and adolescents  

International Nuclear Information System (INIS)

Background and purpose: There is a lack of optimal treatment strategies for managing salivary gland cancers in children and adolescents. This study is aimed at assessing the effect of 125I seed implantation for the treatment of parotid cancers in children and adolescents. Patients and methods: A total of 12 patients younger than 16 years with parotid gland malignant tumors underwent 125I seed implant brachytherapy between October 2003 and November 2008. All patients were assessed after treatment and at the local tumor control appointments. Facial nerve function, maxillofacial development, and radioactive side-effects were assessed. Results: The follow-up period ranged from 41-104 months. One patient with T4b died of pulmonary metastasis. The other patients were alive during the follow-up period. There were no serious radiation-related complications. The treatment did not affect facial nerve function and dentofacial growth in any of the children. Conclusion: For parotid gland cancers in children, 125I seed implant brachytherapy may be an acceptable treatment without serious complications and with satisfactory short-term effects. (orig.)

2013-01-01

30

CT-Guided Radioactive (125)I Seed Implantation Therapy of Symptomatic Retroperitoneal Lymph Node Metastases.  

Science.gov (United States)

PURPOSE: This study explored the clinical efficacy of CT-guided radioactive (125)I seed implantation in treating patients with symptomatic retroperitoneal lymph node metastases. METHODS: Twenty-five patients with pathologically confirmed malignant tumors received CT-guided radioactive (125)I seed implantation to treat metastatic lymph nodes. The diameter of the metastatic lymph nodes ranged from 1.5 to 4.5 cm. Treatment planning system (TPS) was used to reconstruct the three-dimensional image of the tumor and then calculate the corresponding quantity and distribution of (125)I seeds. RESULTS: Follow-up period for this group of patients was 2-30 months, and median time was 16 months. Symptoms of refractory pain were significantly resolved postimplantation (P < 0.05), and Karnofsky score rose dramatically (P < 0.05). Most patients reported pain relief 2-5 days after treatment. Follow-up imaging studies were performed 2 months later, which revealed CR in 7 patients, PR in 13 patients, SD in 3 patients, and PD in 2 patients. The overall effective rate (CR + PR) was 80 %. Median survival time was 25.5 months. Seven patients died of recurrent tumor; 16 patients died of multiorgan failure or other metastases. Two patients survived after 30 months follow-up. Two patients reported localized skin erythema 1 week postimplantation, which disappeared after topical treatment. CONCLUSIONS: CT-guided radioactive (125)I seed implantation, which showed good palliative pain relief with acceptable short-term effects, has proved in our study to be a new, safe, effective, and relatively uncomplicated treatment option for symptomatic retroperitoneal metastatic lymph nodes. PMID:23580117

Wang, Zhongmin; Lu, Jian; Gong, Ju; Zhang, Liyun; Xu, Yingjia; Song, Shaoli; Chen, Kemin; Liu, Fenju; Gang, Huang

2013-04-12

31

CT-Guided Radioactive (125)I Seed Implantation Therapy of Symptomatic Retroperitoneal Lymph Node Metastases.  

UK PubMed Central (United Kingdom)

PURPOSE: This study explored the clinical efficacy of CT-guided radioactive (125)I seed implantation in treating patients with symptomatic retroperitoneal lymph node metastases. METHODS: Twenty-five patients with pathologically confirmed malignant tumors received CT-guided radioactive (125)I seed implantation to treat metastatic lymph nodes. The diameter of the metastatic lymph nodes ranged from 1.5 to 4.5 cm. Treatment planning system (TPS) was used to reconstruct the three-dimensional image of the tumor and then calculate the corresponding quantity and distribution of (125)I seeds. RESULTS: Follow-up period for this group of patients was 2-30 months, and median time was 16 months. Symptoms of refractory pain were significantly resolved postimplantation (P < 0.05), and Karnofsky score rose dramatically (P < 0.05). Most patients reported pain relief 2-5 days after treatment. Follow-up imaging studies were performed 2 months later, which revealed CR in 7 patients, PR in 13 patients, SD in 3 patients, and PD in 2 patients. The overall effective rate (CR + PR) was 80 %. Median survival time was 25.5 months. Seven patients died of recurrent tumor; 16 patients died of multiorgan failure or other metastases. Two patients survived after 30 months follow-up. Two patients reported localized skin erythema 1 week postimplantation, which disappeared after topical treatment. CONCLUSIONS: CT-guided radioactive (125)I seed implantation, which showed good palliative pain relief with acceptable short-term effects, has proved in our study to be a new, safe, effective, and relatively uncomplicated treatment option for symptomatic retroperitoneal metastatic lymph nodes.

Wang Z; Lu J; Gong J; Zhang L; Xu Y; Song S; Chen K; Liu F; Gang H

2013-04-01

32

125I interstitial brachytherapy for primary malignant brain tumors: technical aspects of treatment planning and implantation methods  

International Nuclear Information System (INIS)

Use of interstitial radiation holds promise in the treatment of primary malignant brain tumors, but optimal technical factors have yet to be determined. We have developed a method of precise CT directed stereotactic placement of radioactive sources in a predetermined target volume. We use low activity (1-2 millicurie/speed) sources of 125I loaded in silastic catheters, which are positioned in a parallel array in the target. Positioning of such multiple sources toward the periphery of the volume enhances achievable dose homogeneity. Seeds of various activities can be differentially loaded into each catheter and the catheters can be positioned at various radii from the central target so that the treated volume corresponds to the identified (often irregular) target volume. Although the implant is designed to be permanent, the sources can be removed easily in a second procedure.

1985-01-01

33

Nursing care for patients with local recurrent rectal cancer after CT-guided 125I seed implantation therapy  

International Nuclear Information System (INIS)

Objective: To discuss the nursing care strategy for patients with local recurrent rectal cancer who has been treated with CT-guided 125I seed implantation therapy. Methods: Twenty patients with local recurrent rectal cancer received a series of nursing interventions, including comfort care and pain care. The clinical results were observed and analyzed. Results: The therapy was smoothly accomplished in all patients. The pain was remarkably relived and the anxiety was alleviated. No displacement of implanted 125I seed occurred. Conclusion: For patients with local recurrent rectal cancer occurred after CT-guided 125I seed implantation therapy, careful nursing can effectively relieve the pain and anxiety feeling,and the living quality can also be markedly improved. (authors)

2010-01-01

34

Clinical analysis of 125I seed implants in worst-casts of the malignant tumors after radiography and chemotherapy  

International Nuclear Information System (INIS)

Objective: To investigate the curative effect and side reaction after 125I seed implanted among tissue were treated the malignant neoplasm by radiography and chemotherapy. Methods: Retrospective analysis the cancerous sufferer after the failure of radiography and chemotherapy, percutaneous puncture or intraoperative under gaze forward 125I seed were implanted the bed of the tumour forever. Follow-up blood routine examination, symptom, sign, using USG or CT observe the change of the tumour and the distribution of the particles etc. Results: In 3 cases, treat 2 cases, tumour reduced obviously, symptoms improved obviously, the face of the ulcer cured, the particles did not shift, hemogram did not decline obviously. Conclusion: 125I seed among the tissue implanted forever for the unsuccessful case after radiography and chemotherapy supply a new therapeutic methods. In the neat future curative effect is exactly, toxic reaction is small, which can remedy the deficiency of the treatment for radiography and chemotherapy. (authors)

2006-01-01

35

Relative biologic effectiveness in terms of tumor response of 125I implants compared with 60Co gamma rays  

International Nuclear Information System (INIS)

[en] Purpose: To measure the relative biologic effectiveness (RBE) for 125I seeds compared with external beam radiotherapy using a clinically relevant in vivo system. Methods and Materials: Photon emission from a detailed source model was simulated using the Monte Carlo code MCNP4C, sampling from a 125I spectrum. The mouse RIF-1 tumor was treated with either temporary implant of an 125I seed or with 60Co gamma rays. The tumors were always the same size at the initiation of treatment, and the endpoint was growth inhibition. Results: The dose-response curve for both modalities was close to linear and was independent of the initial 125I activity (dose rate) for the range investigated. Calculation of the RBE for tumor response requires assigning a unique value for the tumor dose that is not homogenous but depends on the distance from the 125I source. Because tumor regrowth will depend on the subpopulation of cells that have the greatest probability of survival (i.e., those at the greatest distance from the 125I source), one approach is to use the dose to this population. On this basis, the RBE for 125I compared with 60Co gamma rays is 1.5. If the 125I dose is computed as the average dose to the tumor, corrected for the dose that is wasted as overkill in the cell population closest to the center of the 125I seed, the RBE is 1.4. Conclusion: The result, an RBE of 1.4-1.5 is similar to findings obtained by other methods, supporting the validity of this approach to derive an RBE with validity in a clinical context

2005-09-01

36

Characterization of some dosimetric parameters of 125I seeds used for prostate implants using Monte Carlo simulations  

International Nuclear Information System (INIS)

[en] In the prostate cancer treatment, there is an increasing interest in the permanent radioactive seeds implant technique, where 125I seeds are inserted into the patient's prostate, allowing the delivery of high doses and preserving nearby organs at risk. For the calculation of dose distributions, treatment planning systems (TPS) makes use of the calculation proposed by the protocol TG-43. According to the document, data of dose distribution should be made more precise, either experimentally or by computational simulations, to be used in the TPS. Several authors used Monte Carlo simulations to generate the parameters of brachytherapy sources (seeds) that are recommended by TG-43 protocol, which are used for dose calculations in the TPS. For a single seed, there are variations in the geometry chosen to calculate the dosimetric parameters recommended and in the medium where the dose distributions are calculated (liquid water or solid water) and also in the Monte Carlo code used. The TPS consider the sources as point entities and do not consider the attenuation effects among the seeds. In this work, computational simulations of the geometry of one of the most used seeds in permanent prostate implants, the Amersham model 6711, were performed through the Monte Carlo method using the MCNP5 code. The dosimetric parameters radial dose function g(r) and anisotropy function F(r,?) were simulated and the results show good agreement with other works. This model can be used in the future to study the impact of the approaches and other problems in the implant procedure. (author)

2009-10-02

37

(125)I monotherapy using D90 implant doses of 180 Gy or greater.  

UK PubMed Central (United Kingdom)

PURPOSE: The purpose of this study was to characterize the oncologic results and toxicity profile of patients treated with (125)I implants using the dose delivered to 90% of the gland from the dose-volume histogram (D90) of greater than 144 Gy. METHODS AND MATERIALS: From June 1995 to Feb 2005, a total of 643 patients were treated with (125)I monotherapy for T1-T2 prostate cancer with a D90 of 180 Gy or greater (median, 197 Gy; range, 180-267 Gy). Implantations were performed using a real-time ultrasound-guided seed-placement method and intraoperative dosimetry to optimize target coverage and homogeneity by using modified peripheral loading. We analyzed biochemical disease-free survival (bDFS) of 435 patients who had a minimum 2-year prostate-specific antigen follow-up (median follow-up, 6.7 years; range, 2.0-11.1 years). RESULTS: Five-year bDFS rates for the entire cohort using the American Society for Therapeutic Radiology and Oncology and Phoenix definitions were 96.9% and 96.5%, respectively. Using the Phoenix definition, 5-year bDFS rates were 97.3% for low-risk patients and 92.8% for intermediate/high-risk patients. The positive biopsy rate was 4.1%. The freedom rate from Grade 2 or higher rectal bleeding at 5 years was 88.5%. Acute urinary retention occurred in 10.7%, more commonly in patients with high pretreatment International Prostate Symptom Scores (p < 0.01). In patients who were potent before treatment, 73.4% remained potent at 5 years after implantation. CONCLUSIONS: Patients with a minimum D90 of 180 Gy had outstanding local control based on prostate-specific antigen control and biopsy data. Toxicity profiles, particularly for long-term urinary and sexual function, were excellent and showed that D90 doses of 180 Gy or greater performed using the technique described were feasible and tolerable.

Kao J; Stone NN; Lavaf A; Dumane V; Cesaretti JA; Stock RG

2008-01-01

38

The value of total mesorectal excision with 125I seed implantation in middle-lower portion of rectal cancer  

International Nuclear Information System (INIS)

Objective: To study the effect of total mesorectal excision (TME) with 125I seed implantation in progressive middle-lower portion rectal cancer. Methods: Sixty-seven middle-lower portion rectal cancer cases (all were Ducks B, C stage) were treated with three different methods. 1) TME with chemotherapy in 24 cases (group 1). 2) TME with radiotherapy in 18 cases (group 2). 3) TME followed by 125I seed implantation in 19 cases (group 3). All cases had been followed up for two years. Recurrence rate in three groups and complications in groups 2 and group 3 were observed. Results: The recurrence rates in three groups in 1.5 years were 46%, 11%, 5% respectively. The recurrence rates in group 2 and group 3 were lower than that in group 1 (P125I seed implication can reduce the recurrence rate of progressive rectal cancer and also lower its incidence of complications. (authors)

2005-01-01

39

Radiation protective nursing intervene of 125I seed implantation in non-small cell lung carcinoma guided by CT  

International Nuclear Information System (INIS)

Objective: To research radiation protective nursing intervene and important notice of 125I seeds minimally invasive implantation in non-small cell lung carcinoma (NSCLC) by CT. Methods: Under the system of therapy planning system (TPS) and posologic validation, 125I seeds were implanted in 89 cases of NSCLC patients. The consistent radiation protective nursing intervene was used in perioperative period management. The operative successful rate, therapeutic effect and complication rate, therapeutic effect and complication rate was observed. Results: The scientific radiation protective nursing intervene can ensure that the radioactive dose distribution of 125I seed implantation brachytherapy is consistent with the principles of effective and minimally invasive. The operative successful rate was 100%. The local control rate and 1 year survival rate respectively was 97.4% and 92.2%. But the early and later incidence rate of radioactive damaging effect was 14.6% and 1.1% respectively. Leakage of radioactive contamination has not occurred. Conclusion: The consistent TPS and posologic validation 125I seeds implantation integrated scientific radiation protective nursing intervene. It is very important to improve the therapeutic effect of NSCLC and reduce the incidence of complications. (authors)

2009-01-01

40

From manual to 3-D computerized treatment planning for 125I stereotactic brain implants  

International Nuclear Information System (INIS)

[en] Aspects of planning for the treatment of high grade primary or recurrent brain tumors with stereotactically placed catheters afterloaded with high activity 125I seeds are discussed. At our institution, planning has evolved from a simple manual process, which assumed geometric symmetry, through a more advanced manual process, that took advantage of certain mechanical properties of the stereotactic frame used, into a sophisticated, computerized planning approach that includes optimization of the source distribution and 3-D displays. Use of the simple manual method is limited to the rare situations where target volumes are quite regular in shape. The advanced manual method provides some customization for irregularly shaped volumes, but is slow and tedious to implement. The interactive, computerized approach permits identification of target volumes directly on CT slices, reconstructions in arbitrary planes, and optimization of catheter placement, source separation along each catheter, and selection of source strengths from an available inventory. A multi-format display feature which includes a probe's eye view perspective is provided to aid in planning. Integral dose-volume histograms for the target volume point out the advantages in using sophisticated, 3-D, computerized planning systems for these implants

1988-01-01

 
 
 
 
41

TACE combined with CT-guided 125I radioactive particle implantation for the treatment of hepatic cancer  

International Nuclear Information System (INIS)

Objective: To investigate the technical points and the clinical effectiveness of transcatheter arterial chemoembolization (TACE) combined with CT-guided 125I radioactive particle implantation for the treatment of liver cancer. Methods: Twenty-seven patients with hepatic cancer, proved by color Doppler ultrasonography, CT and AFP, were enrolled in this study. All the patients received embolization therapy with lipiodol not long before. Of the 27 patients, preoperative CT scanning was performed in 16. Based on the CT findings, the therapeutic protocol was formulated to determine the amount and site of 125I radioactive particle to be implanted. When drawing the outline of target area, the targeted sedimentation extent which was delineated on CT scan should be exceeded the area with deposits of lipiodol by 0.5-1.0 cm. The average energy of 125I radioactive particle was 27-35 keV. Results Of 27 patients, complete remission was seen in 2, partial remission in 16, unchanged condition in 6 and exacerbation of the condition in 3, with a total efficiency of 66.7%. The patients were followed up for 6 months. One patient died of distant metastasis and the remaining ones survived so far. Conclusion: Transcatheter arterial chemoembolization combined with CT-guided 125I radioactive particle implantation is a safe and effective treatment for liver cancer. (authors)

2009-01-01

42

Implantation of the linear 125I seed strand into portal venous trunk: an experimental study in rabbits  

International Nuclear Information System (INIS)

Objective: To evaluate the safety of implanting 125I seed strand into portal vein in experimental rabbits. Methods: Twenty New Zealand white rabbits were equally and randomly divided into experimental group (group T) and control group (group C), and all the rabbits were numbered. Three linear 125I seeds were sealed in a transparent catheter to form a seed strand. The seed strand was inserted into portal vein and rigidly suspended on the inner wall of portal vein in rabbits of group T, while only laparotomy with purse-string suture of portal vein was performed in rabbits of group C. Routine blood exam, liver function, CT scanning and direct portography were carried out at the 14th, 28th, 60th and 120th day after the treatment. Every two rabbits from both groups were sacrificed each time at the 14th, 28th and 60th day after the treatment, and the remaining rabbits were sacrificed at the 120th day after the treatment. Portal venous trunk, both neighboring and distant liver tissues and the duodenum were harvested for pathologic examination. Results: No irradiation related diarrhea, vomiting, body weight loss or death were observed in group T. Both MDCT and DSA showed that the blood flow in the portal vein was unobstructed. Macroscopically, no perforation, stricture or mural thrombus were found in the portal vein, and no adhesion of the implanted 125I seed strand to the inner wall of portal vein was observed. Microscopically, necrosis and exfoliation of endothelial cells were seen, although no obvious pathological changes of tunicae media and adventitia were detected. Market necrosis of the liver tissue adjacent to 125I seed was well seen, while the liver tissue in the inferior area of the right hepatic lobe showed normal. No significant difference in the routine blood count and liver function existed between two groups (P > 0.05). Conclusion: Intraluminal implantation of linear 125I seed strand into portal venous trunk is safe and practicable. (authors)

2009-01-01

43

Radioimmunoassay of tumor markers for monitoring the effect of TPS directed implantation of radioactive seeds 125I into tumor tissue  

International Nuclear Information System (INIS)

Objective: To assess the therapeutic effect of TPS directed implantation of radioseeds 125I into tumor tissue with Radioimmunoassay of tumor markers. Methods: Radio-active seeds 125I was implanted intra-operatively into 78 patients with malignancy (brain 8, lung 15, liver 12, prostate 7, rectum 10, pancreas 8, bileduct 6, breast 10 and malignant teratoma 2). The organ absorption dose was 90-120 Gy and radio activity was 370-925 MBq. Patients were followed up for 6-12 months and Radioimmunoassays of virions tumor markers serum levels (CYFRA21-1, AFP, CEA, PSA, CA119, CA153) were performed as suitable for the specific disease entity. Results: Reduction of tumor mass was very remarkable (9.0% complete regression, 41.0% regression>1/2 and 50% regression>1/3). Correspondingly, the tested serum tumor marker levels were all significantly lowered. Conclusion: For assessing the therapeutic effect of radioactive seeds 125I implantation, determination of tumor marker levels could be a very sensitive and reliable means

2003-01-01

44

{sup 125}I seed implant brachytherapy for the treatment of parotid gland cancers in children and adolescents  

Energy Technology Data Exchange (ETDEWEB)

Background and purpose: There is a lack of optimal treatment strategies for managing salivary gland cancers in children and adolescents. This study is aimed at assessing the effect of {sup 125}I seed implantation for the treatment of parotid cancers in children and adolescents. Patients and methods: A total of 12 patients younger than 16 years with parotid gland malignant tumors underwent {sup 125}I seed implant brachytherapy between October 2003 and November 2008. All patients were assessed after treatment and at the local tumor control appointments. Facial nerve function, maxillofacial development, and radioactive side-effects were assessed. Results: The follow-up period ranged from 41-104 months. One patient with T4b died of pulmonary metastasis. The other patients were alive during the follow-up period. There were no serious radiation-related complications. The treatment did not affect facial nerve function and dentofacial growth in any of the children. Conclusion: For parotid gland cancers in children, {sup 125}I seed implant brachytherapy may be an acceptable treatment without serious complications and with satisfactory short-term effects. (orig.)

Zheng, L.; Zhang, J.; Song, T.; Zhang, J.; Yu, G.; Zhang, Y. [Peking University School and Hospital of Stomatology, Beijing (China). Dept. of Oral and Maxillofacial Surgery

2013-05-15

45

Study of treatment using percutaneous acetabuloplasty and interstitial implantation of 125I seeds for patients with metastatic periacetabular tumors  

Directory of Open Access Journals (Sweden)

Full Text Available Abstract Background The periacetabular area is one of the primary sites of metastatic tumors, which often present as osteolytic bone destruction. Bone destruction in the acetabulum caused by metastatic tumors will cause hip pain and joint dysfunction. It results in decreased quality of life for patients. The aim of our study was to explore the clinical effect of metastatic periacetabular tumors treated with percutaneous cementoplasty and interstitial implantation of 125I seeds. Methods A retrospective analysis was performed on 24 patients with metastatic periacetabular tumors who underwent combined therapy of percutaneous acetabuloplasty and interstitial implantation of 125I seeds between February 2003 and June 2011. There were 13 males and 11 females aged 19–80 years with a mean age of 57.3. The primary tumor site was the lung in eight cases, the breast in six, the prostate cancer in eight, and the liver in two. The amount of implanted 125I seeds was 12–20 seeds/person, with a mean of 16.5 seeds/person, and the matching peripheral dosage (MPD) was 80~100Gy. Routine postoperative chemotherapy and other combined treatments were applied to patients after the surgical operation. Changes in the Karnofsky Score(KPS), Harris Hip Score(Harris), and Visual Analog Scale(VAS) were observed during the follow-up period. Results The 24 patients’ operations were all successful. No major complications occurred. Complete pain relief was achieved in 58% (14 of 24) of patients, and pain reduction was achieved in the 42% remaining (10) patients. The mean duration of pain relief was 8.3 months. Pain recurred in one patient 3 months after surgery. Six patients had died and 18 patients were alive at the time of the 1-year follow-up. Comparing the KPS, Harris and VAS scores pre- and postoperativelyat 1, 6, and 12 months, the combined therapy method was significantly effective in metastatic periacetabular tumor patients (P Conclusions Percutaneous cementoplasty with interstitial implantation of 125I seeds is an effective treatment method for metastatic periacetabular tumor patients, providing tumor resistance, pain relief, increased bone stability, and improved quality of life for patients.

Zhang Jinlei; Yang Zuozhang; Wang Jiaping; Wang Jinde; Liu Pengjie; Sun Hongpu; Li Kun; Yang Yunshan

2012-01-01

46

The effect of seed orientation deviations on the quality of {sup 125}I prostate implants  

Energy Technology Data Exchange (ETDEWEB)

We quantified the effect of seed orientation deviations on five prostate seed implant cases at our institution. While keeping their positions fixed, the iodine-125 seeds were assigned orientations sampled from a realistic probability distribution derived from the post-implant radiographs of ten patients. Dose distributions were calculated with both a model that explicitly includes anisotropy (TG43 anisotropy function) and a point source model (TG43 anisotropy factor). Orientation deviations had only a small influence on prostate dose-volume histograms: the 95% confidence intervals on the volumes receiving 100%, 150% and 200% dose were at most {+-}0.8%, {+-}1.1% and {+-}0.6% of the prostate volume, respectively. The dose-volume histograms of anisotropic seed distributions were marginally better than those with isotropic point-source seeds. Anisotropy caused a displacement of cold spots (regions receiving <100% of the prescribed dose) in <1% of the prostate volume. Our results indicate no net benefit to prostate dosimetry in using more isotropic seeds. Furthermore, we propose a new 'weighted anisotropy function' to better account for the effects of anisotropy when seed orientation is unknown. Conceptually, the TG43 anisotropy factor described in AAPM TG43 averages the effect of anisotropy over all solid angles, with the implicit assumption that all seed orientations are equally probable. In prostate implants, however, seeds are preferentially oriented parallel to the needle axis. The proposed weighted anisotropy function incorporates this non-uniform probability. (author)

Corbett, J.F.; Jezioranski, J.J.; Tran, T. [Department of Radiation Physics, Princess Margaret Hospital, Toronto, ON (Canada); Crook, J. [Department of Radiation Oncology, Princess Margaret Hospital, Toronto, ON (Canada); Department of Radiation Oncology, University of Toronto, Toronto, ON (Canada); Yeung, I.W.T. [Department of Radiation Physics, Princess Margaret Hospital, Toronto, ON (Canada)

2001-11-01

47

Transnasal permanent interstitial implantation for carcinoma of the nasopharynx  

International Nuclear Information System (INIS)

A technique for transnasal permanent interstitial implantation of the nasopharynx with 125I seeds is described. This technique allows the precise placement of radioactive sources into mucosal and submucosal tumors, without the need for palatal fenestration. Preliminary results in 10 patients treated by this technique for recurrent nasopharyngeal carcinoma are presented. In the future the authors also hope to employ this technique for delivering ''boost'' irradiation to the primary site, in the initial definitive management of carcinoma of the nasopharynx

1984-01-01

48

Transnasal permanent interstitial implantation for carcinoma of the nasopharynx.  

UK PubMed Central (United Kingdom)

A technique for transnasal permanent interstitial implantation of the nasopharynx with 125I seeds is described. This technique allows the precise placement of radioactive sources into mucosal and submucosal tumors, without the need for palatal fenestration. Preliminary results in 10 patients treated by this technique for recurrent nasopharyngeal carcinoma are presented. In the future we also hope to employ this technique for delivering "boost" irradiation to the primary site, in the initial definitive management of carcinoma of the nasopharynx.

Vikram B; Hilaris B

1984-01-01

49

125I implantation for carcinoma of prostate. Further follow-up of first 100 cases  

International Nuclear Information System (INIS)

Analysis of the first 100 patients at the Memorial Sloan-Kettering Cancer Center with Stage B or C prostatic cancer treated by pelvic lymph node dissection and Iodine-125 implantation and endocrine therapy when specifically indicated revealed five-year survival rates of 87 and 77 per cent, respectively. Tumor stage, tumor grade, and lymph node metastasis each correlated with survival, but the latter was the most significant factor. Although routine follow-up biopsies were not performed, local tumor control as judged by serial digital rectal examination defined a prognostically favored group of patients. In the absence of controls, however, whether the latter response indicates a salutary effect of the treatment which produces an improved survival or merely identifies a group of patients who were predetermined to have a more favorable survival is undetermined

1982-01-01

50

125I implantation for carcinoma of prostate. Further follow-up of first 100 cases.  

UK PubMed Central (United Kingdom)

Analysis of the first 100 patients at the Memorial Sloan-Kettering Cancer Center with Stage B or C prostatic cancer treated by pelvic lymph node dissection and Iodine-125 implantation and endocrine therapy when specifically indicated revealed five-year survival rates of 87 and 77 per cent, respectively. Tumor stage, tumor grade, and lymph node metastasis each correlated with survival, but the latter was the most significant factor. Although routine follow-up biopsies were not performed, local tumor control as judged by serial digital rectal examination defined a prognostically favored group of patients. In the absence of controls, however, whether the latter response indicates a salutary effect of the treatment which produces an improved survival or merely identifies a group of patients who were predetermined to have a more favorable survival is undetermined.

Grossman HB; Batata M; Hilaris B; Whitmore WF Jr

1982-12-01

51

125I implantation for carcinoma of prostate. Further follow-up of first 100 cases  

Energy Technology Data Exchange (ETDEWEB)

Analysis of the first 100 patients at the Memorial Sloan-Kettering Cancer Center with Stage B or C prostatic cancer treated by pelvic lymph node dissection and Iodine-125 implantation and endocrine therapy when specifically indicated revealed five-year survival rates of 87 and 77 per cent, respectively. Tumor stage, tumor grade, and lymph node metastasis each correlated with survival, but the latter was the most significant factor. Although routine follow-up biopsies were not performed, local tumor control as judged by serial digital rectal examination defined a prognostically favored group of patients. In the absence of controls, however, whether the latter response indicates a salutary effect of the treatment which produces an improved survival or merely identifies a group of patients who were predetermined to have a more favorable survival is undetermined.

Grossman, H.B.; Batata, M.; Hilaris, B.; Whitmore, W.F. Jr.

1982-12-01

52

Pharmacokinetics of 3-[125I]iodo-?-methyl-L-tyrosine, a tumor imaging agent, after probenecid loading in mice implanted with colon cancer DLD-1 cells  

International Nuclear Information System (INIS)

[en] Introduction: In order to improve tumor imaging, changes in the pharmacokinetics of 3-[123I]iodo-?-methyl-L-tyrosine ([123I]IMT), an artificial amino acid that exhibits high tumor accumulation, after probenecid (PBC) loading was studied in mice implanted with colon cancer DLD-1 cells using 125I-labeled IMT ([125I]IMT). Methods: DLD-1-implanted KSN-slc nude male mice received 740 kBq of [125I]IMT via the tail vein at 5 min after 50 mg/kg body weight PBC loading, and autoradiography was performed at 5, 15 and 30 min after injection. Male ddY mice then received 670 kBq of [125I]IMT and 50 mg/kg 2-amino-bicyclo[2,2,1]heptane-2-carboxylic acid (BCH) or p-aminohippurate (PAH) via the tail vein, and kidney autoradiography was performed at 5 min after injection. In vitro inhibition study was then performed based on the accumulation mechanisms of [125I]IMT in DLD-1, using 1 mM L-tyrosine, BCH, ?-(methylamino)-isobutyric acid, N-benzoyl-?-alanine, PBC, PAH, 2,4-dinitrophenol and sodium azide. Both Na+-dependent and Na+-independent uptake were investigated. Results: Higher tumor accumulation in PBC-loaded DLD-1-implanted mice was seen when compared to control mice. PAH and BCH, respectively, reduced renal accumulation in the tubule segment-2 (S2)-like and S1-like regions. We confirmed that [125I]IMT transport is predominantly mediated by L-type amino acid transporter-1 in DLD-1 cells. Conclusions: [125I]IMT uptake is mediated by organic anion and amino acid transporters in the kidney. Organic anion transporter inhibitors may yield better tumor images with good tumor/normal tissue radioactivity ratios if adequate administration plans are developed

2007-01-01

53

Preliminary observations on the results of combined /sup 125/I seed implantation and external irradiation for carcinoma of the prostate  

Energy Technology Data Exchange (ETDEWEB)

Fifty-seven patients with localized carcinoma of the prostate were treated with pelvic lymphadenectomy and a reduced /sup 125/I implant dosage, supplemented by a moderate dose of external beam radiotherapy to the whole pelvis delivered 4 to 6 weeks later. The incidence of pelvic nodal metastases was 28 per cent and the operative morbidity was 15 per cent. Late radiation sequelae developed in 18 patients, including 15 patients with radiation proctitis (29 per cent), among whom 2 (4.6 per cent) suffered rectal ulceration and required diverting colostomy. Followup has been 2 years or longer (median 33 months) in 26 patients, of whom 22 (85 per cent) are free of disease. Three patients are living with osseous metastases or local disease and there has been 1 death of prostatic carcinoma, for an absolute 2-year survival rate of 95 per cent. Of the 7 patients with poorly differentiated tumor and of the 8 patients with positive pelvic lymph nodes 5 and 6, respectively, remain free of disease after a minimum 2-year followup. Potency has been lost in 20 per cent and reduced significantly in 30 per cent of the patients followed 18 months or longer. Prostatic biopsies on 28 asymptomatic patients 12 to 30 months after completion of therapy showed no tumor in 21 (75 per cent).

Ross, G. Jr.; Borkon, W.D.; Landry, L.J.; Edwards, F.M.; Weinstein, S.H.; Abadir, R.

1982-04-01

54

MSCT-guided percutaneous cryoablation combined with 125I-seed implantation for the treatment of lung cancer: an observation of short-term efficacy  

International Nuclear Information System (INIS)

[en] Objective: To evaluate the short-term efficacy of MSCT-guided percutaneous argon-helium cryoablation combined with 125I-seed implantation in treating lung cancer, and to discuss the clinical feasibility and safety of this technique. Methods: Under the guidance of MSCT 3D-reconstruction imaging,percutaneous argon-helium cryoablation was performed in 51 patients with advanced lung cancer, which was followed by 125I-seed implantation with the help of treatment plan system (TPS). The 125I seeds were implanted into the edge and the un-frozen area of the tumor according to the therapeutic dosage and distribution calculated by TPS. After the procedure MSCT 3D-reconstruction imaging was carried out to check the location of the implanted 125I seeds. Both plain and contrast-enhanced CT scans of the chest were conducted 1, 2, 3 and 6 months after the treatment. The therapeutic results were analyzed and evaluated. Results: One, 2, 3 and 6 months after the treatment favorable improvement was seen in 9.8%, 19.6%, 56.9% and 46.0% of patients respectively, with the total effective rate of 31.4%, 62.8%, 98.0% and 92.0% respectively. Conclusion: For the treatment of lung cancer MSCT-guided percutaneous puncture argon-helium cryoablation ablation combined with 125I-seed implantation is a safe and minimally-invasive technique with fewer complications and reliable short-term effect. Therefore, it is of value to popularize this therapy in clinical practice. (authors)

2010-01-01

55

Intra-operative dosimetry of trans-rectal ultrasound guided 125I prostate implants using C-arm fluoroscopic images  

Directory of Open Access Journals (Sweden)

Full Text Available Permanent implantation of radioactive seeds is a viable and effective therapeutic option widely used today for early-stage prostate cancer. The implant technique has improved considerably during the recent years due to the use of image guidance; however, real-time dose distributions would allow potential cold spots to be assessed and additional seeds added. In this study, we investigate the use of a conventional C-arm fluoroscopy unit for image acquisition and evaluation of dose distribution immediately after the implant. The phantom study indicates that it is possible to obtain seed positions within ±2 mm. A pilot study carried out with three patients indicated that it is possible to obtain seed positions and calculate the dose distribution with C-arm fluoroscopy and about 95% of the seeds were reconstructed within ±2 mm. The results could be further improved with better digital imaging.

Ravindran Paul; Lewis C; Van Dyk J; D?Souza D

2006-01-01

56

Linear 125I seed strand implantation combined with portal vein stenting and TACE for the treatment of hepatocellular carcinoma with portal vein tumor thrombus  

International Nuclear Information System (INIS)

Objective: To evaluate the therapeutic efficacy of linear 125I seed strand implantation combined with portal vein stenting and transcatheter hepatic arterial chemoembolization (TACE) in treating hepatocellular carcinoma (HCC) with portal vein tumor thrombus. Methods: Seventeen HCC patients with tumor thrombus in the main branch of the portal vein received a combination therapy of linear 125I seed strand implantation with TACE. A total of 17 - 23 seeds of 125I (model 6711, 0.7 mCi) with a dosage of (73.51 ? 76.22) Gy on the first half-decay period was delivered to each patient. The postoperative complications, tumor response, stent patency rate and the successful rate of the procedure were all recorded, and the Kaplan-Meier method was used for analyzing the survival rate. Results: Stents and 125I seed strands were successfully placed in the portal veins in all patients. No serious complications occurred. The 60-, 180-and 360-day cumulative stent patency rates were 94%, 94% and 94% respectively, and the overall survival (OS) rates were 87%, 65% and 53% respectively. During a follow-up period of (2 - 13) months, twelve patients remained alive and five patients died of hepatic dysfunction (n = 4) or metastasis (n = 1). Conclusion: For the treatment of hepatocellular carcinoma with portal vein tumor thrombus, a combination of linear 125I seed strand implantation with portal vein stenting and TACE can increase the stent patency rate, elongate the survival span, although its long-term efficacy needs to be further studied. (authors)

2009-01-01

57

/sup 125/I implants as an adjuvant to surgery and external beam radiotherapy in the management of locally advanced head and neck cancer  

Energy Technology Data Exchange (ETDEWEB)

/sup 125/I seeds either individually placed or inserted into absorbable Vicryl suture carriers were utilized in conjunction with surgery and external beam radiotherapy in an attempt to increase local control rates in patients with advanced oropharyngeal and laryngopharyngeal cancers (T3-T4, N2-N3), massive cervical lymphadenopathy (N3) and an unknown primary site and locally recurrent head and neck cancers. Forty-eight patients were treated with 55 implants. The carotid artery was implanted in 15 patients, while seven patients had seeds inserted into the base of the skull region, and another three patients had implants near cranial nerves. Eighteen of the 48 patients were treated for cure. The actuarial survival at five years in this subgroup was 50%. The overall local control in the head and neck area was 58%. In this group no patients to date have had a local failure in the implanted volume. Seventeen patients with comparable stage of disease treated prior to 1974 with curative intent without /sup 125/I implants were analyzed retrospectively for comparison with the implanted patients. The actuarial survival of these patients was 18% and the overall head and neck control was 21%. These differences are statistically significant at a P value of 0.01 and 0.007, respectively. Seventeen patients received implants for local recurrence. The local control in the head and neck area was 50%; however, the 2.5 year actuarial survival was only 17%. The complication rate was 11% (six of 55 implants). The improved survival, the high local control, and the minimal complication rates in this series makes the intraoperative implantation of /sup 125/I seeds and effective adjunctive treatment to surgery and external beam irradiation.

Martinez, A.; Goffinet, D.R.; Fee, W.; Goode, R.; Cox, R.S.

1983-03-15

58

A digital model individual template and CT-guided 125I seed implants for malignant tumors of the head and neck  

International Nuclear Information System (INIS)

[en] The purpose of this study was to enhance the accuracy of radioactive seed implants in the head and neck, a digital model individual template, containing information simultaneously on needle pathway and facial features, was designed to guide implantation with CT imaging. Thirty-one patients with recurrent and local advanced malignant tumors of head and neck after prior surgery and radiotherapy were involved in this study. Before 125I implants, patients received CT scans based on 0.75 mm thickness. And the brachytherapy treatment planning system (BTPS) software was used to make the implantation plan based on the CT images. Mimics software and Geomagic software were used to read the data containing CT images and implantation plan, and to design the individual template. Then the individual template containing the information of needle pathway and face features simultaneously was made through rapid prototyping (RP) technique. All patients received 125I seeds interstitial implantation under the guide of the individual template and CT. The individual templates were positioned easily and accurately, and were stable. After implants, treatment quality evaluation was made by CT and TPS. The seeds and dosages distribution (D90, V100, V150) were well meet the treatment requirement. Clinical practice confirms that this approach can facilitate easier and more accurate implantation. (author)

2012-01-01

59

Proposal for a predictive model of erectile function after permanent (125)I prostate brachytherapy for localized prostate cancer.  

UK PubMed Central (United Kingdom)

To determine the risk factors for EDin men treated by prostate brachytherapy (PB) for localized prostate cancer and to propose a model to predict post-implant erectile function. Out of a series of 270 sexually active men treated by PB, 241 (89%) (mean age=66 years (range, 43-80)) accepted to participate in a mail-based study on erectile function. The risk factors for erectile dysfunction were determined by regression analysis and a predictive model was proposed. The performance of the model was determined in this population and subsequently verified in a population of 50 men treated by PB in another treatment center. The risk factors for ED after PB were age, the pre-implant IIEF score and prostate volume. In the studied population, the final model to predict a post-treatment IIEF-5 score, using these factors, had a sensitivity of 69% and a specificity of 68% associated to an area under the ROC curve (AUC) of 0.75. The same performance was obtained in another treatment center. Age, pre-implant IIEF-5 score and prostate volume may be used to predict post-implant erectile function in patients treated by PB.

Huyghe E; Delaunay B; Njomnang Soh P; Delannes M; Walschaerts M; Delavierre D; Soulie M; Bachaud JM

2013-07-01

60

The evaluation of short term effect of CT guided radioactive seed 125I implantation in treating pulmonary metastases from gastrointestinal tumor  

International Nuclear Information System (INIS)

Objective: To investigate the short term effect of CT guided radioactive seed 125I implantation in treating pulmonary metastases from gastrointestinal tumor. Methods: 20 patients (male 13, female 7, the age range of 25 to 73, mean age 49±24) with pulmonary metastases from gastrointestinal tumor accepting CT guided radioactive seed 125I implantation were enrolled in this study. Among these patients, no more than 5 pulmonary metastases lesions occurred in any one case, diameters of all lesions were from 0.5 to 3.0 cm with. average 2.8 lesions per case, and the mean diameter of pulmonary metastases was 2.1 cm. 13 cases presented pulmonary metastases only unilaterally, and 7 others were found bilaterally. All primary tumors were confirmed by pathology, and pulmonary metastases were identified by CT or MRI and confirmed through pathology. Under CT guidance, 125I seeds were implanted into pulmonary metastases according to CT based computerized treatment planning in radio-oncology of the treatment planning system (TPS). All cases were observed two months after the treatment. Results: Among 56 pulmonary metastases in 20 patients, 32 obtained CR, 19 PR, 5 NC. The responsive rate was 91.1%. During follow up, no mortality occurred, but with complications of pneumothorax in 2 cases, bloody sputum in 2 cases, hemothorax in 1 case. Conclusions: CT guided radioactive seed 125I implantation procedure possesses satisfied clinical effects in treating pulmonary metastases from gastrointestinal tumor with minimal damage and few complications, especially in these patients with no more than 5 pulmonary metastases, and less than 3.0 cm in diameter. (authors)

2006-01-01

 
 
 
 
61

Transnasal permanent interstitial implantation for carcinoma of the nasopharynx  

Energy Technology Data Exchange (ETDEWEB)

A technique for transnasal permanent interstitial implantation of the nasopharynx with /sup 125/I seeds is described. This technique allows the precise placement of radioactive sources into mucosal and submucosal tumors, without the need for palatal fenestration. Preliminary results in 10 patients treated by this technique for recurrent nasopharyngeal carcinoma are presented. In the future the authors also hope to employ this technique for delivering ''boost'' irradiation to the primary site, in the initial definitive management of carcinoma of the nasopharynx.

Vikram, B.; Hilaris, B.

1984-01-01

62

Permanent Iodine-125 implants in head and neck cancer.  

UK PubMed Central (United Kingdom)

One hundred twenty-four patients were treated with advanced recurrent head and neck cancer for palliation with radioactive permanent Iodine-125 (125I) implants. Complete regression occurred in 71% of the 118 lesions for which evaluation was possible and greater than 50% regression occurred in 18%; no meaningful regression occurred in 11%. Local recurrence of cancer was subsequently seen in 21% of the lesions which had regressed completely, in 55% of those which had regressed incompletely, and in 100% of those which had not regressed. The incidence of serious complications was 5.5%. Overall, in 64% of the instances the implanted lesions remained controlled until the patient's death, usually due to progression of cancer elsewhere in the body. It is concluded that permanent 125I implants offer useful palliation to the patient with recurrent head and neck cancer with a minimum of toxicity and inconvenience. Because of their low toxicity even after prior full-course external radiation therapy, the authors are currently investigating their use as planned adjunct to external radiation therapy and chemotherapy in the initial definitive management of patients with locally advanced head and neck cancer.

Vikram B; Hilaris BS; Anderson L; Strong EW

1983-04-01

63

Prostate specific antigen (PSA) kinetics after 125I seed implantation (permanent Brachytherapy) for localized prostate cancer  

International Nuclear Information System (INIS)

Prostatic specific antigen (PSA) bounce (over 0.1 ng/ml) was observed in 25.7% of patients (18 of 70) within 30 month after brachytherapy in our series. Several reports demonstrated that PSA bounce was observed in 30-50% of patients, observed within 2 years after brachytherapy and continued following 1 year. PSA bounce should be considered when assessing a patient with a rising PSA level before PSA nadir was achieved 4-5 years after brachytherapy. (author)

2007-01-01

64

Evaluation of CT-guided 125I seed implantation combined with transcatheter arterial chemoembolization in treating portal vein tumor thrombus associated with hepatocellular carcinoma  

International Nuclear Information System (INIS)

Objective: To discuss the therapeutic effect of CT-guided 125I seed implantation combined with transcatheter arterial chemo embolization (TACE) for the treatment of portal vein tumor thrombus (PVTT) associated with hepatocellular carcinoma (HCC). Methods: A total of 58 patients with confirmed HCC accompanied by PVTT were enrolled in this study. Of the 58 patients, CT-guided 125I seed implantation together with TACE was performed in 26 (group A), while only TACE was employed in 32 (group B). The clinical data were retrospectively analyzed and the therapeutic results were compared between two groups. Results: For group A, the one-year and two-year survival rate was 42.3% and 23.0% respectively, with a mean survival time of 15.5 months. Of the 26 patients in group A, the complete remission (CR) was obtained in 3, partial remission (PR) in 9, with a total effective rate (CR + PR) of 46.2% (12 /26). While in group B, the one-year and two-year survival rate was 21.9% and 6.3% respectively, with a mean survival time of 7.5 months. And CR was obtained in 2 cases, PR in 6 cases,with a total effective rate (CR + PR) of 25% (8/32). Both the survival rate and the total effectiveness of group A were significant higher than that of group B (P 125I seed implantation combined with transcatheter arterial chemo embolization can markedly improve the therapeutic effect for portal vein tumor thrombus associated with hepatocellular carcinoma. (authors)

2010-01-01

65

Refractory Nasopharyngeal Carcinoma: Positron Emission Tomography Combined with Computed Tomography-Guided 125I Seed Implantation Therapy after Repeated Traditional Radiochemotherapy.  

UK PubMed Central (United Kingdom)

Objective To evaluate the feasibility of positron emission tomography combined with computed tomography (PET-CT)-guided (125)I seed implantation in the treatment of patients with refractory nasopharyngeal carcinoma after repeated traditional radiochemotherapy. Study Design Case series with chart review. Setting University medical center. Subjects and Methods A total of 26 patients (18 men, 8 women; mean age, 51.3 ± 10.8 years; totaling 53 lesions with an average diameter of 2.86 ± 1.61 cm) were treated by PET-CT-guided (125)I seed implantation. All of the patients received a PET-CT scan 2 months after the treatment. Follow-up was conducted for ~2 to 43 months (median, 28.2 months) to observe the local control rate, overall survival rate, and clinical complications. Results The local control rates of refractory nasopharyngeal carcinoma after repeated traditional radiochemotherapy after 3, 6, 12, 24, and 36 months were 90.6% (48/53), 79.3% (42/53), 71.7% (38/53), 62.3% (33/53), and 56.6% (30/53), respectively. The overall 1-, 2-, and 3-year survival rates were 87.2%, 71.3%, and 56.5%, respectively, with a median survival time of 28.2 months. Of all patients, 19.2% (5/26) died of local recurrence and 15.4% (4/26) died of metastases. One patient died of hypertensive cerebral hemorrhage, and another patient died from cachexia and infection. The long-term complications included hyperpigmentation at operative sites (n = 5), insensible feeling on the lateral cheek (n = 2), dryness of the oral cavity (n = 1), and headache (n = 1). Conclusion PET-CT-guided (125)I seed implantation is an acceptable and feasible method for treating refractory nasopharyngeal carcinoma with minimal damage and few complications.

Zhang F; Wu K; Gao F; Zhang W; Shi F; Li C

2013-09-01

66

Refractory Nasopharyngeal Carcinoma: Positron Emission Tomography Combined with Computed Tomography-Guided 125I Seed Implantation Therapy after Repeated Traditional Radiochemotherapy.  

Science.gov (United States)

Objective To evaluate the feasibility of positron emission tomography combined with computed tomography (PET-CT)-guided (125)I seed implantation in the treatment of patients with refractory nasopharyngeal carcinoma after repeated traditional radiochemotherapy. Study Design Case series with chart review. Setting University medical center. Subjects and Methods A total of 26 patients (18 men, 8 women; mean age, 51.3 ± 10.8 years; totaling 53 lesions with an average diameter of 2.86 ± 1.61 cm) were treated by PET-CT-guided (125)I seed implantation. All of the patients received a PET-CT scan 2 months after the treatment. Follow-up was conducted for ~2 to 43 months (median, 28.2 months) to observe the local control rate, overall survival rate, and clinical complications. Results The local control rates of refractory nasopharyngeal carcinoma after repeated traditional radiochemotherapy after 3, 6, 12, 24, and 36 months were 90.6% (48/53), 79.3% (42/53), 71.7% (38/53), 62.3% (33/53), and 56.6% (30/53), respectively. The overall 1-, 2-, and 3-year survival rates were 87.2%, 71.3%, and 56.5%, respectively, with a median survival time of 28.2 months. Of all patients, 19.2% (5/26) died of local recurrence and 15.4% (4/26) died of metastases. One patient died of hypertensive cerebral hemorrhage, and another patient died from cachexia and infection. The long-term complications included hyperpigmentation at operative sites (n = 5), insensible feeling on the lateral cheek (n = 2), dryness of the oral cavity (n = 1), and headache (n = 1). Conclusion PET-CT-guided (125)I seed implantation is an acceptable and feasible method for treating refractory nasopharyngeal carcinoma with minimal damage and few complications. PMID:23715683

Zhang, Fujun; Wu, Ketong; Gao, Fei; Zhang, Weidong; Shi, Feng; Li, Chuanxing

2013-05-28

67

Influence of 125I seeds para-tracheal implantation on serum level of inflammatory cytokines IL-1?, IL-6 and TNF-? in rabbits  

International Nuclear Information System (INIS)

Objective: To evaluate the influence of 125I seeds para-tracheal implant on serum level of inflammatory cytokines in rabbits. Methods: 30 rabbits were randomized to 5 groups, 4 study groups and control group. The activities of seeds in study groups ranged from 11.1 MBq (0.3 mCi) to 33.3 MBq (0.9 mCi), and D90 were 21.1 to 139.0 Gy. The false seeds were used in control group. Four seeds with equal activity were implanted between trachea and esophagus in each rabbit under general anesthesia. The seeds were arranged according to the Paris principle. Serum samples were collected prior to, 30, 60 and 90 days after implantation. IL-1?, IL-6 and TNF-? levels were measured by ELISA. Results: All rabbits were healthy and had weight gaining during study period except 5 died. Serum levels of IL-1?, IL-6 and TNF-? at the end of the first, second and third month were all slightly higher than those of pretreatment. However, there was no statistical significance among them except for group 2. Conclusions: Interstitial brachytherapy with 125I seeds might not significantly produce systematic inflammatory reaction on rabbits. (authors)

2007-01-01

68

Dosimetric characteristics of three new design {sup 125}I brachytherapy sources  

Energy Technology Data Exchange (ETDEWEB)

For roughly 25 years, {sup 125}I sources have been used in the treatment of various malignant diseases such as prostate cancer. Three new brachytherapy sources, IR01-{sup 125}I, IR02-{sup 125}I and IR03-{sup 125}I, have been developed and are designed for permanent implant application. The Monte Carlo radiation transport code version MCNP 5 was used to calculate the dosimetry parameters around the sources in accordance with the updated report of the American Association of Physicists in Medicine (AAPM), Task Group No. 43. For each source, the dose rate constant {lambda}, the radial dose function g{sub L}(r), and the anisotropy function F(r, {theta}), were obtained. The results indicated a dose rate constant of 0.932 {+-} 0.01, 0.934 {+-} 0.01 and 0.939 {+-} 0.01 Gy h{sup -1} U{sup -1} for the IR01-{sup 125}I, IR02-{sup 125}I and IR03-{sup 125}I sources respectively. With the goal of determining an optimal design for a {sup 125}I source, each seed's parameters were compared with other seeds. In this study, the optimal source IR03-{sup 125}I provides the most isotropic dose distribution in water. Finally, the results for optimal source were compared with published results for those of other commercial sources. (orig.)

Khanmohammadi, Zahra [Islamic Azad Univ., Tehran (Iran, Islamic Republic of). Science and Research Branch; Sadeghi, Mahdi [Agricultural, Medical and Industrial Research School, Karaj (Iran, Islamic Republic of). Nuclear Science and Technology Research Institute

2011-11-15

69

[Permanent implant prostate cancer brachytherapy].  

UK PubMed Central (United Kingdom)

With an experience of more than 20 years for the pionneers (and more than 10 years in France), permanent implant brachytherapy using Iodin 125 seeds is now recognized as a valuable alternative therapy for localized low-risk prostate cancer patients. An extension of the indications of exclusive brachytherapy towards selected patients in the intermediate-risk group is presently under study. Moreover, for patients in the high-risk group, brachytherapy, as an addition to external radiotherapy, could represent one of the best way to escalate the dose for some patients. Various permanent implant brachytherapy techniques have been proposed; preplanning or real-time techniques, loose seeds or stranded seeds, manual or automatic injection of the seeds. The main point here is the ability to perfectly master the procedure and to comply with the dosimetric constraints which have been recently redefined by the Groupe européen de curiethérapie--European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) group. Mid- and long-term results which are now available in the literature indicate relapse-free survival of about 90% at 5-10 years, the best results being obtained with satisfactory dosimetric data. Some comparative data have shown that the incontinence and impotence rates after brachytherapy seemed to be significantly inferior to what is currently observed after surgery. However, a risk of about 3-5% of urinary retention is usually reported after brachytherapy, as well as an irritative urinary syndrome which may be significant and last several months. In spite of those drawbacks, with excellent long-term results and low rates of incontinence and impotence, brachytherapy can be expected to be proposed to an increasing number of patients in France in the next future.

Cosset JM; Flam T; Thiounn N; Pontvert D; Pierrat N; Vallancien G; Chauveinc L

2008-11-01

70

Relationship of pretreatment transurethral resection of the prostate to survival without distant metastases in patients treated with 125I-implantation for localized prostatic cancer  

International Nuclear Information System (INIS)

The authors assessed the relationship between transurethral resection of the prostate (TURP) and the probability of survival without distant metastases (survival) in patients with clinically localized prostatic cancer. Fifty-eight patients with obstructive voiding symptoms who underwent TURP within 12 months before pelvic lymphadenectomy and 125I-implantation were compared with 131 patients who did not require TURP before implantation. None received other treatment for the tumor. The overall survivals for the two groups were not significantly different, P greater than 0.1. When stratified by tumor grade or the presence or absence of pelvic lymph node metastases, the survivals for the two groups were also similar, P . greater than 0.1. However, survival associated with Stage C tumors was greater in the No TURP than in the TURP group (P . 0.003), and survival associated with Stage C tumors was greater in the TURP than in the No TURP group (P . 0.005). These data fail to provide convincing evidence that transurethral resection of prostatic cancers has an unfavorable impact on disease progression

1984-05-01

71

Relationship of pretreatment transurethral resection of the prostate to survival without distant metastases in patients treated with /sup 125/I-implantation for localized prostatic cancer  

Energy Technology Data Exchange (ETDEWEB)

The authors assessed the relationship between transurethral resection of the prostate (TURP) and the probability of survival without distant metastases (survival) in patients with clinically localized prostatic cancer. Fifty-eight patients with obstructive voiding symptoms who underwent TURP within 12 months before pelvic lymphadenectomy and /sup 125/I-implantation were compared with 131 patients who did not require TURP before implantation. None received other treatment for the tumor. The overall survivals for the two groups were not significantly different, P greater than 0.1. When stratified by tumor grade or the presence or absence of pelvic lymph node metastases, the survivals for the two groups were also similar, P . greater than 0.1. However, survival associated with Stage C tumors was greater in the No TURP than in the TURP group (P . 0.003), and survival associated with Stage C tumors was greater in the TURP than in the No TURP group (P . 0.005). These data fail to provide convincing evidence that transurethral resection of prostatic cancers has an unfavorable impact on disease progression.

Fowler, J.E. Jr.; Fisher, H.A.; Kaiser, D.L.; Whitmore, W.F. Jr.

1984-05-01

72

Clinical application of permanent implantation of iodine 125 seeds for osseous metastases  

International Nuclear Information System (INIS)

Objective: To evaluate the clinical efficacy of permanent implantation of iodine 125 seeds in the treatment of osseous metastases. Methods: Radioactive iodine 125 seeds were implanted permanently in 32 lesions of 25 patients with osseous metastases of different origins. The ostalgia-relieving degree and the imaging alterations of the osseous metastasis lesions were observed. Results: The effective pain-relieving rate was 92% caused by permanent implantation of iodine 125 seeds. Of al 1 the patients, 15 patients achieved complete response, 8 patients obtained partial response (PR), and 2 patients had no change. The pain grade was decreased significantly after the treatment (P125I seeds has a definite effect on tumor metastasis and caused minimal damage and few complications. It is worthy of popularization in clinic. (authors)

2010-01-01

73

The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 125I implantation  

Energy Technology Data Exchange (ETDEWEB)

The study evaluates the effect of the locally recurring tumor on the incidence of metastatic disease in early stage carcinoma of the prostate. The probability of distant metastases was studied in 679 patients with Stage B-C/N0 carcinoma of the prostate treated at MSKCC between 1970 and 1985 (median follow-up of 97 months). Patients were staged with pelvic lymph node dissection and treated with retropubic 125I implantation. The actuarial distant metastases free survival (DMFS) for patients at risk at 15 years after initial therapy was 37%. Cox proportional hazard regression analysis of covariates affecting the metastatic outcome showed that local failure, used in the model as a time dependent variable, was the most significant covariate, although stage, grade, and implant volume were also found to be independent variables. The relative risk of metastatic spread subsequent to local failure was 4-fold increased compared to the risk without evidence of local relapse. The 15-year actuarial DMFS in 351 patients with local control was 77% compared to 24% in 328 patients who developed local relapses (p less than 0.00001). The relation of distant spread to the local outcome was observed regardless of stage, grade, or implant dose. Even stage B1/N0-Grade I patient with local control showed a 15-year actuarial DMFS of 82%, compared to 22% in patients with local relapse (p less than 0.00001). The median local relapse-free survival (LRFS) in the 268 patients with local recurrences who did not receive hormonal therapy before distant metastases were detected was 51 months, compared to a median of 71 months for DMFS in the same patients (p less than 0.001), consistent with the possibility that distant dissemination may develop secondary to local failure.

Fuks, Z.; Leibel, S.A.; Wallner, K.E.; Begg, C.B.; Fair, W.R.; Anderson, L.L.; Hilaris, B.S.; Whitmore, W.F. (Memorial Sloan-Kettering Cancer Center, New York, NY (USA))

1991-08-01

74

The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 125I implantation  

International Nuclear Information System (INIS)

The study evaluates the effect of the locally recurring tumor on the incidence of metastatic disease in early stage carcinoma of the prostate. The probability of distant metastases was studied in 679 patients with Stage B-C/N0 carcinoma of the prostate treated at MSKCC between 1970 and 1985 (median follow-up of 97 months). Patients were staged with pelvic lymph node dissection and treated with retropubic 125I implantation. The actuarial distant metastases free survival (DMFS) for patients at risk at 15 years after initial therapy was 37%. Cox proportional hazard regression analysis of covariates affecting the metastatic outcome showed that local failure, used in the model as a time dependent variable, was the most significant covariate, although stage, grade, and implant volume were also found to be independent variables. The relative risk of metastatic spread subsequent to local failure was 4-fold increased compared to the risk without evidence of local relapse. The 15-year actuarial DMFS in 351 patients with local control was 77% compared to 24% in 328 patients who developed local relapses (p less than 0.00001). The relation of distant spread to the local outcome was observed regardless of stage, grade, or implant dose. Even stage B1/N0-Grade I patient with local control showed a 15-year actuarial DMFS of 82%, compared to 22% in patients with local relapse (p less than 0.00001). The median local relapse-free survival (LRFS) in the 268 patients with local recurrences who did not receive hormonal therapy before distant metastases were detected was 51 months, compared to a median of 71 months for DMFS in the same patients (p less than 0.001), consistent with the possibility that distant dissemination may develop secondary to local failure

1991-01-01

75

Radiation protection after interstitial permanent prostate brachytherapy implants  

Energy Technology Data Exchange (ETDEWEB)

Full text of publication follows: In this study we measure patients radiation exposure dose after interstitial {sup 125}I permanent prostate Brachytherapy implants, and correlate it with dose limits for public, total activity implanted, patient preoperative weight(1), distance between prostate walls and anterior skin surface. Methods and Material: We analyse 20 patients who were implanted with {sup 125}I seeds. The instrument used to measure radiation is a calibrated Berthold Umo LB 123 aco-plated to a LB 1236-H10 detector. Three measurements were taken: at the perineal and anterior pelvic zones on contact with the skin and at 1 m from the patient. The maximum value was taken for all measurements. The dose at a distance of one meter is obtained at anterior pelvic zone, perpendicular to the skin, according to the recommendations of A.A.P.M.(1). The distance between prostate walls was determined using post -operative CT images. Results: The doses at the perineal zone have determined an average of 186 {mu}Sv/h (range: 110 340 {mu}Sv/h) and at surface pelvic zone of 41 {mu}Sv/h (range: 15 103 {mu}Sv/h). The dose at a distance of 1 meter has an average value of 0.4 {mu}Sv/h (range: 0.2 1.0 {mu}Sv/h). The average total activity implanted was 25 mCi (range: 17 38 mCi). The distance between prostate walls and skin pelvic surface of the patients has an average value of 8.9 cm (range: 6.6 -11.5 cm). At a distance of 1 meter from the pelvic zone the dose measured is very low and below dose limits imposed by the European Directive EURATOM 2 and the Portuguese law. For general public to reach annual dose limit (EURATOM - 1 mSv/year) when contacting the pelvic zone, we extrapolate that 4 days (range: 1.6 11.1 days) would be needed, assuming a daily contact period of 6 hours. Conclusion: We established a correlation between the distance of prostate walls to the skin perineal surface and the total dose, but we find no correlation between measured doses, total activity implanted and patient weight. Our results show that recommendations to the patients must be very careful, stating that all contact must be as short as possible, at least in the first {sup 125}I half life period. References: (1) Yan Yu et all., 'Permanent prostate seed implant brachytherapy: report of the A.A.P.M. - TG 64', Med. Phys, 26 (10), pp. 2054-2076, 1999. (2) S. Smathers, et all., 'Radiation safety parameters following prostate brachytherapy', Int. J. Rad. Onc. Biol. Phys. Vol 45, no 2, pp. 397 -399, 1999. (3) Council Directive 97/43/EURATOM of 30 of June. (authors)

Pirraco, R.; Pereira, A.; Cavaco, A. [Instituto Portugues de Oncologia Francisco Gentil - Centro R egional de Oncologia do Porto, SA, Porto (Portugal)

2006-07-01

76

Monte Carlo calculated doses to treatment volumes and organs at risk for permanent implant lung brachytherapy  

Science.gov (United States)

Iodine-125 (125I) and Caesium-131 (131Cs) brachytherapy have been used with sublobar resection to treat stage I non-small cell lung cancer and other radionuclides, 169Yb and 103Pd, are considered for these treatments. This work investigates the dosimetry of permanent implant lung brachytherapy for a range of source energies and various implant sites in the lung. Monte Carlo calculated doses are calculated in a patient CT-derived computational phantom using the EGsnrc user-code BrachyDose. Calculations are performed for 103Pd, 125I, 131Cs seeds and 50 and 100 keV point sources for 17 implant positions. Doses to treatment volumes, ipsilateral lung, aorta, and heart are determined and compared to those determined using the TG-43 approach. Considerable variation with source energy and differences between model-based and TG-43 doses are found for both treatment volumes and organs. Doses to the heart and aorta generally increase with increasing source energy. TG-43 underestimates the dose to the heart and aorta for all implants except those nearest to these organs where the dose is overestimated. Results suggest that model-based dose calculations are crucial for selecting prescription doses, comparing clinical endpoints, and studying radiobiological effects for permanent implant lung brachytherapy.

Sutherland, J. G. H.; Furutani, K. M.; Thomson, R. M.

2013-10-01

77

Tumor interventional therapy using 125I seed  

International Nuclear Information System (INIS)

Objective: To explore the feasibility, safety, and effect of interventional technology for inserting 125I seeds into tumor focus and to study the advantage or shortcome of different image equipment used in seed implantation. Methods: Fifteen cases of advanced stage tumor with metastasis and another 15 cases of advanced unresectable esophageal cancer were enrolled. Method of seed implantation was carried out by inserting 125I seeds into tumor foci through percutaneous puncture under ultrasound or CT guidance, and placed the esophageal stent binding with 125I seed to the diseased esophageal segment under DSA. Results: All 125I seeds were successfully released to the target places under ultrasound, CT and DSA guidance, except one seed was found to be lost from one esophageal 125I seed irradiated stent due to misoperation. A follow-up showed obvious improvement of clinical symptom, no significant changes of hemogram, immunity markers, and no complications including esophageal perforation, hemorrhage, and skin necrosis. No radiation seeds shedded during the releasing processes by ECT. One month follow-up by CT showed the target places were thinned in 13 cases, thickened in 2 cases. 3 cases had been followed-up for 13 months, CT revealed the obvious thinning of the foci. Three-month follow up with gastroendoscopy and biopsy demonstrated that the foci within the 125I seede binding stent placement segment resolved markedly, with no tumor cells found in biopsy for 3 of 5 cases. 15 cases by percutaneous puncture implantation had been followed-up for two months, showed the foci becoming obviously small under diagnostic imaging. Conclusions: It is feasible and safe to insert 125I seeds into tumor foci by interventional technology and the confirmed effect is favorable. (authors)

2005-01-01

78

The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation.  

Science.gov (United States)

The study evaluates the effect of the locally recurring tumor on the incidence of metastatic disease in early stage carcinoma of the prostate. The probability of distant metastases was studied in 679 patients with Stage B-C/N0 carcinoma of the prostate treated at MSKCC between 1970 and 1985 (median follow-up of 97 months). Patients were staged with pelvic lymph node dissection and treated with retropubic 125I implantation. The actuarial distant metastases free survival (DMFS) for patients at risk at 15 years after initial therapy was 37%. Cox proportional hazard regression analysis of covariates affecting the metastatic outcome showed that local failure, used in the model as a time dependent variable, was the most significant covariate, although stage, grade, and implant volume were also found to be independent variables. The relative risk of metastatic spread subsequent to local failure was 4-fold increased compared to the risk without evidence of local relapse. The 15-year actuarial DMFS in 351 patients with local control was 77% compared to 24% in 328 patients who developed local relapses (p less than 0.00001). The relation of distant spread to the local outcome was observed regardless of stage, grade, or implant dose. Even stage B1/N0-Grade I patient with local control showed a 15-year actuarial DMFS of 82%, compared to 22% in patients with local relapse; p less than 0.00001). The median local relapse-free survival (LRFS) in the 268 patients with local recurrences who did not receive hormonal therapy before distant metastases were detected was 51 months, compared to a median of 71 months for DMFS in the same patients (p less than 0.001), consistent with the possibility that distant dissemination may develop secondary to local failure. Furthermore, distant metastases in patients with local control, apparently already existing as micrometastases before treatment, were detected earlier (median DMFS of 37 months) than in patients with local relapse (median DMFS of 54 months; p = 0.009). These data suggest that the existence and re-growth of local residual disease in localized prostatic carcinoma promotes an enhanced spread of metastatic disease, and that early and complete eradication of the primary tumor is required if a long term cure is to be achieved, although the clinical expression of secondary metastases may not become apparent for 6.5 years or more in one-half of the patients. PMID:1869452

Fuks, Z; Leibel, S A; Wallner, K E; Begg, C B; Fair, W R; Anderson, L L; Hilaris, B S; Whitmore, W F

1991-08-01

79

Standardization of 125I and 238Pu.  

Science.gov (United States)

A simple distance-variable detection table on which two detectors can be mounted and moved back and forth facing each other centred on a sample source has been constructed for photon-photon and alpha-photon coincidence counting for 125I and 238Pu, respectively. Two NaI(Tl) detectors were used for the standardization of 125I. A Si detector and an NaI(Tl) detector were employed for the standardization of 238Pu. The NaI(Tl) detectors have a very thin aluminium window for measuring low-energy photons from 125I and 238Pu while the Si-detector is a usable-in-air ion-implanted detector for alpha particles from 238Pu. A thin collodion film was used for 238Pu samples, whereas a thick polyester film was used for 125I samples to prevent 125I from leaking from the sample. The key comparison result of 125I showed good agreement, and the result of 238Pu was also compared with that of liquid scintillation counting. PMID:14987674

Lee, J M; Lee, K B; Lee, M K; Oh, P J; Park, T S; Hwang, H Y

80

Standardization of 125I and 238Pu.  

UK PubMed Central (United Kingdom)

A simple distance-variable detection table on which two detectors can be mounted and moved back and forth facing each other centred on a sample source has been constructed for photon-photon and alpha-photon coincidence counting for 125I and 238Pu, respectively. Two NaI(Tl) detectors were used for the standardization of 125I. A Si detector and an NaI(Tl) detector were employed for the standardization of 238Pu. The NaI(Tl) detectors have a very thin aluminium window for measuring low-energy photons from 125I and 238Pu while the Si-detector is a usable-in-air ion-implanted detector for alpha particles from 238Pu. A thin collodion film was used for 238Pu samples, whereas a thick polyester film was used for 125I samples to prevent 125I from leaking from the sample. The key comparison result of 125I showed good agreement, and the result of 238Pu was also compared with that of liquid scintillation counting.

Lee JM; Lee KB; Lee MK; Oh PJ; Park TS; Hwang HY

2004-02-01

 
 
 
 
81

Occupational exposure of professionals during interstitial permanent prostate brachytherapy implants  

Energy Technology Data Exchange (ETDEWEB)

Full text of publication follows: Introduction: In this study we present dose measurements for professionals exposed during interstitial 125 I permanent prostate brachytherapy implants. Methods and Materials: The implant technique used was intra operative real time using strand and loose seeds. The professionals inside the operating room are an oncologist, a radiologist, a physicist, a nurse and an anesthesiologist. The oncologist and the physicist contact directly the loaded needle with radioactive seeds and two types of measurements were taken: total body and extremities (finger) dose. The rest of the team operates at long distances, but measurements were made. To measure total body equivalent dose we use a Berthold Umo LB 123 coupled with a LB 1236-H10 detector, and we recorded dose, time and distance from implant location. Finger dosemeters are thermo -luminescent dosimeter (TLD) rings that were controlled over one month. Results: 50 cases (average number of applications per year) were analysed for extremities measurements and 9 cases for total body measurements (in this case, the results were extrapolated for 50 cases), with an average of 26.1 mCi total activity per implant (in a range of 17.4 - 40.3 mCi). The finger dose was 1.8 mSv for the oncologist and 1.9 mSv for the physicist. The interpolation of total body equivalent dose for the oncologist was 24 mSv, for the radiologist 6 mSv and 9 mSv for the physicist. The rest of the team did not receive anything but background radiation. The annual national limit dose for workers is 20 mSv for total body irradiation, and 500 mSv for extremities. Conclusion: In conclusion we may say that during interstitial permanent prostate brachytherapy implants, total doses received for all groups are not significant when compared to annual limits for Portuguese laws 1. Even so, our main goal is always to get the less possible dose (ALARA principle). References: 1. Decreto Lei n. 180/2002 de 8 de Agosto. (authors)

Pirraco, R.; Pereira, A.; Viterbo, T.; Cavaco, A. [Instituto Portugues de Oncologia Francisco Gentil, Centro R egional de Oncologia do Porto, SA, Porto (Portugal)

2006-07-01

82

Low energy radionuclides for permanent interstitial implantation.  

UK PubMed Central (United Kingdom)

An analysis of 318 permanent implants was carried out in an attempt to establish the effectiveness of iodine 125 as compared with radon 222 and iridium 192; and to derive dose-response curves for iodine 125. Analysis of the clinical results obtained with iodine 125 in comparison with radon 222 and iridium 192 in selected anatomical sites demonstrated that iodine 125 has a higher therapeutic ratio than the other two radionuclides. A tumor control rate of at least 80% with iodine 125 implants might be expected after a good geometrical dose distribution, with a planned initial minimum tumor dose of at least 14,000 +/- 2,000 rads. Rapid tumor shrinkage ensures a more or less steady or even increased dose rate over a period of several weeks and improves the local tumor control. Tumors with a longer cell cycle are especially susceptible to irradiation with radionuclides of long half-lives.

Hilaris BS; Kim JH; Tokita N

1976-01-01

83

Post implant dosimetric evaluation of I-125 permanent prostate implants  

International Nuclear Information System (INIS)

Purpose/Objective: To evaluate the dosimetric quality of ultrasound (US) guided I-125 permanent seed implants for prostate cancer planned using preimplant US images and reconstructed using postimplant CT images. Materials and Methods: Preimplant US images were used to calculate I-125 seed locations on a 0.5 cm grid with parallel needle positions, to obtain the prescription dose to a 5 mm margin around the prostate. Patients were implanted with I-125 seeds in the operating room using a Mick applicator and free hand guidance of the needles/seeds using a 0.5 cm grid template on the ultrasound images. The clearly visualized needle tip in the saggital images was used to determine the seed drop off position. Patients were simulated on a conventional and a CT simulator within 24 hours of the implant. Prostate contours were outlined on the CT images by the radiation oncologist. Seed positions reconstructed from CT images and verified with localization films were used to generate post implant dose distributions. Dose volume histograms of the implant and the prostate were used to obtain the following parameters which were subsequently used to evaluate the quality of the implants: (i) prostate volume covered by prescription dose (PVPD), (ii) implant volume of prescription dose (IVPD), (iii) minimum peripheral dose (MPD), and (iv) heterogeneity index (HI). Results: The table below lists the various dosimetric parameters used for evaluating the implants, for three representative cases. Conclusions: In spite of the observed deviations in the seed locations from the preplan, the implant volumes of the prescription dose were comparable in the pre and post plans. The postimplant CT volumes were consistently larger than the preimplant US volumes. Even though the implant volumes were consistently larger than the postimplant CT prostate volumes, the fraction of the prostate receiving the prescription dose ranged from 75% to 95%, which is consistent with other studies published in the literature. This could be due to either a difference in the US and CT prostate shapes and volumes, or a geometrical mispositioning of the seeds. The areas of the prostate receiving less than the prescribed dose were found to be randomly distributed in all cases. Our implant procedure, based on US based preplanning and CT based postplanning is seen to be comparable to those practised at other centers. Deviations from planned dose distributions most likely indicate the limitations of this concept, which could be overcome by on-line postimplant dose verification and correction in the OR or re-implantation at a later time.

1997-01-01

84

Radiation protection procedures and dose to the staff in brachytherapy with permanent implant of the sources  

Energy Technology Data Exchange (ETDEWEB)

The treatment of intra capsular prostate cancers with the permanent implantation of low energy sealed radioactive sources (''103 Pd-''125I) offers the same probability of curing the tumours as surgery and external-beam radiotherapy with a minimum incidence of unwanted side-effects. The first attempts of using sealed sources for treating prostate cancers go back to 1917, when Barringer reported the results obtained with the implant of ''236Ra needles. Beginning from that period the interest for prostate brachytherapy has shown a fluctuating trend, due especially to the technological possibilities and to the status of the alternative treatment modalities (surgery, external radiotherapy). The main reason of the substantial failure of brachytherapy as compared to the two other treatment modalities had two main causes: the energy, too high ( E{approx_equal} 840 keV), of {gamma}-radiation emitted by ''226 Ra in equilibrium with its decay products and the lack of imaging techniques able to visualize with sufficient accuracy both the prostate and the arrangement, inside it, of the radioactive sources. The employ of low energy {gamma}-emitting radionuclides began in 1974, when Whitmore et al. working at the Sloan Kettering Memorial Cancer Hospital of New York suggested the use of ''125 I sealed sources for the realisation of interstitial permanent implants. Also this attempt, though reducing the side effects typical of the surgical intervention (incontinence, impotence), did non give the expected results in terms of local control of the disease and, as a consequence, of the survival's length. This partial failure was attributed to the fact that, in most cases the dose distribution inside the target volume was not homogeneous, due to the inadequacy of the available imaging techniques used for checking the real position of the sources, during their manual insertion in the tissues. In the last ten years,however, great progresses have been made in the US{sub i}maging techniques, in the manufacture of suitable sealed sources of ''103 Pd and ''125 I, in the development of computer programs able both to acquire US-images and to calculate and display in real time the dose distribution. In selected cases, the permanent implant of such sources has demonstrated of being alternative to the surgical intervention and even to external conformal radiotherapy. (Author)

Tosi, G.; Cattani, F.

2002-07-01

85

Iodine-125 Seed Implantation (Permanent Brachytherapy) for Clinically Localized Prostate Cancer  

Directory of Open Access Journals (Sweden)

Full Text Available From January 2004 to March 2007, 308 patients with clinically localized prostate cancer were treated using iodine-125 (125I) seed implantation (permanent brachytherapy) at Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. We evaluated the treatment’s effi cacy and morbidity in 300 prostate cancer patients who were followed up for more than 1 month after brachytherapy. Based on the National Comprehensive Cancer Network (NCCN) guidelines, patients with a prostate volume of less than 40 ml in transrectal ultrasound imaging were classifi ed as low or intermediate risk. The median patient age was 67 years (range 50 to 79 years), the median prostate-specific antigen (PSA) value before biopsy was 6.95 ng/ml (range 1.13 to 24.7 ng/ml), and the median prostate volume was 24.33 ml (range 9.3 to 41.76 ml). The median follow-up was 18 months (range 1 to 36 months) and the PSA levels decreased in almost all patients after brachytherapy. Although 194 of 300 patients (64.7%) complained of diffi culty in urination, pollakisuria/urgency, miction pain, and/or urinary incontinence, all of which might be associated with radiation prostatitis during the fi rst month after brachytherapy, these symptoms gradually improved. 125I seed implantation brachytherapy is safe and eff ective for localized prostate cancer within short-term follow up.

Ebara,Shin; Katayama,Yoshihisa; Tanimoto,Ryuta; Edamura,Kohei; Nose,Hiroyuki; Manabe,Daisuke; Kobayashi,Tomoko; Kobayashi,Yasuyuki; Kobuke,Makoto; Takemoto,Mitsuhiro; Saika,Takeshi; Nasu,Yasutomo; Kanazawa,Susumu; Kumon,Hiromi

2008-01-01

86

Measured transverse-axis dosimetric parameters of the model STM1251 125I interstitial source.  

UK PubMed Central (United Kingdom)

The recent popularity of permanent implants for treatment of prostate cancer has created a large demand for low energy seed sources. Vendors have introduced new source designs to meet this demand. The AAPM has recommended that all low energy interstitial brachytherapy seed sources be subjected to independent dosimetric evaluations, preferably using experimental measurements as well as Monte Carlo calculations. This work presents the results of Thermo-Luminescence Dosimeter (TLD) measurements of dosimetric parameters on the transverse axis of a new 125I seed source, the Source Tech Medical STM1251 125I seed. Experimental measurements were performed in a Solid Water phantom, with the results corrected to values for liquid water using Monte Carlo calculated correction factors. The parameters measured include the dose rate constant and values of the radial dose function at distances of 0.5 cm through 5 cm. The measured dose rate constant in liquid water for the STM1251 125I seed was 1.039 cGy/U-hr. Measured radial dose function values agreed with Monte Carlo calculated ones to within 10%. These measurements therefore confirm the modeling and simulation of Monte Carlo calculations for this 125I source design, within the statistical uncertainties of the calculation and measurement techniques.

Li Z; Williamson JF

2002-01-01

87

Prophylactic urethral stenting with Memokath® 028SW in prostate cancer patients undergoing prostate 125I seed implants: phase I/II study  

Directory of Open Access Journals (Sweden)

Full Text Available Purpose: To study the feasibility/toxicity of urethral stenting with the Memokath® 028SW stent in patients undergoing prostate implant (PI) for prostate adenocarcinoma. Material and methods: An Investigational Device Exemption from the Food and Drug Administration (FDA) and institutional review board (IRB) approval were obtained. Twenty patients enrolled. Baseline American Urological Association (AUA) score was obtained prior to PI. Follow-up information was obtained with weekly phone calls for the first 12 weeks and biweekly calls for the next 12 weeks to assess toxicity and AUA score. Removal of the stent was planned at six months after PI, or earlier due to excessive toxicity/patient request. Results: Median age was 66.5 years. The median prostate volume was 39 cc (range: 10-90). The median baseline AUA score was 7.5 (range: 1-21). Three patients required intermittent self-catheterization (ISC) within 3 days after PI. No patients required ISC beyond day 3 after PI. The median duration of ISC was 1 day (range: 1-2). AUA scores returned to baseline values 6 weeks after PI. The week 6 AUA score was 10 (range: 4-16). Seven patients (35%) underwent early removal because of patient preference. The reasons were: incontinence (n = 3), discomfort (n = 2), hematuria (n = 1), and obstructive symptoms (n = 1). The median time of stent removal in these patients was 13.9 weeks (range: 0.9-21.4). Thirteen patients (65%) had ISC and/or urinary catheterization post stent removal. Median time for ISC use was 10 days (range: 1-90). Conclusions: Urethral stenting with Memokath® in patients undergoing PI was feasible, but resulted in relatively high rate of urinary incontinence and discomfort. Given the adverse effects experienced by patients of this study, further studies should focus only on patients with highest risk of urinary obstruction from PI or those with obstruction needing ISC.

Samuel T. Chao; Kenneth Angermeier; Eric A. Klein; Chandana A. Reddy; James C. Ulchaker; Andrew Stephenson; Steven Campbell; Jay P. Ciezki

2011-01-01

88

Effects of permanent I-125 interstitial implantation on cortical bone  

International Nuclear Information System (INIS)

From 1973 to 1980, 1427 cancer patients were treated by the Brachytherapy Service, Radiation Oncology Department of Memoral Sloan-Kettering Cancer Center (MSKCC) with I-125 permanent interstitial implantation. Concern has been expressed with regard to the possible toxic effects of the low average photon energy 28 keV) of I-125 on bone, secondary to its increased absorption in these tissues because of the photoelectric effect. In an attempt to address this concern with respect to cortical bone, the authors reviewed pertinent data on those patients whose site of implant was at close proximity to osseous tissue in the pelvic, chest wall and head and neck regions. The review included 74 sites in 58 patients having no prior history or clinical evidence of any pathologic or metabolic bony disorder. Local control rate for the 74 implanted sites was 93%. The implanted activity ranged from 1.6 to 48.8 mCi and the implanted volume from 0.5 to 152 cm3. At this follow-up range, there appears to be no excessive osseous toxicity either clinically or radiologically with I-125 permanent implantation

1984-01-19

89

Effects of permanent I-125 interstitial implantation on cortical bone  

Energy Technology Data Exchange (ETDEWEB)

From 1973 to 1980, 1427 cancer patients were treated by the Brachytherapy Service, Radiation Oncology Department of Memoral Sloan-Kettering Cancer Center (MSKCC) with I-125 permanent interstitial implantation. Concern has been expressed with regard to the possible toxic effects of the low average photon energy 28 keV) of I-125 on bone, secondary to its increased absorption in these tissues because of the photoelectric effect. In an attempt to address this concern with respect to cortical bone, the authors reviewed pertinent data on those patients whose site of implant was at close proximity to osseous tissue in the pelvic, chest wall and head and neck regions. The review included 74 sites in 58 patients having no prior history or clinical evidence of any pathologic or metabolic bony disorder. Local control rate for the 74 implanted sites was 93%. The implanted activity ranged from 1.6 to 48.8 mCi and the implanted volume from 0.5 to 152 cm/sup 3/. At this follow-up range, there appears to be no excessive osseous toxicity either clinically or radiologically with I-125 permanent implantation.

Mandell, L.; Nori, D.; Anderson, L.; Belanich, M.; Hilaris, B.

1985-05-01

90

PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure  

International Nuclear Information System (INIS)

Purpose. To assess the frequency of the PSA 'bouncing' phenomenon after a significant follow-up in a series of patients treated by j permanent implant brachytherapy for a prostate cancer. To look for the clinical and dosimetric parameters possibly linked to this transitory secondary PSA increase. To evaluate in which percentage of cases this bouncing could have mimicked a biochemical relapse according to the ASTRO consensus criteria. Patients and methods. From January 1999, to December 2001, 295 patients were treated by a permanent prostate implantation (real-time technique, with free 125I seeds- Isoseed Bebig-) by the Institut Curie-Hopital Cochin-Hopital Necker Paris group. The mean follow-up is 40.3 months (9--66 months). The PSA level was regularly checked, at least every 6 months. We defined as a 'bouncing' all increase in PSA, starting at 0.1 ng/ml, subsequently followed by a spontaneous (without any treatment) decrease, with return to the previous level or lower. We particularly focused on the patients fulfilling the criteria for a biochemical relapse according to the ASTRO consensus (Three successive increases in PSA). A multivariate analysis tried to identify independent factors among the usual clinical and dosimetric parameters. Results. In our series, 161 patients (55%) showed a transitory PSA increase (bouncing) of at least 0.1 ng/ml; 145 patients (49%) a bouncing of 0.2 ng/ml, 93 patients (32%) a bouncing of 0.4 ng/ml and 43 patients (15%) a bouncing of at least 1 ng/ml. Mean PSA bounce was 0.8 ng/ml (0.1 .1), and mean time to bounce was 19 months. Thirty-two patients (11% of the total number) presented three successive PSA increases with a significant (3 months) interval between the dosages, and therefore were to be considered as being in biochemical relapse according to the ASTRO consensus criteria. Actually, among those 32 patients, 18 (56%) subsequently showed a complete normalization of their PSA, without any treatment. Ten patients went on increasing their PSA, and were considered to be really in biochemical relapse. For the last 4 patients, the situation still remains ambiguous. In multivariate analysis, age 200 Gy (P 200 Gy were found to be independent factors predicting for such a secondary transitory increase in PSA. Interestingly, among 32 patients fulfilling the classical criteria of the ASTRO for a biochemical relapse, 18 (560/0) subsequently showed a spontaneous PSA decrease, demonstrating that the ASTRO consensus is not well adapted to the biochemical follow-up of our patients undergoing permanent implant prostate Brachytherapy. (authors)

2007-01-01

91

Tumor therapy with 125I-octreotide and 125I-UdR  

International Nuclear Information System (INIS)

Purpose: To determine the tumor cell damage effect with Auger-electron emitter 125I in different chemical states. Methods: (1) [Tyr3] octreotide (TOC) and UdR are labeled with 125I,respectively. (2) Receptor analysis of 125I-TOC on small cell lung cancer (SCLC) NCI-H446 cell lines is performed comparing with normal lymph cells. NCI-H446 cells added various dose of 125I-TOC are incubated for different time with 125I-Nal and non-labeled TOC as control. The capacity of NCI-H446 cell lines bound and internalization of 125I TOC are determined. The radiation damage of tumor cells is measured by MTF methods. (3) The killing effects of 125I-UdR in human pancreatic cancer cell line Bax-Pc and Sca-BER bladder carcinoma cells are evaluated with the similar methods. I-UdR penetrating into the Sca-BER cell nucleus is observed with confocal microscope. The grow suppression and clonogenic formation of Sca-BER cells after incubation with 125I-UdR are analyzed. Proliferation fraction and S phase cell fraction of Sca-BER cell added 125I-UdR is measured with flow cytometric analysis. Results: (1) Kd=(0.56?2.0) x 10-11 mol/L and Bmax=(1.17?2.0) x 105 cell site are obtained by receptor analysis of 125I-TOC on NCI-H446 cells. Comparatively, the difference between total binding and non-specific binding is low and there is no saturation of specific binding for normal lymphocyte. About 50% of 125I-TOC is internalized into the NCI-H446 cell nucleus at 24h after incubation. The damige of NCI-H446 cells by 125I-TOC is clearly observed. (2) The penetration amount of 125I-UdR into cell nucleus increases with the incubate time when the concentration of 125I-UdR is in the range of 10?500 kBq/mL and reaches the peak fraction of 94% at 36 h after incubation. The radioactivity of 125I-UdR is then achieved equelibration and no more increased with time. The linear correlation with ?=0.867?0.978 between the concentration of 125I-UdR in cell nucleus and the incubation time is observed before reaching peak value. As a control, very low radioactivities in cells and in neucleus are measured in Na 125I case. Incubating for 36 h, the amount of 125I-UdR entering into the cells and nucleus are 1000 times more than that with Na 125I. The 125I-UdR killing effect of 100 kBq to Bax-Pc cells is 60 times more than Na 125I after 36 h incubation. The Sca-BER bladder carcinoma cells growth cycle in the treatment group with 125I-UdR is suppressed and clonogenic formation is lower in experimental group than in control group. Proliferation fraction and S phase cell fraction decrease and apoptosis fraction increase with 125I-UdR treatment time. The results of confocal microscope shows the Sca-BER cells of treatment group at 48h after administration are entirely broken. Conclusion: 125I-TOC has a better specificity to the somatostatin positive tumors. 125I-UdR is a cell cycle dependent agent. It can be incorporated into DNA of Bax-Pc cells and can selectively kill tumor cells in S phase. Both 125I-TOC and 125I-UdR are more effective for killing tumor cells than Na 125I.

2005-01-01

92

Impact of pre-implant lower urinary tract symptoms on postoperative urinary morbidity after permanent prostate brachytherapy  

International Nuclear Information System (INIS)

The objectives of this study was to assess the impact of baseline lower urinary tract symptoms on postoperative urinary morbidity in patients being treated for prostate cancer with 125-I permanent prostate brachytherapy. A total of 104 prostate cancer patients were enrolled in this study. Their urinary morbidity was followed up using the International Prostate Symptom Score and Expanded Prostate Cancer Index Composite for 12 months or more after permanent prostate brachytherapy. Patients were classified into two groups based on their baseline International Prostate Symptom Score: the low International Prostate Symptom Score group (score?7) and the high International Prostate Symptom Score group (score?8). Urinary morbidity was estimated in each group based on the results of the International Prostate Symptom Score and Expanded Prostate Cancer Index Composite measured before permanent prostate brachytherapy, and at 1, 3, 6, 9 and 12 months after the end of all radiation therapy. The overall mean total International Prostate Symptom Score, International Prostate Symptom Score quality of life score, and urinary-related scores for Expanded Prostate Cancer Index Composite were significantly worse at 1 month after the end of treatment, but they improved gradually after the treatment and recovered to the baseline level within 12 months. Even in the high-International Prostate Symptom Score group, the International Prostate Symptom Score and International Prostate Symptom Score Quality of Life score were significantly worse at 1-3 months after permanent prostate brachytherapy, and then recovered to the baseline level without prolongation. Although the urination-related Expanded Prostate Cancer Index Composite score in the high-International Prostate Symptom Score group was significantly worse at 1 month after permanent prostate brachytherapy in comparison with that in the low-International Prostate Symptom Score group, it recovered to the baseline level without prolongation. The present findings suggest that the presence of lower urinary tract symptoms before implantation does not prolong urinary morbidity after permanent prostate brachytherapy. (author)

2012-01-01

93

Impact of pre-implant lower urinary tract symptoms on postoperative urinary morbidity after permanent prostate brachytherapy.  

UK PubMed Central (United Kingdom)

OBJECTIVES: To assess the impact of baseline lower urinary tract symptoms on postoperative urinary morbidity in patients being treated for prostate cancer with 125-I permanent prostate brachytherapy. METHODS: A total of 104 prostate cancer patients were enrolled in this study. Their urinary morbidity was followed up using the International Prostate Symptom Score and Expanded Prostate Cancer Index Composite for 12 months or more after permanent prostate brachytherapy. Patients were classified into two groups based on their baseline International Prostate Symptom Score: the low International Prostate Symptom Score group (score ? 7) and the high International Prostate Symptom Score group (score ? 8). Urinary morbidity was estimated in each group based on the results of the International Prostate Symptom Score and Expanded Prostate Cancer Index Composite measured before permanent prostate brachytherapy, and at 1, 3, 6, 9 and 12 months after the end of all radiation therapy. RESULTS: The overall mean total International Prostate Symptom Score, International Prostate Symptom Score quality of life score, and urinary-related scores for Expanded Prostate Cancer Index Composite were significantly worse at 1 month after the end of treatment, but they improved gradually after the treatment and recovered to the baseline level within 12 months. Even in the high-International Prostate Symptom Score group, the International Prostate Symptom Score and International Prostate Symptom Score Quality of Life score were significantly worse at 1-3 months after permanent prostate brachytherapy, and then recovered to the baseline level without prolongation. Although the urination-related Expanded Prostate Cancer Index Composite score in the high-International Prostate Symptom Score group was significantly worse at 1 month after permanent prostate brachytherapy in comparison with that in the low-International Prostate Symptom Score group, it recovered to the baseline level without prolongation. CONCLUSIONS: The present findings suggest that the presence of lower urinary tract symptoms before implantation does not prolong urinary morbidity after permanent prostate brachytherapy.

Teishima J; Iwamoto H; Miyamoto K; Shoji K; Masumoto H; Inoue S; Kobayashi K; Kajiwara M; Matsubara A

2012-12-01

94

Routine chest radiography after permanent pacemaker implantation: Is it necessary?  

Directory of Open Access Journals (Sweden)

Full Text Available Background and Aims: Chest radiographs (CXRs) are performed routinely after permanent pacemaker implantation to identify pacemaker lead position and exclude pneumothorax. We assessed the clinical value and need for this procedure. Design: Retrospective analysis of pacemaker data and CXRs following permanent pacemaker insertion between December 2002 and February 2004. Materials and Methods: Post-procedural CXRs were available in 125/126 consecutive patients after either first endocardial pacemaker implantation or insertion of at least one new lead. Subclavian vein puncture was used for venous access in all cases. CXRs were examined to establish the incidence of pneumothorax and assess pacing lead positions. The clinical records were examined in all patients who had subsequent CXRs or a further pacemaker procedure to identify the indication for these and to establish whether CXR had influenced patient management. Results: In total, 192 post-procedural CXRs were performed, either postero-anterior (PA) and/or lateral views. Ventricular and/or atrial pacing lead contour and electrode position was considered radiographically appropriate in 86% CXRs. Fourteen per cent of post-procedural radiographs were considered to have radiologically sub-optimal pacemaker lead positioning. None of the patients with these "abnormal" radiographs experienced subsequent pacemaker complications or had further radiographs recorded at a later date. Later repeat CXRs were performed in 16 patients (13%) but only 3 patients (2%) had pacing abnormalities as the primary indication. All three had satisfactory pacing lead position on initial post-implantation and later radiographs, but required further procedures for lead re-positioning. Iatrogenic pneumothorax occurred in one patient (incidence 0.8%) in our series. CXR confirmed the clinical diagnosis and allowed an assessment of size to guide treatment. Conclusion: Routine CXR after permanent pacemaker insertion is not necessary in uncomplicated cases with adequate pacing characteristics.

Edwards N; Varma M; Pitcher D

2005-01-01

95

Urethral dose and increment of international prostate symptom score (IPSS) in transperineal permanent interstitial implant (TPI) of prostate cancer  

Energy Technology Data Exchange (ETDEWEB)

Purpose: to find the factors which influence the acute increment of international prostate symptom score (IPSS) after transperineal permanent interstitial implant (TPI) using {sup 125}I seeds. Patients and methods: from April 2004 through September 2006, 104 patients with nonmetastatic prostate cancer underwent TPI without external-beam irradiation. Median patient age was 70 years with a median follow-up of 13.0 months. 73 patients (70%) received neoadjuvant hormone therapy. The increment of IPSS was defined as the difference between pre- and postimplant maximal IPSS. Clinical, treatment, and dosimetric parameters evaluated included age, initial prostate-specific antigen, Gleason Score, neoadjuvant hormone therapy, initial IPSS, post-TPI prostatic volume, number of implanted seeds, prostate V{sub 100}, V{sub 150}, D{sub 90}, urethral D{sub max}, and urethral D{sub 90}. In order to further evaluate detailed urethral doses, the base and apical urethra were defined and the dosimetric parameters were calculated. Results: the IPSS peaked 3 months after TPI and returned to baseline at 12-15 months. Multivariate analysis demonstrated a statistically significant correlation of post-TPI prostatic volume, number of implanted seeds, and the dosimetric parameters of the base urethra with IPSS increment. Conclusion: the base urethra appears to be susceptible to radiation and the increased dose to this region deteriorates IPSS. It remains unclear whether the base urethral dose relates to the incidence of late urinary morbidities. (orig.)

Murakami, N.; Itami, J. [Dept. of Radiation Therapy and Oncology, International Medical Center of Japan, Tokyo (Japan); Div. of Radiation Therapy, National Cancer Center Hospital, Tokyo (Japan); Okuma, K.; Marino, H.; Ban, T.; Nakazato, M.; Kanai, K.; Naoi, K.; Fuse, M. [Dept. of Radiation Therapy and Oncology, International Medical Center of Japan, Tokyo (Japan); Nakagawa, K. [Dept. of Radiology, School of Medicine, Tokyo Univ. (Japan)

2008-10-15

96

Urethral dose and increment of international prostate symptom score (IPSS) in transperineal permanent interstitial implant (TPI) of prostate cancer  

International Nuclear Information System (INIS)

Purpose: to find the factors which influence the acute increment of international prostate symptom score (IPSS) after transperineal permanent interstitial implant (TPI) using 125I seeds. Patients and methods: from April 2004 through September 2006, 104 patients with nonmetastatic prostate cancer underwent TPI without external-beam irradiation. Median patient age was 70 years with a median follow-up of 13.0 months. 73 patients (70%) received neoadjuvant hormone therapy. The increment of IPSS was defined as the difference between pre- and postimplant maximal IPSS. Clinical, treatment, and dosimetric parameters evaluated included age, initial prostate-specific antigen, Gleason Score, neoadjuvant hormone therapy, initial IPSS, post-TPI prostatic volume, number of implanted seeds, prostate V100, V150, D90, urethral Dmax, and urethral D90. In order to further evaluate detailed urethral doses, the base and apical urethra were defined and the dosimetric parameters were calculated. Results: the IPSS peaked 3 months after TPI and returned to baseline at 12-15 months. Multivariate analysis demonstrated a statistically significant correlation of post-TPI prostatic volume, number of implanted seeds, and the dosimetric parameters of the base urethra with IPSS increment. Conclusion: the base urethra appears to be susceptible to radiation and the increased dose to this region deteriorates IPSS. It remains unclear whether the base urethral dose relates to the incidence of late urinary morbidities. (orig.)

2008-01-01

97

Temporary and Permanent Inferior Vena Cava Filter Combination in a Young Patient: To Implant or Not to Implant?  

International Nuclear Information System (INIS)

The decision to implant vena cava filters, either temporary or permanent, is difficult in young patients. We present the case of a young man with pulmonary embolism in whom temporary and permanent inferior vena cava filters were implanted. The decision process is discussed in relation to the current literature.

2003-01-01

98

Rectal injury during permanent seed implantation for prostate brachytherapy  

International Nuclear Information System (INIS)

Serious complications have not been previously reported during seed implantation for prostate brachytherapy. We present an unreported case of rectal injury caused by an ultrasound probe. A 67-year-old male presented with a serum prostate-specific antigen level of 5.50 ng/ml, a Gleason score of 7 (3+4) and clinical T2a adenocarcinoma of the prostate. A transperineal permanent prostate brachytherapy implantation was performed. The patient subsequently complained of abdominal pain postoperatively. A gastrointestinal perforation was suspected based on an abdominal X-ray obtained on the day after the brachytherapy. Rectal injury was recognized during an exploratory laparotomy, and a primary closure and temporary diversion ileostomy were performed. The healing of the injury was confirmed by colonoscopy and an ileostomy closure was performed 2 months after the temporary diversion. The investigating committee for this accident concluded that the ultrasound probe had perforated the rectum. This is the first case of a rectal injury during seed implantation for prostate brachytherapy. (author)

2012-01-01

99

Early Complications and Malfunctions of Permanent Pacemaker Implantation: Single Versus Dual Chamber Pacemaker Implantation  

Directory of Open Access Journals (Sweden)

Full Text Available Background-Implantation of transvenous Permanent Pacemakers (PPM) has become standard therapy for sinus node dysfunction and atrioventricular conduction abnormalities. It plays an important role in improving quality of life and preventing death in this group of patients. This study conducted on 477 patients during their hospitalization and eight weeks after their discharge. Complete heart block was the most frequent indication for pacemaker implantation (48.8%).The most frequent early complications of implantations were hematoma (2.1%), hemothorax (0.5%). The most frequent malfunctions were lead displacement (1.9%), exit block (1.5%) and atrial undersensing (1%). There were no significant difference between single and dual chamber PPM in regard to complications and malfunctions (p=0.56). PPM implantations in our center are associated with a low incidence of early complications and malfunctions in comparison with other qualified centers. There is no significant difference between early complications of single versus dual chamber PPMs.

Maryam Moshkani Farahani; Ataallah Bagherzadeh; Majid Hagh joo; Mohammad Ali Sadr Ameli

2006-01-01

100

Interstitial radiotherapy of meningiomas treated with permanent I-125 implantation  

International Nuclear Information System (INIS)

Introduction: Microsurgical removal is usually the best treatment modality for intracranial meningiomas and they are usually cured by complete removal. Paracellar and clival meningiomas located near critical structure are difficult to treat surgically. In old patients surgical mortality and morbidity is considerably increased. Stereotactic radiosurgery and interstitial radiotherapy are adjunct treatment methods. Material and methods: We treated 25 paracellar/clival meningiomas (median age 56 y) and 19 meningiomas in the elderly (median age 77 y) with I-125 seeds using stereotactic implantation. I-125 seeds were implanted permanently in 80 target points within 44 tumours. Seven implantations were made under CT control. The average dose to the tumour margin was between 100-150 Gy. The total dose to the optic nerve was between 50-100 Gy and the surface dose to the pons was limited to 100 Gy. In two cases CT scan showed a misplaced seed, located near the tumour surface. Results and discussion: Meningiomas responded by slow reduction, but none disappeared during a median follow-up of 19 months. In the aged the median relative tumour volume was 73% at 3 months, 66% at 6 months and 46% at 12 months. Of 22 paracellar/clival meningiomas with CT follow-up data at ? 6 months, 4 had shrunk moderately, 13 slightly and 5 not at all. Conclusion: Stereotactic implantation of I-125 seeds into intracranial meningiomas is a simple and mini-invasive procedure. CT-scans showed that most meningiomas responded by shrinking slowly but the follow-up time is so far too short to evaluate long-term outcome.

1996-01-01

 
 
 
 
101

Renal catabolism of 125I-glicentin  

International Nuclear Information System (INIS)

[en] The renal catabolism of 125I-glicentin has been studied in vivo by the disappearance of this peptide from the plasma of bilaterally nephrectomized, ureteral-ligated, or normal rats and by using tubular microinfusion techniques. In addition the catabolism of glicentin by the isolated, perfused kidney has been studied. Results from in vivo studies demonstrated that half-disappearance time was lower in control (59.5 +/- 1.8 min) than in bilaterally nephrectomized rats (97.2 +/- 2.6 min), and this value was significantly higher than that of ureteral-ligated animals (83.2 +/- 1.1 min, P less than 0.005). Microinfusion experiments revealed that when 125I-glicentin was injected into the proximal tubule, no trichloroacetic-precipitable radioactivity was recovered in the urine, whereas most of inulin injected was recovered. By contrast most of the 125I-glicentin injected into the distal tubule was recovered in the urine. In isolated kidney experiments, organ clearance rate of 125I-glicentin averaged 0.88 +/- 0.10 ml/min, a value significantly higher than that of glomerular filtration rate (0.72 +/- 0.06 ml/min, P less than 0.005, paired data), and both parameters showed a close linear relationship (r = 0.90). Urinary clearance of glicentin was negligible. These results demonstrate that the kidney plays a major role in the catabolism of glicentin, mainly by glomerular filtration and tubular catabolism. The site of tubular catabolism appears to be the proximal tubule. Peritubular uptake was minimal

1986-01-01

102

Treatment of recurrent gynecologic malignancies with iodine-125 permanent interstitial irradiation  

International Nuclear Information System (INIS)

Purpose: To analyze the outcome of permanent 125I interstitial radiotherapy for unresectable retroperitoneal recurrences of gynecologic malignancies. Methods and Materials: A retrospective review of 20 patients treated between 1979 and 1993 was performed to evaluate survival and morbidity associated with the interstitial 125I technique. Results: Nineteen tumors were located on the lateral pelvic wall and one in the para-aortic region. Eight patients, not previously irradiated, received external beam radiotherapy (EBRT) along with 125I interstitial implants placed at the time of celiotomy. Nineteen (95%) are dead of disease at 1-69 months of follow-up. The median survival was 7.7 months for patients treated with 125I alone and 25.4 months for those treated with both 125I and EBRT. One patient is alive without evidence of disease 69 months after 125I implantation. Fistulas, bowel obstructions, and fatal complications occurred only among patients previously irradiated. Conclusions: When used in a previously irradiated field, 125I interstitial radiotherapy has major morbidity and is unlikely to be associated with cure or long-term survival. In radiotherapy-naive patients with unresectable isolated recurrent gynecologic malignancies, 125I implants and EBRT are feasible and occasionally may contribute to long-term disease-free survival.

2002-03-01

103

Inhibitory effect of particle 125I on proliferation of intracranial glioma cells in rats  

International Nuclear Information System (INIS)

Objective: To investigate the possibility and mechanism of 125I in treatment of glioma. Methods: SHG-44 glioma cells were cultivated in vitro, the inhibitory effect of 125I on SHG-44 cell proliferation was determined by MTT method. The stereotactic method was used to establish the rat intracranial glioma model. The MRI was performed at 1st week after implantation and 125I was implanted in the glioma area, the MRI was performed to measure the diameter of tumor 2 weeks after implantation. The rats were killed after 2 weeks, PCNA gene experession was determined with immunohistological method both in control and experiment group. Results: One week after implantation the glioma grew, the results of MTT method showed the growth of the SHG-44 was inhibited, 125I inhibited the expression of PCNA gene and enlonged the rat survival period. Conclusion: 125I can inhibit the growth of glioma, the mechanism may be concerned with its inhibitory effect on PCNA gene expression. (authors)

2006-01-01

104

Conformal prostate brachytherapy guided by realtime dynamic dose calculations using permanent 125iodine implants: technical description and preliminary experience  

Scientific Electronic Library Online (English)

Full Text Available Abstract in spanish Objetivo: El tratamiento con braquiterapia de baja tasa de dosis (LDR) con implantes permanentes de 125-I o 103Pb, constituyen en la actualidad una opción terapéutica en los pacientes con cáncer de próstata de bajo riesgo. La variación observada en el posicionamiento espacial de la próstata, así como en el volumen y contorno prostático entre las imágenes obtenidas durante la planificación y posteriormente durante la intervención, hacen dudar de la exactitud de (more) dosificación, en los pacientes tratados con la técnica de preplanificación. Analizamos la técnica basada en la planificación previa, la planificación intraoperatoria interactiva, así como nuestro proceder actual de planificación intraoperatoria por cálculo dinámico en tiempo real y los motivos que nos llevaron a realizar este cambio de técnica. Métodos: Con el cálculo del volumen prostático preoperatorio por ecografía transrectal, determinamos la posibilidad de realizar el implante en base a las consideraciones anatómicas existentes y decidimos la actividad por semilla y la actividad total del implante. El día de la intervención comprobamos de nuevo la volumetría, obtenemos de nuevo las imágenes ecográficas de base a apex, ayudados por un stepper motorizado que va conectado con el ecógrafo y el planificador. Cada aguja que se coloca en la posición que deseamos y no en una coordenada obligada, se identifica en el planificador en la posición real, una vez colocadas todas las agujas y obtenidas unas primeras isodosis adecuadas, realizamos una cistoscopia flexible y a continuación sembramos, identificando todas y cada una de las semillas en la retirada de la aguja guía ecográficamente, con lo que nos permite obtener una postplanificación intraoperatoria en tiempo real y hacer las correcciones oportunas en el propio acto quirúrgico. Realizamos un implante periférico puro. Resultados: Iniciamos los tratamientos con braquiterapia de baja tasa de dosis en 1.999. Superadas las 700 intervenciones, hemos evaluado a los primeros 63 pacientes tratados con la técnica de cálculo dinámico de dosis en tiempo real por presentar un seguimiento mínimo de 10 meses. El tiempo medio del proceso fue de 90 minutos. La media de seguimiento para los 63 pacientes estudiados fue 20 meses con un rango entre 10 y 36 meses. Un 55% de los pacientes fueron estadiados como T1c, 36% T2a y 9% T2b. En el 81% de los pacientes el Gleason fue Abstract in english Objetive: Low dose rate (LDR) prostate brachytherapy (permanent 125I or 103Pd seeds) is an accepted treatment option for low risk prostate cancer patients. However, differences in prostate spatial location, volume and gland deformation between the images obtained during pre-planning and later on during the implant procedure prevent the pre-planned intended dose to be accurately delivered. We are reporting on a new technique based on interactive real-time dynamic intra-ope (more) rative dose calculation with avoidance of post-implant CT for final dosimetry. The reasons leading us to implementing this new technique are discussed and preliminary results reported. Methods: A pre-planning TRUS for volumetric analysis is performed in all our patients prior to implantation. This TRUS accomplishes two objectives: 1) assessment of implantability of the gland, of organs at risk and anatomical considerations and 2) determination of seed activity and total number of seeds. On the day of the implant, new TRUS images from base to apex are obtained using a motorized stepper connected to the ultrasound and planning system. Each real time needle position placed on the target is identified and capture by the planning system in the true position. Once all real needle positions have been captured, dosimetry is performed intra-operatively and the physician approves the corresponding isodoses on real time. Flexible cystoscopy is then performed followed by seed placement. Each seed implanted is then identified upon withdrawing the needle using TRUS guidance. This allows real-time

Prada, Pedro J.; Juan, German; Fernández, José; H, González-Suárez; Martínez, Álvaro; González, José; Alonso, Ana

2006-11-01

105

Preparation of 125I-creatine phosphokinase-MM  

International Nuclear Information System (INIS)

[en] 125I-creatine phosphokinase-MM (125I-CPK-MM) was prepared by 125I-labelled Bolton-Hunter reagent (HPNS). Iodinating conditions of HPNS and its conjugation to protein were studied. 125I-CPK-MM with immune activity was obtained and used to establish the 125I-CPK-MM radioimmunoassay method by the General Hospital of PLA. 125I-CPK-MM in PBS-G solution containing 0.015 mol/l ethyl mercaptan at 4-10 deg C can be used for one month

1988-01-01

106

Biodistribution properties of two 125I labeled novel neurotensin analogues  

International Nuclear Information System (INIS)

Two novel neurotensin analogues NT1(Arg-Lys-Pro-Tyr-TLe-Leu) and NT2 (Lys-Arg-Pro-Tyr-TLe-Leu) are labeled with 125I by Chloramine T method. Biodistribution studies of 125I-NT1 and 125I-NT2 are carried out in ICR mice and Balb/c nude mice bearing HT29 xenografts. The results indicate that 125I-NT1 and 125I-NT2 have similar biodistribution and specific tumor targeting properties. 125I-NT2 shows promising properties and is worth of further investigation. (authors)

2005-01-01

107

Electrophoretic purification of 125I-gliadin  

International Nuclear Information System (INIS)

A sensitive RIA technique is introduced for the estimation of gliadins in foodstuffs allowing the detection of less than 1 mg gliadin per kg of food. 125I-gliadin succinylated is used as a tracer after purification by electrophoresis in polyacrylamide gel. The method can be used for an effective control of gluten-free foods. False positive results cannot be excluded completely, since interfering factors are extracted together with the gliadins from the sample material. Vegetable lectins are discussed as the most probable interfering factors. (author)

1988-01-01

108

Thyroidal /sup 125/I monitoring system using a survey meter for /sup 125/I  

Energy Technology Data Exchange (ETDEWEB)

This paper describes the counting efficiency and detection limit of a thyroidal /sup 125/I monitoring system. Two systems were used: (1) M1 was composed of only a survey meter for /sup 125/I(SM) having a NaI(Tl) crystal of 2inphi x 5 mmt and (2) M2 was composed of the SM having an output terminal for spectroscopy and a multichannel pulse height analyzer. The counting efficiency was determined by using an anthropomorphic neck phantom embedded four simulated thyroids of 17, 20.5, 31 and 40 ml including /sup 125/I solution. The counting efficiency between 0deg and 45deg to the direction from the center of the thyroid to the front of the neck coincided within -4 %. The efficiency of M1 ranged from 7.9 to 1.8 % as the distance between the probe and the neck increased from 0 to 5 cm. Similarly the efficiency of M2 ranged from 8.3 to 2.2 %. The detection limit of M1 ranged from 7 to 34 Bq, and the limit of M2 ranged from 1 to 5.1 Bq. M2 system was applied to monitoring a worker performing iodization with Na/sup 125/I of 74 MBq. Both monitoring systems proved to sensitively detect thyroidal /sup 125/I within the uncertainty +-10 %. (author).

Nishizawa, Kunihide; Maekoshi, Hisashi.

1989-04-01

109

Radiotoxicity of intranuclear 125I atoms not bound to DNA.  

UK PubMed Central (United Kingdom)

The radiotoxicity of 125I covalently bound to DNA is unusually high. This has been attributed both to the Auger electrons which result from the electron capture process accompanying 125I decay and to local transmutation effects which cause extensive damage to nearby structures. We introduced 125I into cell nuclei in the form of iodoantipyrine, a molecule which diffuses freely through cells, and we have compared the survival of these cells to those exposed to radiation from extracellular 125I-labelled albumin or 55Fe-labelled transferrin. We found a value for D0 of 34 rad for 125I decays occurring within the cell nucleus compared to 362 rad for extracellular 125I and 277 rad for extracellular 55Fe. Since transmutation effects are very short range and 125I was distributed uniformly throughout the nucleus rather than bound to DNA, most of the radiotoxicity of intranuclear 125I-labelled iodoantipyrine must be due to Auger electrons.

Commerford SL; Bond VP; Cronkite EP; Reincke U

1980-05-01

110

Continuous and low-energy 125I seed irradiation changes DNA methyltransferases expression patterns and inhibits pancreatic cancer tumor growth  

Directory of Open Access Journals (Sweden)

Full Text Available Abstract Background Iodine 125 (125I) seed irradiation is an effective treatment for unresectable pancreatic cancers. However, the radiobiological mechanisms underlying brachytherapy remain unclear. Therefore, we investigated the influence of continuous and low-energy 125I irradiation on apoptosis, expression of DNA methyltransferases (DNMTs) and cell growth in pancreatic cancers. Materials and methods For in vitro 125I seed irradiation, SW-1990 cells were divided into three groups: control (0 Gy), 2 Gy, and 4 Gy. To create an animal model of pancreatic cancer, the SW 1990 cells were surgically implanted into the mouse pancreas. At 10 d post-implantation, the 30 mice with pancreatic cancer underwent 125I seed implantation and were separated into three groups: 0 Gy, 2 Gy, and 4 Gy group. At 48 or 72 h after irradiation, apoptosis was detected by flow cytometry; changes in DNMTs mRNA and protein expression were assessed by real-time PCR and western blotting analysis, respectively. At 28 d after 125I seed implantation, in vivo apoptosis was evaluated with TUNEL staining, while DNMTs protein expression was detected with immunohistochemical staining. The tumor volume was measured 0 and 28 d after 125I seed implantation. Results 125I seed irradiation induced significant apoptosis, especially at 4 Gy. DNMT1 and DNMT3b mRNA and protein expression were substantially higher in the 2 Gy group than in the control group. Conversely, the 4 Gy cell group exhibited significantly decreased DNMT3b mRNA and protein expression relative to the control group. There were substantially more TUNEL positive in the 125I seed implantation treatment group than in the control group, especially at 4 Gy. The 4 Gy seed implantation group showed weaker staining for DNMT1 and DNMT3b protein relative to the control group. Consequently, 125I seed implantation inhibited cancer growth and reduced cancer volume. Conclusion 125I seed implantation kills pancreatic cancer cells, especially at 4 Gy. 125I-induced apoptosis and changes in DNMT1 and DNMT3b expression suggest potential mechanisms underlying effective brachytherapy.

Ma Jian-xia; Jin Zhen-dong; Si Pei-ren; Liu Yan; Lu Zheng; Wu Hong-yu; Pan Xue; Wang Luo-wei; Gong Yan-fang; Gao Jun; Zhao-shen Li

2011-01-01

111

125I Measurements for Occupational Exposure Assessment  

International Nuclear Information System (INIS)

Whenever there is a risk of occupational exposure to dispersible radioactive material, it is necessary to have a monitoring program to assess the effective dose arising from the intake of radionuclides by workers. In this paper we present our experience in bioassay measurements of 125I in urine samples of workers using high resolution gamma spectrometry. For a 24-hour excretion period, we found activity values of the order of one Bq and estimated the committed effective doses to be less than one ?Sv. Although very small, these values led to a re-evaluation and improvement of the laboratory safety conditions. We discuss the calibration procedure followed for the activity measurements, the estimation of the uncertainty in the excreted activity, the calculation of detection and quantification limits and estimation of performance indicators. Aspects regarding the spectral analysis, true coincidence summing and matrix effects are also considered.

2008-08-14

112

New metallic implant used for permanent contraception in women: evaluation of MR safety.  

UK PubMed Central (United Kingdom)

OBJECTIVE: This ex vivo investigation evaluated the safety of using MR imaging with a new metallic implant designed to provide permanent birth control. CONCLUSION: The findings indicated that it should be safe for patients with this metallic contraceptive implant to undergo MR imaging with systems using static magnetic fields of 1.5 T or less.

Shellock FG

2002-06-01

113

A versatile permanent planar implant technique utilizing iodine-125 seeds imbedded in gelfoam.  

UK PubMed Central (United Kingdom)

Tumors attached or adjacent to critical structures can often not be completely resected or resected with adequate surgical margins. Sites involving major blood vessels, the vertebral column or the brain with small residual tumors or suspicious margins often present technical difficulties for standard I-125 or Ir-192 implants. A relatively simple, accurate and inexpensive implant method is described using I-125 seeds imbedded in gelfoam to implant permanently into small residual tumors or suspicious margins where standard implant techniques may be unsatisfactory. A method for planning the treatment dose for such an implant is described. Cases involving paraspinal and brain tumors are reported to illustrate the technique.

Marchese MJ; Nori D; Anderson LL; Hilaris BS

1984-05-01

114

Versatile permanent planar implant technique utilizing Iodine-125 seeds imbedded in gelfoam  

International Nuclear Information System (INIS)

Tumors attached or adjacent to critical structures can often not be completely resected or resected with adequate surgical margins. Sites involving major blood vessels, the vertebral column or the brain with small residual tumors or suspicious margins often present technical difficulties for standard I-125 or Ir-192 implants. A relatively simple, accurate and inexpensive implant method is decribed using I-125 seeds imbedded in gelfoam to implant permanently into small residual tumors or suspicious margins where standard implant techniques may be unsatisfactory. A method for planning the treatment dose for such an implant is described. Cases involving paraspinal and brain tumors are reported to illustrate the technique

1984-01-01

115

DNA damage induction by 125I-estrogen  

International Nuclear Information System (INIS)

[en] DNA damage induced by the radioactive decay of 125I-estrogen (125I-VME2) in an estrogen receptor expressing CHO cell line, CHO-ER, was measured. 125I-VME2 targeted 125I atoms proximal to DNA estrogen response elements (EREs). 125I decays were accumulated at -135 C, and thereafter assayed by alkaline and neutral filter elution techniques to measure DNA single strand break (ssb) and double strand break (dsb) induction respectively. Increasing DNA damage (both ssbs and dsbs) was detected after exposure of cells to increasing concentrations of 125I-VME2. DNA ssb and dsb dose-response curves for 125I-VME2 were multiphasic. The rates of DNA damage induction by the decay of 125I-VME2 was determined by comparing slopes of all data or by comparing initial slopes. DNA ssb induction per 125I-VME2 decay was approximately 2 times greater compared with DNA dsb induction. 125I-VME2 decay induced approximately 4-8 times more DNA dsbs than 125IUdR decay. (orig.)

1996-01-01

116

DNA damage induction by {sup 125}I-estrogen  

Energy Technology Data Exchange (ETDEWEB)

DNA damage induced by the radioactive decay of {sup 125}I-estrogen ({sup 125}I-VME2) in an estrogen receptor expressing CHO cell line, CHO-ER, was measured. {sup 125}I-VME2 targeted {sup 125}I atoms proximal to DNA estrogen response elements (EREs). {sup 125}I decays were accumulated at -135 C, and thereafter assayed by alkaline and neutral filter elution techniques to measure DNA single strand break (ssb) and double strand break (dsb) induction respectively. Increasing DNA damage (both ssbs and dsbs) was detected after exposure of cells to increasing concentrations of {sup 125}I-VME2. DNA ssb and dsb dose-response curves for {sup 125}I-VME2 were multiphasic. The rates of DNA damage induction by the decay of {sup 125}I-VME2 was determined by comparing slopes of all data or by comparing initial slopes. DNA ssb induction per {sup 125}I-VME2 decay was approximately 2 times greater compared with DNA dsb induction. {sup 125}I-VME2 decay induced approximately 4-8 times more DNA dsbs than {sup 125}IUdR decay. (orig.).

Yasui, L.S. [Northern Illinois Univ., DeKalb, IL (United States). Dept. of Biological Sciences; Hughes, A. [Chicago Univ., IL (United States). Ben May Inst.; DeSombre, E.R. [Chicago Univ., IL (United States). Ben May Inst.

1996-12-31

117

DNA damage induction by 125I-estrogen.  

UK PubMed Central (United Kingdom)

DNA damage induced by the radioactive decay of 125I-estrogen (125I-VME2) in an estrogen receptor expressing CHO cell line, CHO-ER, was measured. 125I-VME2 targeted 125I atoms proximal to DNA estrogen response elements (EREs). 125I decays were accumulated at -135 degrees C, and thereafter assayed by alkaline and neutral filter elution techniques to measure DNA single strand break (ssb) and double strand break (dsb) induction respectively. Increasing DNA damage (both ssbs and dsbs) was detected after exposure of cells to increasing concentrations of 125I-VME2. DNA ssb and dsb dose-response curves for 125I-VME2 were multiphasic. The rates of DNA damage induction by the decay of 125I-VME2 was determined by comparing slopes of all data or by comparing initial slopes. DNA ssb induction per 125I-VME2 decay was approximately 2 times greater compared with DNA dsb induction. 125I-VME2 decay induced approximately 4-8 times more DNA dsbs than 125IUdR decay.

Yasui LS; Hughes A; DeSombre ER

1996-01-01

118

Determination of radiochemical purity of 125I-TOC and 125I-F-PGA  

International Nuclear Information System (INIS)

[en] To explore whether there is accordance among three determination methods of the radiochemical purity of [Tyr3] octreotide (TOC) and folate-penicillin G amidase conjugate (F-PGA), which are both labeled with 125I by Iodogen method, the RCP of the labelings are determined by high performance liquid chromatography (HPLC), paper chromatography and trichloroacetic acid (TCA) precipitation, in which four different concentrations of proteins are used to investigate the effect of them on the determination of RCP. It is shown that both HPLC and paper chromatography can separate the labelings from free iodine efficiently, though HPLC is the most precise and reliable method to determinate RCP of such labelings. In TCA precipitation, the RCP measured with 0.2%BSA is the lowest, but those with three other concentrations of the BSA are similar (P>0.05). When RCP0.05), whereas higher than that with HPLC (P10%, the RCP of 125I-TOC obtained by TCA precipitation is a bit lower than those by two other methods (P0.05), and there are no significant differences to determinate the RCP of 125I-F-PGA (P>0.05). The three methods are correlated each other (r=0.0996-0.999, P

2006-01-01

119

[Use of the thoraco-acromialis vein for implantation of a permanent transvenous PMK (author's transl)].  

Science.gov (United States)

In order to implant a permanent PMK in 35 patients with total heart block the thoraco-acromialis vein has been investigated. The vein was easily found in the groove between the clavicular and sternal part of the musculus pectoralis major and used to implant a permanent pacing lead in 32 patients (91.5%). Following the satisfactory results and taking into account that the complications had reduced to a very low rate (in 2 cases lead tip displacement and pouch haematoma occurred respectively), the Authors consider the adopted method an useful approach for PMK implantation particularly when the use of the vena cephalica is deemed impossible. PMID:540707

Speca, G; Marcellini, G; Di Sabatino, P

1979-01-01

120

[Use of the thoraco-acromialis vein for implantation of a permanent transvenous PMK (author's transl)  

UK PubMed Central (United Kingdom)

In order to implant a permanent PMK in 35 patients with total heart block the thoraco-acromialis vein has been investigated. The vein was easily found in the groove between the clavicular and sternal part of the musculus pectoralis major and used to implant a permanent pacing lead in 32 patients (91.5%). Following the satisfactory results and taking into account that the complications had reduced to a very low rate (in 2 cases lead tip displacement and pouch haematoma occurred respectively), the Authors consider the adopted method an useful approach for PMK implantation particularly when the use of the vena cephalica is deemed impossible.

Speca G; Marcellini G; Di Sabatino P

1979-01-01

 
 
 
 
121

The contamination on farm products from 125I  

International Nuclear Information System (INIS)

The 125I contamination on 15 farm products have been investigated. The effects of 12 farm crops (wheat, bean, eggplants and other vegetables) contaminated by 125I during the growing stage on their fruits and seeds have been studied. The results show that the 125I radioactive substance is mainly concentrated on the fruit surface, and the radioactivity rapidly decreased towards its kernel. The fruits and seeds would not be contaminated when plants were contaminated in the seedling stage

1990-01-01

122

Permanent I-125 interstitial implant in the management of high grade CNS malignancies in children  

International Nuclear Information System (INIS)

Purpose/Objective: To evaluate the efficacy and complications associated with the use of permanent I-125 interstitial implants in children with high grade CNS malignancies. Materials and Methods: Between May of 1990 and September of 1994, fourteen children received permanent I-125 interstitial implant brachytherapy as initial therapy (n=8) or at time of recurrence (n=6). Histologies included Glioblastoma Multiforme (n=2), Anaplastic Astrocytoma (n=9) and others (n=3). Pre-implant surgical procedures included: Gross Total Resection (n=2), Subtotal Resection (n=8) or Biopsy alone (n=4). Six patients received pre-implant external beam irradiation (dose range 3,500-6500 cGy) and three patients received post-implant external beam irradiation (dose range 5,040-5,060 cGy). Implant dose range was 8,294-10,368 cGy over the lifetime of the implant (median 10,368 cGy). Results: At last follow-up (median 17.5 months; range 4-56 months), eight children were alive. Six out of the eight had no evidence of disease progression while the remaining had radiologic evidence of progression. Implant complications (n=2) included skin necrosis and bone flap infection. Conclusions: Based on this initial review, we continue to investigate the use of permanent I-125 interstitial brachytherapy in the treatment of high grade CNS malignancies in children and will discuss and compare these results with those of other 'Boost' series.

1996-01-01

123

Installation of radiochromatography for testosterone-3-carboxymethyloxime-tyramine-125 I (T-3-CMO-Ty-125 I)  

International Nuclear Information System (INIS)

The paper presents a device for radiochromatography of testosterone-3-carboxymethyloxime-tyramine-125 I (T-3-CMO-Ty-125 I), a reagent used as marker in radioimmunoassays (RIA) of steroid hormones. One of the most adequate technique of analyzing the steroid hormones is RIA (radioimmunoassay) due to its sensitivity and specificity. This technique requires advanced purification of the sample. In the view of developing a sensitive RIA technique for assaying the steroid hormones an installation for radiochromatography of testosterone-3-carboxymethyloxime-tyramine-125 I (T-3-CMO-Ty-125 I) is necessary. (authors)

2002-01-01

124

Use of 125I - labeled platelets for quantitation of platelet adhesion to biomaterials in vitro using phosphor imaging  

International Nuclear Information System (INIS)

Measurement of platelet adhesion in vitro is a good indicator of thromboembolic complications of implant devices in vivo. In this paper, emphasis has been laid on detection and quantitation of platelets adhered onto titanium, a candidate material for implant prosthesis, using phosphor imaging. The results indicate the usefulness of 125I - labeled platelets in in vitro studies of platelet adhesion to materials. (author)

2001-01-01

125

Interstitial brachytherapy of localised prostate cancer using iodine 125 permanent implants; Curietherapie interstitielle des cancers localises de prostate par implants permanents d'iode 125  

Energy Technology Data Exchange (ETDEWEB)

Brachytherapy with permanent implants is a validated method of treatment of prostate adenocarcinomas of favourable prognosis. Its technology is based on endorectal ultrasonography and on per-operative visualisation of the implant and the dose distribution. A strict selection of the patients is necessary before this localised treatment. An active collaboration between urologists, radio-physicists and radiation oncologists is necessary during all the process of selection, treatment and follow-up of the patients. An assessment of the carcinological and functional results is necessary. Recommendations are formalized by a joint collaboration between members of the AFU and of the SFRO. (author)

Peiffert, D. [Centre Alexis-Vautrin, Unite de curietherapie, 54 - Vandoeuvre-Les-Nancy (France)

2005-11-15

126

Immunoreactivity of 125I-papain labelled by different methods  

International Nuclear Information System (INIS)

[en] Three different methods of papain iodination (with chloramine-T, lactoperoxidase and conjugation with Bolton-Hunter reagent) have been compared. The highest yield of 125I-papain could be obtained using lactoperoxidase which enabled to achieve the highest immunoreactivity. 125I-papain, labelled this way, is suitable for the radioimmunoassay of papain. (author)

1984-01-31

127

Preparation and metabolism of 125I-sulfobromophthalein.  

UK PubMed Central (United Kingdom)

Metabolism of 125I-sulfobromophthalein (BSP) prepared by the chloramine-T method was studied in rats. 125I-BSP is removed rapidly from the circulation. However, as compared to BSP, its plasma clearance and biliary excretion are delayed, and its accumulation in the liver is prolonged. Although BSP and 125I-BSP show similar binding to albumin in serum, their binding properties to liver cytosolic proteins and to the liver cell plasma membrane organic anion binding protein (OABP) differ. In contrast to the X-, Y- and Z-protein binding of BSP, 125I-BSP binds predominantly to a high molecular weight protein and only a small proportion of 125I-BSP binds to OABP.

Hirano M; Theilmann L; Stollman YR; Sosiak A; Wolkoff AW

1983-03-01

128

Preparation and metabolism of 125I-sulfobromophthalein.  

Science.gov (United States)

Metabolism of 125I-sulfobromophthalein (BSP) prepared by the chloramine-T method was studied in rats. 125I-BSP is removed rapidly from the circulation. However, as compared to BSP, its plasma clearance and biliary excretion are delayed, and its accumulation in the liver is prolonged. Although BSP and 125I-BSP show similar binding to albumin in serum, their binding properties to liver cytosolic proteins and to the liver cell plasma membrane organic anion binding protein (OABP) differ. In contrast to the X-, Y- and Z-protein binding of BSP, 125I-BSP binds predominantly to a high molecular weight protein and only a small proportion of 125I-BSP binds to OABP. PMID:6851140

Hirano, M; Theilmann, L; Stollman, Y R; Sosiak, A; Wolkoff, A W

1983-03-14

129

Preparation and metabolism of 125I-sulfobromophthalein  

International Nuclear Information System (INIS)

[en] Metabolism of 125I-sulfobromophthalein (BSP) prepared by the chloramine-T method was studied in rats. 125I-BSP is removed rapidly from the circulation. However, as compared to BSP, its plasma clearance and biliary excretion are delayed, and its accumulation in the liver is prolonged. Although BSP and 125I-BSP show similar binding to albumin in serum, their binding properties to liver cytosolic proteins and to the liver cell plasma membrane organic anion binding protein (OABP) differ. In contrast to the X-, Y- and Z-protein binding of BSP, 125I-BSP binds predominantly to a high molecular weight protein and only a small proportion of 125I-BSP binds to OABP. (Auth.)

1983-03-14

130

Safety handling of 125I in animal experiments  

International Nuclear Information System (INIS)

Isotope 125I in animal experiments is used for several purposes. One major problem with using 125I is to handle it extremely carefully. The careful handling is required when using 125I in animal experiments because of its higher evaporation and difficulty for sealing. When conducting animal experiments white using 125I, we have encountered several serious problems but have devised new techniques and methods for a long time. In this paper, we will describe the safety handling for requirements based on our experiments. The newly devised safety handling procedures are the following: a device for protecting isotope contamination during the preparation of the injectable solution, collection method of airborne radioactivity from the animals that were injected, enhancing the method for autoradiography of the whole body, finding of elusion of 125I from the tissues during fixative process, estimation of the exposed time for light microscopic autoradiography. (author)

1996-01-01

131

Polymer gel dosimetry close to an 125I interstitial brachytherapy seed  

International Nuclear Information System (INIS)

Despite its advantages, the polymer gel-magnetic resonance imaging (MRI) method has not, as yet, been successfully employed in dosimetry of low energy/low dose rate photon-emitting brachytherapy sources such as 125I or 103Pd interstitial seeds. In the present work, two commercially available 125I seed sources, each of approximately 0.5 U, were positioned at two different locations of a polymer gel filled vial. The gel vial was MR scanned with the sources in place 19 and 36 days after seed implantation. Calibration curves were acquired from the coupling of MRI measurements with accurate Monte Carlo dose calculations obtained simulating the exact experimental setup geometry and materials. The obtained gel response data imply that while linearity of response is sustained, sensitivity (calibration curve slope) is significantly increased (approximately 60%) compared to its typical value for the 192Ir (or 60Co and 6 MV LINAC) photon energies. Water equivalence and relative energy response corrections of the gel cannot account for more than 3-4% of this increase, which, therefore, has to be mainly attributed to physicochemical processes related to the low dose rate of the sources and the associated prolonged irradiation time. The calibration data obtained from one 125I source were used to provide absolute dosimetry results for the other 125I source, which were found to agree with corresponding Monte Carlo calculations within experimental uncertainties. It is therefore suggested that, regardless of the underlying factors accounting for the gel dose response to 125I irradiations, polymer gel dosimetry of new 125I or 103Pd sources should be carried out as originally proposed by Heard and Ibbot (2004 J. Phys.: Conf. Ser. 3 221-3), i.e., by irradiating the same gel sample with the new low dose rate source, as well as with a well-characterized low dose rate source which will provide the dose calibration curve for the same irradiation conditions.

2005-09-21

132

CT-guided percutaneous perineal permanent implants with I-125  

International Nuclear Information System (INIS)

The authors have combined the principles of CT-guided percutaneous biopsy and biplane fluoroscopy in performing outpatient percutaneous pelvic implantations of I-125 seeds for the treatment of unresectable or recurrent tumors of the pelvis, utilizing a transperineal approach. The technique allows implantations up to a depth of 16 cm from the perineum. No complications have been encountered. Twelve procedures have been performed. The types of tumor treated include five cases of recurrent carcinoma of the rectum, five cases of unresectable carcinoma of the prostate, one case of recurrent sarcoma of the rectum, and one case of adenocarcinoma of unknown origin involving the pelvic wall

1986-12-05

133

Treatment planning for permanent and temporary percutaneous implants with custom made templates.  

UK PubMed Central (United Kingdom)

Nine patients who were presented at MSKCC with primary or recurrent pelvic or head and neck tumors and for whom surgery or further external radiation were excluded, were treated with percutaneous permanent or temporary implants, with individual pre-treatment planning and custom made templates. The tumor dose distributions achieved were as good as for implants performed at the time of surgical exploration. No serious complications have been encountered.

Osian AD; Anderson LL; Linares LA; Nori D; Hilaris BS

1989-01-01

134

Treatment planning for permanent and temporary percutaneous implants with custom made templates  

International Nuclear Information System (INIS)

Nine patients who were presented at MSKCC with primary or recurrent pelvic or head and neck tumors and for whom surgery or further external radiation were excluded, were treated with percutaneous permanent or temporary implants, with individual pre-treatment planning and custom made templates. The tumor dose distributions achieved were as good as for implants performed at the time of surgical exploration. No serious complications have been encountered

1989-01-01

135

Treatment planning for permanent and temporary percutaneous implants with custom made templates.  

Science.gov (United States)

Nine patients who were presented at MSKCC with primary or recurrent pelvic or head and neck tumors and for whom surgery or further external radiation were excluded, were treated with percutaneous permanent or temporary implants, with individual pre-treatment planning and custom made templates. The tumor dose distributions achieved were as good as for implants performed at the time of surgical exploration. No serious complications have been encountered. PMID:2912944

Osian, A D; Anderson, L L; Linares, L A; Nori, D; Hilaris, B S

1989-01-01

136

Local relapses after prostatic curie-therapy by permanent implants: radio-resistant prostate cancers or bad quality implant; Rechutes locales apres curietherapie prostatique par implants permanents: cancers de prostate radioresistants ou mauvaise qualite de l'implantation?  

Energy Technology Data Exchange (ETDEWEB)

The assessment of the quality of a permanent implant of grains for a prostate cancer treatment is based on the dosimetric plan performed before the grain implantation or shortly after. The authors report a study of the correlation between 'under-dosed' areas assessed at the time of relapse, and intra-prostatic relapse sites. The study is based on 24 cases of proved intra-prostatic relapse. The prostatic volume has been divided into 12 areas, and three types of under-dosing have been defined. Parameters are the dose received by 90 per cent of the volume, and the volume receiving 100 per cent of the dose. A correlation appears between positive biopsies and 'under-dosing'. This corresponds to a bad quality implantation of grains for patients in a situation of prostatic relapse after implantation. Short communication

Crehange, G.; Krishnamurthy, D.; Cunha, A. J.; Gros, S.; Pickett, B.; Hsu, I.C.; Gottschalk, A.R.; Pouliot, J.; Roach III, M. [UCSF Radiation Oncology, San Francisco (United States)

2011-10-15

137

Obtainment and radioimmunological characterization of 2,4 D-tyramine -125 I and Dicamba -tyramine -125 I  

International Nuclear Information System (INIS)

The paper presents the synthesis and radioimmunological characterization of two radioactive microconjugates: 2,4 dichlorophenoxyacetyl-tyramine-125 I (2,4 D-tyramine-125 I) and 3,5 dichloro-2-metoxybenzoic-tyramine-125 I (Dicamba-tyramine-125 I), reagents used as markers in radioimmunoassays (RIA) of the pesticides 2,4 D and Dicamba from the environmental factors. The pesticides were activated with ethylchloroformate and tributylamine in dioxan and coupled to tyramine (or tyramine-125 I ). Tyramine was labelled by chloramine method. Markers were purified by thin layer chromatography and extracted in methyl alcohol. Radioimmunological characterization of the pesticide markers was carried out with the help of the anti 2,4 D and anti Dicamba antisera also obtained in the laboratory. (authors)

2003-01-01

138

Dosimetric and functional analysis of 227 patients treated by permanents prostate implants; Analyse dosimetrique et fonctionnelle de 227 patients traites par implants prostatiques permanents  

Energy Technology Data Exchange (ETDEWEB)

The brachytherapy of prostate by permanent implants is included in the armamentarium of localized prostate cancers with external radiotherapy and radical prostatectomy. The quality evaluation of implantation is essential for the patient and the team managing him. Our retrospective work consisted in analysing the whole of dosimetry data and urinary, digestive and sexual functional results of patients treated in our centers. conclusion: the post-implantation dosimetry analysis is essential to improve the technique and to understand the evolutions. The method of scanning evaluation is difficult but is currently the most used by its accessibility. The low urinary, rectal and sexual morbidity of the brachytherapy makes of this treatment an attractive technique for the patients should be well selected. (N.C.)

Champeaux-Orange, E.; Wachter, T. [CHR, 45 - Orleans (France); Le Floch, O.; Haillot, O.; Peneau, M.; Raynaud-Bougnoux, A. [CHU, 37 - Tours (France)

2009-10-15

139

Effectiveness of Permanent Implantable Catheter (Polysite) in Children with Cancer  

Directory of Open Access Journals (Sweden)

Full Text Available AbstractBackground Totally implantable central venous access devices (ports) have been available for over 10 years, but have not been achieved widespread use in pediatric oncology patients. Ports facilitate the administration of chemotherapy in children with cancer. Materials and Methods In this study, we investigated early complications of implantable central venous access devices in children who suffered from different type of cancer. All of the complications were recorded by staff nurses by checklist for one week. This study included 68 patients with different cancer (lymphoma-leukemia-sarcoma and wilms’ tumor) who were treated between April 2007 and November 2011 in oncology department of Dr Sheikh hospital, Mashhad University of medical science. ResultsVenous ports were placed in 26 (38.2%) girls and 42 (61.8%) boys aged between 2 and 12 years (mean: 6 years).We implanted all of the venous ports in patients for chemotherapy, and port implantation procedures were performed by one experienced Pediatric Surgery. 3 cases (4.4%) have needle access site infections which were controlled with starting of antibiotics. Catheter leakage in 3 cases (4.4%), port-catheter disconnection in 4(5.8%) cases, Occlusion of the system in 5 cases (7.4%). In this period, there were no major complications.Conclusion With proper placement technique and adequate nursing care, they represent a definite improvement in child cancer therapy. Ports can provide satisfactory for the majority of pediatric oncology patients, with a low risk of line-related complications and a high degree of acceptability to children and their parents.

Hashemizadeh Hayede; Borumand Hale; Hiradfar M

2012-01-01

140

Permanent pacemaker implantation in a pregnant woman with rheumatic mitral valve disease.  

UK PubMed Central (United Kingdom)

We describe a rare case of permanent pacemaker implantation in a pregnant woman with rheumatic mitral valve disease previously undergoing percutaneous balloon valvuloplasty. She presented symptomatic advanced atrioventricular block of non-reversible cause and manifest in the third trimester of gestation.

Esper RB; Furtado RH; Tarasoutchi F; Spina GS; Grinberg M; Avila WS

2009-05-01

 
 
 
 
141

Systemic administration of kainic acid induces selective time dependent decrease in [125I]insulin-like growth factor I, [125I]insulin-like growth factor II and [125I]insulin receptor binding sites in adult rat hippocampal formation  

International Nuclear Information System (INIS)

Administration of kainic acid evokes acute seizure in hippocampal pathways that results in a complex sequence of functional and structural alterations resembling human temporal lobe epilepsy. The structural alterations induced by kainic acid include selective loss of neurones in CA1-CA3 subfields and the hilar region of the dentate gyrus followed by sprouting and permanent reorganization of the synaptic connections of the mossy fibre pathways. Although the neuronal degeneration and process of reactive synaptogenesis have been extensively studied, at present little is known about means to prevent pathological conditions leading to kainate-induced cell death. In the present study, to address the role of insulin-like growth factors I and II, and insulin in neuronal survival as well as synaptic reorganization following kainate-induced seizure, the time course alterations of the corresponding receptors were evaluated. Additionally, using histological preparations, the temporal profile of neuronal degeneration and hypertrophy of resident astroglial cells were also studied. [125I]Insulin-like growth factor I binding was found to be decreased transiently in almost all regions of the hippocampal formation at 12 h following treatment with kainic acid. The dentate hilar region however, exhibited protracted decreases in [125I]insulin-like growth factor I receptor sites throughout (i.e. 30 days) the study. [125I]Insulin-like growth factor II receptor binding sites in the hippocampal formation were found to be differentially altered following systemic administration of kainic acid. A significant decrease in [125I]insulin-like growth factor II receptor sites was observed in CA1 subfield and the pyramidal cell layer of the Ammon's horn at all time points studied whereas the hilar region and the stratum radiatum did not exhibit alteration at any time. A kainate-induced decrease in [125I]insulin receptor binding was noted at all time points in the molecular layer of the dentate gyrus whereas binding in CA1-CA3 subfields and discrete layers of the Ammon's horn was found to be affected only after 12 h of treatment. These results, when analysed with reference to the observed histological changes and established neurotrophic/protective roles of insulin-like growth factors and insulin, suggest possible involvement of these growth factors in the cascade of neurotrophic events that is associated with the reorganization of the hippocampal formation observed following kainate-induced seizures. (Copyright (c) 1997 Elsevier Science B.V., Amsterdam. All rights reserved.)

1997-08-11

142

Effect of 125I interstitial radiotherapy on blood-brain barrier function in normal canine brain  

International Nuclear Information System (INIS)

[en] Blood-brain barrier (BBB) function was studied in 14 normal dogs at time periods from 7 to 717 days after permanent insertion of 5- to 7-mCi seeds of iodine-125 (125I) for interstitial radiation. The BBB function was measured with carbon-14-labeled alpha aminoisobutyric acid (AIB) and quantitative autoradiography, and expressed as a unidirectional blood-to-brain transfer constant, K. The 125I radiation lesions consisted of three concentric histologically and functionally distinct zones: 1) a central zone of calcified necrosis; 2) a spongy fluid-filled zone; and 3) a narrow rim (2.6 +/- 0.6 mm wide) of viable brain tissue with increased permeability. Within this rim, the mean value of the K of AIB was 5.8 times that of normal cortex. Over the 7- to 392-day time period the value of K remained rather constant, and by 716 days K values had returned to normal. There was moderate regional variation in the value of K; it was highest in the white matter and lowest in the gray matter surrounding the radiation lesion. The radiation lesion progressively increased in size from 7 to 80 days, after which there was little change. This study illustrates that the geographically circumscribed radiation from 125I seeds is accompanied by similarly well-defined changes in BBB function, which may persist for over 1 year following insertion of the 125I seed. This altered BBB function is probably responsible for the cerebral edema associated with 125I interstitial radiotherapy

1987-01-01

143

A study on recombinant human interleukin 2 radioiodinated with 125I (125I-rIL-2) for RIA  

International Nuclear Information System (INIS)

RIL-2 was labelled with 125I by Iodogen method. The products were purified by HPLC. Analysis of each radiolabelled preparation showed that greater than 95% of the radioiodine was associated with a single protein peak. The specific activity of radioiodinated rIL-2 was approximately 2.2 x 1016-2.8 x 1016 Bq/mol. The 125I-rIL-2 was designed for quantitating human IL-2 with sensitive radioimmunoassay (RIA). The bioactivity of 125I-rIL-2 is good

1994-01-01

144

125I-labelled cobalamin derivative compatible with intrinsic factor  

International Nuclear Information System (INIS)

[en] A 125I-labelled derivative of cobalamin (vitamin B12) is described which is compatible with intrinsic factor in binding assays. The derivative, [125I]cyanocobalamin-d-iodohistamide, can be readily prepared with a specific activity of 1400 Ci/g. Used as a substitute for [57Co]cyanocobalamin in binding assays, the new derivative can reduce counting times and decrease costs in such assays. (Auth.)

1982-12-23

145

Activated carbon badges as detectors of airborne 125I  

International Nuclear Information System (INIS)

[en] The increasing amount of 125I used in labelled protein studies, has lead to an increased risk of contamination to those handling the radioactive material. The C.D.E. Toxic Hazard Monitor, which is both cheap and convenient to use was assessed and found suitable for the quantitative determination of radioactive 125I present in air and which, through inhalation, could be a source of personnel contamination. (author)

1980-01-01

146

Risk for permanent pacemaker after transcatheter aortic valve implantation: a comprehensive analysis of the literature.  

UK PubMed Central (United Kingdom)

BACKGROUND: Permanent pacemaker (PM) requirement is a known complication after transcatheter aortic valve implantation (TAVI). There are, however, no systematic data concerning this complication. OBJECTIVE: To determine the incidence and potential predictors of permanent PM requirement after TAVI based on published literature. METHODS: We conducted a MEDLINE search to identify potentially relevant literature dealing with PM requirement after TAVI. Data were collected on paper extraction forms by 2 independent investigators. RESULTS: There were 32 relevant published studies comprising data of 5,258 patients without an implanted PM before TAVI. An Edwards-Sapiens® prosthesis (ESP) was implanted in 2,887 patients, whereas 2,371 patients received a CoreValve® prosthesis (CVP). The crude incidence of PM implantation after TAVI was 15%. Six hundred and fourteen of 2,371 (25.8%) CVP patients and 189 of the 2,887 (6.5%) ESP patients had to receive a permanent PM (odds ratio [OR] 4.91, 95% confidence interval [CI] 4.12-5.86, P < 0.001). Presence of right bundle branch block (RBBB) before TAVI was a significant predictor for development of complete atrioventricular (AV) block and subsequent PM need (OR 1.358, 95% CI 1.001-1.841, P = 0.02). More than 90% of all AV-block requiring PM implantation occurred immediately or within 7 days after TAVI. CONCLUSION: Patients undergoing TAVI with implantation of CVP are at significantly higher risk for development of AV block and subsequent need for permanent PM, particularly if RBBB preexists. Since AV block occurs in >90% within the first week after the procedure, careful monitoring should be performed for at least 7 days after TAVI.

Erkapic D; De Rosa S; Kelava A; Lehmann R; Fichtlscherer S; Hohnloser SH

2012-04-01

147

Labeling of OxLDL-Ab with 125I  

International Nuclear Information System (INIS)

OxLDL-Ab was labeled with 125I by the Iodogen method, and the labeling was purified by PD-10 column. The optimal condition of radiolabeling reaction was determined. The stability and affinity to OxLDL of 125I-OxLDL-Ab in vitro were evaluated as well. The labeling yield of 125I-OxLDL-Ab was more than 80% and the radiochemical purity was more than 95%. The results of in vitro stability studies showed that the radiochemical purity of 125I-OxLDL-Ab declined less than 5% after 96 h storage under following condition: 0.9%NaCl, 2%BSA in 0.9%NaCl solution and human serum at 4 degree C respectively. In the binding experiments of 125I-OxLDL-Ab and OxLDL, Ka was (1.06 ± 0.13) x 1010 L/mol. The results showed that 125I-OxLDL-Ab had high stability and high affinity to OxLDL, so it was worthy of further research for in vitro diagnosis kit. (authors)

2009-01-01

148

Superior immunoreactivity of 125I-(Des-Tyr-?Ala)-secretin with rabbit anti-secretin sera compared to 125I-secretin and 125I-6-tyrosyl secretin  

International Nuclear Information System (INIS)

[en] A secretin analogue in which the normal amino acid sequence had been elongated by a (Des-Tyr-?Ala)-residue was studied as tracer for secretin radioimmunoassay. 125I-(DATA)-secretin exhibited superior immunoreactivity with several rabbit anti-secretin sera compared to 125I-6-Tyr-secretin and also to secretin iodinated at its N-terminal histidyl residue. This may be due, at least in part, to higher conformational integrity of the secretin moiety in the 125I-(DATA)-secretin molecule. Thus, at present, 125I-(DATA)-secretin appears to be most suitable as tracer for sensitive secretin radioimmunoassay. (orig.)[de] Eine sekretinanaloge Substanz, in der die normale Aminosaeurefolge durch einen (Des-Tyr-?Ala)-Rueckstand verlaengert wurde, wurde als Tracer fuer den Sekretin-RIA untersucht. 125J-(DATA)-Sekretin zeigte im Vergleich zu 125J-6-Tyr-Sekretin sowie zu Sekretin, dessen Histidylrueckstand am N-Terminal jodiert wurde, eine hoehere Immunreaktivitaet bei verschiedenen Anti-Sekretin-Kaninchenseren. Diese Tatsache ist, zumindest zum Teil, mit einer hoeheren Konformationsintegritaet des Sekretinanteils im 125J-(DATA)-Sekretinmolekuel zu erklaeren. 125J-(DATA)-Sekretin ist demzufolge der geeignetste Tracer fuer einen empfindlichen RIA. (orig.)

1976-01-01

149

The effects of permanent I-125 interstitial implantation on cortical bone.  

Science.gov (United States)

From 1973 to 1980, 1,427 cancer patients were treated by the Brachytherapy Service, Radiation Oncology Department of Memorial Sloan-Kettering Cancer Center (MSKCC) with I-125 permanent interstitial implantation. Concern has been expressed with regard to the possible toxic effects of the low average photon energy (28 kev) of I-125 on bone, secondary to its increased absorption in these tissues because of the photoelectric effect. In an attempt to address this concern with respect to cortical bone, we reviewed pertinent data on those patients whose site of implant was at close proximity to osseous tissue in the pelvic, chest wall and head and neck regions. The review included 74 sites in 58 patients having no prior history or clinical evidence of any pathologic or metabolic bony disorder. Long term (greater than 1 year) follow-up was available in over 50% of the cases, with 10 patients followed more than 4 years. Local control rate for the 74 implanted sites was 93%. The implanted activity ranged from 1.6 to 48.8 mCi and the implanted volume from 0.5 to 152 cm3. At this follow-up range, there appears to be no excessive osseous toxicity either clinically or radiologically with I-125 permanent implantation. PMID:3988553

Mandell, L; Nori, D; Anderson, L; Belanich, M; Hilaris, B

1985-05-01

150

The effects of permanent I-125 interstitial implantation on cortical bone.  

UK PubMed Central (United Kingdom)

From 1973 to 1980, 1,427 cancer patients were treated by the Brachytherapy Service, Radiation Oncology Department of Memorial Sloan-Kettering Cancer Center (MSKCC) with I-125 permanent interstitial implantation. Concern has been expressed with regard to the possible toxic effects of the low average photon energy (28 kev) of I-125 on bone, secondary to its increased absorption in these tissues because of the photoelectric effect. In an attempt to address this concern with respect to cortical bone, we reviewed pertinent data on those patients whose site of implant was at close proximity to osseous tissue in the pelvic, chest wall and head and neck regions. The review included 74 sites in 58 patients having no prior history or clinical evidence of any pathologic or metabolic bony disorder. Long term (greater than 1 year) follow-up was available in over 50% of the cases, with 10 patients followed more than 4 years. Local control rate for the 74 implanted sites was 93%. The implanted activity ranged from 1.6 to 48.8 mCi and the implanted volume from 0.5 to 152 cm3. At this follow-up range, there appears to be no excessive osseous toxicity either clinically or radiologically with I-125 permanent implantation.

Mandell L; Nori D; Anderson L; Belanich M; Hilaris B

1985-05-01

151

Fluoroscopy guided transperineal percutaneous permanent 125iodine implantation of prostate cancer.  

UK PubMed Central (United Kingdom)

The transperineal percutaneous template permanent iodine interstitial brachytherapy under "C-arm" fluoroscopic guidance is a simple, easily-learned, accurate and rapid procedure which can be performed without subjecting the patient to celiotomy. We have treated 58 patients by the transperineal percutaneous permanent interstitial brachytherapy. The use of transperineal percutaneous technique with C-arm fluoroscopic guidance improves the symmetry and dosimetry of the implant. This results in reduction of the incidence of chronic radiation-induced complications. In the group of 22 patients who underwent brachytherapy without celiotomy and lymphadenectomy and without adjuvant external-beam radiotherapy, there were no major complications.

Kumar PP; Good RR; Epstein BE; Hussain MB; Bartone FF

1985-07-01

152

Fluoroscopy guided transperineal percutaneous permanent 125iodine implantation of prostate cancer  

International Nuclear Information System (INIS)

The transperineal percutaneous template permanent iodine interstitial brachytherapy under ''C-arm'' fluoroscopic guidance is a simple, easily-learned, accurate and rapid procedure which can be performed without subjecting the patient to celiotomy. We have treated 58 patients by the transperineal percutaneous permanent interstitial brachytherapy. The use of transperineal percutaneous technique with C-arm fluoroscopic guidance improves the symmetry and dosimetry of the implant. This results in reduction of the incidence of chronic radiation-induced complications. In the group of 22 patients who underwent brachytherapy without celiotomy and lymphadenectomy and without adjuvant external-beam radiotherapy, there were no major complications. (author)

1985-01-01

153

Fluoroscopy guided transperineal percutaneous permanent 125iodine implantation of prostate cancer.  

Science.gov (United States)

The transperineal percutaneous template permanent iodine interstitial brachytherapy under "C-arm" fluoroscopic guidance is a simple, easily-learned, accurate and rapid procedure which can be performed without subjecting the patient to celiotomy. We have treated 58 patients by the transperineal percutaneous permanent interstitial brachytherapy. The use of transperineal percutaneous technique with C-arm fluoroscopic guidance improves the symmetry and dosimetry of the implant. This results in reduction of the incidence of chronic radiation-induced complications. In the group of 22 patients who underwent brachytherapy without celiotomy and lymphadenectomy and without adjuvant external-beam radiotherapy, there were no major complications. PMID:3834521

Kumar, P P; Good, R R; Epstein, B E; Hussain, M B; Bartone, F F

154

Influence of Prostatic Edema on 131CS Permanent Prostate Seed Implants: A Dosimetric and Radiobiological Study  

International Nuclear Information System (INIS)

[en] Purpose: To study the influence of prostatic edema on postimplant physical and radiobiological parameters using 131Cs permanent prostate seed implants. Methods and Materials: Thirty-one patients with early prostate cancer who underwent 131Cs permanent seed implantation were evaluated. Dose-volume histograms were generated for each set of prostate volumes obtained at preimplantation and postimplantion days 0, 14, and 28 to compute quality indices (QIs) and fractional doses at level x (FDx). A set of equations for QI, FDx, and biologically effective doses at dose level Dx (BEDx) were defined to account for edema changes with time after implant. Results: There were statistically significant differences found between QIs of pre- and postimplant plans at day 0, except for the overdose index (ODI). QIs correlated with postimplant time, and FDx was found to increase with increasing postimplant time. With the effect of edema, BED at different dose levels showed less improvement due to the short half-life of 131Cs, which delivers about 85% of the prescribed dose before the prostate reaches its original volume due to dissipation of edema. Conclusions: Results of the study show that QIs, FDx, and BEDs at the level of Dx changed from preneedle plans to postimplant plans and have statistically significant differences (p 131C seed implantation, the effect of edema must be accounted for when defining the seed positions, to avoid the possibility of poor dosimetric and radiobiologic results for 131Cs seed implants.

2011-06-01

155

[Insterstitial brachytherapy of localised prostate cancer using iodine 125 permanent implants].  

UK PubMed Central (United Kingdom)

Brachytherapy with permanent implants is a validated method of treatment of prostate adenocarcinomas of favourable prognosis. Its technology is based on endorectal ultrasonography and on peroperative visualisation of the implant and the dose distribution. A strict selection of the patients is necessary before this localised treatment. An active collaboration between urologists, radiophysicists and radiation oncologists is necessary during all the process of selection, treatment and follow-up of the patients. An assessment of the carcinologic and functional results is necessary. Recommendations are formalized by a joint collaboration between members of the AFU and of the SFRO.

Peiffert D

2005-11-01

156

Percutaneous permanent pacemaker implantation via the azygous vein in a patient with superior vena cava occlusion.  

UK PubMed Central (United Kingdom)

Occlusion of the superior vena cava (SVCO) makes implantation of permanent pacemakers challenging and difficult. We describe an extended application of a Medtronic Attain (Medtronic Inc., Minneapolis, MN, USA) guide catheter (a tool designed for delivery of left ventricular pacing leads into the coronary sinus) for delivery of a right ventricular pacing lead via the azygous vein in a 72-year-old woman with SVCO secondary to long-term central venous hemodialysis catheters. This approach allowed the use of an endocardial pacing lead, implantation under local anesthesia, and conventional positioning of the pacemaker generator in the pectoral region in a patient with SVCO.

Kamdar RH; Schilling RJ

2008-03-01

157

A novel radioiodination technique for the production of T3 125 I and T4 125 I for sensitive radioimmunoassay  

International Nuclear Information System (INIS)

Radioiodination of triiodothyronine (T3) using N-bromosuccinimide (NBS) compared with chloramine-T as oxidizing agents was performed to produce a high specific activity T3 125 I and T4 125 I tracers for radioimmunoassay (RIA). Use of NBS as oxidizing agent in radioiodination is being sought for more accuracy. Reaction components of 500 Ci Na-125 I:500 ng T3:250 ng NBS were found the most proper for higher yield (67%) and less damage (5%) in comparison with chloramine-T method. Specific activity (S A) of T3-125 I and T4-125 I produced by NBS procedure were 1451 and 1644 Ci/g respectively. Sensitivity (50% displacement point) of T3 and T4 RIA standard curves made, Using NBS prepared tracers, were 126.7 and 645 pg/tube, respectively. Chloramine-T produced tracers gave sensitivity values of 237.7 and 545 pg/tube, respectively. The NBS procedure is simple economic and gave more satisfactory T3 and T4 tracers than conventional chloramine-T method. 4 figs., 3 tabs.

1993-01-01

158

Rotational bands in $^{121,123,125}$I nuclei  

CERN Document Server

The odd-proton nuclei /sup 121/I, /sup 123/I and /sup 125/I have been studied in /sup 121/Sb( tau ,3n)/sup 121/I, /sup 121/Sb( alpha ,2n) /sup 123/I and /sup 123/Sb( alpha ,2n)/sup 125/I reactions. Two separated structures of levels have been observed. One group of levels shows a strong Delta J=2 pattern predicted by the particle vibration coupling model. The Delta J=1 sequence on a 9/2/sup +/ state is described as a rotational structure built on a deformed state.

Hagemann, U

1976-01-01

159

Electrocardiographic and imaging predictors for permanent pacemaker requirement after transcatheter aortic valve implantation.  

UK PubMed Central (United Kingdom)

BACKGROUND AND AIM OF THE STUDY: Pacemaker (PM) implantation is a possible requirement after transcatheter aortic valve implantation (TAVI). The study aim was to evaluate the electrocardiographic and imaging predictors of the need for PM implantation after TAVI. METHODS: A total of 80 consecutive patients (mean age 82 +/- 6 years) who had been referred for TAVI were included in the study. Transfemoral TAVI was performed in 58 patients (CoreValve ReValving; 72%), while 22 patients (28%) underwent transapical TAVI using the Edwards SAPIEN valve. Patient characteristics, and the frequency of atrioventricular (AV) block, right bundle branch block (RBBB) and left bundle branch block (LBBB), were evaluated for the prediction of PM implantation after TAVI. In addition, the severity and distribution of aortic valve calcification (AVC) were assessed by calculating the Agatston AVC score for the total aortic valve, as well as for each cusp, using dual-source computed tomography. RESULTS: Pre-procedural RBBB was present in six patients (8%), while eight patients (10%) showed pre-procedural LBBB. In 20 of the 80 patients (25%), a new LBBB was observed after TAVI. In 17 TAVI patients (21%; only CoreValve patients) there was an indication for permanent PM implantation that was related to complete AV block (n = 13) or complete RBBB or LBBB with AV delay (n = 4). Four of six patients (67%) with pre-procedural RBBB received a PM after TAVI. Multivariate logistic regression analysis revealed that only prosthesis type (r = 0.30, p = 0.01) and pre-procedural RBBB (r = 0.4, p = 0.02) were significantly associated with the need for permanent PM implantation after TAVI. CONCLUSION: TAVI is frequently associated with new conduction disturbances. A higher incidence of new LBBB and of permanent PM requirement occurred with the CoreValve ReValving system. There was no relationship between the severity or distribution of AVC and the need for PM implantation after TAVI. Patients with pre-procedural RBBB are deemed to be at risk for PM implantation after TAVI.

Koos R; Mahnken AH; Aktug O; Dohmen G; Autschbach R; Marx N; Hoffmann R

2011-01-01

160

Dosimetric and functional analysis of 227 patients treated by permanents prostate implants  

International Nuclear Information System (INIS)

[en] The brachytherapy of prostate by permanent implants is included in the armamentarium of localized prostate cancers with external radiotherapy and radical prostatectomy. The quality evaluation of implantation is essential for the patient and the team managing him. Our retrospective work consisted in analysing the whole of dosimetry data and urinary, digestive and sexual functional results of patients treated in our centers. conclusion: the post-implantation dosimetry analysis is essential to improve the technique and to understand the evolutions. The method of scanning evaluation is difficult but is currently the most used by its accessibility. The low urinary, rectal and sexual morbidity of the brachytherapy makes of this treatment an attractive technique for the patients should be well selected. (N.C.)

2009-01-01

 
 
 
 
161

The experimental study of 125I seed brachytherapy in human hepatocellular carcinoma bearing nude mice  

International Nuclear Information System (INIS)

Objective: To explore the effect and influence of tumor growth, cell proliferation and apoptosis related protein of 125I seed brachytherapy in human hepatocellular carcinoma (HHC) bearing nude mice. Methods: Twelve HHC BEL-7402 cells bearing nude mice were equally divided into treated and control group. One 125I seed with 33.3 MBq was implanted into each mouse in treated group. Afterward the dimensions of tumor in both groups were measured every 3-4 d and also the tumor volume inhibition rates were calculated. Twenty-one days later, nude mice sacrificed and routine pathological examination proceeded. The expression of proliferating cell nuclear antigen (PCNA), bcl-2 and bax were detected by immunohistochemical methods. Results: The maximum tumor inhibition rate of treated group was 49.2%. Routine pathological examination found degenerative necrosis at the site was nearby the seed but the alive tumor cell still presented faraway from the seed. The expression of PCNA and the ratio of bcl-2/bax in treated group were lower than those in control group. Conclusion: The sustained irradiation of 125I seed brachytherapy can direct kill the HHC cell in nude mice or inhibit the proliferation of tumor cells. (authors)

2006-01-01

162

Experimental study on H22 hepatoma transplanted subcutaneously treated by 125I interstitial brachytherapy  

International Nuclear Information System (INIS)

Objective: To evaluate the effectiveness of 125I interstitial brachytherapy in the treatment of H22 hepatoma and to study its mechanism. Methods: H22 hepatoma was inoculated subcutaneously in the right axilla of mice. Seven days later, models were established. Mice were anesthetized by introperitoneal injection of 10% chloral hydrate (0.4 g/kg), 125I seeds were implanted perpendicularly into the tumors. Mice were irradiated for 9-18 days. At the end of the irradiation period, mice were anesthetized and seeds were removed, the size of tumors were measured, whole blood counts, flow cytometry and pathologic examination of tumors were performed, the expression of bax/bcl-2 was evaluated by immunohistochemical method. They were compared with that in the normal group and in the control group. Results: After irradiation all mice were alive, the size of tumors were about 0.44 cm (P0/G1 phase was 37.41% and 51.01% respectively (P1 phase and the expression of bax increased but the expression of bcl-2 decreased (18.51% and 4.94%, respectively, P125I interstitial brachytherapy is a feasible and effective method to treat H22 hepatoma, which produces radiation-induced apoptosis and is arrested in G1 stage. (authors)

2006-01-01

163

Ranges of low energy /sup 119/Sb and /sup 125/I in metals  

Energy Technology Data Exchange (ETDEWEB)

Mean ranges of /sup 119/Sb in tin and /sup 125/I in copper have been measured for the energy region of 10 keV to 60 keV by using the samples prepared by ion-implantation of these nuclides into vacuum-evaporated layers of metals. The observed ranges are in good agreement with those predicted by the theory of Lindhard et al. for 0.1 > epsilon > 0.02, but they are slightly smaller for 0.02 > epsilon > 0.01 in terms of the dimensionless energy epsilon.

Miura, T.; Hatsukawa, Y.; Muramatsu, H.; Nakahara, H.

1985-05-01

164

Electrocardiographic and further predictors for permanent pacemaker requirement after transcatheter aortic valve implantation.  

Science.gov (United States)

The objective of this study was to identify electrocardiographic (ECG) and further predictors for atrioventricular (AV) block with a need for pacemaker (PM) implantation after transcatheter aortic valve implantation (TAVI). Pre- and post-procedural ECGs of patients with severe aortic stenosis and ongoing TAVI were investigated in a prospective study. From 50 consecutive patients enrolled in the study (mean age 80 +/- 6 years, 46% men), 17 (34%) experienced an AV block with subsequent requirement of a permanent PM [16 of 36 (44.4%) with CoreValve System and 1 of 14 (7.1%) with Edwards Sapiens System]. In patients with right bundle branch block (RBBB), PM implantation had to be performed more frequently [6 of 6 (100%) with CoreValve System and none with Edwards Sapiens System], P = 0.005. An AV block (Mobitz II second degree and third degree) occurred mostly within the first 24 h (range: Days 0-13) after the index procedure. No recovery of AV conduction with a change in PM indication occurred in a mean follow-up time of 13 +/- 6 days. Our data demonstrate that patients with pre-operative RBBB and those receiving CoreValve prosthesis are at a significantly higher risk for PM implantation after TAVI. Therefore, patients with the presence of RBBB before TAVI may be at lower risk for PM implantation using the Edwards Sapiens System. PMID:20353965

Erkapic, Damir; Kim, Won K; Weber, Michael; Möllmann, Helge; Berkowitsch, Alexander; Zaltsberg, Sergey; Pajitnev, Dmitri J; Rixe, Johannes; Neumann, Thomas; Kuniss, Malte; Sperzel, Johannes; Hamm, Christian W; Pitschner, Heinz F

2010-03-30

165

Electrocardiographic and further predictors for permanent pacemaker requirement after transcatheter aortic valve implantation.  

UK PubMed Central (United Kingdom)

The objective of this study was to identify electrocardiographic (ECG) and further predictors for atrioventricular (AV) block with a need for pacemaker (PM) implantation after transcatheter aortic valve implantation (TAVI). Pre- and post-procedural ECGs of patients with severe aortic stenosis and ongoing TAVI were investigated in a prospective study. From 50 consecutive patients enrolled in the study (mean age 80 +/- 6 years, 46% men), 17 (34%) experienced an AV block with subsequent requirement of a permanent PM [16 of 36 (44.4%) with CoreValve System and 1 of 14 (7.1%) with Edwards Sapiens System]. In patients with right bundle branch block (RBBB), PM implantation had to be performed more frequently [6 of 6 (100%) with CoreValve System and none with Edwards Sapiens System], P = 0.005. An AV block (Mobitz II second degree and third degree) occurred mostly within the first 24 h (range: Days 0-13) after the index procedure. No recovery of AV conduction with a change in PM indication occurred in a mean follow-up time of 13 +/- 6 days. Our data demonstrate that patients with pre-operative RBBB and those receiving CoreValve prosthesis are at a significantly higher risk for PM implantation after TAVI. Therefore, patients with the presence of RBBB before TAVI may be at lower risk for PM implantation using the Edwards Sapiens System.

Erkapic D; Kim WK; Weber M; Möllmann H; Berkowitsch A; Zaltsberg S; Pajitnev DJ; Rixe J; Neumann T; Kuniss M; Sperzel J; Hamm CW; Pitschner HF

2010-08-01

166

Utility of the NavX® Electroanatomic Mapping System for Permanent Pacemaker Implantation in a Pregnant Patient with Chagas Disease.  

UK PubMed Central (United Kingdom)

Chagas disease is a highly prevalent zoonosis in Mexico, Central, and South America. Early cardiac involvement is one of the most serious complications of this disease, and conduction disturbances may occur at an early age. We describe a young pregnant woman with Chagas disease and a high degree atrioventricular block, who required implantation of a permanent dual chamber pacemaker. Using an electroanatomic navigation EnSite NavX® system the pacemaker was successfully implanted with minimal fluoroscopic exposure. This case demonstrates the safety and feasibility of using an electroanatomic navigation system to guide permanent pacemaker implantation minimizing x-ray exposure in pregnant patients.

Velasco A; Velasco VM; Rosas F; Cevik C; Morillo CA

2013-01-01

167

Getting on with life: accepting the permanency of an implantable cardioverter defibrillator.  

UK PubMed Central (United Kingdom)

Increasing numbers of people with cardiovascular disease are requiring the insertion of Implantable Cardioverter Defibrillators (ICDs). Although these devices are an effective life-saving treatment, psychological distress sometimes accompanies their insertion. A qualitative approach was used to explore the experiences, concerns and needs of recipients of the device in Western Australia. Twenty-two tape-recorded interviews were carried out and transcribed verbatim. This paper focuses on the physical and psychological adjustments following the insertion of the device. A central theme of 'getting on with it' used to cope with the permanency of the device was identified. This was an approach to life in which the presence of the device was accepted and then put aside while life was continued and optimized. This study provides directions for the identification of persons who might be experiencing difficulties adjusting, or who are taking extended amounts of time to accept the permanency of the device.

Williams AM; Young J; Nikoletti S; McRae S

2007-06-01

168

Getting on with life: accepting the permanency of an implantable cardioverter defibrillator.  

Science.gov (United States)

Increasing numbers of people with cardiovascular disease are requiring the insertion of Implantable Cardioverter Defibrillators (ICDs). Although these devices are an effective life-saving treatment, psychological distress sometimes accompanies their insertion. A qualitative approach was used to explore the experiences, concerns and needs of recipients of the device in Western Australia. Twenty-two tape-recorded interviews were carried out and transcribed verbatim. This paper focuses on the physical and psychological adjustments following the insertion of the device. A central theme of 'getting on with it' used to cope with the permanency of the device was identified. This was an approach to life in which the presence of the device was accepted and then put aside while life was continued and optimized. This study provides directions for the identification of persons who might be experiencing difficulties adjusting, or who are taking extended amounts of time to accept the permanency of the device. PMID:17518790

Williams, Anne M; Young, Jeanne; Nikoletti, Sue; McRae, Shelley

2007-06-01

169

[Permanent implant prostate cancer brachytherapy: 2013 state-of-the art].  

UK PubMed Central (United Kingdom)

With an experience of more than 25 years for the pioneers (and more than 14 years in France), permanent implant brachytherapy using iodine 125 seeds (essentially) is now recognized as a valuable alternative therapy for localized low-risk prostate cancer patients. The possible extension of the indications of exclusive brachytherapy towards selected patients in the intermediate-risk group has now been confirmed by several studies. Moreover, for the other patients in the intermediate-risk group and for the patients in the high-risk group, brachytherapy, as an addition to external radiotherapy, could represent one of the best ways to escalate the dose. Different permanent implant brachytherapy techniques have been proposed; preplanning or real-time procedure, loose or stranded seeds (or both), manual or automatic injection of the seeds. The main point here is the ability to perfectly master the procedure and to comply with the dosimetric constraints, which have been recently redefined by the international societies, such as the GEC-ESTRO group. Mid- and long-term results, which are now available in the literature, indicate relapse-free survival rates of about 90% at 5-10 years, the best results being obtained with satisfactory dosimetric data. Comparative data have shown that the incontinence and impotence rates after brachytherapy seemed to be significantly inferior to what is currently observed after surgery. However, a risk of about 3 to 5% of urinary retention is usually reported after brachytherapy, as well as an irritative urinary syndrome, which may significantly alter the quality of life of the patients, and last several months. In spite of those drawbacks, with excellent long-term results, low rates of incontinence and impotence, and emerging new indications (focal brachytherapy, salvage brachytherapy after localized failure of an external irradiation), permanent implant prostate brachytherapy can be expected to be proposed to an increasing number of patients in the next future.

Cosset JM; Hannoun-Lévi JM; Peiffert D; Delannes M; Pommier P; Pierrat N; Nickers P; Thomas L; Chauveinc L

2013-04-01

170

Transatrial permanent pacing lead implantation in a patient of Ebstein's anomaly after one and half repair.  

UK PubMed Central (United Kingdom)

Several innovative approaches have been described to achieve endocardial pacing in patients with operated complex congenital heart diseases. We report herein a case of Ebstein's anomaly who underwent a Hardy's repair with a bidirectional Glenn shunt, tricuspid valve annuloplasty and atrial septal defect closure following which she developed complete heart block. The chest was reopened through the previous midsternotomy and a screw-in lead implanted transatrially that resulted in optimal pacing thresholds. This technique offers a viable alternative for endocardial pacing in peri-operative patients requiring permanent pacing.

Juneja R; Saxena A; Choudhary S; Airan B

2004-11-01

171

Scintillation proximity radioimmunoassay utilizing 125I-labeled ligands  

Energy Technology Data Exchange (ETDEWEB)

A unique type of radioimmunoassay is described that does not require centrifugation or separation. Microbeads containing a fluorophor are covalently linked to antibody. When an /sup 125/I-labeled antigen is added it binds to the beads and, by its proximity, the emitted short-range electrons of the /sup 125/I excite the fluorophor in the beads. The light emitted can be measured in a standard scintillation counter. Addition of unlabeled antigen from tissue extracts displaces the labeled ligand and diminishes the fluorescent signal. Application of scintillation proximity immunoassay to tissue enkephalins, serum thyroxin, and urinary morphine is described. Applications of the principle to study the kinetics of interaction between receptors and ligands are discussed.

Udenfriend, S.; Gerber, L.D.; Brink, L.; Spector, S.

1985-12-01

172

Preparation and evaluation of 125I-aflatoxin B1  

International Nuclear Information System (INIS)

Aflatoxin B1 (AfB1), present in fungus infested crops is highly carcinogenic and is measured by immunoassays. 125I labeled aflatoxin B1 is a key reagent for development of radioimmunoassay (RIA) which exhibits less interference and better sensitivity than other immunoassays. Since AfB1 lacks suitable functional groups for radiolabeling, an oxime derivative of AfB1 was synthesised and evaluated by UV-spectrophotometry and 1H NMR spectroscopy. 125I-histamine was conjugated to AfB1 oxime by mixed anhydride method and purified by solvent extraction followed by TLC. The tracer obtained was immunoreactive, stable as ethanolic solution and could be used in RIA. (author)

2001-01-01

173

Studies on the radiation burden using 125I for radioimmunoassays  

International Nuclear Information System (INIS)

[en] Radiation burden resulting from use of 125I was estimated measuring 125I-concentrations in the laboratories (air, tables, walls and ceiling) and in the urin of the staff during one year. It is shown up that nobody exceeded the allowed radiation dose, however, for optimum radiation protection it is useful to perform radioimmunoassays under a fume-cabinet and applicate iodine tablets to the staff in order to reduce thyroidal iodine clearance. (orig.)[de] Im radioimmunologischen Labor wurden die Konzentrationen an 125J in der Luft, auf den Arbeitsflaechen, in den Arbeitsraeumen (Fenster, Fussboden) sowie im Urin der exponierten Personen im Verlauf eines Jahres gemessen und die resultierende Strahlenbelastung abgeschaetzt. Es ergab sich, dass zu keinem Zeitpunkt eine Erhoehung der erlaubten Personendosis auftrat. Alle untersuchten Personen hatten nachweislich 125J inkorporiert. Zur Vermeidung dieser wenn auch geringen Strahlenbelastung wird das Arbeiten unter Abzuegen empfohlen sowie die Verabreichung von Jodidtabletten zur Reduzierung der Jodidanraffung der Schilddruese. (orig.)

1977-01-01

174

Standardization of 125I by the Sum Peak Method  

International Nuclear Information System (INIS)

This paper describes the standardization of a solution of 125I by the sum peak method, which is based on the single and coincident detection of x rays and ? photons produced in the decay of this nuclide. Two measurement systems have been used, one based on a NaI (well) detector, the other on a extended range Ge detector. Results obtained with both systems agree within 0,3%. (Author) 5 refs

1999-01-01

175

Renal catabolism of /sup 125/I-glicentin  

Energy Technology Data Exchange (ETDEWEB)

The renal catabolism of /sup 125/I-glicentin has been studied in vivo by the disappearance of this peptide from the plasma of bilaterally nephrectomized, ureteral-ligated, or normal rats and by using tubular microinfusion techniques. In addition the catabolism of glicentin by the isolated, perfused kidney has been studied. Results from in vivo studies demonstrated that half-disappearance time was lower in control (59.5 +/- 1.8 min) than in bilaterally nephrectomized rats (97.2 +/- 2.6 min), and this value was significantly higher than that of ureteral-ligated animals (83.2 +/- 1.1 min, P less than 0.005). Microinfusion experiments revealed that when /sup 125/I-glicentin was injected into the proximal tubule, no trichloroacetic-precipitable radioactivity was recovered in the urine, whereas most of inulin injected was recovered. By contrast most of the /sup 125/I-glicentin injected into the distal tubule was recovered in the urine. In isolated kidney experiments, organ clearance rate of /sup 125/I-glicentin averaged 0.88 +/- 0.10 ml/min, a value significantly higher than that of glomerular filtration rate (0.72 +/- 0.06 ml/min, P less than 0.005, paired data), and both parameters showed a close linear relationship (r = 0.90). Urinary clearance of glicentin was negligible. These results demonstrate that the kidney plays a major role in the catabolism of glicentin, mainly by glomerular filtration and tubular catabolism. The site of tubular catabolism appears to be the proximal tubule. Peritubular uptake was minimal.

Lopez-Novoa, J.M.; Santos, J.C.; Villamediana, L.M.; Garrote, F.J.; Thim, L.; Moody, A.J.; Valverde, I.

1986-05-01

176

Preparation of 19-iodocholesterol labelled with 125 I  

International Nuclear Information System (INIS)

[en] In this paper a new method of synthesis of 19-iodo cholesterol labelled with ''125 I, from commercial cholesterol, is described. Its high chemical (96%) and radiochemical (99.9%) purities high yield and short time of preparation permit us to dispose or a more accessible labelled compound, which results appropriates for clinical investigations and in the diagnosis of disturbances of the suprarenal glands. (Author) 9 refs

1986-01-01

177

Breast reconstruction using permanent Becker expander implants: an 18 year experience.  

UK PubMed Central (United Kingdom)

BACKGROUND: Single-stage reconstruction using permanent expander implants is an established technique following mastectomy. Short and long-term outcome data following breast reconstruction using Becker tissue expanders is limited. METHOD: A retrospective case note review of patients undergoing expander-based procedures between 1989 and 2007 was undertaken. Data recorded included postoperative symptoms and complications, the use of radiotherapy, revisional surgery, and device failure. RESULTS: Three hundred and thirteen expanders were used in 276 patients with a mean age of 48.3 (17-78) years, over the 18 year study period. The mean follow up period was 64.6 (1-199) months. 256 Becker expanders were used during 175 latissimus dorsi (LD) and 52 subpectoral (SP) reconstructions, 13 contralateral augmentations and 16 implant replacements. The postoperative infection rate was 5.8%, leading to an expander loss rate of 3.8%. The use of prophylactic antibiotics was associated with an increased postoperative infection rate (p = 0.046). Six haematomas (2.5%) and 12 cases of skin envelope necrosis (5.0%) required unscheduled intervention. Symptoms of pain, distortion and hardness were experienced by 21.3% of patients, and radiotherapy was associated with a significantly higher risk of adverse symptoms (p < 0.0001). No patient developed symptomatic implant rupture or silicone granuloma but 17.9% of reconstructions underwent revisional surgery, the rate being highest following SP reconstruction (p = 0.029). Nine patients developed injection port complications (3.8%), and the overall device failure rate was 1.3%. The original expander has been retained by 74.2% of women. CONCLUSION: The Becker permanent expander is a reliable implant associated with a low complication rate and a high retention rate when used during breast reconstruction.

Goh SC; Thorne AL; Williams G; Laws SA; Rainsbury RM

2012-12-01

178

In patients undergoing aortic valve replacement, what factors predict the requirement for permanent pacemaker implantation?  

UK PubMed Central (United Kingdom)

A best evidence topic in cardiac surgery was written according to a structured protocol. The question was to determine what preoperative, perioperative and postoperative factors influence the requirement for permanent pacemaker (PPM) implantation postisolated aortic valve replacement (AVR). Transcatheter aortic valve intervention was not included in this analysis. Using the reported search method outlined below, 705 papers were found. No randomised controlled trials, meta-analyses or registries were identified. Seven single-centre retrospective observational studies represent the best evidence on the subject. The author, journal, date and country of publication, level of evidence, patient group studied, study type, outcomes and results were tabulated. The incidence of PPM implantation following AVR varied from 3.0% to 11.8% (mean 7.0%, median 7.2%). Current best available evidence suggests that baseline evidence of conducting system disease - first degree atrioventricular block (AVB), left anterior hemiblock, right bundle branch block (RBBB) or left bundle branch block (LBBB) is the most powerful independent predictor of PPM requirement following AVR. Other important predictors are surgery for aortic regurgitation, preoperative myocardial infarction and longer perioperative cardiopulmonary bypass time. No consistent postoperative factors were identified. The mean time to PPM implant postAVR ranged from 6 to 13 days in the four studies that reported it. Current European Society of Cardiology guidelines recommend a period of seven days of persistent AVB postsurgery prior to PPM implantation.

Matthews IG; Fazal IA; Bates MG; Turley AJ

2011-03-01

179

In patients undergoing aortic valve replacement, what factors predict the requirement for permanent pacemaker implantation?  

Science.gov (United States)

A best evidence topic in cardiac surgery was written according to a structured protocol. The question was to determine what preoperative, perioperative and postoperative factors influence the requirement for permanent pacemaker (PPM) implantation postisolated aortic valve replacement (AVR). Transcatheter aortic valve intervention was not included in this analysis. Using the reported search method outlined below, 705 papers were found. No randomised controlled trials, meta-analyses or registries were identified. Seven single-centre retrospective observational studies represent the best evidence on the subject. The author, journal, date and country of publication, level of evidence, patient group studied, study type, outcomes and results were tabulated. The incidence of PPM implantation following AVR varied from 3.0% to 11.8% (mean 7.0%, median 7.2%). Current best available evidence suggests that baseline evidence of conducting system disease - first degree atrioventricular block (AVB), left anterior hemiblock, right bundle branch block (RBBB) or left bundle branch block (LBBB) is the most powerful independent predictor of PPM requirement following AVR. Other important predictors are surgery for aortic regurgitation, preoperative myocardial infarction and longer perioperative cardiopulmonary bypass time. No consistent postoperative factors were identified. The mean time to PPM implant postAVR ranged from 6 to 13 days in the four studies that reported it. Current European Society of Cardiology guidelines recommend a period of seven days of persistent AVB postsurgery prior to PPM implantation. PMID:21138915

Matthews, Iain G; Fazal, Iftikhar A; Bates, Matthew G D; Turley, Andrew J

2010-12-07

180

Radioactive 125I Seed Inhibits the Cell Growth, Migration, and Invasion of Nasopharyngeal Carcinoma by Triggering DNA Damage and Inactivating VEGF-A/ERK Signaling  

Science.gov (United States)

Although radiotherapy technology has progressed rapidly in the past decade, the inefficiency of radiation and cancer cell resistance mean that the 5-year survival rate of patients with nasopharyngeal carcinoma (NPC) is low. Radioactive 125I seed implantation has received increasing attention as a clinical treatment for cancers. Vascular endothelial growth factor-A (VEGF-A) is one of the most important members of the VEGF family and plays an important role in cell migration through the extracellular-signal-regulated kinase (ERK) pathway. Here we show that radioactive 125I seeds more effectively inhibit NPC cell growth through DNA damage and subsequent induction of apoptosis, compared with X-ray irradiation. Moreover, cell migration was effectively inhibited by 125I seed irradiation through VEGF-A/ERK inactivation. VEGF-A pretreatment significantly blocked 125I seed irradiation-induced inhibition of cell migration by recovering the levels of phosphorylated ERK (p-ERK) protein. Interestingly, in vivo study results confirmed that 125I seed irradiation was more effective in inhibiting tumor growth than X-ray irradiation. Taken together, these results suggest that radioactive 125I seeds exert novel anticancer activity by triggering DNA damage and inactivating VEGF-A/ERK signaling. Our finding provides evidence for the efficacy of 125I seeds for treating NPC patients, especially those with local recurrence.

Tian, Yunming; Liu, Ying; Huang, Zuoping; Fan, Cundong; Hou, Bing; Sun, Dan; Yao, Kaitai; Chen, Tianfeng

2013-01-01

 
 
 
 
181

Radioactive (125)I Seed Inhibits the Cell Growth, Migration, and Invasion of Nasopharyngeal Carcinoma by Triggering DNA Damage and Inactivating VEGF-A/ERK Signaling.  

Science.gov (United States)

Although radiotherapy technology has progressed rapidly in the past decade, the inefficiency of radiation and cancer cell resistance mean that the 5-year survival rate of patients with nasopharyngeal carcinoma (NPC) is low. Radioactive (125)I seed implantation has received increasing attention as a clinical treatment for cancers. Vascular endothelial growth factor-A (VEGF-A) is one of the most important members of the VEGF family and plays an important role in cell migration through the extracellular-signal-regulated kinase (ERK) pathway. Here we show that radioactive (125)I seeds more effectively inhibit NPC cell growth through DNA damage and subsequent induction of apoptosis, compared with X-ray irradiation. Moreover, cell migration was effectively inhibited by (125)I seed irradiation through VEGF-A/ERK inactivation. VEGF-A pretreatment significantly blocked (125)I seed irradiation-induced inhibition of cell migration by recovering the levels of phosphorylated ERK (p-ERK) protein. Interestingly, in vivo study results confirmed that (125)I seed irradiation was more effective in inhibiting tumor growth than X-ray irradiation. Taken together, these results suggest that radioactive (125)I seeds exert novel anticancer activity by triggering DNA damage and inactivating VEGF-A/ERK signaling. Our finding provides evidence for the efficacy of (125)I seeds for treating NPC patients, especially those with local recurrence. PMID:24040157

Tian, Yunhong; Xie, Qiang; Tian, Yunming; Liu, Ying; Huang, Zuoping; Fan, Cundong; Hou, Bing; Sun, Dan; Yao, Kaitai; Chen, Tianfeng

2013-09-10

182

Permanent pacemaker implantation in the cardiac catheterization laboratory versus the operating room: an analysis of hospital charges and complications.  

UK PubMed Central (United Kingdom)

Permanent pacemakers may be implanted in operating rooms, special procedure laboratories, or cardiac catheterization laboratories. Previous investigators have shown no difference in efficacy or complications in the operating room versus the cardiac catheterization laboratory. We retrospectively analyzed the hospital bills of 30 patients undergoing permanent pacemaker implantation at our institution. Group I was 15 consecutive patients implanted in the operating room and group II was 15 consecutive patients implanted in the cardiac catheterization laboratory, all by the same operators. Hospital charges that were specific to the site of implantation were analyzed. Physician charges for implantation, anesthesiologist, and radiologist charges were not analyzed. There were no in-hospital complications in either group. The mean charges for group I were $1,856.00 and group II were $1,075.00 (P < 0.001). We conclude that implantation of permanent pacemakers in the cardiac catheterization laboratory is associated with significantly lower hospital charges compared to implantation in the operating room and has an equally low complication rate.

Stamato NJ; O'Toole MF; Enger EL

1992-12-01

183

Intraoperative modification method in the transperineal permanent implant of I-125 seed in prostate cancer  

International Nuclear Information System (INIS)

In the Department of Radiation Therapy and Oncology, International Medical Center of JAPAN, transperineal permanent implant (TPI) of I-125 seeds have been performed since April 2004. In April the planning method was changed from the preplanning to the intraoperative modification method in April 2006. Various dose parameters were compared between the 106 patients treated by preplanning and the 42 patients undergoing the intraoperative modification. The mean operation time was 84 minutes in the preplanned method and 92 minutes in the intraoperative modification. The prostatic volume reduced at the postplanning, compared to the preplanning. Dosimetric parameters of prostate (V100, V150, and D90%) diminished at the time of postplanning with a statistical significance, while the degree of the reductions was greater in the patients treated by the preplanned method. The mean prostate V100 of the preplanning and the intraoperative modification was 89% and 93.3%, respectively, and the mean prostate D90% was 100% and 111%, respectively, both with a statistically significant difference. In contrast, urethral and rectal dose parameters were the same in both methods. The intraoperative modification method was useful to attain the high quality permanent implant of I-125 seeds. (author)

2007-01-01

184

Case report on extensive left atrial myxoma removal with permanent pacemaker implantation  

Directory of Open Access Journals (Sweden)

Full Text Available Aim: To represent a case report of extensive left atrial myxoma removal with permanent pacemaker implantation. Methods: A 56-year old female patient admitted to the Bakulev Center of Cardiovascular Surgery with cardiac evaluation. She noted progressive chest pain associated with dyspnea and fatigue. After physical examination, transthoracic echocardiography and other methods of evolution confirmed the diagnosis: Tumor of the left atrium. Left atrial dilatation. Left ventricle hypertrophy. Arterial hypertension 2 stage of high risk. Circulatory failure 2 stage (by Strazhesko-Vasilenko), functional class II by NYHA. The huge tumor was successfully excised with closure of atrial septal defect by patch. Results: Transthoracic echocardiography in postoperative period showed a normal left and right ventricular function and no residual shunts. The presence of conduction abnormalities in early postoperative period predicted the need for permanent pacemaker implantation. Conclusions: It must be noted rare occurrence of a huge tumor (myxoma) filling left atrium. Large left atrial tumor is approached by biatrial incision with further excision. It is believed that the case can be beneficial in huge cardiac tumors management. Early detection and surgical treatment of heart tumors can reduce the risk of heart failure, systemic embolization, syncope and sudden cardiac death.

Bokeria L.A.; Bokeria O.L; Donakanyan S. A.; Biniashvili M.B.; Petrosyan A.D.

2013-01-01

185

Preparation of 19-iodo cholesterol labelled with 125 I; Preparacion del 19-yodocolesterol marcado con 125 I  

Energy Technology Data Exchange (ETDEWEB)

In this paper a new method of synthesis of 19-iodo cholesterol labelled with ''125 I, from commercial cholesterol, is described. Its high chemical (96%) and radiochemical (99.9%) purities high yield and short time of preparation permit us to dispose or a more accessible labelled compound, which results appropriates for clinical investigations and in the diagnosis of disturbances of the suprarenal glands. (Author) 9 refs.

Rodriguez, L.; Rebollo, D. V.; Ruiz, J. M.

1986-07-01

186

Dose rate effect of [sup 125]I irradiation on normal rabbit eyes and experimental choroidal melanoma  

Energy Technology Data Exchange (ETDEWEB)

The dose rate effect of radiation by [sup 125]I plaque on choroidal melanoma and normal intraocular tissue was studied. In the first part of the experiment, high activity plaques (HAP) and low activity plagues (LAP) were implanted on rabbit eyes with experimental Greene choroidal melanoma to deliver a total dose of 10 000 cGy to the tumor apex. The mean dose rate calculated at 0.5 mm from the inner sclera in eight eyes with high activity plaques was 3341.5 cGy hr[sup -1] while that in ten eyes with low activity plaques was 239.9 cGy hr[sup -1]. For tumors less than 1.0 mm in height, both groups showed complete tumor regression at the tumor implantation site after plaque treatment. For tumours more than 1.0 mm in height, two out of two eyes in the low activity plaque group and one of four eyes in the high activity plaque group failed to show complete tumor regression. In the second part of the experiment, [sup 125]I plaques were implanted on the sclera of 12 normal rabbits' eyes. Six received high dose rate plaque treatment, while the other six received low dose rate plaque treatment. Clinical and histologic examinations demonstrated more damaging effects to the normal chorioretinal tissues at the plaque implantation site in the high dose rate plaque group. These results suggest that high dose rate plaques are more effective than low dose rate plaques when tumor height is statistically controlled. (Author).

Yang, C.M.; Olsen, K.R. (Bascom Palmer Eye Inst., Miami, FL (United States)); Schwade, J.G.; Houdek, P.V.; Markoe, A.M.; Pisciotta, V.; Xiaodong Wu (Miami Univ., FL (United States). School of Medicine)

1993-11-01

187

Synthesis and radioimmunological characterization of testosterone-3-carboxymethyloxime-tyramine-125 I (T-3-Cmo-Ty-125 I)  

International Nuclear Information System (INIS)

The paper presents the synthesis and radioimmunological characterization of testosterone-3-carboxymethyloxime-tyramine-15 I (T-3-CMO-Ty-125 I), a reagent used as marker in radioimmunoassay (RIA) of steroid hormones. Some of the most adequate techniques of analyzing the steroid hormones are RIA and ELISA (enzyme linked immunosorbent assay) due to their sensitivity and specificity. These techniques do not require advanced purification of the sample. In the view of developing a sensitive RIA technique for assaying the testosterone-3-carboxymethyloxime-tyramine-125 I it is necessary to obtain the reagents as anti-testosterone antibody and radioactive labeled testosterone. The carboxy derivative of the steroid hormone was activated with ethylchloroformiate and tributylamine in dioxan and coupled with tyramine-125 I. Tyramine was labelled by chloramine method. The marker was purified by thin layer chromatography and extracted in methylic alcohol. Radioimmunological characterization of the marker was carried out with the help of the anti testosterone antibody obtained in our laboratory. (authors)

2002-01-01

188

The use of new GAFCHROMIC EBT film for 125I seed dosimetry in Solid Water phantom.  

UK PubMed Central (United Kingdom)

Radiochromic film dosimetry has been extensively used for intravascular brachytherapy applications for near field within 1 cm from the sources. With the recent introduction of new model of radiochromic films, GAFCHROMIC EBT, with higher sensitivity than earlier models, it is promising to extend the distances out to 5 cm for low dose rate (LDR) source dosimetry. In this study, the use of new model GAFCHROMIC EBT film for 125I seed dosimetry in Solid Water was evaluated for radial distances from 0.06 cm out to 5 cm. A multiple film technique was employed for four 125I seeds (Implant Sciences model 3500) with NIST traceable air kerma strengths. Each experimental film was positioned in contact with a 125I seed in a Solid Water phantom. The products of the air kerma strength and exposure time ranged from 8 to 3158 U-h, with the initial air kerma strength of 6 U in a series of 25 experiments. A set of 25 calibration films each was sequentially exposed to one 125I seed at about 0.58 cm distance for doses from 0.1 to 33 Gy. A CCD camera based microdensitometer, with interchangeable green (520 nm) and red (665 nm) light boxes, was used to scan all the films with 0.2 mm pixel resolution. The dose to each 125I calibration film center was calculated using the air kerma strength of the seed (incorporating decay), exposure time, distance from seed center to film center, and TG43U1S1 recommended dosimetric parameters. Based on the established calibration curve, dose conversion from net optical density was achieved for each light source. The dose rate constant was determined as 0.991 cGy U(-1)h(-1) (+/-6.9%) and 1.014 cGy U(-1)h(-1) (+/-6.8%) from films scanned using green and red light sources, respectively. The difference between these two values was within the uncertainty of the measurement. Radial dose function and 2D anisotropy function were also determined. The results obtained using the two light sources corroborated each other. We found good agreement with the TG43U1S1 recommended values of radial dose function and 2D anisotropy function, to within the uncertainty of the measurement. We also verified the dosimetric parameters in the near field calculated by Rivard using Monte Carlo method. The radial dose function values in Solid Water were lower than those in water recommended by TG43U1S1, by about 2%, 3%, 7%, and 14% at 2, 3, 4, and 5 cm, respectively, partially due to the difference in the phantom material composition. Radiochromic film dosimetry using GAFCHROMIC EBT model is feasible in determining 2D dose distributions around low dose rate 125I seed. It is a viable alternative to TLD dosimetry for 125I seed dose characterization.

Chiu-Tsao ST; Medich D; Munro J 3rd

2008-08-01

189

Decline of dose coverage between intraoperative planning and post implant dosimetry for I-125 permanent prostate brachytherapy: Comparison between loose and stranded seed implants  

International Nuclear Information System (INIS)

[en] Background and purpose: In permanent prostate brachytherapy the dose distributions 4 weeks post implant differ from the intraoperative dose distributions. The purpose of this study is to compare intraoperative planning and post implant dosimetry for loose and stranded seed implants. Materials and methods: This study investigates prostate dose coverage in 389 patients with stage T1 or T2 prostate cancer treated in the years 2005, 2006 and 2007. The patients received either a loose seed or a stranded seed implant. All patients had US-based intraoperative planning and CT/MRI-based post implant dosimetry after 4 weeks. Results: Intraoperative and post implant D90 values amounted 183 ± 13 Gy (mean ± standard deviation) and 161 ± 30 Gy, respectively. Decline of D90 values (mean and 95% confidence interval) between intraoperative planning and post implant dosimetry for RAPID strand (n = 67), Intersource strand (n = 136) and loose selectSeeds (n = 186) implants amounted to -40 (-45 to -34) Gy, -25 (-28 to -21) Gy and -15 (-18 to -21) Gy, respectively. Conclusions: The patients treated in the period 2005-2007 with stranded or loose seed implants had on average adequate D90 values of 161 ± 30 Gy. Post implant D90 values were 22 ± 27 Gy lower compared to intraoperative planning. Decline of dose coverage between intraoperative planning and post implant dosimetry was significantly larger for the stranded seed implants.

2009-01-01

190

Study on agroecology contamination from 125I gas and control measures in a simulated ecosystem  

International Nuclear Information System (INIS)

The study was made in an air-tight space in which a simulated agricultural ecosystem was contaminated from 125I gas. The contents of the study were summarized as follows: The space and time distribution of 125I gas, contamination of foliage of the plants, accumulation and transfer of 125I fallen on the soil and entered into the plants from the roots of crops and vegetables, the time distribution of 125I in crops in water contaminated from 125I fallout, distribution, accumulation and transfer of 125I in chickens and rabbits which inhaled 125I gas or fed the fodder contaminated from 125I. The control measures of contamination in agroenvironment from 125I were discussed. (7 refs., 20 figs., 29 tabs.).

1995-01-01

191

Implantation port-catheter permanent indwelling of pulmonary artery in treating lung metastasis from HCC  

International Nuclear Information System (INIS)

Objective: To observe the efficacy of a percutaneous implantation port-catheter permanent indwelling pulmonary artery for regional chemotherapy of the metastatic lung cancer from HCC. Methods: Between 1995 and 1999, 62 patients (42 males, 20 females; mean age 46 years) suffering from the metastatic lung cancer from HCC underwent percutaneous implantation of port-catheter permanent indwelling pulmonary artery using the right subclavian vein. In 19 patients with metastatic tumor located on one side of the lung, an indwelling catheter was placed into the ipsilateral side pulmonary artery. With metastasis of both sides, the catheter was inserted into the main trunk of pulmonary artery. The regimens of the chemotherapy were 5-FU + CDDP + MMC(FDM) or 5-FU + CDDP + MMC(FDA). Results: The interventional procedure was successfully completed in all 62 cases (100%). The complications occurred in 8% cases, including infections (3.2%), unhealed wound (1.6%) and pneumothorax (3.2%). The treatment effects of 3-months after the procedure were as follows: the obvious decrease of lung tumor size was 35.5%; stable disease (SD) 32.3% and progressive disease (PD) 32.3%. 6 months follow-up: 12 patients were dead (12/62) and the others are still doing well. The response rates were 22.6%, partial response (PR) 32.3%; stable disease (SD) 25.8% and progressive disease (PD) 32.3%. Conclusions: The percutaneous implantation techniques of pulmonary arterial port-catheter could be a good method in the treatment of metastatic lung cancer from HCC because of it is simple, with few complications and positive effect

2000-01-01

192

Third-generation mobile phones (UMTS) do not interfere with permanent implanted pacemakers.  

UK PubMed Central (United Kingdom)

AIMS: Third-generation mobile phones, UMTS (Universal Mobile Telecommunication System), were recently introduced in Europe. The safety of these devices with regard to their interference with implanted pacemakers is as yet unknown and is the point of interest in this study. METHODS AND RESULTS: The study comprised 100 patients with permanent pacemaker implantation between November 2004 and June 2005. Two UMTS cellular phones (T-Mobile, Vodafone) were tested in the standby, dialing, and operating mode with 23 single-chamber and 77 dual-chamber pacemakers. Continuous surface electrocardiograms (ECGs), intracardiac electrograms, and marker channels were recorded when calls were made by a stationary phone to cellular phone. All pacemakers were tested under a "worst-case scenario," which includes a programming of the pacemaker to unipolar sensing and pacing modes and inducing of a maximum sensitivity setting during continuous pacing of the patient. Patients had pacemaker implantation between June 1990 and April 2005. The mean age was 68.4 +/- 15.1 years. Regardless of atrial and ventricular sensitivity settings, both UMTS mobile phones (Nokia 6650 and Motorola A835) did not show any interference with all tested pacemakers. In addition, both cellular phones did not interfere with the marker channels and the intracardiac ECGs of the pacemakers. CONCLUSION: Third-generation mobile phones are safe for patients with permanent pacemakers. This is due to the high-frequency band for this system (1,800-2,200 MHz) and the low power output between 0.01 W and 0.25 W.

Ismail MM; Badreldin AM; Heldwein M; Hekmat K

2010-07-01

193

Radiation effect of 125I UdR on growth of Sca-BER cells  

International Nuclear Information System (INIS)

Objective: To determine the inhibition effects of 125I UdR in human bladder cancer cell line Sca-BER. Methods: 125I UdR were added to the RPMI1640 culturing medium. The amount of 125I UdR uptaken by Sca-BER cells was evaluated through measuring the radioactivity per cell; the killing effects of 125I UdR on Sca-BER cells were estimated by colony forming method. To determine the co-inhibition effects of MTX, 125I UdR and MTX were added to medium, measuring the radioactivity per cell. Results: The amounts of 125I UdR uptaken by Sca-BER was growing up as function of 125I UdR dose in the medium (r=0.99). The surviving fraction was correlated with the concentration of 125I UdR (r=-0.9). The LD50 of 125I UdR group was (1.17 ± 0.27) kBq/ml and the surviving fraction of 125I UdR group was significantly lower than that of Na125I group (P125I UdR of the same concentration was added to the medium. With time elapsing, the amount of 125I UdR and MTX were added to medium, the amount of 125I UdR uptaken was increased for 10 times. Conclusions: 125I UdR can be incorporated into Sca-BER cells, and the concentration of 125I UdR in Sca-BER cells was influenced by 125I UdR dose in the medium. The inhibitory radiation effects of 125I UdR on Sca-BER cells are obvious. (authors)

2004-01-01

194

Killing effect of 125I-UdR on human lymphoma Raji and Daudi cell lines  

International Nuclear Information System (INIS)

Objective: To evaluate the killing effect and the uptake of 125I-UdR on human lymphoma Raji and Daudi cell lines. Methods: The amount of 125I-UdR in the cells and cell nuclei were determined after incubation of different time in RPMI 1640 culturing medium containing different concentrations of 125I-UdR. The killing effects of 125I-UdR on Raji and Daudi cell lines were estimated through MTT assay and cell cycle was analyzed by propidium iodide (PI) staining. Results: The amounts of 125I-UdR in Raji and Daudi cells and cell nuclei were much higher than that of Na125I( P125I-UdR in Raji and Daudi cells were 14 414 ± 95 and (6916 ± 53.69) Bq/106 cell when the concentration was 100 kBq/ml. The amounts of Na125I were 68±3.8 and (324±32.8) Bq/106 cell. The uptake of 125I-UdR in Raji and Daudi cells and cell nuclei increased with the 125I-UdR concentration and incubated time. The cell surviving fractions of 125I-UdR groups was much lower than that of Na125I groups (P125I-UdR groups were (19.78±1.39)% and (43.17±2.69)%; those of Na125I groups were(79.10±1.79)% and (80.36±6.12)%. The surviving fi:actions of 125I-UdR groups reduced with the 125I-UdR concentration. Conclusions: 125I-UdR can Be specially ingested by Raji and Daudi cells and incorporated into DNA, then the cells will be killed. The uptake of 125I-UdR is dose and time dependent. (authors)

195

Permanent interstitial implantation using palladium-103: the New York Medical College preliminary experience.  

UK PubMed Central (United Kingdom)

Palladium-103 is a low energy photon emitter available for permanent interstitial implantation. Pd-103 has energy and safety characteristics similar to Iodine-125, but its initial peripheral dose rate is approximately three times greater. This may provide improved control of rapidly proliferating tumors. At the Westchester Campus of New York Medical College, 15 patients with residual or recurrent unresectable lesions were implanted with Pd-103. There were five males and 10 females with an age range of 41 to 93 years (median 58). Implanted sites included the chest wall, nasopharynx, vagina, and zygomatic region. Peripheral doses ranged from 55 to 203 Gy (median 107 Gy). A complete response was achieved in eight patients and a partial response in seven patients, for an overall response rate of 100%. We noted improved control with smaller volumes and peripheral doses at or above 115 Gy. No unusual skin or mucosal reactions were recorded. Possible advantages of Pd-103 as a substitute for I-125 include improved control of rapidly proliferating tumors and a more rapid clinical response of lesions. Disadvantages include current higher cost and an impracticality in maintaining a running inventory because of the short half-life of the isotope. Our experience suggests that Pd-103 is an attractive alternative to I-125.

Porrazzo MS; Hilaris BS; Moorthy CR; Tchelebi AE; Mastoras CA; Shih LL; Stabile L; Salvaras N

1992-01-01

196

Permanent interstitial implantation using palladium-103: the New York Medical College preliminary experience.  

Science.gov (United States)

Palladium-103 is a low energy photon emitter available for permanent interstitial implantation. Pd-103 has energy and safety characteristics similar to Iodine-125, but its initial peripheral dose rate is approximately three times greater. This may provide improved control of rapidly proliferating tumors. At the Westchester Campus of New York Medical College, 15 patients with residual or recurrent unresectable lesions were implanted with Pd-103. There were five males and 10 females with an age range of 41 to 93 years (median 58). Implanted sites included the chest wall, nasopharynx, vagina, and zygomatic region. Peripheral doses ranged from 55 to 203 Gy (median 107 Gy). A complete response was achieved in eight patients and a partial response in seven patients, for an overall response rate of 100%. We noted improved control with smaller volumes and peripheral doses at or above 115 Gy. No unusual skin or mucosal reactions were recorded. Possible advantages of Pd-103 as a substitute for I-125 include improved control of rapidly proliferating tumors and a more rapid clinical response of lesions. Disadvantages include current higher cost and an impracticality in maintaining a running inventory because of the short half-life of the isotope. Our experience suggests that Pd-103 is an attractive alternative to I-125. PMID:1639637

Porrazzo, M S; Hilaris, B S; Moorthy, C R; Tchelebi, A E; Mastoras, C A; Shih, L L; Stabile, L; Salvaras, N

1992-01-01

197

Hematoma complicating permanent pacemaker implantation: the role of periprocedural antiplatelet or anticoagulant therapy.  

UK PubMed Central (United Kingdom)

BACKGROUND: Periprocedural management of antiplatelet or anticoagulant therapy at the time of device implantation remains controversial. METHODS: We reviewed all cases for whom a pacemaker was implanted in our institution between January 2008 and June 2009. In addition, beginning in June 2009, we prospectively collected data from all patients admitted to our institution, for whom a pacemaker was placed. Clinical characteristics and anticoagulant/antiplatelet drug use were evaluated. RESULTS: A total of 574 patients underwent a permanent pacemaker implantation. Of these, 20 patients (3.6%, 9 women) experienced a hematoma on pacemaker pocket site. Patients were aged between 35 and 79 years (mean 60.6 ± 12 years). The frequency of hematoma formation was significantly higher (p<0.001) in those who used warfarin than in those who did not. Aspirin (ASA), clopidogrel, dual antiplatelet therapy (DAT), and bridging to low-molecular-weight heparin (LMWH) did not increase the risk of hematoma formation (p>0.05). Eleven pocket revisions for hematoma evacuation were needed in 9 patients (1.6%), six of whom were on warfarin therapy (p>0.05). Co-morbidities were similar in patients with and without hematoma (p>0.05). CONCLUSION: The frequency of hematoma is within acceptable ranges after pacemaker placement. The use of warfarin seriously increases the risk of hematoma. Bridging to LMWH safely prevents thromboembolism.

Özcan KS; Osmonov D; Y?ld?r?m E; Altay S; Türkkan C; Ekmekçi A; Güngör B; Erdinler I

2013-08-01

198

Development of procedure using plasma welding process to produce 125I seeds  

International Nuclear Information System (INIS)

The prostate cancer, which is the second cause of death by cancer in men, overcome only by lung cancer, is a problem of public health in Brazil. Brachytherapy is among the possible available treatments for prostate cancer, in which small seeds containing 125I radioisotope are implanted in the prostate. The seed consists of a titanium sealed capsule with 0.8 mm external diameter and 4.5 mm length, containing a central silver wire with adsorbed 125I. The plasma arc welding is one of the viable techniques for the sealing process. The equipment used in this technique is less costly than in other processes. The main objective of this work was the development and the validation of the welding procedure using plasma welding process and the elaboration of a sealing routine according to Good Manufacturing Practices. The development of this work has presented the following phases: cut and cleaning of the titanium material, determination of the welding parameters, development of a device for holding the titanium tube during the welding process, validation of sealed sources according to ISO 2919 Sealed Radioactive Sources - General Requirements and Classification, leakage test according to ISO 9978 Sealed Radioactive Sources - Leakage Test Methods and metallographic assays. The developed procedure, to seal 125I seeds using plasma welding process, has shown to be efficient, satisfying all the established requirements of ISO 2919. The results obtained in this work have given the possibility to establish a routine production process according to the orientations presented in resolution RDC number 59 - Good Manufacturing Practices do Medical Products of the ANVISA - Brazilian Nacional Agency of Sanitary Surveillance. (author)

2006-01-01

199

Thermoluminescent dosimetry of the SourceTech Medical model STM1251 125I seed  

International Nuclear Information System (INIS)

Many new models of 125I seeds are being introduced, mainly due to the increase in prostate seed implants. We have evaluated the SourceTech Medical (STM), model STM1251, 125I seed using thermoluminescent dosimeters (TLDs) in a solid water phantom. TLD cubes, LiF TLD-100, with dimension 1 mm on each edge, were irradiated at various distances, 1, 2, 3, and 5 cm, at angles ranging from 0 deg. to 90 deg. in 10 deg. increments. Sensitivity calibration of the TLDs was achieved by irradiation to 10 cGy with 6 MV x rays from a clinical linear accelerator, Clinac 600C. Concurrent with the 125I seed exposures, several TLDs were also exposed to 10 cGy with the 600C as a control set. Dose rates per unit air kerma strength were determined based on the 1999 NIST traceable standard for the STM1251 seed. They are presented as a function of distance r and angle ?. The TG-43 parameters, including the dose rate constant, ?, anisotropy function, F(r,?), radial dose function, g(r), anisotropy factor, ?an(r), and anisotropy constant, ?, were obtained for use in radiation treatment planning software. The value of ? was determined as 1.07±5.5% cGy U-1 h-1, which is comparable to model 6702 and to the value determined using the point extrapolation method by Kirov and Williamson. We also find agreement between our TLD data and their Monte Carlo results for g(r), F(r,?), ?an(r), and ?. Additionally, agreement is found with the TLD data of Li and Williamson for ? and g(r)

2003-01-01

200

Distribution of progesterone receptor in the 20-day-old fetal mouse: an autoradiographic study with [125I]progestin  

International Nuclear Information System (INIS)

The distribution of progestin target sites in 20-day-old fetuses of estrogen-primed pregnant mice was investigated by thaw-mount autoradiography. Pregnant mice received a Silastic estradiol implant on day 17 and were ovariectomized on day 19 of pregnancy. Twenty-four hours after ovariectomy 10 prematurely delivered fetuses were each injected with 0.33 microgram/100 g BW [125I]progestin (SA, 2200 Ci/mM). To show specificity of progestin localization two additional fetuses were each injected sc with 20 micrograms R5020, a synthetic progestin, 1 h before the injection of [125I]progestin. The fetuses were frozen 2 h after injection of [125I]progestin, sectioned, and processed for thaw-mount autoradiography. Cells with nuclear uptake and retention of radioactivity were observed in numerous tissues, including certain regions of the oral mucosa and developing teeth, esophagus, larynx, skin, mammary gland, skeletal muscle, kidney, and reproductive glands and ducts. Injection of unlabeled R5020 1 h before [125I]progestin prevented nuclear concentration of radioactivity in all target tissues. The results indicate that progesterone receptors are expressed with a regional, cellular, and subcellular distribution in term fetal mouse tissues and suggest that progesterone is important to the growth and development of certain fetal tissues.

1988-01-01

 
 
 
 
201

Treatment of hyperthyroidism: use of 131I and 125I  

International Nuclear Information System (INIS)

[en] Factors related to late hypothyroidism following the use of 131I for treatment of hyperthyroidism are discussed with regard to age of patient, size of dose, previous surgery, immune status, and others. Possible reasons for the post-therapeutic hypothyroidism are discussed with regard to effects of radiation on the reproductive capacity of thyroid cells, effects of radiation on blood vessels, and dose distribution of radioiodine. The following therapeutic strategies are discussed: reduction of initial dose; multiple small doses; high dose radioiodine followed by replacement therapy; the use of external beam irradiation; and the use of 125I

1977-03-19

202

Practical application of 125I-fibrinogen leg scanning  

International Nuclear Information System (INIS)

The diagnosis of venous thrombosis by radioiodine-labeled fibrinogen scanning depends upon the incorporation of circulating labeled fibrinogen into a developing or established thrombus which is then detected by measuring the increase of overlying surface radioactivity with an isotope detector. The scanning procedure is simple and rapid, and one technician can screen 15 to 20 patients daily. A single intravenous injection of 100 ?Ci of 125I-fibrinogen enables scanning to be performed for approximately 7 days. leg scanning has been a valuable research tool and is also useful for the clinical management of patients with venous thrombosis. Its limitations are its insensitivity to iliac vein thrombosis and relative insensitivity to thrombi in the upper thigh, and when used diagnostically in patients with clinically suspected venous thrombosis there is a delay of up to 2 days before a positive result is obtained. For these reasons leg scanning should not be used alone in patients with clinically suspected venous thrombosis. The practical indications for using 125I-fibrinogen leg scanning are (1) for diagnosis of clinically suspected venous thrombosis when used in combination with impedance plethysmography; (2) detection of acute venous thrombosis in patients with chronic venous insufficiency; (3) screening patients who develop calf vein thrombosis when there is contraindication to anticoagulant therapy; and (4) screening certain high-risk patients and patient groups in whom the prophylaxis is either contraindicated or ineffective.

1981-01-01

203

Effect of /sup 125/I interstitial radiotherapy on blood-brain barrier function in normal canine brain  

Energy Technology Data Exchange (ETDEWEB)

Blood-brain barrier (BBB) function was studied in 14 normal dogs at time periods from 7 to 717 days after permanent insertion of 5- to 7-mCi seeds of iodine-125 (/sup 125/I) for interstitial radiation. The BBB function was measured with carbon-14-labeled alpha aminoisobutyric acid (AIB) and quantitative autoradiography, and expressed as a unidirectional blood-to-brain transfer constant, K. The /sup 125/I radiation lesions consisted of three concentric histologically and functionally distinct zones: 1) a central zone of calcified necrosis; 2) a spongy fluid-filled zone; and 3) a narrow rim (2.6 +/- 0.6 mm wide) of viable brain tissue with increased permeability. Within this rim, the mean value of the K of AIB was 5.8 times that of normal cortex. Over the 7- to 392-day time period the value of K remained rather constant, and by 716 days K values had returned to normal. There was moderate regional variation in the value of K; it was highest in the white matter and lowest in the gray matter surrounding the radiation lesion. The radiation lesion progressively increased in size from 7 to 80 days, after which there was little change. This study illustrates that the geographically circumscribed radiation from /sup 125/I seeds is accompanied by similarly well-defined changes in BBB function, which may persist for over 1 year following insertion of the /sup 125/I seed. This altered BBB function is probably responsible for the cerebral edema associated with /sup 125/I interstitial radiotherapy.

Groothuis, D.R.; Wright, D.C.; Ostertag, C.B.

1987-12-01

204

Bypassing the learning curve in permanent seed implants using state-of-the-art technology  

International Nuclear Information System (INIS)

Purpose: The aim of this study was to demonstrate, based on clinical postplan dose distributions, that technology can be used efficiently to eliminate the learning curve associated with permanent seed implant planning and delivery. Methods and Materials: Dose distributions evaluated 30 days after the implant of the initial 22 consecutive patients treated with permanent seed implants at two institutions were studied. Institution 1 (I1) consisted of a new team, whereas institution 2 (I2) had performed more than 740 preplanned implantations over a 9-year period before the study. Both teams had adopted similar integrated systems based on three-dimensional (3D) transrectal ultrasonography, intraoperative dosimetry, and an automated seed delivery and needle retraction system (FIRST, Nucletron). Procedure time and dose volume histogram parameters such as D90, V100, V150, V200, and others were collected in the operating room and at 30 days postplan. Results: The average target coverage from the intraoperative plan (V100) was 99.4% for I1 and 99.9% for I2. D90, V150, and V200 were 191.4 Gy (196.3 Gy), 75.3% (73.0%), and 37.5% (34.1%) for I1 (I2) respectively. None of these parameters shows a significant difference between institutions. The postplan D90 was 151.2 Gy for I1 and 167.3 Gy for I2, well above the 140 Gy from the Stock et al. analysis, taking into account differences at planning, results in a p value of 0.0676. The procedure time required on average 174.4 min for I1 and 89 min for I2. The time was found to decrease with the increasing number of patients. Conclusion: State-of-the-art technology enables a new brachytherapy team to obtain excellent postplan dose distributions, similar to those achieved by an experienced team with proven long-term clinical results. The cost for bypassing the usual dosimetry learning curve is time, with increasing team experience resulting in shorter treatment times.

2007-01-01

205

Scattering of gaseous {sup 125}I from a bottle containing Na{sup 125}I solution for iodination in a calm condition  

Energy Technology Data Exchange (ETDEWEB)

Scattering of gaseous {sup 125}I from a bottle containing Na{sup 125}I solution for iodination has been measured by distributing active charcoal granule at various heights on the inner surface of a plastic cylinder surrounding the bottle and counting the activities of granule samples. The result shows that about 70% of total scattered {sup 125}I exist below the level of mouth of the bottle. By drawing the air from the bottle of the cylinder through a tube filled with active charcoal, about 90% of scattered {sup 125}I collected. (author)

Aoki, Katsumi; Furuse, Yuko; Nishimaki, Toshiyuki; Shinozuka, Akiko [Kitasato Univ., Sagamihara, Kanagawa (Japan). School of Medicine

1997-05-01

206

Retrospective analysis of 1650 permanent pacemaker implantations experience over two different consecutive time periods in a single cardiology clinic  

Directory of Open Access Journals (Sweden)

Full Text Available Objective: Indications for pacing, pacing modes, and demographics of patients who underwent pacemaker implantation between two different time periods were compared in this study.Methods: Pacemaker registry of our cardiology department was used to evaluate these changes from 1986 to 2007 (First period: 1986-1996, second period: 1997-2007) retrospectively. Results: Registry revealed 776 implantations in the first and 874 implantations in the second period. The percentages of first implantation were 89% and 70.1% respectively. Nearly 50% of the patients in both periods were female. Main indications for pacing were atrioventricular (AV) block, sick sinus syndrome (SSS) and slow ventricular rate during atrial fibrillation in both periods. Implantation of VVI-AAI pacemakers have decreased (77.8%/1.5% to 51%/0.3%, p<0.05) and implantation of DDD-VDD pacemakers have increased (19.3%/1.3% to 42.3%/6.3%, p<0.05) during the second period compared to the first period. Permanent pacemaker implantation for SSS has decreased significantly from 31.1% in the first period to 12.0% (p<0.05) in the second period. Implantation for AV block has increased significantly from 63.3% to 79.7% (p<0.05) in the second period.Conclusion: Our data revealed temporal changes in pacemaker implantation practice during last twenty years in the cardiology department of a teaching hospital. Implantation of VVI-AAI pacemakers have decreased significantly during the second period. Permanent pacemaker implantation for AV block has also decreased during the last period.

Serdar Bayata; Murat Ye?il; Erdinç Ar?kan; Nur?en Postac?; Rida Beril?en; Özgür Ceylan; Eyüp Avc?

2010-01-01

207

Psychosocial aspects and mental health in children after permanent pacemaker implantation.  

UK PubMed Central (United Kingdom)

The present study was designed to evaluate the psychosocial status and the mental health of children receiving a permanent pacemaker during childhood. Nineteen children under the age of 19 years had a permanent pacemaker implanted. Contact was established to 15 of these patients, 7 girls and 8 boys, and they were given a child-psychiatric evaluation consisting of a semi-structured and a child-psychiatric interview. The psychological interview used intelligence tests and the Draw-A-Person test as well as the Rorschach test. The patients had had their pacemakers during an average of 6.7 years (range 3-14). Generally the psychological condition was strained in 7 families, in which psychiatric and social therapy had been necessary. The children's intelligence was within normal ranges, average IQ being 110 (range 80-135). The children had abnormal body image related to the pacemaker. Adults virtually incorporate the pacemaker in their body image without disturbance, but children who are forming their body image and identity, are influenced by having a pacemaker. This may give psychosocial implication.

Andersen C; Hørder K; Kristensen L; Mickley H

1994-01-01

208

Standardisation of 125I using seven techniques for radioactivity measurement  

Science.gov (United States)

Seven methods of radioactivity measurement were used to standardise an 125I solution within the frame of an international key comparison organised by BIPM: photon photon coincidence counting with two NaI detectors, photon sum-peak counting in a NaI well detector and in a 4? CsI(Tl) sandwich spectrometer, total emission counting in a windowless 4? CsI(Tl) sandwich spectrometer, electron-X,? coincidence counting and electron-X,? sum counting in a pressurised proportional counter inside a NaI well detector and liquid scintillation counting with the CIEMAT/NIST method. The solid sources were prepared by quantitative drop deposition with addition of AgNO3. The measurement methods, the results and the applied corrections are described and discussed.

Pommé, S.; Altzitzoglou, T.; van Ammel, R.; Sibbens, G.

2005-06-01

209

Preparation and biodistribution of 125I radiolabeled glycosylated somatostatin  

International Nuclear Information System (INIS)

Natural somatostatin, dextran-10 and tyramine are used to synthesis somatostatin-dextran-tyramine (SMS-Dx10-tyramine, glycosylated somatostatin). The somatostatin receptor competition binding study of glycosylated somatostatin in vitro is carried out using rat brain cortex membranes (expressing somatostatin receptor type 2) and the radioligand of 125I-Tyr3-Octreotide. The radioiodinated glycosylated somatostatin is prepared by Iodogen method. The biodistribution and blood half life are investigated in normal rats. The glycosylated somatostatin posses of high somatostatin type 2 receptor binding affinity, the same IC50 value as the reference ligand Octreotide, and the blood half-life is 6.7 h after post injection. The digestion and excretion is mainly through the hepatobiliary and kidney system. The adrenals gland has higher uptake, which is a somatostatin receptor positive organ. The radioiodinated glycosylated somatostatin shows promising properties and is worthy of further investigation. (authors)

2005-01-01

210

Standardisation of 125I using seven techniques for radioactivity measurement  

International Nuclear Information System (INIS)

Seven methods of radioactivity measurement were used to standardise an 125I solution within the frame of an international key comparison organised by BIPM: photon-photon coincidence counting with two NaI detectors, photon sum-peak counting in a NaI well detector and in a 4? CsI(Tl) sandwich spectrometer, total emission counting in a windowless 4? CsI(Tl) sandwich spectrometer, electron-X,? coincidence counting and electron-X,? sum counting in a pressurised proportional counter inside a NaI well detector and liquid scintillation counting with the CIEMAT/NIST method. The solid sources were prepared by quantitative drop deposition with addition of AgNO3. The measurement methods, the results and the applied corrections are described and discussed.

2005-06-01

211

Tissue distribution of 125I-iRNA in liposome after intravenous injection in mice  

International Nuclear Information System (INIS)

The liposome containing 125I-iRNA of large unilamellar vesicles were prepared by the reverse phase evaporation method, with the encapsulation efficiency ranging from 32.5% to 38.2%. Through observation of 125I labelled iRNA after i.v. injection, the comparative distribution of iRNA in some of the chief organs in mice, including 125I-iRNA entrapped in liposome or free 125I-iRNA, was determined. The results showed that the spleen and the liver had high liposome uptake. The interaction time of iRNA in mice was increased with liposome containing 125I-iRNA.

1994-01-01

212

Localization of linked 125I seeds in postimplant TRUS images for prostate brachytherapy dosimetry  

International Nuclear Information System (INIS)

Purpose: To demonstrate that 125I seeds can be localized in transrectal ultrasound (TRUS) images obtained with a high-resolution probe when the implant is performed with linked seeds and spacers. Adequate seed localization is essential to the implementation of TRUS-based intraoperative dosimetry for prostate brachytherapy. Methods and Materials: Thirteen preplanned peripherally loaded prostate implants were performed using 125I seeds and spacers linked together in linear arrays that prevent seed migration and maintain precise seed spacing. A set of two-dimensional transverse images spaced at 0.50-cm intervals were obtained with a high-resolution TRUS probe at the conclusion of the procedure with the patient still under anesthesia. The image set extended from 1.0 cm superior to the base to 1.0 cm inferior to the apex. The visible echoes along each needle track were first localized and then compared with the known construction of the implanted array. The first step was to define the distal and proximal ends of each array. The visible echoes were then identified as seeds or spacers from the known sequence of the array. The locations of the seeds that did not produce a visible echo were interpolated from their known position in the array. A CT scan was obtained after implantation for comparison with the TRUS images. Results: On average, 93% (range, 86-99%) of the seeds were visible in the TRUS images. However, it was possible to localize 100% of the seeds in each case, because the locations of the missing seeds could be determined from the known construction of the arrays. Two factors complicated the interpretation of the TRUS images. One was that the spacers also produced echoes. Although weak and diffuse, these echoes could be mistaken for seeds. The other was that the number of echoes along a needle track sometimes exceeded the number of seeds and spacers implanted. This was attributed to the overall length of the array, which was approximately 0.5 cm longer than the center-to-center distance between the first and last seed owing to the finite length of the seeds at the ends of the array. When this occurred, it was necessary to disregard either the most distal or most proximal echo, which produced a 0.5-cm uncertainty in the location of the array in the axial direction. For these reasons, simply localizing the visible echoes in the TRUS images did not guarantee the reliable identification of the seeds. Conclusion: Our results have demonstrated that a high percentage (>85%) of the implanted 125I seeds can be directly visualized in postimplant TRUS images when the seeds and spacers are linked to preclude seed migration and rotation and when the images are obtained with a high-resolution TRUS probe. Moreover, it is possible to localize 100% of the seeds with the mechanism of linked seeds because the locations of the missing seeds can be determined from the known construction of the arrays.

2005-07-01

213

Incidence and predictors of permanent pacemaker implantation following transcatheter aortic valve implantation: Analysis from the german transcatheter aortic valve interventions registry.  

UK PubMed Central (United Kingdom)

OBJECTIVES: To determine predictors of permanent pacemaker (PPM) implantation up to 30 days after transcatheter aortic valve implantation (TAVI) in a prospective multicenter registry. BACKGROUND: Conduction disorders requiring PPM implantation are one of the most common complications seen after TAVI. Knowledge about possible predictors may help to decrease the rate of PPM implantations. METHODS: In total, 1347 consecutive patients who underwent TAVI in 22 centers were prospectively enrolled in the German transcatheter aortic valve interventions registry. Both Medtronic CoreValve™ and Edwards Sapien™ valves were implanted. Patients with preprocedurally implanted PPM or implantable cardioverter defibrillator were excluded from the analysis (n?=?199). Regression analysis of baseline and procedure characteristics of the remaining 1,147 patients was performed. RESULTS: Procedural success was achieved in 97.4% of the cases. The rate for PPM after TAVI was 33.7%. The absence of prior valve surgery, the use of Medtronic CoreValve™ prosthesis and the presence of a porcelain aorta were identified as independent predictors for PPM after TAVI. Mortality at 30 days did not differ between patients with or without PPM necessity (6.0% vs. 8.1%, respectively; HR 0.72; CI (0.45-1.16); P?=?0.17). CONCLUSIONS: PPM is a common postprocedure requirement after TAVI. The absence of prior valve surgery, the implantation of Medtronic CoreValve™ prosthesis, and the presence of a porcelain aorta were independently associated with PPM after TAVI. © 2013 Wiley Periodicals, Inc.

Ledwoch J; Franke J; Gerckens U; Kuck KH; Linke A; Nickenig G; Krülls-Münch J; Vöhringer M; Hambrecht R; Erbel R; Richardt G; Horack M; Zahn R; Senges J; Sievert H

2013-10-01

214

Metabolism of (125I)tyramine cellobiose-labeled low density lipoproteins in squirrel monkeys  

International Nuclear Information System (INIS)

Low density lipoproteins labeled with (125I)tyramine cellobiose ((125I)TC-LDL) were removed from the circulation of squirrel monkeys at a similar but slightly slower rate than LDLs labeled with 125I, (125I)hydroxypenyl propionic acid, or (3H)leucine. After the simultaneous injection of ((125I)TC-LDL) and (131I)LDL labeled with 131ICI, the 125I was also removed at a slightly slower rate than 131I. Most of the radioactivity was retained in tissues and not excreted during the 24 h after injection of (125I)TC-LDL. This finding supports the claim of Pittman et al. (18) that (125I)TC-LDL can be used to determine the irreversible uptake of LDL by different tissues. The liver cleared more LDL than any other organ, but the adrenals and ovaries were more active per gram. Trichloroacetic acid (TCA) precipitated more than 80% of the radioactivity in the tissues that had low 125I uptake, but only about 50% of the 125I in more active tissues (liver, adrenals, ovaries and spleen). Only a small percentage of 125I in urine and bile was TCA-precipitable. In the dual label experiment with (125I)TC-LDL and (131I)LDL there was a selective retention of 125I in samples from liver, spleen, adrenals, and perhaps testes, and an almost complete selectivity for 125I in bile and feces. The aortic intima plus inner media (AIM) cleared much less LDL than other tissues, but the uptake by the entire AIM was proportional to the cholesterol concentration and weight of the total AIM. There was, however, no correlation between either of the latter two measurements and the uptake of LDL per pram of AIM. (author)

1985-01-01

215

125I brachytherapy for localized prostate cancer: a single institution experience.  

UK PubMed Central (United Kingdom)

AIMS AND BACKGROUND: To evaluate the clinical outcome of a cohort of localized prostate cancer patients treated with 125I permanent brachytherapy at the University of Turin. METHODS AND STUDY DESIGN: A retrospective analysis was carried out on 167 consecutive patients with early stage prostate adenocarcinoma who underwent 125I brachytherapy between January 2003 and December 2010. A minimum follow-up of ? 12 months was mandatory for inclusion. Biochemical disease-free survival (defined on the basis of the ASTRO definition and the ASTRO-Phoenix definition) was chosen as the primary end point. Secondary end points were gastrointestinal and genitourinary toxicity (acute and late, defined according to the RTOG scale). RESULTS: With a median follow-up of 42 months (range, 13.5-90.7), biochemical disease-free survival at 3 and 5 years was respectively 91.1% and 85.7%, according to the ASTRO definition and 94.5% and 85.1% according to ASTRO-Phoenix definition (for statistical purposes, only the ASTRO definition was used). Hormone treatment and nadir PSA (cutoff of 0.35 ng/ml) were the only factors affecting biochemical disease-free survival both on univariate (P = 0.02 and P = 0.001, respectively) and multivariate analysis (HR 0.024; P = 0.021 and HR 21.6; P = 0.006, respectively). Only 3.6% of patients experienced ? grade 3 acute urinary toxicity and 5% ? grade 3 late urinary toxicity. Prior transurethral prostate resection was the only independent predictor of grade 3 late urinary toxicity on multivariate analysis (HR 0.13; P = 0.009). CONCLUSIONS: This mono-institutional series confirmed that brachytherapy is an effective and safe treatment modality for localized prostate cancer, with acceptable short- and long-term morbidity rates.

Guarneri A; Botticella A; Filippi AR; Munoz F; Beltramo G; Casetta G; Giglioli FR; Tizzani A; Ragona R; Ricardi U

2013-01-01

216

Symptomatic sick sinus syndrome requiring permanent pacemaker implantation in a patient uwith mirror image dextrocardia with situs inversus and infertility.  

UK PubMed Central (United Kingdom)

Situs inversus with dextrocardia is a congenital condition in which the heart is a mirror image of the anatomically normal heart on the right side. A patient presented with the sick sinus syndrome accompanying mirror image dextrocardia which was associated with double superior vena cava and a left sided inferior vena cava A permanent transvenous demand pacemaker was inserted because of repeated episodes of dizziness and a single episode of syncope with ECG showing bradycardia with junctional escape rhythm. Precise knowledge of the venous system and the location of the apex of the right ventricle were necessary prior to permanent pacemaker implantation. Without such knowledge pacing may be technically challenging.

Kahali D; Mandal S; Mandal D; Ghose A; Kanjilal S

2013-01-01

217

Symptomatic sick sinus syndrome requiring permanent pacemaker implantation in a patient uwith mirror image dextrocardia with situs inversus and infertility.  

Science.gov (United States)

Situs inversus with dextrocardia is a congenital condition in which the heart is a mirror image of the anatomically normal heart on the right side. A patient presented with the sick sinus syndrome accompanying mirror image dextrocardia which was associated with double superior vena cava and a left sided inferior vena cava A permanent transvenous demand pacemaker was inserted because of repeated episodes of dizziness and a single episode of syncope with ECG showing bradycardia with junctional escape rhythm. Precise knowledge of the venous system and the location of the apex of the right ventricle were necessary prior to permanent pacemaker implantation. Without such knowledge pacing may be technically challenging. PMID:24000510

Kahali, Dhiman; Mandal, Saroj; Mandal, Debasmita; Ghose, Arijit; Kanjilal, Souvik

2013-01-01

218

Postimplantation Analysis Enables Improvement of Dose-Volume Histograms and Reduction of Toxicity for Permanent Seed Implantation  

International Nuclear Information System (INIS)

Purpose: To demonstrate how postimplantation analysis is useful for improving permanent seed implantation and reducing toxicity. Patients and Methods: We evaluated 197 questionnaires completed by patients after permanent seed implantation (monotherapy between 1999 and 2003). For 70% of these patients, a computed tomography was available to perform postimplantation analysis. The index doses and volumes of the dose-volume histograms (DVHs) were determined and categorized with respect to the date of implantation. Differences in symptom scores relative to pretherapeutic status were analyzed with regard to follow-up times and DVH descriptors. Acute and subacute toxicities in a control group of 117 patients from an earlier study (June 1999 to September 2001) by Wust et al. (2004) were compared with a matched subgroup from this study equaling 110 patients treated between October 2001 and August 2003. Results: Improved performance, identifying a characteristic time dependency of DVH parameters (after implantation) and toxicity scores, was demonstrated. Although coverage (volume covered by 100% of the prescription dose of the prostate) increased slightly, high-dose regions decreased with the growing experience of the users. Improvement in the DVH and a reduction of toxicities were found in the patient group implanted in the later period. A decline in symptoms with follow-up time counteracts this gain of experience and must be considered. Urinary and sexual discomfort was enhanced by dose heterogeneities (e.g., dose covering 10% of the prostate volume, volume covered by 200% of prescription dose). In contrast, rectal toxicities correlated with exposed rectal volumes, especially the rectal volume covered by 100% of the prescription dose. Conclusion: The typical side effects occurring after permanent seed implantation can be reduced by improving the dose distributions. An improvement in dose distributions and a reduction of toxicities were identified with elapsed time between 1999 and 2003.

219

[Fertility after prostate brachytherapy with Iode 125 permanent implants for localized prostate cancer].  

UK PubMed Central (United Kingdom)

OBJECTIVES: Preservation of fertility in men of middle age is an issue that is experiencing a growing interest. Prostate cancer is the second most common cancer in men and is diagnosed earlier than before. Brachytherapy is a treatment for prostate cancer that preserves ejaculation. Our aim was to study the fertility of men treated with prostate brachytherapy in order to improve patient information. PATIENTS AND METHODS: In a series of 270 sexually active men with localized prostate cancer treated with brachytherapy (permanent implants of Iode 125) at the Institute Claudius Regaud between 2000 and 2006, mean age 65 years (43-80), four patients spontaneously expressed their interest in the preservation of fertility and had an andrological evaluation. RESULTS: Four patients were aged 43, 48, 57 and 61 years, all working (including two businessmen), their partner was aged respectively 42, 37, 47 and 38 years. All four had a post-treatment semen analysis (done over a year after brachytherapy) rich in spermatozoa, with moderate asthenospermia, the main anomaly being severe hypospermia. These spermiograms were nonetheless consistent with the occurrence of spontaneous pregnancy (occurrence of miscarriage in the patient 1). CONCLUSION: There is an interest in applying to men with prostate cancer their position on fertility in order to inform them about the morbidity of various treatments, options for fertility preservation, and the need to continue a contraception after brachytherapy if the partner is not menopausal.

Delaunay B; Delannes M; Bachaud JM; Bouaziz M; Salloum A; Thoulouzan M; Soulié M; Plante P; Huyghe E

2012-01-01

220

Use of brachytherapy with permanent implants of iodine-125 in localized prostate cancer  

International Nuclear Information System (INIS)

[en] Approximately 15,000 cases of early stage prostate cancer T1 and T2 are diagnosed every year in France by testing for PSA and performing prostatic biopsies. The treatment of these localized forms is based in most cases on radical prostatectomy or nn external beam radiotherapy. Although the ontological results obtained by these two therapeutic methods are satisfactory and equivalent in the long term, the side effects can be important. For a number of years, trans-perineal brachytherapy using permanent implants of iodine -125 or palladium-103 has proved itself as an alternative therapy with equivalent medium to long-term results. The low urinary, digestive and sexual side effects of prostate brachytherapy are important reasons for the enthusiasm among patients and the medical community for this therapy and the growing number of applications and centres which practice it. In September 1998 we started the prostate brachytherapy programmes- in Marseilles with close collaboration between the department of urology of the Hopital Salvator, and the departments of radiotherapy, medical imaging and medical physics of the Institut Paoli-Calmettes. To date, around 250 patients with localized adenocarcinoma of the prostate have benefited from this alternative therapy in our centre. Preliminary results, with a 3 year-follow-up, are comparable to results published in the literature by pioneer teams. (authors)

2002-01-01

 
 
 
 
221

An improved synthesis of [125I]N-(diethylaminoethyl)-4-iodobenzamide: a potential ligand for imaging malignant melanoma  

International Nuclear Information System (INIS)

[en] To improve the radiolabeling yield and the specific activity of [125I]N-(2-diethylaminoethyl)-4-iodobenzamide(DAB), the aryltributyltin precursor was synthesized from the N-(2-diethylaminoethyl)-4-bromobenzamide derivative by palladium catalyzed stannylation using bis(tributyltin). The radiolabeled product, [125I]DAB, was obtained by an iododestannylation reaction in high radiochemical yields (85-94%, radiochemical purity, > 98%) using chloramine-T as an oxidizing agent. The specific activity was greater than 1600 Ci/mmol. The biodistribution studies in nude mice implanted with human malignant melanoma xenograft showed a good tumor uptake (6.14% ID/g at 1 h, 2.81% ID/g at 6 h and 0.42% ID/g at 24 h) of [125I]DAB. Unfortunately, a high uptake in the non-target organs, such as liver and lung was found. At 1 h post-injection the activity level in liver and lung was 11.76 and 7.58% ID/g, respectively. A slow clearance of activity from liver and lung was observed at 6 h (3.43 and 0.49% ID/g). These results demonstrate that iodinated IDAB is a potential radiopharmaceutical for the management of patients with malignant melanoma. (Author)

1993-01-01

222

125I-LSD: a high sensitivity ligand for serotonin receptors  

International Nuclear Information System (INIS)

125I-labeled receptor ligands offer unique advantages over their 3H-labeled counterparts. Carrier-free 125I-labeled ligands can be synthesized with specific activities of up to 2170 Ci/mmol while (mono) tritium labeled ligands are limited to 29 Ci/mmol. Therefore, 125I-labeled ligands can be approximately 70-fold more sensitive than 3H-labeled ligands in detecting receptor sites. In addition, 125I-labeled ligands emit relatively energetic X-rays and ?-rays which are readily detected by gamma counting equipment. The authors report here the serotonergic binding properties of 125I-LSD the first reported 125I-labeled ligand for serotonin receptors. (Auth.)

1983-05-06

223

/sup 125/I-LSD: a high sensitivity ligand for serotonin receptors  

Energy Technology Data Exchange (ETDEWEB)

/sup 125/I-labeled receptor ligands offer unique advantages over their /sup 3/H-labeled counterparts. Carrier-free /sup 125/I-labeled ligands can be synthesized with specific activities of up to 2170 Ci/mmol while (mono) tritium labeled ligands are limited to 29 Ci/mmol. Therefore, /sup 125/I-labeled ligands can be approximately 70-fold more sensitive than /sup 3/H-labeled ligands in detecting receptor sites. In addition, /sup 125/I-labeled ligands emit relatively energetic X-rays and ..gamma..-rays which are readily detected by gamma counting equipment. The authors report here the serotonergic binding properties of /sup 125/I-LSD the first reported /sup 125/I-labeled ligand for serotonin receptors.

Hartig, P.R.; Kadan, M.J.; Evans, M.J.; Krohn, A.M. (Johns Hopkins Univ., Baltimore, MD (USA). Dept. of Biology)

1983-05-06

224

Advantages of using thin sodium iodide detectors for thyroid monitoring of personnel working with 125I  

International Nuclear Information System (INIS)

[en] Measurements of neck count-rates for personnel who regularly iodinated proteins with 125I showed that, generally, count rates were higher after iodination than before. The major pathway for the intake of 125I during iodination was through skin that was exposed to the free-iodine atmosphere of the fume hood. Neck count-rates were measured in 34 other subjects who were working with 125I. The rates for 25 of them were significantly greater than for a control group of 36 subjects. Significant activities were also detected in seven of nine subjects who had never worked directly with 125I but who were located within areas where it was used extensively. To minimize thyroid burdens of 125I, it is essential that neck count-rates be measured routinely, in order to monitor the safety of procedures involving the use of 125I

1980-01-01

225

The preparation of 125I - gastrin I and 125 - minigastrin for medical diagnostics  

International Nuclear Information System (INIS)

Gastrin I G-17 and minigastrin G-13 were iodinated using direct methods with chloramin T and iodogen procedures and by indirect method with Bolton-Hunter reagent. 125I - gastrin and 125I - minigastrin were isolated from the iodination mixtures by gel filtration on Sephadex G-10 and Sephadex G-25 (PD-10 column) and by HPLC system (Lichrospher WP-300-RP-18 column). Radiochemical purity was shown by HPLC also. It was confirmed that iodogen procedure is the best for iodination of these peptides. 125I - gastrin I obtained by this method with specific activity 80 ?Ci/nmol was homogeneous but iodination to higher specific activity (440?Ci/nmol) caused appearance of two subfractions. 125I - minigastrin with high and low specific activity were isolated by HPLC as the two forms (subfractions). It was shown that high performance liquid chromatography (HPLC) was the best method for isolation and purification of 125I - gastrin I and 125I - minigastrin. (author)

2002-01-01

226

Update on the need for a permanent pacemaker after transcatheter aortic valve implantation using the CoreValve® Accutrak™ system.  

UK PubMed Central (United Kingdom)

AIMS: High rates of permanent pacemaker (PPM) implantation are reported after transcatheter aortic valve implantation (TAVI) using the Medtronic CoreValve® system. The Accutrak™ catheter is designed to allow a more predictable landing zone. Little is known about the real clinical impact of this catheter. The aims of this paper were to describe the potential impact of the Accutrak™ catheter on the accuracy of positioning a 26 or 29 mm CoreValve® across the aortic annulus and its impact on the need for a pacemaker. METHODS AND RESULTS: A total of 134 patients were treated with the CoreValve® Accutrak™ system at two French centres (Lille and Toulouse). Mean age was 82.4 ± 4.7 years; logistic EuroSCORE was 24.3 ± 9.5%. Procedural success rate was 99.2%; mean depth of implantation was 4.9 mm. A final position between 0 and 6 mm was achieved in 85.8% of the patients. All-cause mortality at 30 days was 6%. The PPM implantation rate was 10.6%. Due to a limited number of events, we could not identify any predictor of need for a PPM: pre-existing right bundle branch block (RBBB) (OR 2.72 [0.63-11.87], p=ns), use of a 29 mm prosthesis (OR 2.73 [0.33-22.90], p=ns) and left ventricular septal hypertrophy (OR 2.63 [0.08-83.32], p=ns). CONCLUSIONS: In this cohort of patients treated with the CoreValve® Accutrak™ system, the incidence of permanent pacemaker implantation was low, which may be a consequence of an average small implantation depth. The Accutrak™ catheter seems to be helpful in achieving higher and more predictable implants. Operators could standardise their technique to place the CoreValve® prostheses less than 6 mm below the aortic annulus.

Tchetche D; Modine T; Farah B; Vahdat O; Sudre A; Koussa M; Lereun C; Nejjari M; Choby M; Rosencher J; Sorbets E; Fajadet J

2012-09-01

227

Dosimetric characterization of the GammaClip™ 169Yb low dose rate permanent implant brachytherapy source for the treatment of nonsmall cell lung cancer postwedge resection.  

UK PubMed Central (United Kingdom)

PURPOSE: A novel (169)Yb low dose rate permanent implant brachytherapy source, the GammaClip™, was developed by Source Production & Equipment Co. (New Orleans, LA) which is designed similar to a surgical staple while delivering therapeutic radiation. In this report, the brachytherapy source was characterized in terms of "Dose calculation for photon-emitting brachytherapy sources with average energy higher than 50 keV: Report of the AAPM and ESTRO" by Perez-Calatayud et al. [Med. Phys. 39, 2904-2929 (2012)] using the updated AAPM Task Group Report No. 43 formalism. METHODS: Monte Carlo calculations were performed using Monte Carlo N-Particle 5, version 1.6 in water and air, the in-air photon spectrum filtered to remove photon energies below 10 keV in accordance with TG-43U1 recommendations and previously reviewed (169)Yb energy cutoff levels [D. C. Medich, M. A. Tries, and J. M. Munro, "Monte Carlo characterization of an Ytterbium-169 high dose rate brachytherapy source with analysis of statistical uncertainty," Med. Phys. 33, 163-172 (2006)]. TG-43U1 dosimetric data, including SK, D?(r,?), ?, gL(r), F(r, ?), ?an(r), and ?an were calculated along with their statistical uncertainties. Since the source is not axially symmetric, an additional set of calculations were performed to assess the resulting axial anisotropy. RESULTS: The brachytherapy source's dose rate constant was calculated to be (1.22±0.03) cGy?h(-1)?U(-1). The uncertainty in the dose to water calculations, D?(r,?), was determined to be 2.5%, dominated by the uncertainties in the cross sections. The anisotropy constant, ?an, was calculated to be 0.960±0.011 and was obtained by integrating the anisotropy factor between 1 and 10 cm using a weighting factor proportional to r(-2). The radial dose function was calculated at distances between 0.5 and 12 cm, with a maximum value of 1.20 at 5.15±0.03 cm. Radial dose values were fit to a fifth order polynomial and dual exponential regression. Since the source is not axially symmetric, angular Monte Carlo calculations were performed at 1 cm which determined that the maximum azimuthal anisotropy was less than 8%. CONCLUSIONS: With a higher photon energy, shorter half-life and higher initial dose rate 169Yb is an interesting alternative to 125I for the treatment of nonsmall cell lung cancer.

Currier B; Munro JJ 3rd; Medich DC

2013-08-01

228

Influence of glucose and urea on {sup 125}I transport across an anion exchange paper membrane  

Energy Technology Data Exchange (ETDEWEB)

In order to study the influence of glucose and urea on the {sup 125}I transport across an anion exchange paper membrane, the transmembrane potential, the fluxes, and the concentrations of {sup 125}I, glucose and urea within the membrane were measured in the Na{sup 125}I concentration-cell system containing glucose or urea. Glucose and urea increased the membrane/solution distribution of the iodide ion, but scarcely affected the diffusion process of iodide ion within the membrane.

Inoue, Hiroyoshi E-mail: hiroin@med.kurume-u.ac.jp

2001-02-01

229

Influence of glucose and urea on 125I transport across an anion exchange paper membrane  

International Nuclear Information System (INIS)

[en] In order to study the influence of glucose and urea on the 125I transport across an anion exchange paper membrane, the transmembrane potential, the fluxes, and the concentrations of 125I, glucose and urea within the membrane were measured in the Na125I concentration-cell system containing glucose or urea. Glucose and urea increased the membrane/solution distribution of the iodide ion, but scarcely affected the diffusion process of iodide ion within the membrane

2001-01-01

230

Incidence rate and predictors of permanent pacemaker implantation after transcatheter aortic valve implantation with self-expanding CoreValve prosthesis.  

UK PubMed Central (United Kingdom)

BACKGROUND: Conduction disorders and permanent pacemaker (PPM) implantation are common complications in patients undergoing transcatheter aortic valve implantation (TAVI). Previous studies, evaluating small populations, have identified several different predictors of PPM implantation after TAVI. The aim of this study was to assess the incidence rate of conduction disorders and the predictors of postoperative PPM requirement in a large series of patients undergoing TAVI. METHODS: Data were analyzed from 181 consecutive patients at high-risk surgery who underwent TAVI at our institute between July 2007 and April 2011. All patients underwent implantation of the third-generation percutaneous self-expanding CoreValve® prosthesis (CoreValve, Inc., Irvine, CA, USA). In all patients, a 12-lead electrocardiogram and a 24-h holter monitoring was recorded before and after the procedure in order to assess the presence of conduction disorders. Clinical data, preoperative conduction disorders, echocardiographic patterns, and procedural data were tested as predictors of PPM implantation after TAVI. RESULTS: Left bundle branch block (LBBB) was the most common conduction disorder, with an incidence of 50.3% at discharge. Fifty-two (32.1%) patients developed a persistent complete AVB requiring PPM implantation. PPM implantation was strongly correlated with the presence of preoperative right bundle branch block (RBBB) which was found to be the only independent predictor of PPM implantation (HR 16.5, CI 3.3-82.3, p < 0.001). CONCLUSIONS: LBBB and PPM implantation requirement after TAVI are common occurrences using the self-expanding CoreValve prosthesis. In this large series of consecutive patients, only RBBB was found to be a strong predictor of PPM requirement.

Calvi V; Conti S; Pruiti GP; Capodanno D; Puzzangara E; Tempio D; Di Grazia A; Ussia GP; Tamburino C

2012-08-01

231

Transport of 125I and 36Cl across an anion-exchange paper membrane  

International Nuclear Information System (INIS)

[en] The membrane characteristics controlling 125I and 36Cl transport across anion-exchange paper membranes are examined using three different paper membranes treated with different anion exchange groups: a trimethylhydroxypropylamino group, a diethylaminoethyl group, and a 50% quaternary diethylaminoethyl group. The membrane permeability for 125I is higher than that for 36Cl in all cases. Treatment with trimethylhydroxypropylamino group improves the 125I diffusion process, and the use of 50% quaternary diethylaminoethyl group improves the 125I solution/membrane distribution process

2002-01-01

232

Measurements of the effect of ''thyroid blocking'' in patients investigated with 125I-fibrinogen  

International Nuclear Information System (INIS)

Venous thrombosis is routinely diagnosed by the injection of around 3.7 MBq 125I-fibrinogen. 125I- is released from degrading 125I-fibrinogen (biological half-life approximately 4 days). About 300 mg KI is given daily for 1-2 weeks after the injection to prevent uptake of 125I- in the thyroid. The effects of such a ''blocking'' regime on the thyroid uptake using a 124 mm (diam) x 1.5 mm NaI(Tl) detector were studied. Accurate determinations of the 125I activity in the thyroid were carried out using coincident registrations of two 28 keV photons from the 125I decay. The accuracy in the determinations of the absolute activity was better than 10%, the reproducibility of measurements on the same patient being +-2%. From thyroid measurements 1-2 days after the injection (when the thyroid uptake of 125I can be neglected) the relation between the counting rate from activity circulating outside the thyroid and over the arm was derived and then used for background correction. The contribution from extra thyroid activity was then carefull). estimated from subsequent measurements of the thyroid. It was concluded that it is possible to make accurate determinations of the 125I uptake in the thyroid usinn coincident registrations of two 28 keV photons from the 125I decay and that 300 mg KI given daily gives a very good ''blocking'' effect. (H.K.)

1980-03-14

233

Effects of lysosomal inhibitors on /sup 125/I-insulin and /sup 125/I-asialofetuin degradation by the isolated, perfused rat liver and isolated rat hepatocytes  

Energy Technology Data Exchange (ETDEWEB)

To further evaluate the role of the lysosomal system in insulin degradation, the authors have compared the effects of inhibitors of lysosomal function on the degradation of /sup 125/I-insulin with /sup 125/I-asialofetuin, a lysosomally targeted molecule, by the intact, perfused rat liver and the isolated rat hepatocyte. The inhibitors employed were chloroquine (/sup 125/ microM), NH/sub 4/Cl (10 mM), and leupeptin (50 micrograms/ml). In the intact, perfused liver the observed inhibition of /sup 125/I-asialofetuin degradation at 30 min was as follows: chloroquine, 38%; NH/sub 4/Cl, 32%; and leupeptin, 86%. Chloroquine also inhibited /sup 125/I-insulin degradation in the intact, perfused liver (29%), but NH/sub 4/Cl and leupeptin had no effect. Using the isolated hepatocyte, the observed values for inhibition of 125I-asialofetuin at 60 min were: chloroquine, 85%; NH/sub 4/Cl, 76%; and leupeptin, 81%. Chloroquine produced a 28% inhibition of 125I-insulin degradation, while NH/sub 4/Cl and leupeptin had no effect. Chloroquine and NH/sub 4/Cl decreased cell-associated radioactivity when isolated hepatocytes were incubated with 125I-asialofetuin (leupeptin had no effect), whereas chloroquine caused a 107% increase in cell-associated radioactivity when 125I-insulin was added to the incubation media (NH/sub 4/Cl and leupeptin had no effect). These results indicate that the effects of chloroquine on insulin degradation are an extralysosomal action and that lysosomes appear not to be involved in the physiologic degradation of the insulin molecule.

Ward, W.F.; Moss, A.L.

1985-05-01

234

Effects of lysosomal inhibitors on 125I-insulin and 125I-asialofetuin degradation by the isolated, perfused rat liver and isolated rat hepatocytes  

International Nuclear Information System (INIS)

To further evaluate the role of the lysosomal system in insulin degradation, the authors have compared the effects of inhibitors of lysosomal function on the degradation of 125I-insulin with 125I-asialofetuin, a lysosomally targeted molecule, by the intact, perfused rat liver and the isolated rat hepatocyte. The inhibitors employed were chloroquine (125 microM), NH4Cl (10 mM), and leupeptin (50 micrograms/ml). In the intact, perfused liver the observed inhibition of 125I-asialofetuin degradation at 30 min was as follows: chloroquine, 38%; NH4Cl, 32%; and leupeptin, 86%. Chloroquine also inhibited 125I-insulin degradation in the intact, perfused liver (29%), but NH4Cl and leupeptin had no effect. Using the isolated hepatocyte, the observed values for inhibition of 125I-asialofetuin at 60 min were: chloroquine, 85%; NH4Cl, 76%; and leupeptin, 81%. Chloroquine produced a 28% inhibition of 125I-insulin degradation, while NH4Cl and leupeptin had no effect. Chloroquine and NH4Cl decreased cell-associated radioactivity when isolated hepatocytes were incubated with 125I-asialofetuin (leupeptin had no effect), whereas chloroquine caused a 107% increase in cell-associated radioactivity when 125I-insulin was added to the incubation media (NH4Cl and leupeptin had no effect). These results indicate that the effects of chloroquine on insulin degradation are an extralysosomal action and that lysosomes appear not to be involved in the physiologic degradation of the insulin molecule

1985-01-01

235

Preparation of 1-phenyl 3-methyl 4-nitro 5-125I-pyrazole (5-125I-MNPP) as a possible cannabinoid receptor imaging agent  

International Nuclear Information System (INIS)

[en] A rapid method for labelling of 1-phenyl 3-methyl 4-nitro 5-chloro pyrazole (5-Cl-MNPP) with radioactive iodide Na125I via 125I-for-Cl exchange has been reported. This method has been done in dry state (without catalyst and in presence of acetamide), in dimethyl formamide (DMF) as a solvent (without catalyst and in presence of tetrabutyl ammonium bromide (TBAB) as phase transfer catalyst (PTC)). In dry state, a trial to reduce the reaction temperature from 170 to 120 deg C for the reaction between 5-Cl-MNPP and Na125I in presence of acetamide as a molten medium was tested. Using some organic solvents such as ethanol, dimethyl sulfoxide (DMSO), acetonitrile, and DMF, it was found that DMF gave low radiochemical yield of 5-125I-MNPP (25%) within 30 min. However, the addition of 1 mg of TBAB to DMF increased the radiochemical yield of 5-125I-MNPP from 25 to 95 within 30 minutes. The product 5-125I-MNPP was purified by reverse phase, high performance liquid chromatography (HPLC), with radiochemical purity of greater than 98.0%. The biodistribution of 5-125I-MNPP was demonstrated in normal mice through intravenous injection in the tail vein. High uptake in the target organs equal to 2.5±0.22, 10.5±0.21, 4.3±0.27, 3.2±0.18 and 48.5±0.26 for brain, intestines, heart, kidneys and liver respectively was shown. This indicates that, 5-125I-MNPP can be freely penetrate the blood brain barrier (B.B.B.) and can be expected its usefulness in the quantitative determination of cannabinoid receptor in the brain. (author)

2001-01-01

236

Multi-center clinical experience with a lumenless, catheter-delivered, bipolar, permanent pacemaker lead: implant safety and electrical performance.  

UK PubMed Central (United Kingdom)

PURPOSE: Reduced lead diameter and reliability can be designed into transvenous permanent pacing leads through use of redundant insulation and removal of the stylet lumen. The model 3830 lead (Medtronic Inc., Minneapolis, MN, USA) is a bipolar, fixed-screw, steroid-eluting, lumenless, 4.1-Fr pacing lead. Implantation can be performed in a variety of right heart sites using a deflectable catheter (Model 10600, Medtronic). Lead performance and safety were studied. METHODS: Two prospective trials of 338 implanted subjects from 56 global sites were conducted. Electrical and safety data were obtained at implant, pre-discharge, and up to 18 months post-implant. Leads were implanted at traditional and alternate right heart sites. RESULTS: The study enrolled 338 subjects (204 males, 70.6 +/- 11.6 years) followed-up for a mean of 10.2 months (range, 0-21.6). Mean P-wave amplitudes ranged from 3.2 mV at 3 months to 2.9 mV at 18 months, while mean atrial pulse width thresholds at 2.5 V ranged from 0.07 ms at 3 months to 0.09 ms at 18 months. Mean R-wave amplitudes ranged from 11.3 mV to 11.1 mV and mean ventricular pulse width thresholds at 2.5 V ranged from 0.10 ms to 0.14 ms. There were 22 ventricular and 12 atrial lead complications within 3 months post-implant. Survival from lead-related complications improved to a clinically acceptable rate in the cohort of patients when revised implant techniques were employed. CONCLUSIONS: With the use of recommended implant techniques, the study results support the electrical efficacy and safety of a catheter-delivered, lumenless lead in traditional or alternate right atrium or right ventricle sites through 18 months post-implant.

Gammage MD; Lieberman RA; Yee R; Manolis AS; Compton SJ; Khazen C; Schaaf K; Oleson KA; Crossley GH

2006-08-01

237

Surface modification of zirconium by anodisation as material for permanent implants: in vitro and in vivo study.  

UK PubMed Central (United Kingdom)

The potential use of anodised zirconium as permanent implant has been investigated. Zirconium was anodised at constant potential between 3 and 30 V in H(3)PO(4). Electrochemical assays were conducted in simulated body fluid solution (SBF) in order to evaluate the effect of the surface oxide on the corrosion resistance in vitro after 30 days of immersion. The rupture potential increases when increasing thickness of the anodic surface film. The increase in the barrier effect when increasing anodising potential is also verified by EIS. Anodisation in H(3)PO(4) proved to increase the apatite formation capability of zirconium in a single step. In vivo bone formation was also analysed by implanting the modified materials in Wistar rats. Anodised Zr presents higher corrosion resistance in SBF in all the studied immersion times when compared with non anodised Zr. Additionally, in vivo experiments evidence bone generation and growth in contact with zirconium implants both in the as-received and anodised condition.

Gomez Sanchez A; Ballarre J; Orellano JC; Duffó G; Ceré S

2013-01-01

238

A comparative study of 19-iodo cholesterol-125I 3-acetate and Na 125I in liquid scintillation measurements; Estudio comparativo del acetato de 19-iodocolesterol- -125I con Nal25I en medidas por centelleo liquido  

Energy Technology Data Exchange (ETDEWEB)

A comparative study of performance of 19-iodo cholesterol {sup 1}25I 3-acetate and sodium iodide samples labeled with 125I is presented for liquid scintillation counting measurements. Quench effect, count rate stability and spectral evolution of samples have been followed for several weeks in Toluene, Hisafe II, Instagel, Dioxane-naphthalene and Toluene-alcohol scintillators. Organic samples have negligible quench effect in the interval of I concentration of 0-90 {mu}g and inorganic samples only show a very small variation, lower than 12%, for Dioxane-naphthalene, in the same range of concentration. Satisfactory stability is obtained in general for both, organic and inorganic samples, but small counting losses, 0.03% for 19-iodocholesterol 1 I 3-acetate samples in Tolue ne-alcohol and 0 .04% for Na 125I samples in Dioxane-naphthalene and Toluene-alcohol, have been reported. (Author) 8 refs.

Rodriguez Barquero, L.; Grau Malonda, A.; Los Arcos Merino, J. M.; Grau Carles, A.

1994-07-01

239

125I seed irradiation induces up-regulation of the genes associated with apoptosis and cell cycle arrest and inhibits growth of gastric cancer xenografts  

Directory of Open Access Journals (Sweden)

Full Text Available Abstract Background Iodine 125 (125I) seed irradiation can be used as an important supplementary treatment for unresectable advanced gastric cancer. Here, we aim to comprehensively elucidate the biological effects induced by 125I seed irradiation in human gastric cancer xenograft model by using global expression and DNA methylation analyses. Methods The 48 mice bearing NCI-N87 gastric cancer xenografts were randomly separated into 2 groups: sham seeds (O mCi) were implanted into the control group (n?=?24); 125?l seeds (0.9?mCi) were implanted into the treatment group (n?=?24). The mitotic index and apoptotic index were evaluated by quantitative morphometric analysis of the expression of proliferating cell nuclear antigen (PCNA) and in situ terminal transferase-mediated fluorescein deoxy- UTP nick end labeling (TUNEL), respectively. Global gene expression changes induced by 125I seed irradiation were analyzed by using Nimblegen Human gene expression array. DNA methylation profile in the tumors from control group was investigated with methylated DNA immunoprecipitation (MeDIP) and Nimblegen CpG promoter microarrays. The changes in the methylation status of selected genes were further investigated by using MeDIP-PCR. Results 125I seed irradiation suppresses the growth of gastric cancer xenografts in nude mice. PCNA staining and tissue TUNEL assays showed that both inhibition of cell proliferation and induction of apoptosis contribute to the 125I-induced tumor suppression in nude mouse model. Gene expression profiles revealed that the expression levels of several hundred genes, many of which are associated with apoptosis or cell cycle arrest, including BMF, MAPK8, BNIP3, RFWD3, CDKN2B and WNT9A, were upregulated following 125I seed irradiation. Furthermore, the up-regulation of some of these genes, such as BNIP3 and WNT9A, was found to be associated with irradiation-induced DNA demethylation. Conclusions This study revealed that 125I seed irradiation could significantly induce the up-regulation of apoptosis- and cell cycle-related genes in human gastric cancer xenografts. And some of the up-regulation might be attributed to 125I-irradiation induced demethylation in gene promoter regions. Collectively, these findings provided evidence for the efficacy of this modality for the treatment of gastric cancer.

Ma Zhen-Huan; Yang Yong; Zou Lei; Luo Kai-Yuan

2012-01-01

240

78 FR 41125 - Interim Enforcement Policy for Permanent Implant Brachytherapy Medical Event Reporting  

Science.gov (United States)

...implanted based on the conditions encountered during the surgical procedure and to document such adjustments in the portion...implanted based on the conditions encountered during the surgical procedure and to document such adjustments in the...

2013-07-09

 
 
 
 
241

[Treatment of partially edentulous patients using permanent fixed dentures on Branemark osseointegrated implants: 50 months observation  

UK PubMed Central (United Kingdom)

78 partialyedentulous patients are reviewed, the treatment is 120 implant supported fixed prosthesis. Psothetic index of success is 100%, surgical index of success is 97.81% al the moment to connect abutments (4 implants non integrated) and 99.26% of success about fixations connected to porsthesis and masticatory charged (2 implants lost).

Barrachina Mataix M; Barrachina Mataix MJ; Barrachina Mataix J

1990-12-01

242

Levels in 123I and 125I from (3He,d) reactions  

International Nuclear Information System (INIS)

[en] Proton states in 123I and 125I have been observed by means of the 123,124Te(3He,d)123,125I reactions at a bombarding energy of 19.5 MeV. Results regarding spin assignments and spectroscopic factors are presented

243

Labelling monoclonal antibody 10D9 with 125I using the iodogen method  

International Nuclear Information System (INIS)

To establish the method radiolabeled monoclonal antibody 10D9 against human costimulatory molecules CD80 with 125I, 10D9 was labeled with 125I using the Iodogen method at room temperature. The labeling efficiency and radiochemical purity were tested with TCA, and the immune activity and stability of the labeling product were analyzed. The optimum labeling condition was 10 ?g Iodogen, 20 ?g 10D9 and 22.2 MBq Na125I. The reaction time was 8 min at room temperature. The labeled yield was (84.10±3.18)%, and the radiochemical purity was (98.49±1.14)%. The radio-activity of 125I-10D9 was 933.51 MBq/mg. The specific binding efficiency of 125I-10D9 with Daudi cell was(23.21±1.14)%. The radiochemical purity of 125I-10D9 was over 90% after three weeks of mixing with PBS. In conclusion, the method is simple and easy to perform. The labeling efficiency and radiochemical purity is high. The stability of 125I-10D9 is fine in vitro and 125I-10D9 keeps its immune activity after Iodogen labeling. (authors)

2009-01-01

244

Quality of permanent prostate implants using automated delivery with seedSelectronTM versus manual insertion of RAPID StrandsTM  

International Nuclear Information System (INIS)

Background and purpose: To compare the quality of manually inserted RAPID Strand implants with automatically inserted selectSeed implants using volumetric and dosimetric parameters. Patients and methods: Patients with T1 to T2 prostate carcinoma were treated with brachytherapy. The 125I seeds were implanted in the prostate in three different ways: manual insertion of RAPID Strands (R); insertion of selectSeeds using the seedSelectron (S); a combination of both techniques: manual insertion of RAPID Strands in the left half of the prostate and insertion of selectSeeds with the seedSelectron in the right half of the prostate (RS). The comparison is based on implant and target specific parameters. The implant specific parameters, V100, homogeneity index (HI), and natural dose ratio (NDR), were determined at the time of implantation and four weeks later. MR images taken four weeks after the implantation were used for the calculation of the target specific parameters: D90, HI, external index (EI), and conformation number (CN). Results: We found no significant difference between the groups of implants (R, S, RS) for the implant specific parameters V100, HI, and NDR at t0 and neither at t4w. For each group, the V100 values decreased significantly with time between t0 and t4w. The target specific parameters D90, HI, EI and CN were not significantly different between the groups. For the group of patients with both RAPID Strands and selectSeeds, we found a significant difference in D90 between both halves of the prostate. Conclusions: The dosimetry parameters of a newly introduced implant technique using an automatic seed afterloader were not significantly different from the parameters of a manual insertion technique using RAPID Strands. Since either technique has its advantages and disadvantages regarding seed migration, physics quality assurance, efficiency, logistics, and ease of use, it was decided to use both techniques and to continue evaluations.

2004-01-01

245

Prostate dose calculations for permanent implants using the MCNPX code and the Voxels phantom MAX  

International Nuclear Information System (INIS)

This paper presents the modeling of 80, 88 and 100 of 125I seeds, punctual and volumetric inserted into the phantom spherical volume representing the prostate and prostate phantom voxels MAX. Starting values of minimum and maximum activity, 0.27 mCi and 0.38 mCi, respectively, were simulated in the Monte Carlo code MCNPX in order to determine whether the final dose, according to the integration of the equation of decay at time t = 0 to t = ? corresponds to the default value set by the AAPM 64 which is 144 Gy. The results showed that consider sources results in doses exceeding the percentage discrepancy of the default value of 200%, while volumetric consider sources result in doses close to 144 Gy. (author)

2010-01-01

246

Prostate dose calculations for permanent implants using the MCNPX code and the Voxels phantom MAX  

Energy Technology Data Exchange (ETDEWEB)

This paper presents the modeling of 80, 88 and 100 of {sup 125}I seeds, punctual and volumetric inserted into the phantom spherical volume representing the prostate and prostate phantom voxels MAX. Starting values of minimum and maximum activity, 0.27 mCi and 0.38 mCi, respectively, were simulated in the Monte Carlo code MCNPX in order to determine whether the final dose, according to the integration of the equation of decay at time t = 0 to t = {infinity} corresponds to the default value set by the AAPM 64 which is 144 Gy. The results showed that consider sources results in doses exceeding the percentage discrepancy of the default value of 200%, while volumetric consider sources result in doses close to 144 Gy. (author)

Reis Junior, Juraci Passos dos; Silva, Ademir Xavier da, E-mail: jjunior@con.ufrj.b, E-mail: Ademir@con.ufrj.b [Coordenacao dos Programas de Pos-Graduacao de Engenharia (COPPE/UFRJ), RJ (Brazil). Programa de Engenharia Nuclear; Facure, Alessandro N.S., E-mail: facure@cnen.gov.b [Comissao Nacional de Energia Nuclear (CNEN), Rio de Janeiro, RJ (Brazil)

2010-07-01

247

Experimental and clinical treatment of bladder cancer with 125I-iododeoxyuridine  

International Nuclear Information System (INIS)

Radionuclide can cause auger effect through disintegration low-energy electron (125I-iododeoxyuridine (125I-UdR) is an efficient carrier inducting 125I to cell nucleolus, it is incorporated into DNA specificity only in S-phase cells. A series of studies show that 125I can absorb more likely to tumor cells, instead of the normal cell division, thus effectively splitting radiotherapy of malignant lesions. As bladder is a natural lumen, it has a unique easy perfusion and observational. 125I-UdR can kill effiently and selectively the cells of bladder turnout, reducing markedly the ratio of its recurrence of surgical treatment of patients with bladder cancer, so as to improve the survival rate. It can be used as a surgical adjuvant treatment method, is expected to be a safe, efficient and less adverse reaction the new therapies for bladder cancer treatment. (authors)

2009-01-01

248

Isolation of /sup 125/I-concanavalin A-labeled plasma membrane from unfertilized mouse eggs  

Energy Technology Data Exchange (ETDEWEB)

A procedure was developed for isolation of plasma membrane (PM) preparations from unfertilized mouse eggs. Zona-free mouse eggs prepared by the method of Boldt and Wolf (Gamete Res 13:213-222, 1986) were labeled with 125I-concanavalin A (ConA) prior to sonication and fractionation on iso-osmotic self-generated Percoll density gradients. Experiments using the ConA-specific sugar alpha-methylmannoside (alpha MM) indicated that 125I-ConA bound specifically to the egg PM. Greater than 95% of 125I-ConA binding to zona-free eggs was blocked in the presence of 0.1 M alpha MM, and incubation of eggs in alpha MM after 125I-ConA labeling caused release of 85-90% of bound label. Fractionation of 125I-ConA-labeled eggs by Percoll density gradient centrifugation yielded a single radioactive peak at density = 1.025, corresponding to egg PM material. Prolonged incubation of 125I-ConA-labeled eggs or egg sonicates prior to fractionation did not alter the location of the radioactive peak, indicating that 125I-ConA did not label other organelles. As a control, human erythrocytes were labeled with 125I-ConA and fractionated under identical experimental conditions and yielded a single radioactive peak at density (1.020) comparable to that observed for 125I-ConA-labeled eggs. These results indicate that 125I-ConA can be used as a specific marker to support PM isolation from small numbers of zona-free mouse eggs.

Boldt, J.; Wolf, D.P.

1987-04-01

249

Isolation of 125I-concanavalin A-labeled plasma membrane from unfertilized mouse eggs  

International Nuclear Information System (INIS)

A procedure was developed for isolation of plasma membrane (PM) preparations from unfertilized mouse eggs. Zona-free mouse eggs prepared by the method of Boldt and Wolf (Gamete Res 13:213-222, 1986) were labeled with 125I-concanavalin A (ConA) prior to sonication and fractionation on iso-osmotic self-generated Percoll density gradients. Experiments using the ConA-specific sugar alpha-methylmannoside (alpha MM) indicated that 125I-ConA bound specifically to the egg PM. Greater than 95% of 125I-ConA binding to zona-free eggs was blocked in the presence of 0.1 M alpha MM, and incubation of eggs in alpha MM after 125I-ConA labeling caused release of 85-90% of bound label. Fractionation of 125I-ConA-labeled eggs by Percoll density gradient centrifugation yielded a single radioactive peak at density = 1.025, corresponding to egg PM material. Prolonged incubation of 125I-ConA-labeled eggs or egg sonicates prior to fractionation did not alter the location of the radioactive peak, indicating that 125I-ConA did not label other organelles. As a control, human erythrocytes were labeled with 125I-ConA and fractionated under identical experimental conditions and yielded a single radioactive peak at density (1.020) comparable to that observed for 125I-ConA-labeled eggs. These results indicate that 125I-ConA can be used as a specific marker to support PM isolation from small numbers of zona-free mouse eggs.

1987-01-01

250

Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy  

International Nuclear Information System (INIS)

Purpose: Urinary retention requiring catheterization is a known complication among prostate cancer patients treated with permanent interstitial radioactive seed implantation. However, the factors associated with this complication are not well known. This study was conducted to determine these factors. Methods and Materials: Ninety-one consecutive prostate cancer patients treated with permanent interstitial implantation at our institution from 1996 to 1999 were evaluated. All patients underwent pre-implant ultrasound and postimplant CT volume studies. Isotopes used were 125I (54 patients) or 103Pd (37 patients). Twenty-three patients were treated with a combination of 45 Gy of external beam radiation therapy as well as seed implantation, of which only 3 patients were treated with 125I. Mean pretreatment prostate ultrasound volume was 35.4 cc (range, 10.0-70.2 cc). The mean planning ultrasound target volume (PUTV) was 39.6 cc (range, 16.1-74.5 cc), whereas the mean posttreatment CT target volume was 55.0 cc (range, 20.2-116 cc). Patient records were reviewed to determine which patients required urinary catheterization for relief of urinary obstruction. The following factors were analyzed as predictors for urinary retention: clinical stage; Gleason score; prostate-specific antigen; external beam radiation therapy; hormone therapy; pre-implant urinary symptoms (asymptomatic/nocturia x 1 vs. more significant urinary symptoms); pretreatment ultrasound prostate volume; PUTV; PUTV within the 125%, 150%, 200%, 250%, 300% isodose lines; postimplant CT volume within the 125%, 150%, 200%, 250%, 300% isodose lines; D90; D80; D50; ratio of post-CT volume to the PUTV; the absolute change in volume between the CT volume and PUTV; number of needles used; activity per seed; and the total activity of the implant. Statistical analyses using logistic regression and ?2 were performed. Results: Eleven of 91 (12%) became obstructed. Significant factors predicting for urinary retention were the total number of needles used (p

251

Exclusive curietherapy by permanent iodine-125 implants: selection of patients and results after eight years; Curietherapie exclusive par implants permanents d'iode-125: selection des patients et resultats a huit ans  

Energy Technology Data Exchange (ETDEWEB)

The authors report a retrospective study which assesses the results obtained over eight years and the toxicity of an exclusive curietherapy by permanent iodine-125 implants performed at the Nancy centre of struggle against cancer. More than five hundred patients have been treated between December 1999 and December 2007, a first group comprising patients suffering from a low risk cancer and a second group suffering from a medium risk cancer. The authors discuss the survival rates, the existence of side effects, and rectal toxicity results. Short communication

Boutenbat, G.; Peiffert, D.; Bernier, V.; Moreau, J.L.; Boudran, G.; Noel, A.; Marchesi, V.; Huget, S. [Centre Alexis Vautrin, 54 - Vandoeuvre-Les-Nancy (France); Moreau, J.L. [Cabinet prive d' urologie, 54 - Nancy (France); Boudran, G. [Centre Hospitalier Universitaire de Brabois, 54 - Vandoeuvre-Les-Nancy (France)

2010-10-15

252

Very late pacemaker extrusion: A rare complication of permanent pacemaker implantation  

Directory of Open Access Journals (Sweden)

Full Text Available Pacemaker extrusion is an uncommon complication of device implantation. Mostly, it happens either beuse of infection or secondary to various mechanical factors. It usually occurs days to months after the implantation, however very late pacemaker extrusion has not been described in the literature. We present a case of 70 years old male, who had pacemaker extrusion 11 years after its implantation. The various management issues related with such patient is discussed in the article.

Rajesh Vijayvergiya; Ram Chitlangia; Mukesh Yadav; Asif Hasan

2012-01-01

253

Exploration of dopamine transporter and D2 receptors in morphine dependent rats through 125I-?-CTT, 125I-IBZM cerebral autoradiography and the biodistribution study  

International Nuclear Information System (INIS)

[en] Objective: To explore the variation of cerebral dopamine (DA) transmitting system in morphine dependent (MD) rats using dopamine transporter (DAT) and D2 receptors imaging agent. Methods: MD model rats were established by using a two-compartment (C1 and C2-morphine conditioned compartment) apparatus for assessing morphine conditioned place preferences in rats. 125I-2?-carbomethoxy-3?-(4-iodophenyl) tropane (125I-?-CIT) and 125I-3-iodo-2-hydroxy-6-methoxy-N[(1-ethyl-2-pyrrolidinyl) methyl] benzamide (125I-IBZM) cerebral DAT and D2 receptor autoradiography and biodistribution study were used to evaluate the variation of DAT and D2 receptors in morphine dependent rats. Results: The mean time of MD rats entering from C1 to C2 was (0.84 +- 0.50) min after 6 days' conditioned place preference training, shorter than that of the control group [(2.40 +- 1.10) min, P 125I-?-CIT uptake ratio of striatum (ST)/cerebellum (CB) and nucleus acumens (NAC)/CB in MD group were 4.76 +- 0.92 and 2.72 +- 0.96, significantly lower than that of control group (5.92 +- 0.67 and 4.16 +- 0.56, P 125I-IBZM uptake ratio in MD group were 4.11 +- 0.56 and 2.64 +- 0.25, lower than that in control group (5.43 +- 0.74 and 3.49 +- 0.65, P 125I-?-CIT, 125I-IBZM biodistribution study also showed that the DAT and D2 binding sites were reduced in ST of MD group by (21.68 +- 11.11)% and (18.69 +- 9.97)% comparing to the controls, respectively. Conclusions: The DAT and D2 receptors in both ST and NAC were all involved and reduced to some extent in morphine dependent model rats, the DAT and D2 receptor imaging agent could reflect the variation of DAT and D2receptors, this would afford the theoretical basis for D2 receptors and DAT imaging in study on preventing drug addiction and on its abstinence

2001-01-01

254

( sup 125 I)Iodoazidococaine, a photoaffinity label for the haloperidol-sensitive sigma receptor  

Energy Technology Data Exchange (ETDEWEB)

A carrier-free radioiodinated cocaine photoaffinity label, (-)-3-({sup 125}I)iodo-4-azidococaine (({sup 125}I)IACoc), has been synthesized and used as a probe for cocaine-binding proteins. Photoaffinity labeling with 0.5 nM ({sup 125}I)IACoc resulted in selective derivatization of a 26-kDa polypeptide with the pharmacology of a sigma receptor in membranes derived from whole rat brain, rat liver, and human placenta. ({sup 125}I)IACoc labeling of the 26-kDa polypeptide was also inhibited by 10 {mu}M imipramine, amitriptyline, fluoxetine, benztropine, and tetrabenazine. The size of the ({sup 125}I)I-ACoc-labeled proteins is consistent with the size of proteins photolabeled in guinea pig brain and liver membranes by using the sigma photolabel azido-({sup 3}H)DTG. Kinetic analysis of ({sup 125}I)IACoc binding to rat liver microsomes revealed two sites with K{sub d} values of 19 and 126 pM, respectively. The presence or absence of proteolytic inhibitors during membrane preparation did not alter the size of the photolabeled sigma receptor, indicating that the 26-kDa polypeptide was not derived from a larger protein. In summary, ({sup 125}I)IACoc is a potent and highly specific photoaffinity label for the haloperidol-sensitive sigma receptor and will be useful for its biochemical and molecular characterization.

Kahoun, J.R.; Ruoho, A.E. (Univ. of Wisconsin, Madison (United States))

1992-02-15

255

(125I)Iodoazidococaine, a photoaffinity label for the haloperidol-sensitive sigma receptor  

International Nuclear Information System (INIS)

A carrier-free radioiodinated cocaine photoaffinity label, (-)-3-(125I)iodo-4-azidococaine [(125I)IACoc], has been synthesized and used as a probe for cocaine-binding proteins. Photoaffinity labeling with 0.5 nM (125I)IACoc resulted in selective derivatization of a 26-kDa polypeptide with the pharmacology of a sigma receptor in membranes derived from whole rat brain, rat liver, and human placenta. (125I)IACoc labeling of the 26-kDa polypeptide was also inhibited by 10 ?M imipramine, amitriptyline, fluoxetine, benztropine, and tetrabenazine. The size of the (125I)I-ACoc-labeled proteins is consistent with the size of proteins photolabeled in guinea pig brain and liver membranes by using the sigma photolabel azido-[3H]DTG. Kinetic analysis of (125I)IACoc binding to rat liver microsomes revealed two sites with Kd values of 19 and 126 pM, respectively. The presence or absence of proteolytic inhibitors during membrane preparation did not alter the size of the photolabeled sigma receptor, indicating that the 26-kDa polypeptide was not derived from a larger protein. In summary, (125I)IACoc is a potent and highly specific photoaffinity label for the haloperidol-sensitive sigma receptor and will be useful for its biochemical and molecular characterization

1992-02-15

256

A Radiation Badge Survey for Family Members Living With Patients Treated With a 103Pd Permanent Breast Seed Implant  

International Nuclear Information System (INIS)

Purpose: Sixty-seven patients with early-stage breast cancer were treated in a Phase I/II clinical trial using a 103Pd permanent breast seed implant as adjuvant radiotherapy after breast-conserving surgery. We report the dose received by family members living with these patients and compare measured doses with theoretical worst-case scenario estimates. Methods and Materials: Exposure-rate measurements were taken at 1 m from the patient by using a calibrated low-energy survey meter. Landauer (Landauer Inc., Glenwood, IL) Luxel badges, with sensitivity of 0.01 mSv, were given to family members to wear after the implantation. Badge readings for 33 spouses and 28 other family members were used to estimate effective doses, and these were compared with theory. Results: Average preimplantation planning target volume from computed tomography was 50.3 ml (range, 18.0-96.7 ml), and average preimplantation distance between the skin and the most anterior planning target volume margin was 0.57 cm. The average maximum exposure rate was measured to be 2.4 ± 1.1 mR/h, and average measured dose to a spouse was 0.99 ± 1.0 mSv. The calculated exposure rates and spousal doses using preimplantation computed tomography scan data overestimated those measured. Average measured family member dose (excluding spouses) was 0.20 ± 0.58 mSv. Conclusions: Based on measured and calculated spousal doses, a permanent breast seed implant using 103Pd is safe for the public. However, it is recommended that extra precautions in the way of a breast patch be used when patients with an implant will be in the vicinity of toddlers or pregnant women.

2008-01-01

257

One-year cardiac morphological and functional evolution following permanent pacemaker implantation in right ventricular septal position in chagasic patients.  

UK PubMed Central (United Kingdom)

INTRODUCTION: The septal position is an alternative site for cardiac pacing (CP) that is potentially less harmful to cardiac function. METHODS: Patients with Chagas disease without heart failure submitted to permanent pacemaker (PP) implantation at the Clinics Hospital of the Triângulo Mineiro Federal University (UFTM), were selected from February 2009 to February 2010. The parameters analyzed were ventricular remodeling, the degree of electromechanical dyssynchrony (DEM), exercise time and VO2 max during exercise testing (ET) and functional class (NYHA). Echocardiography was performed 24 to 48 h following implantation and after one year follow-up. The patients were submitted to ET one month postprocedure and at the end of one year. RESULTS: Thirty patients were included. Patient mean age was 59 ± 13 years-old. Indication for PP implantation was complete atrioventricular (AV) block in 22 (73.3%) patients and 2nd degree AV block in the other eight (26.7%). All patients were in NYHA I and no changes occurred in the ET parameters. No variations were detected in echocardiographic remodeling measurements. Intraventricular dyssynchrony was observed in 46.6% of cases and interventricular dyssynchrony in 33.3% of patients after one year. CONCLUSIONS: The findings of this work suggest that there is not significant morphological and functional cardiac change following pacemaker implantation in septal position in chagasic patients with normal left ventricular function after one year follow-up. Thus, patients may remain asymptomatic, presenting maintenance of functional capacity and no left ventricular remodeling.

Silva Júnior Od; Maeda PM; Borges MC; Melo CS; Correia D

2012-06-01

258

(125I)LDL uptake in rabbit arteries refused in situ  

International Nuclear Information System (INIS)

The uptake of (125I)LDL by rabbit abdominal and thoracic aortae, and arteries perfused in situ was studied. (125I)LDL uptake in vessels with intact endothelial covering was saturable, Ca2+, Mg2+-dependent and was inhibited by a 100-fold excess of LDL and HDL, on the average by 30% and 60%, respectively. In de-endothelialized vessels (125I)LDL uptake increased by approximately 3-fold, and was not reduced in the presence of excess of unlabelled LDL and HDL. (author)

1983-01-01

259

Intraperitoneal (125I) insulin absorption during intermittent and continuous peritoneal dialysis  

International Nuclear Information System (INIS)

[en] The authors have measured intraperitoneal (125I) insulin absorption during intermittent and continuous peritoneal dialysis in order to study the following: insulin regulation of blood glucose when administered continuously via dialysate during continuous ambulatory peritoneal dialysis (CAPD) versus when given intermittently and subcutaneously before CAPD; the degree of (125I) insulin retention in plastic CAPD bags, after complete drainage of the dialysis fluid; absorption of (125I) insulin from the dialysate in the peritoneal cavity of diabetic and non-diabetic patients. (Auth.)

1981-06-19

260

In vivo study about specific captation of 125 I-insulin by rat brain structures  

International Nuclear Information System (INIS)

The specific captation of 125 I-insulin was evaluated by brain structures, as olfactory bulbous, hypothalamus and cerebellum in rats, from in vivo experiences that including two different aspects: captation measure of 125 I-insulin after the intravenous injection of the labelled hormone, in fed rats and in rats with 48 h of fast or convulsion, procedure by the pentylene tetrazole; captation measure of 125 I-insulin after intra-cerebral-ventricular injection of the labelled hormone in fed rats. (C.G.C.).

1986-01-01

 
 
 
 
261

OER and RBE for 125I and 192Ir at low dose rate on mammalian cells  

International Nuclear Information System (INIS)

The oxygen enhancement ratio (OER) for 125I and 192Ir as well as the relative biological effectiveness (RBE) at low dose rates (40-80 cGy h-1) were determined for B16 melanoma cells in culture. The OER was found to be 2.1±0.03 for 125I and 2.7±0.04 for 192Ir. The RBE for 125I relative to 192Ir was determined as 1.8±0.03 under aerated conditions and as 2.4±0.03 under hypoxia. 18 refs.; 5 figs.; 1 table

1987-01-01

262

m-[125I]iodoaniline: a useful reagent for radiolabeling biotin  

International Nuclear Information System (INIS)

Biotinyl-m-[125I]iodoanilide (BIA) was synthesized by coupling biotin to m-[125I]iodoaniline via a mixed anhydride reaction. m-[125I]Iodoaniline was produced from the tin precursor, which was prepared using a palladium catalyzed reaction of hexabutylditin with m-bromoaniline. The radioiodinated BIA derivative is characterized by a stable amide and/or intact ureido group on the biotin molecule, it may thus be a useful carrier for targeting radionuclides to avidin-conjugated antibodies previously localized on tumors. (author).

1992-01-01

263

M-[[sup 125]I]iodoaniline: a useful reagent for radiolabeling biotin  

Energy Technology Data Exchange (ETDEWEB)

Biotinyl-m-[[sup 125]I]iodoanilide (BIA) was synthesized by coupling biotin to m-[[sup 125]I]iodoaniline via a mixed anhydride reaction. m-[[sup 125]I]Iodoaniline was produced from the tin precursor, which was prepared using a palladium catalyzed reaction of hexabutylditin with m-bromoaniline. The radioiodinated BIA derivative is characterized by a stable amide and/or intact ureido group on the biotin molecule, it may thus be a useful carrier for targeting radionuclides to avidin-conjugated antibodies previously localized on tumors. (author).

Khawli, L.A.; Kassis, A.I. (Harvard Medical School, Boston, MA (United States))

1992-04-01

264

A preliminary study on the targeting localization of human hepatocellular carcinoma grafted in nude mice with 125I labelled lectins  

International Nuclear Information System (INIS)

[en] BSAI, PSA and RCAI which can bind to glycoconjugates of hepatocellular carcinoma (HCC) were radiolabelled with 125I and the targeting localization of human HCC grafted in nude mice were observed with 125I-lectins. The results indicated that the planted human HCC in nude mice was clearly imaged with the three 125I-lectins though other tissues in the mice also contained different amounts of 125I-lectins. The planted tumors could not be showed with Na 125I or 125I-cytochrome C in controls. It is suggested that lectins specific for HCC had a potential application in the targeting localization of HCC

1991-01-01

265

Progestin receptors in brain and pituitary of 20-day-old fetal mice: an autoradiographic study using (/sup 125/I)progestin  

Energy Technology Data Exchange (ETDEWEB)

The distribution of progestin target sites in the brain and pituitary of estrogen-primed 20-day-old fetal mice was investigated by thaw-mount autoradiography. Three pregnant mice were each implanted sc with a Silastic tube containing estrogen on day 17 and ovariectomized on day 19 of gestation. Twenty-four hours after ovariectomy 10 fetuses (5 males and 5 females) were collected and each injected sc with 0.33 microgram/100 g BW (/sup 125/I)progestin (SA, 2200 Ci/mM). For competition, two additional fetuses were injected with 20 micrograms R5020 1 h before (Z)-17 beta-hydroxy-17 alpha-(2(/sup 125/I)iodovinyl)4-estren-3-one ((/sup 125/I)Progestin) to demonstrate that nuclear uptake and retention of radioactivity were specific for progestin. Two hours after injection of (/sup 125/I)Progestin all fetuses were mounted, frozen, and sectioned in a cryostat. After 1-37 days of exposure, sections were developed and scanned for labeled cells. Cells with nuclear concentration were found in the male and female preoptic area, within certain nuclear groups in the basal hypothalamus, in the central gray of the midbrain, and in the pituitary. No labeling was detected in the cortex or amygdala. The results indicate that cells in certain regions of the brain and pituitary express progestin receptors at the end of gestation and suggest that progesterone is important for the normal development of these cells.

Shughrue, P.J.; Stumpf, W.E.; Sar, M.; Elger, W.; Schulze, P.E.

1989-01-01

266

Distribution of progesterone receptor in the 20-day-old fetal mouse: an autoradiographic study with (/sup 125/I)progestin  

Energy Technology Data Exchange (ETDEWEB)

The distribution of progestin target sites in 20-day-old fetuses of estrogen-primed pregnant mice was investigated by thaw-mount autoradiography. Pregnant mice received a Silastic estradiol implant on day 17 and were ovariectomized on day 19 of pregnancy. Twenty-four hours after ovariectomy 10 prematurely delivered fetuses were each injected with 0.33 microgram/100 g BW (/sup 125/I)progestin (SA, 2200 Ci/mM). To show specificity of progestin localization two additional fetuses were each injected sc with 20 micrograms R5020, a synthetic progestin, 1 h before the injection of (/sup 125/I)progestin. The fetuses were frozen 2 h after injection of (/sup 125/I)progestin, sectioned, and processed for thaw-mount autoradiography. Cells with nuclear uptake and retention of radioactivity were observed in numerous tissues, including certain regions of the oral mucosa and developing teeth, esophagus, larynx, skin, mammary gland, skeletal muscle, kidney, and reproductive glands and ducts. Injection of unlabeled R5020 1 h before (/sup 125/I)progestin prevented nuclear concentration of radioactivity in all target tissues. The results indicate that progesterone receptors are expressed with a regional, cellular, and subcellular distribution in term fetal mouse tissues and suggest that progesterone is important to the growth and development of certain fetal tissues.

Shughrue, P.J.; Stumpf, W.E.; Sar, M.

1988-11-01

267

Progestin receptors in brain and pituitary of 20-day-old fetal mice: an autoradiographic study using [125I]progestin  

International Nuclear Information System (INIS)

The distribution of progestin target sites in the brain and pituitary of estrogen-primed 20-day-old fetal mice was investigated by thaw-mount autoradiography. Three pregnant mice were each implanted sc with a Silastic tube containing estrogen on day 17 and ovariectomized on day 19 of gestation. Twenty-four hours after ovariectomy 10 fetuses (5 males and 5 females) were collected and each injected sc with 0.33 microgram/100 g BW [125I]progestin (SA, 2200 Ci/mM). For competition, two additional fetuses were injected with 20 micrograms R5020 1 h before (Z)-17 beta-hydroxy-17 alpha-(2[125I]iodovinyl)4-estren-3-one [(125I]Progestin) to demonstrate that nuclear uptake and retention of radioactivity were specific for progestin. Two hours after injection of [125I]Progestin all fetuses were mounted, frozen, and sectioned in a cryostat. After 1-37 days of exposure, sections were developed and scanned for labeled cells. Cells with nuclear concentration were found in the male and female preoptic area, within certain nuclear groups in the basal hypothalamus, in the central gray of the midbrain, and in the pituitary. No labeling was detected in the cortex or amygdala. The results indicate that cells in certain regions of the brain and pituitary express progestin receptors at the end of gestation and suggest that progesterone is important for the normal development of these cells.

1989-01-01

268

Distribution and levels of [{sup 125}I]IGF-I, [{sup 125}I]IGF-II and [{sup 125}I]insulin receptor binding sites in the hippocampus of aged memory-unimpaired and -impaired rats  

Energy Technology Data Exchange (ETDEWEB)

The insulin-like growth factors (IGF-I and IGF-II) and insulin are localized within distinct brain regions and their respective functions are mediated by specific membrane receptors. High densities of binding sites for these growth factors are discretely and differentially distributed throughout the brain, with prominent levels localized to the hippocampal formation. IGFs and insulin, in addition to their growth promoting actions, are considered to play important roles in the development and maintenance of normal cell functions throughout life. We compared the anatomical distribution and levels of IGF and insulin receptors in young (five month) and aged (25 month) memory-impaired and memory-unimpaired male Long-Evans rats as determined in the Morris water maze task in order to determine if alterations in IGF and insulin activity may be related to the emergence of cognitive deficits in the aged memory-impaired rat. In the hippocampus, [{sup 125}I]IGF-I receptors are concentrated primarily in the dentate gyrus (DG) and the CA3 sub-field while high amounts of [{sup 125}I]IGF-II binding sites are localized to the pyramidal cell layer, and the granular cell layer of the DG. [{sup 125}I]insulin binding sites are mostly found in the molecular layer of the DG and the CA1 sub-field. No significant differences were found in [{sup 125}I]IGF-I, [{sup 125}I]IGF-II or [{sup 125}I]insulin binding levels in any regions or laminae of the hippocampus of young vs aged rats, and deficits in cognitive performance did not relate to altered levels of these receptors in aged memory-impaired vs aged memory-unimpaired rats. Other regions, including various cortical areas, were also examined and failed to reveal any significant differences between the three groups studied.It thus appears that IGF-I, IGF-II and insulin receptor sites are not markedly altered during the normal ageing process in the Long-Evans rat, in spite of significant learning deficits in a sub-group (memory-impaired) of aged animals. Hence, recently reported changes in IGF-I receptor messenger RNA levels in aged memory-impaired rats [42] are apparently not reflected at the level of the translated protein. (Copyright (c) 1997 Elsevier Science B.V., Amsterdam. All rights reserved.)

Quirion, R.; Rowe, W.; Kar, S.; Dore, S. [Douglas Hospital Research Centre, Department of Psychiatry, McGill University, Montreal (Canada)

1997-08-11

269

Comparison of radiation doses in permanent cardiac pacemaker implantation in three Greek hospitals  

International Nuclear Information System (INIS)

[en] Full text: Permanent cardiac pacemaker implantation is a simple Interventional Cardiology (IC) procedure during which fluoroscopy is employed for aiding in the manipulations required for the successful placement of the pacemaker. However, it is also known that these procedures involve high radiation doses due to long fluoroscopy times. During the SENTINEL European project, radiation doses were measured in three major hospitals in Greece in order to: (1) investigate the levels of dose imparted to the patient, (2) explore the various factors that could have an impact on patient dose, and finally (3) compare the results of this study to corresponding values found in the recent literature. One hundred and eighty four (184) patients participated in the study, 24 of which were treated in Hospital A, 52 in Hospital B and 108 in Hospital C. The radiation dose imparted to the patient was measured in terms of dose area product (DAP) measured in Gycm2 by using DAP meters, all calibrated according to the National Protocol of the National Radiation Protection Board (NRPB) of the United Kingdom. Other patient data collected were the following: age (A), weight (W), height (H), body mass index (BMI), which is the ratio of patient weight in kilogram (kg) to square height in meters (m) (BMI = W/H2), the kilovoltage (kVp) and the fluoroscopy time (T). It was found that results did not exhibit a normal distribution in any of the hospitals and, therefore, DAP and T were calculated in terms of median values. According to our results, median values of DAP and T were: 6.7 Gycm2 and 2.6 min (Hospital A), 9.0 Gycm2 and 3.0 min (Hospital B), 7.7 Gycm2 and 6.5 min (Hospital C). It appears that Hospital A gave the lowest dose to the patient with the lowest fluoroscopy time. However, at comparable fluoroscopy time with Hospital A and even less than half the fluoroscopy time of Hospital C, Hospital B presented the highest DAP. The results show that probably its X ray equipment is calibrated in higher dose rate than the other two hospitals. The correlation between every patient clinical and technical factor collected (W, H, BMI, kVp and T) and DAP were investigated separately. No correlation was found between DAP and patient weight, height or BMI. No correlation was also found between DAP and kilovoltage. Finally, significant correlation was found in all three hospitals between DAP and T (r=0.72 Hospital A, r=0.87 Hospital B, r=0.87 Hospital C). Comparison of results with recent literature such as those reported by the National Radiation Protection Board (NRPB) (27 Gycm2 and 10.7 min) showed that radiation doses are lower for all three Greek hospitals. The results of the study showed that comparable radiation doses are given in the three hospitals participating in the study. These doses are lower than internationally established reference levels. It was found that patient dimensions do not affect patient radiation dose. The limitation of the study was that the X ray equipment dose rate was not investigated in detail to explain small differences between hospitals and this should be done in the near future. (author)

2006-01-01

270

Incidence of seed migration to the chest, abdomen, and pelvis after transperineal interstitial prostate brachytherapy with loose 125I seeds  

Directory of Open Access Journals (Sweden)

Full Text Available Abstract Background The aim was to determine the incidence of seed migration not only to the chest, but also to the abdomen and pelvis after transperineal interstitial prostate brachytherapy with loose 125I seeds. Methods We reviewed the records of 267 patients who underwent prostate brachytherapy with loose 125I seeds. After seed implantation, orthogonal chest radiographs, an abdominal radiograph, and a pelvic radiograph were undertaken routinely to document the occurrence and sites of seed migration. The incidence of seed migration to the chest, abdomen, and pelvis was calculated. All patients who had seed migration to the abdomen and pelvis subsequently underwent a computed tomography scan to identify the exact location of the migrated seeds. Postimplant dosimetric analysis was undertaken, and dosimetric results were compared between patients with and without seed migration. Results A total of 19,236 seeds were implanted in 267 patients. Overall, 91 of 19,236 (0.47%) seeds migrated in 66 of 267 (24.7%) patients. Sixty-nine (0.36%) seeds migrated to the chest in 54 (20.2%) patients. Seven (0.036%) seeds migrated to the abdomen in six (2.2%) patients. Fifteen (0.078%) seeds migrated to the pelvis in 15 (5.6%) patients. Seed migration occurred predominantly within two weeks after seed implantation. None of the 66 patients had symptoms related to the migrated seeds. Postimplant prostate D90 was not significantly different between patients with and without seed migration. Conclusion We showed the incidence of seed migration to the chest, abdomen and pelvis. Seed migration did not have a significant effect on postimplant prostate D90.

Sugawara Akitomo; Nakashima Jun; Kunieda Etsuo; Nagata Hirohiko; Mizuno Ryuichi; Seki Satoshi; Shiraishi Yutaka; Kouta Ryuichi; Oya Mototsugu; Shigematsu Naoyuki

2011-01-01

271

inhibition effects of 125I-UdR on the growth of HepG2 cells  

International Nuclear Information System (INIS)

Objective: To determine the inhibition effects of 125I-UdR on the growth of human hepatoma cell line HepG2 and the influencing factors. Methods: 125I-UdR was added to the HepG2 culture medium. The amount of 125I-UdR uptake by HepG2 cells was evaluated through measuring the radioactivity per cell; the inhibiting effects of 125I-UdR on HepG2 growth were estimated by clonal forming method. Results: The amounts of 125I-UdR uptaken by HepG2 increased with the dose of 125I-UdR escalating in the culture medium (r=0.99). The uptake of 125I-UdR by HepG2 cells was higher than that of Na125I. As the 125I-UdR concentration in HepG2 escalating, the inhibition effects became stronger (r=-0.943) and the LD50 was (0.87 +- 0.29) kBq/mL. The survival fraction of 125I-UdR group was significantly lower than that of Na125I group. Conclusions: The inhibition effects of 125I-UdR on HepG2 cell growth were obvious. 125I-UdR may be incorporated inside the HepG2 cells and the uptake of HepG2 was dose dependent

2002-01-01

272

Radioiodination of ibuprofen with 125I and its biological behavior in mice  

International Nuclear Information System (INIS)

A procedure for radioiodination of Ibuprofen with iodine-125 is carried out via an electrophilic substitution reaction. The reaction parameters were studied Ibuprofen concentration, pH of the reaction mixture, reaction time temperature, and different oxidizing agents to optimize the conditions for the labeling of Ibuprofen to abstain a high radiochemical yield of 125I-Ibuprofen (125I-Ib up). Using 3.7 MBq of of Na 125I, 100?g of ibuprofen as substrate and 100?g of iodogen as oxidizing agent in ethanol at 60 OC for 10 min, a maximum radiochemical yield of 125I-Ib up (78%) was obtained. The labeled compound was separated and purified from inactive Ibuprofen by means of high-pressure liquid chromatography (HPLC). The biological distribution in normal and inflamed mice indicates the suitability of radioiodinated Ibuprofen for imaging of inflammation only induced with turpentine oil. (Author)

2012-01-01

273

Upregulation of [125I] CGP42112 binding in the rat brainstem following nodose ganglionectomy  

International Nuclear Information System (INIS)

Full text: [125I] CGP42112 is a specific ligand which has been used to demonstrate the presence of angiotensin AT2 receptors in peripheral and brain tissue, although [125I] CGP42112 also binds to a non-angiotensin II (Ang II) site. In the present study we have examined [125I] CGP42112 binding in the brainstem following nodose ganglionectomy using autoradiography. Male spontaneously hypertensive rats (SHR) and Wistar Kyoto (WKY) rats underwent unilateral nodose ganglionectomy or sham operation (anaesthetised with methohexitone, 60mg/kg ip). Following a 14 day recovery period, animals were killed and slide mounted brainstem sections (14?m) were prepared and incubated in the presence of either [125I] (Sar1Ile8)Ang II (0.5nM), [125I] CGP42112 (0.3nM) or [3H] PKI11195 (3nM, a marker for activated microglia). Following incubation, slides were apposed to film for 10 days. Specific binding was determined in adjacent sections by co-incubations with either the AT1 receptor antagonist losartan, the AT2 receptor antagonist PD 123319, Ang II or PKI11195 (all at 10?M). In the ganglionectomised groups, there were significant reductions in [125I] (Sar1Ile8)Ang II binding on the denervated side of the nucleus of the solitary tract (NTS) by 30 ± 2 % (n=5, P125I] CGP42112 binding in the NTS revealed an AT2 receptor component which was displaceable by PD 123319 and Ang II (?60%), and a non-Ang II component (?40%). Nodose ganglionectomy increased the density of [125I] CGP42112 binding on the denervated side of the NTS by 55 ± 3 % (n=5, P125I] CGP42112 binding in the NTS of the ganglionectomised groups was comprised of a greater non-Ang II component than in the sham group, since only ?30% was displaced by PD123319 and Ang II. [125I] CGP42112 also revealed high binding density in the dorsal motor nucleus and the nucleus ambiguus on the denervated side in both SHR and WKY rats. This binding was absent in shams and was only ?30-40% displaceable by PD 123319 and Ang II. Analogous experiments were also carried out with [3H] PKI 1195 which revealed a significant increase in binding density on the denervated side in the dorsal motor nucleus (52 ± 4%) and in the nucleus ambiguus (48 ± 3%) in WKY rats (n=6, P3H] PKI 1195 shows a similar upregulation in the ganglionectomised group to that seen by [125I] CGP42112. Copyright (1999) Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists

1999-01-01

274

Impact of different dose distribution of 125I seeds interstitial brachytherapy on the effects in human gastric carcinoma bearing nude mice  

International Nuclear Information System (INIS)

Objective: 125I seeds interstitial brachytherapy has been clinically used for years. How- ever, how the dose distribution affects the therapeutic response remains to be elucidated. The present study was undertaken to investigate the impact of different dose distribution on the effects of 125I seeds interstitial brachytherapy. Methods: Thirty-two human gastric carcinoma bearing nude mice were randomly divided in- to three treated groups and one control group with eight mice in each group. 125I seeds were implanted in the treated groups with the same total activity (33.30 MBq). Based on the dose distribution and activity of single seed, the treated groups were classified to high activity group (33.30 MBq x 1), moderate activity group (16.65 MBq x 2) and low activity group (11.10 MBq x 3). The control group was implanted radioactivity-free seeds. The evaluation parameters were obtained after 30 d, which included survival rate, body weight, volume inhibitory rate, histological tumor regression and regional skin reaction. Analysis of variance and Kruskal-Wallis H test were used for data statistical analysis. Results: All mice survived during the observation period. There was no significant difference of the body weight among the groups after 125I seeds implantation (F=2.23, P>0.05). The volume inhibitory rates in high, moderate and low activity groups were 92.47%, 97.15% and 89.01%, respectively. After treatment the average tumor volume was (138.85 ± 16.45) mm3 in high activity group, (52.52 ± 30.54) mm3 in moderate activity group, (202.72 ± 126.97) mm3 in low activity group and (1843.99 ± 447.63) mm3 in control group. In all treated groups, the average tumor volume was significantly smaller than that in control group (t=3.092, 3.376, 3.269, all P125I seed and the dose distribution may exert critical impact on the therapeutic effects and radiation injury in 125I seeds interstitial brachytherapy. (authors)

2008-01-01

275

Experimental evaluation of an online gamma-camera imaging of permanent seed implantation (OGIPSI) prototype for partial breast irradiation  

International Nuclear Information System (INIS)

[en] Previously, our team used Monte Carlo simulation to demonstrate that a gamma camera could potentially be used as an online image guidance device to visualize seeds during permanent breast seed implant procedures. This could allow for intraoperative correction if seeds have been misplaced. The objective of this study is to describe an experimental evaluation of an online gamma-camera imaging of permanent seed implantation (OGIPSI) prototype. The OGIPSI device is intended to be able to detect a seed misplacement of 5 mm or more within an imaging time of 2 min or less. The device was constructed by fitting a custom built brass collimator (16 mm height, 0.65 mm hole pitch, 0.15 mm septal thickness) on a 64 pixel linear array CZT detector (eValuator-2000, eV Products, Saxonburg, PA). Two-dimensional projection images of seed distributions were acquired by the use of a digitally controlled translation stage. Spatial resolution and noise characteristics of the detector were measured. The ability and time needed for the OGIPSI device to image the seeds and to detect cold spots was tested using an anthropomorphic breast phantom. Mimicking a real treatment plan, a total of 52 103Pd seeds of 65.8 MBq each were placed on three different layers at appropriate depths within the phantom. The seeds were reliably detected within 30 s with a median error in localization of 1 mm. In conclusion, an OGIPSI device can potentially be used for image guidance of permanent brachytherapy applications in the breast and, possibly, other sites

2008-01-01

276

/sup 125/I-labelled cobalamin derivative compatible with intrinsic factor  

Energy Technology Data Exchange (ETDEWEB)

A /sup 125/I-labelled derivative of cobalamin (vitamin B/sub 12/) is described which is compatible with intrinsic factor in binding assays. The derivative, (/sup 125/I)cyanocobalamin-d-iodohistamide, can be readily prepared with a specific activity of 1400 Ci/g. Used as a substitute for (/sup 57/Co)cyanocobalamin in binding assays, the new derivative can reduce counting times and decrease costs in such assays.

Houts, T.M. (Saint Bartholomew' s Hospital, London (UK))

1982-12-23

277

Inhibition effects of 125I-triplex forming oligonucleotide to hepatoma cells  

International Nuclear Information System (INIS)

Objective: Triplex forming oligonucleotide (TFO) has been reported as a new antigene strategy. The purpose of this study was to observe the inhibition effects of 125I-TFO on hepatoma cells and to investigate the possibility of using 125I-TFO as an antigene radiotherapy technique for hepatocellular carcinoma (HCC) related to HBV. Methods: TFO complementary to the initiator of S gene of HBV was synthesized and labeled with 125I. HepG2.2.15 cells, in which HBV genome was integrated, were incubated with 125I-TFO, TFO and 125I respectively. After incubation, hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) of each group were assayed with ELISA and the survival rate of cells in each group was determined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-trazolium bromide (MTT) reduction assay. Results: 125I-TFO showed a high stability with a radiolabeling rate of >93%. The radiochemical purity of labeled compound was 90.8%, 81.1% and 73.2% respectively after 12, 48 and 72 h at 37 degree C. The peak inhibition effect of 125I-TFO on synthesizing HBsAg and HBeAg by HepG2.2.15 cells were found at 48 h after transfection, with significantly the highest inhibition rate of 45.2% for HBsAg and 74.5% for HBeAg expression among the three groups(P125I-TFO may inhibit the antigen expression of HBV and the growth of hepatocarcinoma cells, thus it may provide a new approach to develop gene-based radiotherapeutic pharmaceuticals for anti-HBV and HCC. (authors)

2007-01-01

278

Preparation of 125I-labeled secretin of high specific radioactivity  

International Nuclear Information System (INIS)

[en] A simple and rapid method of preparing 125I-labeled secretin of high specific radioactivity has been developed. Synthetic porcine secretin was iodinated with Na[125I] by a modification of the chloramine T method. Purification and separation of labeled from unlabeled secretin was achieved by chromatography on SP-Sephadex C-25 column. The labeled secretin possessed specific radioactivity as high as 500 to 550 ?Ci/?g

1975-01-01

279

Transport of [125I]transferrin through the rat blood-brain barrier.  

UK PubMed Central (United Kingdom)

Transferrin receptors are present in the plasma membrane of brain endothelial cells but it is unclear if these receptors mediate transport of transferrin across the blood-brain barrier (BBB). In the present study, the transport of rat holo-transferrin (rTf) across the BBB in vivo was evaluated in ketamine anesthetized rats (250-300 g) both by in situ brain perfusion coupled with capillary depletion analysis and by thaw-mount autoradiography. [125I]rTf was infused through the right internal carotid artery at a rate of 3.65 ml/min for 2.5-5 min. After a 5 min perfusion, the volume of distribution (VD) of [125I]rTf in the brain homogenate, the postvascular supernatant, or the vascular pellet was 55.8 +/- 4.5, 43.5 +/- 4.8, and 8.7 +/- 2.3 microliters/g, respectively. Co-infusion of [125I]rTf with unlabeled rTf or with a high dose of OX26 monoclonal antibody to the rat transferrin receptor significantly reduced the [125I]rTf transport, and in the presence of 10% rat serum [125I]rTf transport was nearly entirely abolished. The transport of [125I]rTf across the BBB in vivo was demonstrated by thaw-mount autoradiography, which showed silver grains well within brain parenchyma following a 5 min internal carotid artery perfusion. These studies are consistent with the following conclusions: (a) in the absence of competing plasma transferrin, [125I]holo-transferrin is transported through the BBB at a rate comparable to the OX26 monoclonal antibody; and (b) the ability to detect measurable transport of perfused [125I]transferrin is greatly inhibited by a small contamination of the perfusate by rat serum, which contains high concentrations of competing transferrin.

Skarlatos S; Yoshikawa T; Pardridge WM

1995-06-01

280

Transport of [125I]transferrin through the rat blood-brain barrier.  

Science.gov (United States)

Transferrin receptors are present in the plasma membrane of brain endothelial cells but it is unclear if these receptors mediate transport of transferrin across the blood-brain barrier (BBB). In the present study, the transport of rat holo-transferrin (rTf) across the BBB in vivo was evaluated in ketamine anesthetized rats (250-300 g) both by in situ brain perfusion coupled with capillary depletion analysis and by thaw-mount autoradiography. [125I]rTf was infused through the right internal carotid artery at a rate of 3.65 ml/min for 2.5-5 min. After a 5 min perfusion, the volume of distribution (VD) of [125I]rTf in the brain homogenate, the postvascular supernatant, or the vascular pellet was 55.8 +/- 4.5, 43.5 +/- 4.8, and 8.7 +/- 2.3 microliters/g, respectively. Co-infusion of [125I]rTf with unlabeled rTf or with a high dose of OX26 monoclonal antibody to the rat transferrin receptor significantly reduced the [125I]rTf transport, and in the presence of 10% rat serum [125I]rTf transport was nearly entirely abolished. The transport of [125I]rTf across the BBB in vivo was demonstrated by thaw-mount autoradiography, which showed silver grains well within brain parenchyma following a 5 min internal carotid artery perfusion. These studies are consistent with the following conclusions: (a) in the absence of competing plasma transferrin, [125I]holo-transferrin is transported through the BBB at a rate comparable to the OX26 monoclonal antibody; and (b) the ability to detect measurable transport of perfused [125I]transferrin is greatly inhibited by a small contamination of the perfusate by rat serum, which contains high concentrations of competing transferrin. PMID:7552351

Skarlatos, S; Yoshikawa, T; Pardridge, W M

1995-06-19

 
 
 
 
281

The experimental measurement of dose field distribution of 125I seed source  

International Nuclear Information System (INIS)

The dose field distribution of 125I seed source is measured by the method of slowly sensitive film, ionized chamber and Monte Carlo simulation respectively. The results show that the trends of dose field distribution of seed source are basically agreeable. The absorbed dose rate appears exponential decay and the distribution is more eren. So the new produced 125I seed source has a better distribution of dose field. (authors)

2007-01-01

282

Biodistribution analysis of 125I-albumin-IFN-alpha2b fusion protein in rats  

International Nuclear Information System (INIS)

125I-albumin-IFN-alpha2b was prepared with the methods of Ch-T and purified with PD-10 column. The radiochemical purity was measured with TCA (trichloroacetic acid) precipitation. The antiviral activities of 125I-albumin-IFN-alpha2b and albumin-IFN-alpha2b were compared with WISH/VSV system in vitro. SD rats were injected with 125I-albumin-IFN-alpha2b subcutaneously and sacrificed at 0.5, 2, 6, 24, 48, 90, 180 and 300 h post-injection. Selected organs were dissected, weighed and their radioactivity was measured using ?-counter. The accumulated radioactivity in the tissues was calculated in terms of percentage of injected dose per gram organ (%ID·g-1). The labeling yield was 82.72%. The radiochemical purity of 125I-albumin-IFN-alpha2b was 95.53%, and its radioactivity was 0.26 MBq/?g. The antiviral bioactivities of albumin-IFN-alpha2b and 125I-albumin- IFN-alpha2b did not change. Biodistribution analysis of 125I-albumin-IFN-alpha2b in rats showed that concentrated 125I-albumin-IFN-alpha2b in blood reached maximum at 6 h post injection, and eliminated slowly. No specific accumulation was seen in other tissues. 125I-albumin-IFN-alpha2b could maintain in peripheral blood for a long time and it meant albumin-IFN-alpha2b would be an effective long-term interferon. (authors)

2009-01-01

283

Effects of 125I seed brachytherapy on apoptosis and cell cycle distribution in hepatoma carcinoma cells  

International Nuclear Information System (INIS)

Continuous irradiation of low dose rate 125I seed resulted in an increase in the apoptosis and an increased expression of Bax and a decreased expression of Bcl-2. The cell-cycle arrest of hepatoma carcinoma cells was induced remarkably. The results demonstrated that low dose rate of continuous 125I seed irradiation is effective on inducing the damage of the tumor cells. (authors)

2009-01-01

284

Microchemical synthesis of the serotonin receptor ligand, 125I-LSD  

International Nuclear Information System (INIS)

The synthesis and properties of 2-[125I]-lysergic acid diethylamide, the first 125I-labeled serotonin receptor ligand, are described. A novel microsynthesis apparatus was developed for this synthesis. The apparatus employs a micromanipulator and glass micro tools to handle microliter to nanoliter volumes on a microscope stage. This apparatus should be generally useful for the synthesis of radioligands and other compounds when limited amounts of material must be handled in small volumes

1985-02-01

285

Microchemical synthesis of the serotonin receptor ligand, /sup 125/I-LSD  

Energy Technology Data Exchange (ETDEWEB)

The synthesis and properties of 2-(/sup 125/I)-lysergic acid diethylamide, the first /sup 125/I-labeled serotonin receptor ligand, are described. A novel microsynthesis apparatus was developed for this synthesis. The apparatus employs a micromanipulator and glass micro tools to handle microliter to nanoliter volumes on a microscope stage. This apparatus should be generally useful for the synthesis of radioligands and other compounds when limited amounts of material must be handled in small volumes.

Hartig, P.R.; Krohn, A.M.; Hirschman, S.A.

1985-02-01

286

Influence of breast composition and interseed attenuation in dose calculations for post-implant assessment of permanent breast 103Pd seed implant  

International Nuclear Information System (INIS)

The impact of tissue heterogeneity and interseed attenuation is studied in post-implant evaluation of five clinical permanent breast 103Pd seed implants using the Monte Carlo (MC) dose calculation method. Dose metrics for the target (PTV) as well as an organ at risk (skin) are used to visualize the differences between a TG43-like MC method and more accurate MC methods capable of considering the breast tissue heterogeneity as well as the interseed attenuation. PTV dose is reduced when using a breast tissue model instead of water in MC calculations while the dose to the skin is increased. Furthermore, we investigate the effect of varying the glandular/adipose proportion of the breast tissue on dose distributions. The dose to the PTV (skin) decreases (increases) with the increasing adipose proportion inside the breast. In a complete geometry and compared to a TG43-like situation, the average PTV D90 reduction varies from 3.9% in a glandular breast to 35.5% when the breast consists entirely of adipose. The skin D10 increases by 28.2% in an entirely adipose breast. The results of this work show the importance of an accurate and patient-dependent breast tissue model to be used in the dosimetry for this kind of low energy implant.

2010-08-21

287

Heparin blocks 125I-calmodulin internalization by isolated rat renal brush border membrane vesicles  

International Nuclear Information System (INIS)

[en] 125I-Calmodulin is internalized by isolated rat renal brush border membrane vesicles (BBV) in a time, temperature and calcium dependent manner. Internalization of 125I-calmodulin into the osmotically sensitive space of BBV was distinguished from binding of the ligand to the outer BBV surface by examining the interaction of ligand and BBV at different medium osmolarities (300-1100 mosm), uptake was inversely proportional to medium osmolarity. Internalized 125I-calmodulin was intact and Western blots of solubilized BBV with 125I-calmodulin demonstrated the presence of several calmodulin-binding proteins of 143, 118, 50, 47.5, 46.5 and 35 kilodaltons which could represent potential intravesicular binding sites for the ligand. Heparin and the related glycosaminoglycan heparin sulfate both showed a dose-dependent inhibition (0.5-50 ?g/ml) of 125I-calmodulin uptake by BBV, but other sulfated and nonsulfated glycosaminoglycans including chondroitin sulfates, keratan sulfate and hyaluronic acid showed little or no inhibitory effect. Desulfation of heparin virtually abolished the inhibition of uptake while depolymerization reduced it. Heparin did not block the binding of 125I-calmodulin to BBV proteins as assessed by Western blotting technique suggesting its effect was on internalization of the ligand rather than on its association with internal membrane proteins

1986-03-05

288

Heparin blocks /sup 125/I-calmodulin internalization by isolated rat renal brush border membrane vesicles  

Energy Technology Data Exchange (ETDEWEB)

/sup 125/I-Calmodulin is internalized by isolated rat renal brush border membrane vesicles (BBV) in a time, temperature and calcium dependent manner. Internalization of /sup 125/I-calmodulin into the osmotically sensitive space of BBV was distinguished from binding of the ligand to the outer BBV surface by examining the interaction of ligand and BBV at different medium osmolarities (300-1100 mosm), uptake was inversely proportional to medium osmolarity. Internalized /sup 125/I-calmodulin was intact and Western blots of solubilized BBV with /sup 125/I-calmodulin demonstrated the presence of several calmodulin-binding proteins of 143, 118, 50, 47.5, 46.5 and 35 kilodaltons which could represent potential intravesicular binding sites for the ligand. Heparin and the related glycosaminoglycan heparin sulfate both showed a dose-dependent inhibition (0.5-50 ..mu..g/ml) of /sup 125/I-calmodulin uptake by BBV, but other sulfated and nonsulfated glycosaminoglycans including chondroitin sulfates, keratan sulfate and hyaluronic acid showed little or no inhibitory effect. Desulfation of heparin virtually abolished the inhibition of uptake while depolymerization reduced it. Heparin did not block the binding of /sup 125/I-calmodulin to BBV proteins as assessed by Western blotting technique suggesting its effect was on internalization of the ligand rather than on its association with internal membrane proteins.

Meezan, E.; Elgavish, A.; Roden, L.; Wallace, R.W.

1986-03-05

289

Chloroquine allows the secretion of internalized 125I-epidermal growth factor from fibroblasts  

International Nuclear Information System (INIS)

Incubation of cells with labelled hormone in the presence of the lysosomotropic agent chloroquine produces an enhanced intracellular accumulation of hormone and receptor. Using a pulse-chase paradigm in which cell surface receptors were labelled with 125I-EGF at 4 degrees C, it was found that when 100 microM chloroquine was present in the 37 degrees C chase medium intact hormone was accumulated in the medium. Without chloroquine, low molecular weight (mw) degradation products were found in the medium. The processes of receptor-mediated endocytosis and subcellular distribution of 125I-EGF-receptor complexes were unchanged by chloroquine. The source of the intact hormone accumulating in the medium was therefore an intracellular compartment(s). The 125I-EGF released from the cells could rebind to surface receptors and be re-internalized; rebinding was inhibited by unlabelled EGF or Concanavalin A in the incubation medium. The concentration of unlabelled EGF required to inhibit rebinding was more than three orders of magnitude greater than the amount of 125I-EGF whose rebinding was inhibited. Thus, the 125I-EGF released from intracellular sites was rebound preferentially over exogenous EGF. The possible pathways for secretion of intact 125I-EGF and mechanisms of its preferential rebinding are discussed

1985-01-01

290

sup 125 I disk source using charcoal activated polyurethane foam rubber mat  

Energy Technology Data Exchange (ETDEWEB)

Uniform {sup 125}I disk sources were prepared as a reference source to calibrate NaI(Tl) scintillation detector to measure {sup 125}I activity on a filter of air monitor in a laboratory. The base of the disk source was a charcoal activated polyurethane foam rubber mat of 75 mm in diameter, 2 mm in thickness. {sup 125}I disk sources of approximate 0.5 kBq, 1 kBq, and 10 kBq were obtained through immersing disks in ethanol solution containing Na{sup 125}I of 0.5 kBq/ml, 1 kBq/ml and 10 kBq/ml, respectively, and then drying up them. The uniformity of the distribution of {sup 125}I on the disk source was estimated by analyzing the autoradiograph of the disk source using an imaging analyzer. The radioactivity of {sup 125}I was distributed uniformly on the surface of the disk source within an uncertainty of about 10%. (author).

Yamamoto, Ikuko; Furukawa, Hideyuki (Meijo Univ., Nagoya (Japan). Faculty of Pharmaceutical Science); Nishizawa, Kunihide

1992-01-01

291

Faster and easier radiochemical purity testing for [125I]sodium iothalamate  

International Nuclear Information System (INIS)

[en] A previous method for determination of the radiochemical purity (RCP) value of [125I]sodium iothalamate uses two paper strips and solvents (total developing time is ?2.5 h). To simplify and shorten the RCP testing procedure, our laboratory has developed a single-strip chromatography method that not only distributes free 125I and [125I]sodium iothalamate to different relative front (Rf) locations, but is also faster and easier to perform. RCP of [125I]sodium iothalamate was determined with the use of a 10-cm instant thin-layer chromatography strip impregnated with polysilicic acid gel (ITLC-SA) as the solid phase, and a mobile phase of 2-butanol:acetic acid:water (140:2.5:70, v/v). By using autoradiography and counting the strip segments in a gamma counter, our results indicated that free 125I migrated to Rf = 0.89-1.00 while the [125I]sodium iothalamate moved to Rf 0.44-0.67. The total developing time for the single-strip ITLC-SA system was ? 1 h

1997-01-01

292

The preparation of 125I-?-CIT and its biological distribution in animal  

International Nuclear Information System (INIS)

Objective: To prepare and label the 125I-?-CIT and study its biological distribution in animal. Methods: 125I-?-CIT was prepared by the peracetic acid method and the chloramine-T method, and dopamine transporter (DAT) binding properties of 125I-?-CIT were examined by in vivo biodistribution and inhibition studies in mice and whole body autoradiography in rats. Results: The radiolabelling yields of the peracetic acid and the chloramine-T methods were (53.4 +- 7.9)% and (88.4 +- 3.49)%, respectively. Following intravenous injection in mice, 125I-?-CIT showed high accumulation in striatum, time to peak level uptake was 2 h after injection. GBR12909 significantly inhibited 125I-?-CIT binding in striatum, while clomipramine significantly inhibited 125I-?-CIT binding in hippocampus and cerebral cortex. The rat whole body autoradiography showed that the clearance of the tracer occurred through the hepatobiliary route. Conclusions: The results indicate ?-CIT is an agent suitable for DAT imaging and can be used for the study of Parkinson's disease

2000-01-01

293

ACTH Receptors in the Adrenal: Specific Binding of ACTH-125I and Its Relation to Adenyl Cyclase  

Digital Repository Infrastructure Vision for European Research (DRIVER)

Pure monoiodo ACTH-125I was prepared that was biologically active and free of unlabeled ACTH. Extracts of adrenal cortex that contained ACTH-sensitive adenyl cyclase, bound ACTH-125I; extracts that lacked the ACTH-sensitive cyclase did not bind ACTH-125I. Unlabeled ACTH inhibited the binding of ACTH...

Lefkowitz, Robert J.; Roth, Jesse; Pricer, William; Pastan, Ira

294

DNA strand breakage by 125I-decay in oligoDNA  

International Nuclear Information System (INIS)

[en] Full text: A double-stranded oligodeoxynucleotide containing 125I-dC in a defined location, with 5'- or 3'-32P-end-labelling of either strand, was used to investigate DNA strand breakage resulting from 125I decay. Samples of the 32P-end-labelled and 125I-dC containing oligoDNA were incubated in 20 mM phosphate buffer (PB), or PB + 2 M dimethylsulphoxide (DMSO) at 4 deg during 18-20 days. The 32P-end-labelled DNA fragments produced by 125I decays were separated on denaturing polyacrylamide gels, and the 3P activity in each fragment was determined by scintillation counting after elution from the gel. The fragment size distribution was then converted to a distribution of single stranded break probabilities at each nucleotide position. The results indicate that each 125I decay event produces at least one break in the 125I-dC containing strand, and causes breakage of the opposite strand in 75-80% of events. Thus, the double stranded break is produced by 125I decay with probability ?0.8. Most of single stranded breaks (around 90%) occurred within 5-6 nucleotides of the 125I-dC, however DNA breaks were detected up to 18-20 nucleotides from the decay site. The average numbers of single stranded breaks per decay are 3.7 (PB) and 3.3 (PB+DMSO) in 125I-dC containing strand, and 1.5 (PB) and 1.3 (PB+DMSO) in the opposite strand. Deconvolution of strand break probabilities as a function of separation from the 125I, in terms of both distance (to target deoxyribosyl carbon atoms, in B-DNA) and nucleotide number, show that the latter is an important parameter for the shorter-range damage. This could indicate a role for attenuation/dissipation of damage through the stacked bases. In summary, the results represent a much more extensive set of data than available from earlier experiments on DNA breakage from l25I-decay, and may provide new mechanistic insights

1996-01-01

295

Experimental study on differential diagnosis of tumor from inflammation by using /sup 125/I labeled Pisum sativum agglutinin  

Energy Technology Data Exchange (ETDEWEB)

We have reported that Pisum sativum agglutinin (PSA), a plant lectin which recognizes mannosyl residues, accumulates markedly in Ehrlich solid tumor (EST) and suggested the possibility of applying PSA to tumor imaging radiopharmaceuticals. In the present work, an inflammation was induced by implantation of cotton thread in the left rear leg skeletal muscle of ddY mice and Ehrlich ascites tumor cells were inoculated into the right rear leg. /sup 67/Ga-citrate accumulated in the tumor tissue and the inflammatory lesion to almost equal extents. On the other hand, /sup 125/I-PSA preferentially accumulated in tumor tissues in mice bearing both tumor and inflammation. The results suggest that differential diagnosis of tumor from inflammation using radiolabeled PSA may be possible.

Kojima, Shuji; Jay, M.

1987-12-01

296

Implante de marcapasso definitivo em gestante portadora de valvopatia mitral reumática Implante de marcapaso definitivo en gestante portadora de valvulopatía mitral reumática Permanent pacemaker implantation in a pregnant woman with rheumatic mitral valve disease  

Directory of Open Access Journals (Sweden)

Full Text Available Descrevemos um caso raro de implante de marcapasso definitivo em gestante, portadora de valvopatia mitral reumática, previamente submetida à valvoplastia percutânea por cateter-balão. A paciente apresentava bloqueio atrioventricular de grau avançado, de causa não-reversível, sintomático e manifesto no 3º trimestre da gestação.Describimos un caso raro de implante de marcapaso definitivo en gestante, portadora de valvulopatía mitral reumática, previamente sometida a valvuloplastia percutánea por catéter balón La paciente presentaba bloqueo atrioventricular en grado avanzado, de causa irreversible, sintomático y manifiesto en el 3º trimestre de gestación.We describe a rare case of permanent pacemaker implantation in a pregnant woman with rheumatic mitral valve disease previously undergoing percutaneous balloon valvuloplasty. She presented symptomatic advanced atrioventricular block of non-reversible cause and manifest in the third trimester of gestation.

Rodrigo Barbosa Esper; Remo Holanda de Mendonça Furtado; Flávio Tarasoutchi; Guilherme Sobreira Spina; Max Grinberg; Walkiria Samuel Ávila

2009-01-01

297

Implante de marcapasso definitivo em gestante portadora de valvopatia mitral reumática/ Permanent pacemaker implantation in a pregnant woman with rheumatic mitral valve disease/ Implante de marcapaso definitivo en gestante portadora de valvulopatía mitral reumática  

Scientific Electronic Library Online (English)

Full Text Available Abstract in portuguese Descrevemos um caso raro de implante de marcapasso definitivo em gestante, portadora de valvopatia mitral reumática, previamente submetida à valvoplastia percutânea por cateter-balão. A paciente apresentava bloqueio atrioventricular de grau avançado, de causa não-reversível, sintomático e manifesto no 3º trimestre da gestação. Abstract in spanish Describimos un caso raro de implante de marcapaso definitivo en gestante, portadora de valvulopatía mitral reumática, previamente sometida a valvuloplastia percutánea por catéter balón La paciente presentaba bloqueo atrioventricular en grado avanzado, de causa irreversible, sintomático y manifiesto en el 3º trimestre de gestación. Abstract in english We describe a rare case of permanent pacemaker implantation in a pregnant woman with rheumatic mitral valve disease previously undergoing percutaneous balloon valvuloplasty. She presented symptomatic advanced atrioventricular block of non-reversible cause and manifest in the third trimester of gestation.

Esper, Rodrigo Barbosa; Furtado, Remo Holanda de Mendonça; Tarasoutchi, Flávio; Spina, Guilherme Sobreira; Grinberg, Max; Ávila, Walkiria Samuel

2009-05-01

298

Comparison of sperm abnormalities of mice induced by 125I and 131I  

International Nuclear Information System (INIS)

[en] A comparison of effects of 125I and 131I on the rate of abnormal sperm and the radioactivity in testicles of mice was described. In the experiment, different doses of 125I and 131I was injected intraperitoneally into male ICR mice, respectively. The results show that for mice into which 0.185, 370 and 555 kBq of 125I was injected, rates of abnormal sperm were 9.0%, 9.6%, 11.6% and 13.9% at 4 and 5 weeks after injection, and that for animals into which the above-mentioned doses of 131I were injected, the same parameter was 8.5%, 12.5%, 14.7% and 15.5% respectively. No significant difference (x2 test, p > 0.05) was found in the rate of abnormal sperm of mice between 125I and 131I. For 125I and 131I, the results also show a similar pattern of change in the radioactivity of testicle tissue at 2 hrs and up to 7 days after injection: a peak of radioactivity in testicle tissue was found at 2 hrs after injection and the activity per gram of testicle tissue was 0.72% (for 125I) and 0.50% (for 131I) of the original, then the activity per gram of testicle tissue decreased quickly and only 0.035%(for 125I) and 0.011% (for 131I) of the original at the end of first week after injection

1992-01-01

299

Autoradiographic localization of putative nicotinic receptors in the rat brain using 125I-neuronal bungarotoxin  

International Nuclear Information System (INIS)

Neuronal bungarotoxin (NBT), a snake venom neurotoxin, selectively blocks nicotinic receptors in many peripheral and central neuronal preparations. alpha-Bungarotoxin (alpha BT), on the other hand, a second toxin isolated from the venom of the same snake, is an ineffective nicotinic antagonist in most vertebrate neuronal preparations studied thus far. To examine central nicotinic receptors recognized by NBT, we have characterized the binding of 125I-labeled NBT (125I-NBT) to rat brain membranes and have mapped the distribution of 125I-NBT binding in brain sections using quantitative light microscopic autoradiography. The binding of 125I-NBT was found to be saturable, of high affinity, and heterogeneously distributed in the brain. Pharmacological studies suggested that more than one population of sites is labeled by 125I-NBT. For example, one component of 125I-NBT binding was also recognized by alpha BT, while a second component, not recognized by alpha BT, was recognized by the nicotinic agonist nicotine. The highest densities of these alpha BT-insensitive, nicotine-sensitive sites were found in the fasciculus retroflexus, the lateral geniculate nucleus, the medial terminal nucleus of the accessory optic tract, and the olivary pretectal nucleus. alpha BT-sensitive NBT binding sites were found in highest density in the lateral geniculate nucleus, the subthalamic nucleus, the dorsal tegmental nucleus, and the medial mammillary nucleus (lateral part). The number of brain regions with a high density of 125I-NBT binding sites, blocked either by alpha BT or by nicotine, is low when compared with results obtained using other approaches to studying the central distribution of nicotinic receptors, such as labeling with 3H-nicotine or labeling with cDNA probes to mRNAs coding for putative receptor subunits.

1991-01-01

300

[(125)I]EYF: a new high affinity radioligand to neuropeptide FF receptors.  

Science.gov (United States)

[(125)I]EYF ([(125)I]EYWSLAAPQRFamide), a new radioiodinated probe derived from a peptide present in the rat Neuropeptide FF precursor (EFWSLAAPQRFamide, EFW-NPSF) was synthesized and its binding characteristics investigated on sections of the rat spinal cord and on membranes of mouse olfactory bulb. In both tissues, [(125)I]EYF binding was saturable and revealed a very high affinity interaction with a single class of binding sites in rat and mouse (K(D) = 0.041 and 0.019 nM, respectively). Competition studies showed that [(125)I]EYF bound to one class of binding sites exhibiting a high affinity for all the different peptides the precursor could generate (NPA-NPFF, SPA-NPFF, NPFF, EFW-NPSF, QFW-NPSF) with the exception of NPSF which displayed a low affinity. Autoradiographic studies demonstrated that [(125)I]EYF binding sites were fully inhibited by a synthetic Neuropeptide FF agonist (1DMe) in all areas of the rat brain. The density of [(125)I]EYF binding sites was high in the intralaminar thalamic nuclei, the parafascicular thalamic nucleus and in the superficial layers of the dorsal horn. Non specific binding reached 5-10% of the total binding in all brain areas. Similarly, in mouse brain experiments, the non-specific binding was never superior to 10%. These findings demonstrate that putative neuropeptides generated by the Neuropeptide FF precursor and containing the NPFF or NPSF sequences should bind to the same receptor. Furthermore, these data indicate that [(125)I]EYF is a useful radiolabeled probe to investigate the NPFF receptors; its major advantages being its high affinity and the very low non-specific binding it induces. PMID:11311733

Gouardères, C; Mollereau, C; Tafani, J A; Mazarguil, H; Zajac, J M

2001-04-01

 
 
 
 
301

[(125)I]EYF: a new high affinity radioligand to neuropeptide FF receptors.  

UK PubMed Central (United Kingdom)

[(125)I]EYF ([(125)I]EYWSLAAPQRFamide), a new radioiodinated probe derived from a peptide present in the rat Neuropeptide FF precursor (EFWSLAAPQRFamide, EFW-NPSF) was synthesized and its binding characteristics investigated on sections of the rat spinal cord and on membranes of mouse olfactory bulb. In both tissues, [(125)I]EYF binding was saturable and revealed a very high affinity interaction with a single class of binding sites in rat and mouse (K(D) = 0.041 and 0.019 nM, respectively). Competition studies showed that [(125)I]EYF bound to one class of binding sites exhibiting a high affinity for all the different peptides the precursor could generate (NPA-NPFF, SPA-NPFF, NPFF, EFW-NPSF, QFW-NPSF) with the exception of NPSF which displayed a low affinity. Autoradiographic studies demonstrated that [(125)I]EYF binding sites were fully inhibited by a synthetic Neuropeptide FF agonist (1DMe) in all areas of the rat brain. The density of [(125)I]EYF binding sites was high in the intralaminar thalamic nuclei, the parafascicular thalamic nucleus and in the superficial layers of the dorsal horn. Non specific binding reached 5-10% of the total binding in all brain areas. Similarly, in mouse brain experiments, the non-specific binding was never superior to 10%. These findings demonstrate that putative neuropeptides generated by the Neuropeptide FF precursor and containing the NPFF or NPSF sequences should bind to the same receptor. Furthermore, these data indicate that [(125)I]EYF is a useful radiolabeled probe to investigate the NPFF receptors; its major advantages being its high affinity and the very low non-specific binding it induces.

Gouardères C; Mollereau C; Tafani JA; Mazarguil H; Zajac JM

2001-04-01

302

Study on preparation and brain distribution of 125I-?-CIT  

International Nuclear Information System (INIS)

Objective: To develop a relatively simpler and faster method for the routine preparation of 125I-?-CIT and animal brain distribution of 125I-?-CIT. Methods: Peracetic acid or Iodogen as an oxidant was used to prepare 125I-?-CIT and comparison was made between them. The HPLC purification technique was used to identify the labeled tracer. Stability and safety of the radioiodinated ?-CIT were also studied. Groups of mice (n=5) were injected i.v. into the tail vein with 125I-?-CIT . Animals were killed at 5, 15, 30 and 45 minutes, and 1, 2, 4, 6, 8 and 24 hours. Autoradiography was performed on brains of mice at 4 hours after injection. Results: Two kinds of labeling methods using Iodogen or peracetic acid produced 125I-?-CIT of radiochemical yields 91.10% ± 8.09%, 54.70 ± 9.81% respectively, with high radiochemical purity (RCP) 99.33% ± 0.15%, 18-25 degree C and pH 1 or 2 is the best for Iodogen preparation. The labeled product was stable for at least 23 days when kept in room temperature, and stable for at least 10 weeks when kept in -4 degree C refrigerator. The peak time of uptake of 125I-?-CIT in striatum was at four hours after injection and the highest value was 22.93% ± 3.11% ID/g. It's highest uptake rate is 20.09 ± 2.11. Conclusions: The Iodogen preparation method is simpler and has a higher labeling yield than peracetic acid labeling method and the labeling yield is higher than which ever reported abroad. The labeled radiopharmaceutical is stable. 125I-?-CIT showed the highest accumulation in striatum with high densities of dopamine transporters in brain

2002-01-01

303

A novel 125I-labeled daunorubicin derivative for radionuclide-based cancer therapy  

International Nuclear Information System (INIS)

Introduction: Auger electron emitters, such as 125I, are getting increasingly wider recognition as alternatives to current anticancer treatments. The effectiveness of Auger electrons is strongly dependent on their proximity to DNA and is therefore considered as harmless outside the nucleus. Methods: 125I or 127I was conjugated with Comp1, Comp2 or Comp3 - three derivatives of the chemotherapeutic drug daunorubicin. Their capacity factors, DNA-binding constants and exclusion parameters, and the degree of DNA fragmentation after incubating isolated DNA with our 127I- or 125I-conjugated daunorubicin derivatives were determined. Human breast adenocarcinoma (SK-BR-3) cells were incubated with the derivatives; fluorescent microscopy and autoradiography images were generated; and cell growth was monitored. Results and Discussion: The capacity factor of 127I-Comp1 was similar to those of daunorubicin and doxorubicin, whereas lower capacity factors of 127I-Comp2 and 127I-Comp3 suggested reduced interactions with lipid membranes. DNA exclusion parameters and binding constants of 127I-Comp1 and 127I-Comp2, but not of 127I-Comp3, were similar to those of doxorubicin. Fluorescent microscopy and autoradiography images of SK-BR-3 cells revealed that 127I-Comp1 and 125I-Comp1 accumulated in tumor cell nuclei, whereas 127I-Comp2 and 127I-Comp3 were present predominantly in other cell compartments. The binding of 125I-Comp1 to isolated chromosomal DNA led to major fragmentation. Incubation of SK-BR-3 cells with 125I-Comp1 inhibited cell growth, whereas doxorubicin or 127I-Comp1 administered at the same concentration had no effect on cell growth. Our results thus suggest that 125I-Comp1 has the potential to become a new tool for anticancer therapy.

2006-01-01

304

Radiolabeled externally with 125I and internally with 35S IgM monoclonal antibodies 10B12 in a syngenic rat model  

International Nuclear Information System (INIS)

Comparative biokinetics of radiolabeled externally with 125I and internally with 35S IgM monoclonal antibodies in a new syngeneic rat model with an implanted rat colon carcinoma for 8 days were performed. The 35S-10B12 rapidly accumulated in the tumours, and the amount of 35S in the tumours remained relatively constant during 6 to 48h. High uptake of 35S-10B12 was recorded in the liver and bone marrow. These were not obtained for 12'5I-10B12. The results proved that dehalogenation of iodinated IgM was a serious problem. Therefore, the author suggests that internally labeled McAbs should be used for biokinetic studies and that studies should be carried out in a syngeneic model as it seems to better reflect antibody biodistribution and metabolism in vivo

1992-01-01

305

A comparison of MRI and CT based post implant dosimetric assessment of transperineal interstitial permanent prostate brachytherapy  

International Nuclear Information System (INIS)

PURPOSE: To investigate how a recently developed MRI based post implant dosimetric assessment technique for ultrasound guided transperineal interstitial permanent prostate brachytherapy (TIPPB) compares with the currently accepted CT based technique. MATERIALS AND METHODS: This study was based upon serial MRI and CT scans of 15 patients who had received ultrasound guided TIPPB with either I-125 (n = 8) or Pd-103 (n = 7) sources (mean number of sources 75, range 46 to 95). Each patient was imaged using both modalities within 24 hours of receiving the implant and within 1 hour of each other. Prostate volumes were determined by the same physician for both modalities. Contours and sources were digitized, and calculations performed using an in house treatment planning system with a nearest neighbor seed sorting routine and TG-43 formalism. Reference doses were 144 Gy and 115 Gy for I-125 and Pd-103, respectively. Post implant dosimetric assessment consisted of a comparison of MRI and CT based prostate volumes, dose volume histograms, and conformity and uniformity descriptors. RESULTS: The values reported are the mean ± one standard deviation for each modality. Differences (%) and ranges (%) were calculated as {(VolMRI-VolCT)/(VolCT)}*100. The correlation coefficient is the Pearson product moment correlation. CONCLUSION: MRI based post implant dosimetric assessment for ultrasound guided TIPPB produces results which, while on average for the study population are similar, can be significantly different from those of CT based evaluations as is demonstrated by the weak correlations between the two groups of data. Since any assessment of implant quality is dependent upon the ability to accurately localize both the sources and target volume, differences in implant quality as determined by dosimetric results must be attributable to either source or prostate localization differences from MRI to CT, or both. The high correlation between reference isodose volumes strongly suggests that the predominant cause of the differences are due to variations in target definition. These preliminary results demonstrate that MRI based dosimetric evaluation is possible and sufficiently different from that based on CT to warrant further study. There is clearly a need to investigate whether recognition of these differences will result in improved correlation with clinical outcome.

1997-01-01

306

Labelling of antisense oligonucleotide with 125I and the experimental research of identification of the lymphoma cell by using 125I-FR-ASON  

International Nuclear Information System (INIS)

Objective: To establish a new method of labeling oligonucleotide with radioisotope of iodine and to investigate the possibility of using 125I-FR-ASON as imaging agent or therapeutic antisense radiopharmaceutical in lymphoma. Methods: A 18 mer oligonucleotide sequence was synthesized and grafted in 5' with a tyramine group. Radioiodination of the tyramine conjugated oligonucleotide with 125I was performed using the Chloramine T method. The Namalwa and HL-60 cell lines were transduced with DMRIE-C mediated 125I-ASON, then the transduction efficiency was calculated, authors also compared it with the transduction efficiency without DMRIE-C reagent. After incubation with serum, the tyramine-ASON was analysed by electrophoresis in 20% polyacrylamide gel. Results: The radiolabeling efficiency, radiochemical purity and specific activity were 80.7%, 98.7% and 100 kBq/?g, respectively. The transduction efficiency in Namalwa cell line reached (26.8 ±1.54)% that was as 18 times greater as that in transduction without mediation. The transduction efficiency in HL-60 cell line was only (13.6 ± 2.54)%, that was far lower than in Namalwa cell line. The gel electrophoresis showed that there wasn't any additional band at 2, 6 and 24 h post-incubation. Conclusions: The radioiodination method by conjugating the oligonucleotide with tyramine was very successful. The 125I-FR-ASON showed high specificity in Namalwa cell line and it could be used as an antisense imaging agent or antisense radiopharmaceutical in therapeutic research on lymphoma

2003-01-01

307

Tolerance and Acceptance Results of a Palladium-103 Permanent Breast Seed Implant Phase I/II Study  

International Nuclear Information System (INIS)

Purpose: To test, in a prospective Phase I/II trial, a partial breast irradiation technique using a 103Pd permanent breast seed implant (PBSI) realized in a single 1-h procedure under sedation and local freezing. Methods and Materials: Eligible patients had infiltrating ductal carcinoma ?3 cm in diameter, surgical margin ?2 mm, no extensive intraductal component, no lymphovascular invasion, and negative lymph nodes. Patients received a permanent seed implant, and a minimal peripheral dose of 90 Gy was prescribed to the clinical target volume, with a margin of 1.5 cm. Results: From May 2004 to April 2007, 67 patients received the PBSI treatment. The procedure was well tolerated, with 17% of patients having significant pain after the procedure. Only 1 patient (1.5%) had an acute skin reaction (Grade 3 according to the National Cancer Institute Common Toxicity Criteria). The rates of acute moist desquamation, erythema, and indurations were 10.4%, 42%, and 27%, respectively. At 1 year the rate of Grade 1 telangiectasia was 14%. The rate of skin reaction decreased from 65% to 28% when skin received less than the 85% isodose. According to a Radiation Therapy Oncology Group questionnaire, 80-90% of patients were very satisfied with their treatment, and the remainder were satisfied. One patient (1.5%) developed an abscess, which resolved after the use of antibiotics. There was no recurrence after a median follow-up of 32 months (range, 11-49 months). Conclusions: The feasibility, safety, and tolerability of PBSI compares favorably with that of external beam and other partial breast irradiation techniques.

2009-04-01

308

Postimplantation dosimetric analysis of permanent transperineal prostate implantation: improved dose distributions with an intraoperative computer-optimized conformal planning technique  

International Nuclear Information System (INIS)

Purpose: To compare the target coverage and dose to normal tissues after I-125 transperineal permanent implantation (TPI) of the prostate in 90 patients treated with one of three different transperineal techniques. Methods and Materials: Detailed postimplant dosimetric evaluations of permanent I-125 implantation procedures were performed on 30 consecutive patients treated between 1995-1996 who underwent TPI using a preplanning CT-based technique, on 30 consecutive patients treated in 1997-1998 who underwent an ultrasound-guided approach with intraoperative determination of seed distribution based on an I-125 nomogram, and on 30 consecutive patients in 1998-1999 who underwent TPI with intraoperative computer-based 3-dimensional conformal optimization. For all three techniques, postimplant CT scans were obtained 4-6 hours after TPI. Dosimetric parameters included V100, V90, V150, D100, D90, D80, as well as maximal and average doses to the urethra and rectal wall. These parameter outcomes are reported as a percentage of the prescription dose. Results: The intraoperative 3D-optimized technique (I-3D) provided superior target coverage with the prescription dose for all dosimetric variables evaluated compared to the other treatment techniques. The median V100, V90, and D90 values for the I-3D technique were 96%, 98%, and 116%, respectively. In contrast, the V100, V90, and D90 values for the CT preplan and ultrasound manual optimization approaches were 86%, 89%, and 88%, respectively and 88%, 92%, and 94%, respectively (I-3D versus other techniques: p

2000-01-01

309

A sensitive radioimmunoassay for corticotropin using a fully biologically active 125I-labeled ligand  

Energy Technology Data Exchange (ETDEWEB)

The human corticotropin (ACTH) analog, Phe2,Nle4-ACTH-(1-38) was iodinated by the chloramine-T procedure and the product was purified by reverse phase high performance liquid chromatography. The specific radioactivity of (/sup 125/I)Tyr23,Phe2,Nle4-ACTH-(1-38) was determined by comparing the antiserum binding curves of the iodinated peptide and (3H)ACTH of known specific activity. This method gave a value of 1800 +/- 75 Ci/mmol, which is close to the theoretical radioactivity expected for the introduction of a single /sup 125/I atom into the peptide. (/sup 125/I)Tyr23,Phe2,Nle4-ACTH-(1-38) was as potent as ACTH in stimulating corticosterone production in isolated rat adrenocortical cells. The concentrations for half-maximal steroidogenesis were 36.5 +/- 6.1 pM for the /sup 125/I derivative and 37.6 +/- 6.7 pM for ACTH. By the use of this /sup 125/I-labeled ligand, a highly sensitive RIA capable of detecting 1 pg ACTH was developed.l The antiserum employed in this study appeared to be directed against residues 11-13 of ACTH.

Buckley, D.I.; Hagman, J.; Ramachandran, J.

1981-07-01

310

Radioimmunoassay for etorphine in horses with a 125I analog of etorphine  

International Nuclear Information System (INIS)

To improve the sensitivity and specificity of screening for etorphine in horses, an 125I-labeled etorphine analog was synthesized and an antibody to etorphine was raised in rabbits. A radioimmunoassay (RIA) for etorphine was developed, using these reagents. Bound and free 125I-labeled etorphine was separated by a double-antibody method that reduced interference from materials associated with equine urine. The 125I-labeled etorphine binding was rarely greater than 250 pg of background etorphine equivalents/ml in raw urine and was 100 pg/ml in hydrolyzed urine. The 125I-RIA was capable of detecting etorphine equivalents in urine above these background values. Etorphine equivalents were detected in equine urine samples for about 7 days after 4 mares were dosed with 0.22 microgram of etorphine/kg of body weight, IV. The stability of etorphine in urine from these mares was evaluated. Urine from these dosed mares was held in constant -20 C storage, and aliquots were repeatedly frozen and thawed. When analyzed for etorphine equivalents using an 125I-RIA, etorphine and its metabolites in urine samples were stable for less than or equal to 38 days if continuously frozen and also were resistant to repeated freezing and thawing.

1988-01-01

311

Radioimmunoassay for etorphine in horses with a /sup 125/I analog of etorphine  

Energy Technology Data Exchange (ETDEWEB)

To improve the sensitivity and specificity of screening for etorphine in horses, an /sup 125/I-labeled etorphine analog was synthesized and an antibody to etorphine was raised in rabbits. A radioimmunoassay (RIA) for etorphine was developed, using these reagents. Bound and free /sup 125/I-labeled etorphine was separated by a double-antibody method that reduced interference from materials associated with equine urine. The /sup 125/I-labeled etorphine binding was rarely greater than 250 pg of background etorphine equivalents/ml in raw urine and was 100 pg/ml in hydrolyzed urine. The /sup 125/I-RIA was capable of detecting etorphine equivalents in urine above these background values. Etorphine equivalents were detected in equine urine samples for about 7 days after 4 mares were dosed with 0.22 microgram of etorphine/kg of body weight, IV. The stability of etorphine in urine from these mares was evaluated. Urine from these dosed mares was held in constant -20 C storage, and aliquots were repeatedly frozen and thawed. When analyzed for etorphine equivalents using an /sup 125/I-RIA, etorphine and its metabolites in urine samples were stable for less than or equal to 38 days if continuously frozen and also were resistant to repeated freezing and thawing.

Tai, C.L.; Wang, C.; Weckman, T.J.; Popot, M.A.; Woods, W.E.; Yang, J.M.; Blake, J.; Tai, H.H.; Tobin, T.

1988-05-01

312

Influence of acetylcholine on binding of 4-[125i]iododexetimide to muscarinic brain receptors  

International Nuclear Information System (INIS)

[en] The distribution of nicotinic and muscarinic cholinergic receptors in the human brain in vivo has been successfully characterized using radiolabeled tracers and emission tomography. The effect of acetylcholine release into the synaptic cleft on receptor binding of these tracers has not yet been investigated. The present study examined the influence of acetylcholine on binding of 4-[125I]iododexetimide to muscarinic cholinergic receptors of porcine brain synaptosomes in vitro. 4-Iododexetimide is a subtype-unspecific muscarinic receptor antagonist with high affinity. Acetylcholine competed with 4-[125I]iododexetimide in a dose-dependent manner. A concentration of 500 ?M acetylcholine inhibited 50% of total specific 4-[125I]iododexetimide binding to synaptosomes when both substances were given simultaneously. An 800 ?M acetylcholine solution reduced total specific 4-[125I]iododexetimide binding by about 35%, when acetylcholine was given 60 min after incubation of synaptosomes with 4-[125I]iododexetimide. Variations in the synaptic acetylcholine concentration might influence muscarinic cholinergic receptor imaging in vivo using 4-[123I]iododexetimide. Conversely, 4-[123I]iododexetimide might be an appropriate molecule to investigate alterations of acetylcholine release into the synaptic cleft in vivo using single photon emission computed tomography

1998-01-01

313

Synthesis and biologic studies of iodinated (125I/127I) ethidium  

International Nuclear Information System (INIS)

An iodinated (125I/127I) ethidium derivative (3,8-diamino-5-[6'-(p-iodobenzoylamino)-4'-azahexyl]-6 -phenylphenanthridinium chloride hydrochloride) was synthesized and characterized. The labeling yield of the 125I-labeled derivative was 75% for carrier-free 125I, with a radiochemical purity of 95%. The incubation of iodoethidium with calf thymus DNA resulted in a substantial enhancement of fluorescence yield, indicating the intercalation of this compound into DNA. In the presence of iodoethidium, the nuclei of methanol-treated mammalian cells fluoresced, while those of viable cells did not (since the plasma membrane is impermeable to iodoethidium). When viable cells were incubated with the reduced form of the derivative, 125I/127I-dihydroethidium traversed the plasma membrane, was oxidized in the cytoplasm, and intercalated into nuclear DNA. Finally, we tested the hypothesis that larger malignant solid tumors, containing a relatively greater percentage of degenerating permeable cells, can be targeted with 125I-ethidium. In-vivo studies demonstrated a small but positive correlation (R = 0.72) between tumor volume and the uptake of the derivative. Because of the ubiquitous presence of abnormal permeable cells and necrosis in tumors, our results support the belief that radiolabeled DNA-intercalating or DNA-binding molecules may be of diagnostic and therapeutic value for a variety of solid tumors in humans.

2001-01-01

314

Biodistribution and dosimetry of free (211)at, (125)i(-) and (131)i(-) in rats.  

UK PubMed Central (United Kingdom)

Abstract (131)I is widely used for therapy in the clinic and (125)I and (131)I, and increasingly (211)At, are often used in experimental studies. It is important to know the biodistribution and dosimetry for these radionuclides to determine potential risk organs when using radiopharmaceuticals containing these radionuclides. The purpose of this study was to investigate the biodistribution of (125)I(-), (131)I(-), and free (211)At in rats and to determine absorbed doses to various organs and tissues. Male Sprague Dawley rats were injected simultaneously with 0.1-0.3?MBq (125)I(-) and 0.1-0.3?MBq (131)I(-), or 0.05-0.2?MBq (211)At and sacrificed 1 hour to 7 days after injection. The activities and activity concentrations in organs and tissues were determined and mean absorbed doses were calculated. The biodistribution of (125)I(-) was similar to that of (131)I(-) but the biodistribution of free (211)At was different compared to (125)I(-) and (131)I(-). The activity concentration of radioiodine was higher compared with (211)At in the thyroid and lower in all extrathyroidal tissues. The mean absorbed dose per unit injected activity was highest to the thyroid. (131)I gave the highest absorbed dose to the thyroid, and (211)At gave the highest absorbed dose to all other tissues studied.

Spetz J; Rudqvist N; Forssell-Aronsson E

2013-11-01

315

N-iodoacetyltyramine: Preparation and use in sup 125 I labeling by alkylation of sulfhydryl groups  

Energy Technology Data Exchange (ETDEWEB)

Preparation and use of N-iodoacetyltyramine in generation of {sup 125}I-labeled compounds is described. The kinetics of alkylation of N-acetylcysteine by N-iodoacetyltyramine (k2 = 3.0 M-1 s-1) and N-chloroacetyltyramine (k2 = 0.12 M-1 s-1) indicate that N-iodoacetyltyramine is more useful for labeling sulfhydryl-containing compounds to high specific activity with {sup 125}I. Conditions for preparation of carrier-free {sup 125}I-labeled N-iodoacetyl-3-monoiodotyramine in 50% yield based on starting iodide are described. The high degree of group specificity of N-iodoacetyl-3-monoiodotyramine reaction with sulfhydryl groups is demonstrated by the high reactivity toward sulfhydryl-containing bovine serum albumin and low reactivity toward N-ethylmaleimide-blocked bovine serum albumin and IgG. {sup 125}I-labeled N-iodoacetyl-3-monoiodotyramine was also used to prepare an {sup 125}I-labeled ACTH derivative that retains full biological activity, further demonstrating the selectivity toward reactions with sulfhydryl groups.

Lin, C.M.; Mihal, K.A.; Krueger, R.J. (Univ. of Nebraska, Lincoln (USA))

1989-06-01

316

Excretion of 125I-HSA-IFN?2b Fusion Protein in Rats  

International Nuclear Information System (INIS)

125I-HSA-IFN?2b was prepared with Ch-T method. The labeling yield is 82.72%, the radiochemical purity is 95.53%, and the specific activity is 0.26 MBq/?g. The antiviral activities of 125I-HSA-IFN?2b are almost same as HSA-IFN?2b analyzed with WISH/VSV system in vitro. After SD rats injected with 125I-HSA-IFN?2b subcutaneously, the radioactivity in urine and faeces in seven different periods of 0-6, 6-12, 12-24, 24-48, 48-96, 96-192 and 192-300 h shows that 125I-HSA-IFN?2b is excreted mainly by kidneys, partly by diachorema, and average accumulation excretory rates of 300 h in urine and feces are 80.10% and 16.00%, respectively; the radioactivity in bile in seven periods of 0-1, 1-2, 2-4, 4-6, 6-12, 12-24 and 24-30 h shows that 125I-HSA-IFN?2b also can be excreted by bile after being metabolized by liver, and average accumulation excretory rate of 30 h in bile is only 1.61%. (authors)

2010-01-01

317

Biodistribution and dosimetry of free (211)at, (125)i(-) and (131)i(-) in rats.  

Science.gov (United States)

Abstract (131)I is widely used for therapy in the clinic and (125)I and (131)I, and increasingly (211)At, are often used in experimental studies. It is important to know the biodistribution and dosimetry for these radionuclides to determine potential risk organs when using radiopharmaceuticals containing these radionuclides. The purpose of this study was to investigate the biodistribution of (125)I(-), (131)I(-), and free (211)At in rats and to determine absorbed doses to various organs and tissues. Male Sprague Dawley rats were injected simultaneously with 0.1-0.3?MBq (125)I(-) and 0.1-0.3?MBq (131)I(-), or 0.05-0.2?MBq (211)At and sacrificed 1 hour to 7 days after injection. The activities and activity concentrations in organs and tissues were determined and mean absorbed doses were calculated. The biodistribution of (125)I(-) was similar to that of (131)I(-) but the biodistribution of free (211)At was different compared to (125)I(-) and (131)I(-). The activity concentration of radioiodine was higher compared with (211)At in the thyroid and lower in all extrathyroidal tissues. The mean absorbed dose per unit injected activity was highest to the thyroid. (131)I gave the highest absorbed dose to the thyroid, and (211)At gave the highest absorbed dose to all other tissues studied. PMID:23789969

Spetz, Johan; Rudqvist, Nils; Forssell-Aronsson, Eva

2013-06-22

318

Studies of the distribution of intrathecally injected 125I-tetanus antitoxin-F(ab')2  

International Nuclear Information System (INIS)

[en] Overall F(ab')2 and antitetanus-f(ab')2 - fragments were labelled with 125I and injected i.th. into normal juvenile cats and adult rats. One group of rats was normal; in the other, unilateral local tetanus had been induced by injection of tetanus toxin into a M. gastrocnemius. The animals were sacrificed 24 h after the i.th. injection, and tissue samples were taken for histoautoradiography. 125I-antitetanus-F(ab')2 permeated into the extracellular space of the spinal cord, roots, and ganglia but not into the neuronal intracellular space. 125I-overall-F(ab') showed identical permeation behaviour. 125I-antitetanus-F(ab')2 reacted with tetanus toxin issuing from the motoneurons after i.th. injection, forming an immunocomplex around the motorneurons. The immunocomplex was not formed around pseudo-unipolar ganglian cells in the spinal ganglia even though some of the ganglian cells contained tetanus toxin, and 125I-antitetanus-F(ab')2 was present in the extracellular space. As an explanation, it was suggested that tetanus toxin does not permeate into the extracellular space through the membrane of the pseudo-unipolar ganglian cells so that immune reactions will not occur. These findings help to explain the widely divergent results of tetanus therapy by means of i.th. injection of tetanus antitoxin. Recommendations for future therapy measures are derived from the findings. (orig./MG)

1981-01-01

319

Thyroidal sup 125 I monitoring system using an NaI (Tl) survey meter  

Energy Technology Data Exchange (ETDEWEB)

This paper describes the counting efficiency and detection limit of a thyroidal {sup 125}I monitoring system. Two systems were used: (1) M1 was composed simply of one survey meter for {sup 125}I (SM) having an NaI (Tl) crystal of 5.08-cm diameter by 5-mm thick, and (2) M2 was composed of the SM having an output terminal for spectroscopy and a multichannel pulse height analyzer. The counting efficiency was determined by using four simulated thyroids of 17, 20.5, 31, and 40 mL containing {sup 125}I solution. The simulated thyroids were embedded in an anthropomorphic neck phantom. The counting efficiency between 0 degrees and 45 degrees to the normal of the thyroid (front of the neck) changed by +/-2%. The efficiency of M1 ranged from 1.8 to 7.9% as the distance between the probe and the neck increased from 0 to 5 cm. Similarly, the efficiency of M2 ranged from 2.2 to 8.3%. The detection limit ranged from 7 to 34 Bq for M1 and from 1 to 5.1 Bq for M2. The M2 system was applied to monitoring a worker performing iodination with 74 MBq Na {sup 125}I. Both monitoring systems provided the necessary sensitivity to detect thyroidal {sup 125}I within the uncertainty of +/-10%.

Nishizawa, K.; Maekoshi, H. (Nagoya Univ. (Japan))

1990-02-01

320

{sup 125}I-iomazenil-benzodiazepine receptor binding during psychological stress in rats  

Energy Technology Data Exchange (ETDEWEB)

We investigated the changes in {sup 125}I-iomazenil ({sup 125}I-IMZ) benzodiazepine receptor (BZR) binding with psychological stress in a rat model. Six male Wistar rats were placed under psychological stress for 1 hour by using a communication box. No physical stress was not received. 1.85 MBq of {sup 125}I-IMZ was injected into the lateral tail vein and the rat was killed 3 hours later. Twenty-micormeter-thick sections of the brain were collected and % injected dose per body weight (% ID/BW) of eleven regions (frontal, parietal, temporal, occipital cortices, caudate putamen, accumubens nuclei, globus pallidus, amygdala, thalamus, hippocampus and hypothalamus) were calculated by autoradiography. The %ID/BW of rats which were placed under psychological stress was compared with that of 6 control rats. The %ID/BW of rats which were placed under psychological stress diffusely tended to show a reduction in {sup 125}I-IMZ-BZR binding. A significant decrease in BZR binding was observed in the hippocampus of the rats which were placed under psychological stress. {sup 125}I-IMZ-BZR binding tended to decrease throughout the brain. (author)

Fukumitsu, Nobuyoshi; Tsuchida, Daisuke; Ogi, Shigeyuki; Uchiyama, Mayuki; Mori, Yutaka [Jikei Univ., Tokyo (Japan). School of Medicine

2002-05-01

 
 
 
 
321

Distal movement of upper permanent molars using midpalatal mini-implant  

Scientific Electronic Library Online (English)

Full Text Available Abstract in portuguese OBJETIVO: verificar se o mini-implante no palato é eficaz como ancoragem direta para distalização dos molares superiores. MÉTODOS: foi utilizado um modelo em acrílico da arcada superior. Após a confecção da canaleta na região correspondente aos alvéolos dentários, os dentes em acrílico foram fixados com cera #7, montado aparelho ortodôntico com a técnica Edgewise e inserido um mini-implante (SIN, São Paulo) no local correspondente à rafe palatina. Foram co (more) locados arco 0,19" x 0,25" e barra transpalatina, soldados na barra dois ganchos para retenção de dois elásticos em cadeia de dois elos, a uma carga de 150g/f de cada lado (Unitek), que se estenderam dos ganchos até o mini-implante. O modelo da maxila foi mergulhado 40 vezes em banheira e fotografado após cada mergulho para observação da movimentação dentária. Os dados foram analisados pela análise da variânçia (ANOVA) e teste de Tukey. RESULTADOS: os molares deslocaram-se distalmente 3,1mm, em média, com inclinação distal entre 3 e 5mm. CONCLUÕES: a movimentação dos molares ocorreu pela inclinação distal, com leve rotação, mas sem efeito extrusivo. Abstract in english OBJECTIVE: To assess whether palatal mini-implants are effective as direct anchorage for distal movement of the upper molars. METHODS: It was used an acrylic model of the upper dental arch. After making a groove in the region corresponding to dental alveolus, acrylic teeth were fixed in groove with #7 wax, with the roots being previously immersed in adhesive wax. The orthodontic appliance was placed according to the Edgewise technique and then a mini-implant (SIN, São Pa (more) ulo, Brazil) was inserted at the site corresponding to the palatal raphe. A 0.019 x 0.025-in stainless steel archwire was made and attached to the upper arch with elastics. A transpalatal arch bar (0.019 x 0.025in) was mounted and two hooks were soldered to it in order to retain chain elastics (Unitek, Brazil) to be connected to the mini-implant under a force of 1.5 N on each side. The maxillary model was immersed in water 40 times and photographed after each immersion, for observation of dental movements. Analysis of variance (ANOVA) and Tukey's test were employed for analyzing the obtained data. RESULTS: Molars displaced distally 3.1 mm, in average, with distal inclination ranging from 3 to 5 mm. CONCLUSIONS: Molar movements occurred due to distal inclination, with a slight rotation and no extrusive effect.

Lira, Ana de Lourdes Sá de; Prado, Sávio; Araújo, Mônica Tirre; Sant'Anna, Eduardo Franzotti; Ruellas, Antonio Carlos de Oliveira

2013-04-01

322

Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds  

International Nuclear Information System (INIS)

Purpose: To report the side effects and complications after I-125 seeds prostate implant after 8.5 years experience. Methods and materials: Six hundred and sixty seven (667) patients were treated between March 1995 and December 2001. The median follow up is 31 months with a maximum of 98.2 months. Morbidity data were collected from a review of patient case-notes. Patients also provided prospective data on urinary symptoms using the International Prostate Symptom Score (IPSS) scoring chart before treatment and at regular follow up. Patients were also sent a questionnaire detailing symptoms and side effects following their brachytherapy. This enabled them to record urinary, bowel and sexual function side effects independently. Logistic regression analysis was carried out to identify the risk of catheterisation in relation to the pre-implant prostate volume and potential implant factors such as the number of seeds and needles and implant dose. Result: The urinary symptom score rises in the first few months after implantation and returns to within one or two points of the pre-treatment score within one year. Nine patients reported incontinence prior to treatment and 15, 12 and 10 patients reported incontinence 6, 12 and 24 months after treatment, respectively. Catheterisation was reported in 97 (14.5%) patients. At six months 84.9% of patients reported no change in bowel function and 78.9% at 12 months. 6.4% of patients complained of some increased bowel frequency at 6 months and 5.7% at 12 months. 402 (77.2%) patients reported being fully potent before treatment and that this fell to 32.4% after treatment. Logistic regression showed that the most significant factors which correlate with the probability of catheterisation are the pre-treatment prostate volume and the number of seeds and needles implanted. Conclusion: The side effects and complications after prostate brachytherapy as reported here and elsewhere confirm that the treatment is not only convenient but also has a low risk of serious long term side effects

2007-01-01

323

Polyclonal 111In-IgG, 125I-LDL and 125I-endothelin-1 accumulation in experimental arterial wall injury  

International Nuclear Information System (INIS)

To test iodine-125 labelled low-density lipoprotein (125I-LDL), polyclonal indium-111 labelled immunoglobulin G(111In-IgG) and iodine-125 labelled endothelin-1 uptake in metabolically active atheromatous plaques after arterial wall injury, we performed balloon de-endothelialization of carotid arteries or abdominal aortas in 24 New Zealand male rabbits which were fed with a normal diet (n=14) or a hypercholesterolaemic diet (n=10) after surgery. Six weeks later the animals were injected with 200 ?Ci of 125I-LDL and/or with 100 ?Ci of 111In-IgG or with 9 ?Ci of 125I-endothelin-1. Forty-eight hours later the animals were sacrificed. Carotid arteries and aortas were removed, counted and fixed for autoradiography and light microscopic examination. Contralateral carotid arteries and thoracic aortas served as controls. Significant 111In-IgG uptake was observed in the injured arteries at autoradiography, with localization mainly in the healing edges, and at well counting. The percentage of the injected dose per gram (%D.inj/g) was 0.0188±0.06 versus 0.0059±0.003 in controls (P111In-IgG uptake between arteries with injury alone and those with active atheroma formation at the site of the injury. Significant 125I-LDL uptake was observed only when lipid deposition was present at light microscopy (%D.inj/g of 0.0024±0.0005 vs 0.0010±0.0003 in controls, P125I-endothelin-1 accumulation was observed in four of five injured aortas both at autoradiography, with diffuse localization, and at well couting (%D.inj/g of 0.0012±0.0004 in the abdominal aortas vs 0.0008±0.0003 in the thoracic aortas). Polyclonal IgG may accumulate in injured arteries without active atheroma formation. Inflammatory reaction at the site of the injury may cause 111In-IgG uptake independently of atheromatous plaque formation. LDL accumulation takes place only with active atheroma formation at the site of the injury. Use of labelled peptides such as endothelin-1 may provide further insight into the mechanisms of atheromatous plaque formation. (orig.)

1993-01-01

324

Distal movement of upper permanent molars using midpalatal mini-implant.  

UK PubMed Central (United Kingdom)

OBJECTIVE: To assess whether palatal mini-implants are effective as direct anchorage for distal movement of the upper molars. METHODS: It was used an acrylic model of the upper dental arch. After making a groove in the region corresponding to dental alveolus, acrylic teeth were fixed in this groove with #7 wax, with the roots being previously immersed in adhesive wax. The orthodontic appliance was placed according to the Edgewise technique and then a mini-implant (SIN, São Paulo, Brazil) was inserted at the site corresponding to the palatal raphe. A 0.019 x 0.025-in stainless steel archwire was made and attached to the upper arch with elastics. A transpalatal bar (0.019 x 0.025-in) was mounted and two hooks were welded to it in order to retain chain elastics (Unitek, Brazil) to be connected to the mini-implant under a force of 1.5 N on each side. The maxillary model was immersed in water 40 times and photographed after each immersion, for observing dental movements. Analysis of variance (ANOVA) and Tukey's test were used for analyzing the obtained data. RESULTS: Molars displaced distally 3.1 mm, in average, with distal inclination ranging from 3 to 5 mm. CONCLUSIONS: Molar movements occurred due to distal inclination, with a slight rotation and no extrusive effect.

de Lira Ade L; Prado S; Araújo MT; Sant'Anna EF; Ruellas AC

2013-03-01

325

Inulin-125I-tyramine, an improved residualizing label for studies on sites of catabolism of circulating proteins  

Energy Technology Data Exchange (ETDEWEB)

Residualizing labels for protein, such as dilactitol-125I-tyramine (125I-DLT) and cellobiitol-125I-tyramine, have been used to identify the tissue and cellular sites of catabolism of long-lived plasma proteins, such as albumin, immunoglobulins, and lipoproteins. The radioactive degradation products formed from labeled proteins are relatively large, hydrophilic, resistant to lysosomal hydrolases, and accumulate in lysosomes in the cells involved in degradation of the carrier protein. However, the gradual loss of the catabolites from cells (t1/2 approximately 2 days) has limited the usefulness of residualizing labels in studies on longer lived proteins. We describe here a higher molecular weight (Mr approximately 5000), more efficient residualizing glycoconjugate label, inulin-125I-tyramine (125I-InTn). Attachment of 125I-InTn had no effect on the plasma half-life or tissue sites of catabolism of asialofetuin, fetuin, or rat serum albumin in the rat. The half-life for hepatic retention of degradation products from 125I-InTn-labeled asialofetuin was 5 days, compared to 2.3 days for 125I-DLT-labeled asialofetuin. The whole body half-lives for radioactivity from 125I-InTn-, 125I-DLT-, and 125I-labeled rat serum albumin were 7.5, 4.3, and 2.2 days, respectively. The tissue distribution of degradation products from 125I-InTn-labeled proteins agreed with results of previous studies using 125I-DLT, except that a greater fraction of total degradation products was recovered in tissues. Kinetic analyses indicated that the average half-life for retention of 125I-InTn degradation products in tissues is approximately 5 days and suggested that in vivo there are both slow and rapid routes for release of degradation products from cells.

Maxwell, J.L.; Baynes, J.W.; Thorpe, S.R.

1988-10-05

326

Inulin-125I-tyramine, an improved residualizing label for studies on sites of catabolism of circulating proteins  

International Nuclear Information System (INIS)

Residualizing labels for protein, such as dilactitol-125I-tyramine (125I-DLT) and cellobiitol-125I-tyramine, have been used to identify the tissue and cellular sites of catabolism of long-lived plasma proteins, such as albumin, immunoglobulins, and lipoproteins. The radioactive degradation products formed from labeled proteins are relatively large, hydrophilic, resistant to lysosomal hydrolases, and accumulate in lysosomes in the cells involved in degradation of the carrier protein. However, the gradual loss of the catabolites from cells (t1/2 approximately 2 days) has limited the usefulness of residualizing labels in studies on longer lived proteins. We describe here a higher molecular weight (Mr approximately 5000), more efficient residualizing glycoconjugate label, inulin-125I-tyramine (125I-InTn). Attachment of 125I-InTn had no effect on the plasma half-life or tissue sites of catabolism of asialofetuin, fetuin, or rat serum albumin in the rat. The half-life for hepatic retention of degradation products from 125I-InTn-labeled asialofetuin was 5 days, compared to 2.3 days for 125I-DLT-labeled asialofetuin. The whole body half-lives for radioactivity from 125I-InTn-, 125I-DLT-, and 125I-labeled rat serum albumin were 7.5, 4.3, and 2.2 days, respectively. The tissue distribution of degradation products from 125I-InTn-labeled proteins agreed with results of previous studies using 125I-DLT, except that a greater fraction of total degradation products was recovered in tissues. Kinetic analyses indicated that the average half-life for retention of 125I-InTn degradation products in tissues is approximately 5 days and suggested that in vivo there are both slow and rapid routes for release of degradation products from cells

1988-10-05

327

The balance of the impeller-driver magnet affects the antithrombogenicity in the Gyro permanently implantable pump.  

UK PubMed Central (United Kingdom)

The Gyro permanently implantable (PI) pump is activated magnetically when a double pivot bearing supported impeller is rotated at predetermined revolutions per minute (rpm). The male bearing shaft of the impeller is supported by the top and bottom female pivot bearing in a loosely mated fashion. The Gyro PI pump's impeller transfers to a floating condition when the rpm is increased. The design objective of the Gyro PI pump is to drive the impeller while maintaining a top contact position to prevent thrombus formation. As a left ventricular assist device (LVAD), the Gyro PI pumps achieved long-term survivals in calves without thrombus formation. However, thrombus formation occurred during a biventricular assist device (BVAD) implantation. Our hypothesis was that the impeller remaining in the bottom contact position during the BVAD experiment caused this thrombus formation. Therefore, a replica of the Gyro PI pump housing was fabricated from a transparent plastic to observe the floating conditions of the impeller. When simulating an LVAD animal experiment, the impeller was at a non-bottom contact position. However, when simulating the BVAD animal experiment, the impeller remained at the bottom contact position. This study shows that the magnet balance affects the antithrombogenicity in a Gyro PI pump.

Ichikawa S; Nishimura I; Mikami M; Nonaka K; Linneweber J; Kawahito S; Motomura T; Ishitoya H; Glueck J; Shinohara T; Nosé Y

2002-11-01

328

Radiolabelling and assay of Chinese agkistrodon acutus venom with carrier-free Na 125I  

International Nuclear Information System (INIS)

[en] Chinese agkistrodon acutus venom (CAAV) was radiolabelled with carrier-free Na125I by the method of Iodogen. The specific activity and radiochemical purity for radiolabelled products were 4236.5 x 1010 Bq/mmol and 98%, respectively. Each CAAV molecule carried 0.52 125I atom. Physical and chemical characterization of radiolabelled CAAV was similar to unradiolabelled CAAV. Binding analysis showed that 125I-CAAV was bound to platelet in a saturable manner. Binding sites per platelet were 13255 +-6292/platelet. The dissociation constant (Kd) was 3.2 +- 0.69 x 10-10 mol/L. These results are similar to binding sites of other snake venom on platelet. The investigation showed that radiolabelled CAAV made by our laboratory was useful for radioligand binding assay

1995-01-01

329

Radioimmunoassay of testosterone - comparison of 3H and 125I labeling  

International Nuclear Information System (INIS)

[en] In steroid molecule iodinated testosterone prepared by simple melting method was isolated and used as alternative radioligand for testosterone radioimmunoassay. The reliability criteria of the method using tritiated or iodinated testosterone were compared. The sensitivity calculated was 6 pg for 3H and 12 pg for 125I labelling, respectively. Precision expressed as intraassay coefficient of variation averaged 4.8 and 7.7% for 3H and 125I radioligand used, respectively. Recovery of various amounts (12.5-1600 pg) of testosterone added to normal male sheep plasma (16 samples) averaged 97.2+-7.9 and 95.0+-8.1% for 3H and 125I labelling, respectively. The recovery did not depend on the amount of steroid added in this range. (T.I.)

1978-06-30

330

Development of a 125I source for its application in bone densitometry.  

UK PubMed Central (United Kingdom)

This paper describes a method for the preparation of (125)I sources for their use in bone densitometer. The process consists of preparation of silver pellets of size ?2.5 mm (?) × 0.6 mm (l) by 'Cold die compaction technique', palladium coating of the silver pellets, adsorption of (125)I on the palladium coated silver pellets and encapsulation source matrix in a titanium capsule [ 3 mm (?) × 10 mm(l)] using Nd:YAG laser. The texture and morphology of the source matrix were examined by SEM and EDS analyses. Encapsulated sources containing (125)I activity up to ?1.85 GBq (50 mCi) were prepared. Quality control tests that were necessary before application were performed and gave satisfactory results.

Saxena SK; Kumar Y; Pillai KT; Dash A

2012-03-01

331

Preparations of ginsenoside Rg1 immnogen and125I-labeled antigen  

International Nuclear Information System (INIS)

This work began with the side chain of ginsenoside Rg1 which was acetylized with Ac2O-Pyr and oxidized by OsO4 and NaIO4 to give ginsenoside Rg1 aldehyde, which was further converted into an unsaturated ester by Wittig-Horner reaction. The unsaturated ester was teated with N2H4 and HNO2 to yield Rg1 azide which was directly conjugated with BSA to give immunogen: ginsenoside Rg1BSA conjugate. This azide was conjugated with tyramine to give ginsenoside Rg1 tyramine conjugate which was labelled with free Na125I by CH-T to yield 125I-labeled antigen: ginsenoside Rg1-125I-tyramin. The labelling rate was 40%-50% and specific activity was 1.0-4.0MBq/?g. (author). 6 refs.

1996-01-01

332

Binding of 125I-hCG to rainbow trout (Salmo gairdneri) testis in vitro  

International Nuclear Information System (INIS)

[en] Homogenates of maturing rainbow trout testes show specific binding sites for 125I-labeled hCG (. 125I-labeled hCG). The binding is competitively inhibited by unlabeled hCG and by a hypophyseal extract of rainbow trout. It could be demonstrated that the tissue 125I-hCG binding specificity is restricted to the gonadal preparation. The trout testis was characterized by determining affinity and capacity from Scatchard plot analysis giving a high constant of dissociation Kd 3.65 x 10(-10)/M and a low binding capacity of 0.88 x 10(-15) M/mg tissue. The test system is markedly dependent on temperature, incubation-time, and pH. The maximum binding was found at 37 degrees during 2 hr of incubation in a buffer of pH 7.5

1983-01-01

333

Monte Carlo evaluation of specific dose constants in water for /sup 125/I seeds  

Energy Technology Data Exchange (ETDEWEB)

To clinically utilize relative three-dimensional dose distribution data for /sup 125/I seeds in water, the specific dose constant must be known. This constant is the ratio of absolute dose rate in medium, 1 cm from the source on its transverse bisector, to source strength. We have used the Monte Carlo method to calculate specific dose constants in water for three types of /sup 125/I seeds (models 6711, 6701, and 6702). Our photon transport code realistically models the complex internal structure of these interstitial sources as well as the exposure standardization experiments conducted at the National Bureau of Standards which form the basis of /sup 125/I source strength specification. In addition, relative attenuation factors for the three seed types are presented. Our results indicate that published data overestimate the specific dose constant by 10% to 14%.

Williamson, J.F.

1988-09-01

334

[Permanent iodine 125 implant brachytherapy in localized prostate cancer: results of the first 4 years of experience].  

UK PubMed Central (United Kingdom)

OBJECTIVE: This study reports the preliminary national results of permanent Iodine 125 implant brachytherapy for the treatment of localized prostate cancer with a follow-up of 4 years. MATERIAL AND METHODS: The authors analyse a series of 260 patients treated consecutively according to the same technique (single-centre, with estimated dosimetry and the use of fixed implants) in terms of morbidity, recorded prospectively, and in terms of cancer control. In the group of 260 patients with stage T1-T2 prostate cancer 68.4% belonged to the low-risk group (PSA < 10 and Gleason score < 7), 28.4% belonged to the intermediate-risk group (PSA > 10 or Gleason score > 6) and 3% belonged to the high-risk group (PSA > 10 and Gleason score > 6). The mean follow-up was 29.5 months (range: 8-56 months). Adverse effects were dominated by obstructive and/or irritating voiding disorders in the majority of cases, with progressive improvement in 98% of cases. Acute urinary retention required drainage in 10.7% of cases. An endoscopic disobstruction operation was performed after at least 6 months in 2.3% of cases. Anorectitis was reported in 21.91% of cases: stage I in 20.3% and stage II in 1.5%, treated medically in every case. In the year following implantation, 34.2% of patients complained of erectile dysfunction that was successfully treated medically. Analysis of the dosimetric data after implantation demonstrated a learning curve in which optimal coverage of the therapeutic target by the dose of irradiation prescribed was obtained between the first 20 and 30 patients. This systematic, patient-by-patient analysis allowed optimization of the implantation technique, especially by ensuring better coverage of the base and anterior part of the prostate. RESULTS: The 3-year laboratory recurrence-free survival was 93.8% for all patients and 97. 7% for the good prognosis group. Fifteen of the 16 recurrences occurred during the first 18 months of the experience. The results of this study are concordant with those of North American teams at the same stage of experience. In this programme, optimization of the technique and patient selection criteria achieved excellent results in terms of morbidity and cancer control. The authors propose elective brachytherapy to the group of patients with a poor prognosis, a prostate volume less than 50 ml and with no obvious urinary functional disorders. An analysis is underway to confirm these results with a longer follow-up.

Bladou F; Salem N; Simonian-Sauve M; Rosello R; Ternier F; Resbeut M; Alzieu C; Karsenty G; Serment G; Gravis G; Maraninchi D

2004-06-01

335

Development of a sensitive 125I thyroid monitoring system suitable for production plant environment  

International Nuclear Information System (INIS)

During the production of Radioimmunoassay (RIA) kits, there is a possibility of inhalation of some 125I activity by the workers which may get accumulated in the thyroid. A sensitive 125I thyroid monitoring system has been set up with modification to minimise the interference from the scattered photons emerging from isotopes such as 99Mo and 131I handled in the laboratory and contamination on the body other than thyroid of the subject by suitably shielding the detector, incorporating a collimator and by adjusting the window range of detection. The system consists of a thin NaI(TI) detector (25 mm dia x 2 mm thick) and a photo multiplier tube housed in a 2 mm thick stainless steel hollow cylinder lined inside with 2 mm thick lead and coupled to a single channel analyser. Another movable stainless steel collimator (2 mm thick) minimises the interference from any possible external contamination on the body of the subject. Counting of the subject is done by keeping the end of the collimator just touching the neck of the subject so that the cylindrical volume between thyroid and detector is covered. The distance between the detector and the neck of the subject can be exactly measured by a scale provided on the detector housing. The system has been calibrated with known activity of 125I kept in a REMCAL phantom. Thyroid 125I activity as low as 13 Bq could be estimated in a counting time of 5 minutes at a distance of 5 cm from the detector (ALI for 125I is 2000 kBq). Counting errors were minimised by suitably optimising the distance of the detector from the thyroid of the subject. The system allows follow up of 125I intake by the RIA kit production workers without sacrificing their working hours. (author).

1997-01-01

336

Simple detection of hepatitis C virus using 125I-2'-deoxyuridine triphosphate and gamma counter  

International Nuclear Information System (INIS)

Hepatitis C Virus (HCV) is the major cause of post transfusion and sporadic non A, non B hepatitis. Current infection of HCV can be detected by PCR method. Using PCR, it has been possible to detect HCV viremia prior to immunological sero-conversion and to detect fluctuation of viremia in antibody-positive chronic HCV patients undergoing therapy with interferon. In this study, we established the simple method to detect HCV DNA by incorporation of 125I-deoxyuridine triphosphate(dUTP) into DNA during the PCR, and counted the radioactivity of PCR product by gamma counter. 125I-2'-deoxyuridine 5'-triphosphate was prepared, and incorporated into DNA during PCR. dUTP was radiolabeled by the iododemercuration of 5-mercuri intermediate. Iododemercuration labeling was completed with 98% yield and the obtained product was incorporated into DNA without further purification. After incorporation, covalently bonded radioiodine substituent was remained stable during PCR procedure HCV positive standard and positive patient sera in immunological assay were centrifuged. HCV RNA is isolated from by GTC(Guanidine Thiocyanate) and phenol/chloroform extraction method and synthesized complementary DNA by using reverse transcriptase. The '125I-dUTP was incorporated into HCV C DNA during PCR. PCR product purified by fiber matrix column and counted by gamma counter. PCR products were electrophoresized, and autoradiography image obtained. Amplified HCV DNA by 125I-dUTP PCR obtained the band on the gel by electrophoresis and autoradiography at the same position. In patient sera, radioactivity of HCV positive sample was 8 times higher than HCV negative viremia sample. We established HCV detection method using 125I-dUTP. 125I-dUTP PCR detection of HCV is convenient and reporducible.

2000-01-01

337

Use of 2-(/sup 125/I)iodomelatonin to characterize melatonin binding sites in chicken retina  

Energy Technology Data Exchange (ETDEWEB)

2-(/sup 125/I)Iodomelatonin binds with high affinity to a site possessing the pharmacological characteristics of a melatonin receptor in chicken retinal membranes. The specific binding of 2-(/sup 125/I)iodomelatonin is stable, saturable, and reversible. Saturation experiments indicated that 2-(/sup 125/I)iodomelatonin labeled a single class of sites with an affinity constant (Kd) of 434 +/- 56 pM and a total number of binding sites (Bmax) of 74.0 +/- 13.6 fmol/mg of protein. The affinity constant obtained from kinetic analysis was in close agreement with that obtained in saturation experiments. Competition experiments showed a monophasic reduction of 2-(/sup 125/I)iodomelatonin binding with a pharmacological order of indole amine affinities characteristic of a melatonin receptor: 2-iodomelatonin greater than 6-chloromelatonin greater than or equal to melatonin greater than or equal to 6,7-dichloro-2-methylmelatonin greater than 6-hydroxymelatonin greater than or equal to 6-methoxymelatonin much greater than N-acetyltryptamine greater than N-acetyl-5-hydroxytryptamine greater than 5-methoxytryptamine greater than 5-hydroxytryptamine (inactive). The affinities of these melatonin analogs in competing for 2-(/sup 125/I)iodomelatonin binding sites were correlated closely with their potencies for inhibition of the calcium-dependent release of (3H)dopamine from chicken and rabbit retinas, indicating association of the binding site with a functional response regulated by melatonin. The results indicate that 2-(/sup 125/I)iodomelatonin is a selective, high-affinity radioligand for the identification and characterization of melatonin receptor sites.

Dubocovich, M.L.; Takahashi, J.S.

1987-06-01

338

Use of 2-[125I]iodomelatonin to characterize melatonin binding sites in chicken retina  

International Nuclear Information System (INIS)

2-[125I]Iodomelatonin binds with high affinity to a site possessing the pharmacological characteristics of a melatonin receptor in chicken retinal membranes. The specific binding of 2-[125I]iodomelatonin is stable, saturable, and reversible. Saturation experiments indicated that 2-[125I]iodomelatonin labeled a single class of sites with an affinity constant (Kd) of 434 +/- 56 pM and a total number of binding sites (Bmax) of 74.0 +/- 13.6 fmol/mg of protein. The affinity constant obtained from kinetic analysis was in close agreement with that obtained in saturation experiments. Competition experiments showed a monophasic reduction of 2-[125I]iodomelatonin binding with a pharmacological order of indole amine affinities characteristic of a melatonin receptor: 2-iodomelatonin greater than 6-chloromelatonin greater than or equal to melatonin greater than or equal to 6,7-dichloro-2-methylmelatonin greater than 6-hydroxymelatonin greater than or equal to 6-methoxymelatonin much greater than N-acetyltryptamine greater than N-acetyl-5-hydroxytryptamine greater than 5-methoxytryptamine greater than 5-hydroxytryptamine (inactive). The affinities of these melatonin analogs in competing for 2-[125I]iodomelatonin binding sites were correlated closely with their potencies for inhibition of the calcium-dependent release of [3H]dopamine from chicken and rabbit retinas, indicating association of the binding site with a functional response regulated by melatonin. The results indicate that 2-[125I]iodomelatonin is a selective, high-affinity radioligand for the identification and characterization of melatonin receptor sites

1987-01-01

339

Optimization of the synthesis of a high specific activity 125 I-labelled hapten for radioimmunoassays  

International Nuclear Information System (INIS)

In this first report it is described the synthesis, separation and purification of the 2-radioiodinated histamine ''125 I-labelled histamine by a mixed anhydride reaction. About 75% incorporation of I''1125, from Na''125, I, was achieved with a molecular ratio of 1:1 mixed anhydride:histamine. The radiochemical purity of the conjugate by TLC was >99% and its theoretical specific activity, 3850 mu Ci/mug. Dissolved in ethanol and held at -20 degree centigree under darkness decomposition on storage did not exceed 1% per month.

1994-01-01

340

Increased /sup 125/I-labelled concanavalin A binding to erythrocytes in diabetes mellitus  

Energy Technology Data Exchange (ETDEWEB)

Percentage binding of /sup 125/I-labelled concanavalin A to erythrocytes in diabetic patients was significantly higher than that in normal subjects (12.2 +- 2.8 versus 8.1 +- 1.8%, mean +- SD, p < 0.001). Insulin-dependent diabetic patients showed significantly higher concanavalin A binding than non-insulin-dependent diabetic subjects (15.0 +- 1.4 versus 11.4 +- 2.5%, p < 0.01). There was a highly significant correlation between percentage binding of /sup 125/I-labelled concanavalin A and glycosylated haemoglobin.

Okada, Y.; Arima, T.; Okazaki, S.; Nakata, K.; Nagashima, H.; Yamabuki, T.

1982-03-01

 
 
 
 
341

Preparation and isolation of a homogeneous 125I-cortisol derivative  

International Nuclear Information System (INIS)

[en] Tracer specificity plays an important role in the radioimmunoassay (RIA) of steroid hormones. In this paper, we describe the preparation and purification of 125I-labeled cortisol derivative with a carboxymethyloxime-histamine bridge. The investigation on the method of purification showed that HPLC could be adopted for the routine preparation of a pure, homogeneous tracer. The retention time observed in HPLC for 125I-histamine-CMO-cortisol conjugate could be used as an index for qualitative and quantitative assessments. (author)

1997-01-01

342

Tissue distribution of 125I-labelled bovine superoxide dismutase (SOD) in the rat  

International Nuclear Information System (INIS)

Bovine copper/zink superoxide dismutase (SOD) was labelled with 125I using the chloramine-T method. The tissue distribution of 125I-SOD (dose of SOD 5 mg/kg) was studied with whole-body and microautoradiography at various times after an intravenous injection. The distribution of 125I-SOD showed a remarkable organ specificity in that the localization of the enzyme to the kidneys and the urinary tract completely dominated the autoradiograms. The time pattern of localization of 125I-SOD also gives a clear picture of the renal handling of the enzyme in that, as a consequence of the renal elimination, the enzyme rapidly disappears from the circulation with an elimination half time of about 6 min. Up to 20 min. after the injection, there were high concentrations of 125I-SOD in the renal pelvis, ureter and urinary bladder showing that in addition to renal uptake there was an initial substantial urinary excretion of the enzyme. From the microautoradiography it is clear that the grains were exclusively localized over proximal tubular cells and tended to be concentrated at the luminal rather than the peritubular side of tubule. This would be compatible with renal uptake secondary to glomerular filtration of 125I-SOD, which is what one would expect from the renal handling of a protein with a molecular weight around 31,000 and an isoelectric point around pH 5.4. Pretreatment with a large dose of SOD (88 mg/kg) tended to competitively decrease the renal uptake of labelled SOD after 5 min. and apparently further increase its renal excretion. However, a noticable renal uptake of 125I-SOD was still apparent. The radioactivity in the kidneys subsided gradually, from 4 hours up to 48 hours with a parallel increase in the radioactivity in the thyroid, indicating metabolic degradation of 125I-SOD by tubular cells and suggesting ''retention'' by the kidney of at least some of the enzyme and/or its end products. (author).

1988-01-01

343

(E)-[{sup 125}I]-5-AOIBV: a SPECT radioligand for the vesicular acetylcholine transporter  

Energy Technology Data Exchange (ETDEWEB)

The premise that, over the course of Alzheimer's disease (AD), changes in the levels of the vesicular acetylcholine transporter (VAChT) occur in parallel with changes to other cholinergic marker proteins provides the basis for the applicability of benzovesamicol derivatives as radioligands for AD studies by single photon emission computed tomography or positron emission tomography. We report the synthesis of enantiopure benzovesamicol derivatives: (R,R) or (S,S)-(E)-2-hydroxy-5-(3-iodoprop-2-en-1-oxy)-3- (4-phenylpiperidino)tetralin [(R,R)-AOIBV: K{sub d}=0.45 nM or (S,S)-5-AOIBV: K{sub d}=4.3 nM] and their corresponding tributyltin precursors for radioiodination. (R,R or S,S)-5-AOIBV was labeled with iodine-125 from their corresponding n-tributyltin precursors. Both compounds were obtained with radiochemical and optical purity greater than 97% and in radiochemical yields ranging 34-36%. To determine if these compounds could provide an advantage when compared to [{sup 125}I]-iodo benzovesamicol (IBVM), IBVM was also labeled and used as the reference compound in all ex vivo experiments. Ex vivo biodistribution experiments in rats revealed that [{sup 125}I]-(R,R)-5-AOIBV displayed the most suitable pharmacological profile as the radioactivity distribution corresponded well with the known VAChT brain density. Moreover, pre-injection of vesamicol prevented the uptake of [{sup 125}I]-(R,R)-5-AOIBV in striatum, cortex and hippocampus, demonstrating selectivity for the VAChT. However, even if time activity curves of [{sup 125}I]-(R,R)-5-AOIBV confirmed that this compound could be used to visualize the VAChT in vivo, at each point of the kinetic study, [{sup 125}I]-(R,R)-5-AOIBV showed a lower specific binding compared to [{sup 125}I]-IBVM. These results made [{sup 125}I]-( R,R)-5-AOIBV inferior to [{sup 125}I]-IBVM for the VAChT exploration in vivo.

Emond, Patrick [INSERM U619, 37000 Tours (France); Universite Francois-Rabelais de Tours, CHRU, Hopital Bretonneau, Service de Medecine nucleaire, 37000 Tours (France); Mavel, Sylvie [INSERM U619, 37000 Tours (France); Universite Francois-Rabelais de Tours, CHRU, Hopital Bretonneau, Service de Medecine nucleaire, 37000 Tours (France)], E-mail: sylvie.mavel@univ-tours.fr; Zea-Ponce, Yolanda [INSERM U619, 37000 Tours (France); Universite Francois-Rabelais de Tours, CHRU, Hopital Bretonneau, Service de Medecine nucleaire, 37000 Tours (France); Kassiou, Michael [Discipline of Medical Radiation Sciences, Brain and Mind Research Institute, University of Sydney, NSW 2050 (Australia); School of Chemistry, University of Sydney, NSW 2006 (Australia); Garreau, Lucette; Bodard, Sylvie; Drossard, Marie-Laure; Chalon, Sylvie; Guilloteau, Denis [INSERM U619, 37000 Tours (France); Universite Francois-Rabelais de Tours, CHRU, Hopital Bretonneau, Service de Medecine nucleaire, 37000 Tours (France)

2007-11-15

344

Synthesis of 123I- and 125I-labelled 5-iodo-6-nitroquipazine  

International Nuclear Information System (INIS)

[en] The syntheses of the potent and selective serotonin reuptake complex radioligands [123I]- and 125I]5-iodo-6-nitroquipazine (5-iodo-6-nitro-2-piperazinylquinoline) are reported. A seven step synthetic sequence provided the BOC-protected 5-tributyltin-6-nitroquipazine precursor for radioiodination. End of sy nthesis radioiodination yields of ? 40% for 123I and ? 60% for 125I were achieved resulting in labelled products with high specific activities (> 4000 and > 2000 Ci/mmol, respectively) and radiochemical purities (> 98%). (author)

1994-01-01

345

(E)-[125I]-5-AOIBV: a SPECT radioligand for the vesicular acetylcholine transporter  

International Nuclear Information System (INIS)

[en] The premise that, over the course of Alzheimer's disease (AD), changes in the levels of the vesicular acetylcholine transporter (VAChT) occur in parallel with changes to other cholinergic marker proteins provides the basis for the applicability of benzovesamicol derivatives as radioligands for AD studies by single photon emission computed tomography or positron emission tomography. We report the synthesis of enantiopure benzovesamicol derivatives: (R,R) or (S,S)-(E)-2-hydroxy-5-(3-iodoprop-2-en-1-oxy)-3- (4-phenylpiperidino)tetralin [(R,R)-AOIBV: Kd=0.45 nM or (S,S)-5-AOIBV: Kd=4.3 nM] and their corresponding tributyltin precursors for radioiodination. (R,R or S,S)-5-AOIBV was labeled with iodine-125 from their corresponding n-tributyltin precursors. Both compounds were obtained with radiochemical and optical purity greater than 97% and in radiochemical yields ranging 34-36%. To determine if these compounds could provide an advantage when compared to [125I]-iodo benzovesamicol (IBVM), IBVM was also labeled and used as the reference compound in all ex vivo experiments. Ex vivo biodistribution experiments in rats revealed that [125I]-(R,R)-5-AOIBV displayed the most suitable pharmacological profile as the radioactivity distribution corresponded well with the known VAChT brain density. Moreover, pre-injection of vesamicol prevented the uptake of [125I]-(R,R)-5-AOIBV in striatum, cortex and hippocampus, demonstrating selectivity for the VAChT. However, even if time activity curves of [125I]-(R,R)-5-AOIBV confirmed that this compound could be used to visualize the VAChT in vivo, at each point of the kinetic study, [125I]-(R,R)-5-AOIBV showed a lower specific binding compared to [125I]-IBVM. These results made [125I]-( R,R)-5-AOIBV inferior to [125I]-IBVM for the VAChT exploration in vivo

2007-01-01

346

Dosimetry on transverse axes of sup 125 I and sup 192 Ir interstitial brachytherapy sources  

Energy Technology Data Exchange (ETDEWEB)

Dose rates along the transverse axes of {sup 125}I model 6702, {sup 125}I model 6711 and {sup 192}Ir 0.2-mm steel sources for interstitial brachytherapy have been measured in a solid-water phantom for distances up to 10 cm using LiF thermoluminescent dosimeters (TLDs). Specific dose rate constants, the dose rates in water per unit source strength 1 cm along the perpendicular bisector of the source, are determined to be 0.90{plus minus}0.03, 0.85{plus minus}0.03, and 1.09{plus minus}0.03 cGy h{sup {minus}1} U{sup {minus}1} for {sup 125}I model 6702, {sup 125}I model 6711 and {sup 192}Ir 0.2-mm steel sources, respectively (1 U=unit of air kerma strength =1 {mu}Gy m{sup 2} h{sup {minus}1}=1 cGy cm{sup 2} h{sup {minus}1}). In older and obsolete units of source strength (i.e., mCi apparent), these are 1.14{plus minus}0.03, 1.08{plus minus}0.03, and 4.59{plus minus}0.15 cGy h{sup {minus}1} mCi{sup {minus}1} (apparent). Currently accepted values of specific dose rate constant for {sup 125}I sources are up to 20% higher than our measured values which are in good agreement with the results of our Monte Carlo simulations. But for {sup 192}Ir there is good agreement between our measured value of the specific dose rate constant and currently accepted values. The radial dose function for {sup 125}I model 6702 is found to be consistently larger than that for {sup 125}I model 6711, with an increasing difference as the distance from the source increases. Our measured values for the radial dose function for {sup 125}I sources are in good agreement with the results of our Monte Carlo simulation as well as the measured values of Schell {ital et} {ital al}. (Int. J. Radiat. Oncol. Biol. Phys. {bold 13}, 795--799 (1987)) for model 6702 and Ling {ital et} {ital al}. (Int. J. Radiat. Oncol. Biol. Phys. {bold 9}, 1747--1752 (1983)) for model 6711.

Nath, R.; Meigooni, A.S.; Meli, J.A. (Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT (USA))

1990-11-01

347

Dosimetry on transverse axes of 125I and 192Ir interstitial brachytherapy sources  

International Nuclear Information System (INIS)

Dose rates along the transverse axes of 125I model 6702, 125I model 6711 and 192Ir 0.2-mm steel sources for interstitial brachytherapy have been measured in a solid-water phantom for distances up to 10 cm using LiF thermoluminescent dosimeters (TLDs). Specific dose rate constants, the dose rates in water per unit source strength 1 cm along the perpendicular bisector of the source, are determined to be 0.90±0.03, 0.85±0.03, and 1.09±0.03 cGy h-1 U-1 for 125I model 6702, 125I model 6711 and 192Ir 0.2-mm steel sources, respectively (1 U=unit of air kerma strength =1 ?Gy m2 h-1=1 cGy cm2 h-1). In older and obsolete units of source strength (i.e., mCi apparent), these are 1.14±0.03, 1.08±0.03, and 4.59±0.15 cGy h-1 mCi-1 (apparent). Currently accepted values of specific dose rate constant for 125I sources are up to 20% higher than our measured values which are in good agreement with the results of our Monte Carlo simulations. But for 192Ir there is good agreement between our measured value of the specific dose rate constant and currently accepted values. The radial dose function for 125I model 6702 is found to be consistently larger than that for 125I model 6711, with an increasing difference as the distance from the source increases. Our measured values for the radial dose function for 125I sources are in good agreement with the results of our Monte Carlo simulation as well as the measured values of Schell et al. [Int. J. Radiat. Oncol. Biol. Phys. 13, 795--799 (1987)] for model 6702 and Ling et al. [Int. J. Radiat. Oncol. Biol. Phys. 9, 1747--1752 (1983)] for model 6711

1990-01-01

348

An instrument for measurement of 125I with automatic efficiency correction  

International Nuclear Information System (INIS)

Counting efficiencies for 125I are often uncertain because of self-absorption of the low-energy radiation. A special purpose instrument, AEP-5285, has been designed to simplify the measurement of 125I activities using a known technique in which the observed counting rate is compensated for self-absorption and any other uncertainties in the counting efficiency by making use of the coicidence properties of the radiation. The instrument contains pulse amplifiers, discriminators to define the energy regions of interest, and operational amplifier circuits to perform the necessary calculations automatically, and it displays an estimate of the source activity in becquerels. (auth).

1979-01-01

349

p-[125I]iodoclonidine is a partial agonist at the alpha 2-adrenergic receptor  

International Nuclear Information System (INIS)

The binding properties of p-[125I]iodoclonidine [( 125I]PIC) to human platelet membranes and the functional characteristics of PIC are reported. [125I]PIC bound rapidly and reversibly to platelet membranes, with a first-order association rate constant (kon) at room temperature of 8.0 +/- 2.7 x 10(6) M-1 sec-1 and a dissociation rate constant (koff) of 2.0 +/- 0.8 x 10(-3) sec-1. Scatchard plots of specific [125I]PIC binding (0.1-5 nM) were linear, with a Kd of 1.2 +/- 0.1 nM. [125I]PIC bound to the same number of high affinity sites as the alpha 2-adrenergic receptor (alpha 2-AR) full agonist [3H] bromoxidine (UK14,304), which represented approximately 40% of the sites bound by the antagonist [3H]yohimbine. Guanosine 5'-(beta, gamma-imido)triphosphate greatly reduced the amount of [125I]PIC bound (greater than 80%), without changing the Kd of the residual binding. In competition experiments, the alpha 2-AR-selective ligands yohimbine, bromoxidine, oxymetazoline, clonidine, p-aminoclonidine, (-)-epinephrine, and idazoxan all had Ki values in the low nanomolar range, whereas prazosin, propranolol, and serotonin yielded Ki values in the micromolar range. Epinephrine competition for [125I]PIC binding was stereoselective. Competition for [3H]bromoxidine binding by PIC gave a Ki of 1.0 nM (nH = 1.0), whereas competition for [3H]yohimbine could be resolved into high and low affinity components, with Ki values of 3.7 and 84 nM, respectively. PIC had minimal agonist activity in inhibiting adenylate cyclase in platelet membranes, but it potentiated platelet aggregation induced by ADP with an EC50 of 1.5 microM. PIC also inhibited epinephrine-induced aggregation, with an IC50 of 5.1 microM. Thus, PIC behaves as a partial agonist in a human platelet aggregation assay. [125I]PIC binds to the alpha 2B-AR in NG-10815 cell membranes with a Kd of 0.5 +/- 0.1 nM.

1990-01-01

350

Synthetic heparinoids labelled with /sup 125/I and /sup 35/S  

Energy Technology Data Exchange (ETDEWEB)

The labelling of a water-soluble synthetic polyelectrolyte, having anticoagulant activity, has been studied. The polyelectrolyte is derived from cis-1,4-polyisoprene and contains N-sulfate and carboxylate groups. (/sup 125/I)-Iodination of the polyelectrolyte, using the Chloramine-T method and an electrolytic method, resulted in a (/sup 125/I)-labelled polyelectrolyte from which release of the label occurred. Resulfation of a partially desulfated polyelectrolyte with a (/sup 35/S)-sulfur trioxide trimethylamine complex resulted in a (/sup 35/S)-labelled polyelectrolyte which showed no release of the label.

Sederel, L.C.; van der Does, L.; Bantjes, A. (Technische Hogeschool Twente, Enschede (Netherlands)); Kolar, Z. (Interuniversitair Reactor Inst., Delft (Netherlands))

1982-10-01

351

Estado da arte do procedimento percutâneo: paciente octogenário submetido com sucesso, em apenas uma sessão, a valvotomia pulmonar, implante de stent coronário e implante de marcapasso definitivo/ State of the art percutaneous procedure: octogenarian patient successfully submitted, in a single session, to a pulmonary valvotomy, coronary stent implant and permanent pacemaker implant  

Scientific Electronic Library Online (English)

Full Text Available Abstract in portuguese É relatado caso de paciente de 82 anos, portador de insuficiência renal leve, estenose valvar pulmonar (EVP) severa, estenose severa de artéria descendente anterior e bloqueio atrioventricular total, submetido a angioplastia coronária com implante de stent coronário, valvotomia pulmonar e implante de marcapasso definitivo no mesmo procedimento, com sucesso. Abstract in english This report describes a case involving an 82 year old patient with mild renal insufficiency, severe pulmonary valve stenosis (PVS), severe anterior descending artery stenosis and complete atrioventricular block, who successfully underwent, in a single session, coronary angioplasty and a stent implant, pulmonary valvotomy and a permanent pacemaker implant.

Pimentel Filho, Wilson Albino; Soares Neto, Milton de Macedo; Cividanis, Gil Vicente; Feijó Júnior, Rubens Vaz

2005-10-01

352

Estado da arte do procedimento percutâneo: paciente octogenário submetido com sucesso, em apenas uma sessão, a valvotomia pulmonar, implante de stent coronário e implante de marcapasso definitivo State of the art percutaneous procedure: octogenarian patient successfully submitted, in a single session, to a pulmonary valvotomy, coronary stent implant and permanent pacemaker implant  

Directory of Open Access Journals (Sweden)

Full Text Available É relatado caso de paciente de 82 anos, portador de insuficiência renal leve, estenose valvar pulmonar (EVP) severa, estenose severa de artéria descendente anterior e bloqueio atrioventricular total, submetido a angioplastia coronária com implante de stent coronário, valvotomia pulmonar e implante de marcapasso definitivo no mesmo procedimento, com sucesso.This report describes a case involving an 82 year old patient with mild renal insufficiency, severe pulmonary valve stenosis (PVS), severe anterior descending artery stenosis and complete atrioventricular block, who successfully underwent, in a single session, coronary angioplasty and a stent implant, pulmonary valvotomy and a permanent pacemaker implant.

Wilson Albino Pimentel Filho; Milton de Macedo Soares Neto; Gil Vicente Cividanis; Rubens Vaz Feijó Júnior

2005-01-01

353

Affinity of binding of radiolabelled (125I) heparin and low molecular weight heparin fraction CY 222 to endothelium in culture  

International Nuclear Information System (INIS)

[en] Binding of 125I-heparin and its low molecular weight fraction CY 222 to human and porcine cultured endothelium was investigated. The binding was measured over a wide range of heparin or CY 222 concentration in culture medium, from less than 20 times up to more than 30 times of the therapeutic heparin level. A relatively small fraction (less than 1%) of tested products was bound to the endothelium. The process of binding was temperature-independent. A comparable number of endothelial binding sites (approx. 1012/cm2) for both 125I-heparin and 125I-CY 222 was calculated. About 40% totally bound 125I-heparin and 30% of 125I-CY 222 was found in the extracellular matrix of cultured endothelium. The endothelium exhibited a 2.4 times lower affinity for 125I-CY 222 (Kd = 5.59 ± 1.77 ?M) than for 125I-heparin (Kd = 2.35 ± 0.78 ?M). A similar affinity of human and porcine endothelium for 125I-heparin was demonstrated. Cultured endothelium exhibited the same affinity for unlabelled heparin as for 125I-heparin. The endothelium depleted of sialic acid residues bound 1.5 times more of 125I-CY 222 than the control endothelium in culture. (author)

1987-01-01

354

The experimental study of 125I seeds interstitial brachytherapy combined with external beam radiotherapy for lewis lung cancer in C57BL/6 mice  

International Nuclear Information System (INIS)

Objective: The purpose of this study was to investigate the efficacy of 125I seeds interstitial brachytherapy combined with external beam radiotherapy for lung neoplasm. Methods: Each set of six C57BL/6 mice bearing Lewis tumor was stratified into four groups on day 1:vehicle control, 125I seeds interstitial brachytherapy alone, external beam radiotherapy (15 Gy) alone, and combination of 125I seeds interstitial brachytherapy with external beam radiotherapy (8 Gy). After treatment.the volulne of the tumors was measured every 3 days. The animals were executed, the weight of tumors was measured.tumor control rate was calculated and pathological examination was performed on day 15. The intratumoral micro-vaseular density (MVD) in each group was evaluated by inmmnohistochemical methads. Tumor volume.weight and MVD were compared by one-way ANOVA, student. newlnan-keuls (SNK) -q analysis. Results: Comparing with control group, the other three groups had significant inhibiting effect on the growth of lewis tumor (q=11.06, 17.13, 16.31, all P125I seeds interstitial brachytherapy group (28.6%). while the difference of tumor weisht was not significant between the former two groups (q=0.50. P>0.05). Immunohistochemistry analysis showed that the MVD value in the four groups wag (23.33 ± 4.84). (17.50 ± 3.67), (11.83 ± 2.14) and (12.67 ± 3.39) / (high power field x 200) regpectively. The MVD value of 125I seeds interstitial brachytherapy alone group was much lower than that of control group, and higher than combination group (q=3.92 and 3.25, both P0.05). Conclusions: Radiotherapy can. significantly reduce the MVD values of tumor and inhibit tumor growth through the mechanisms of antiangiogenesis. The combined treatment of lung tumors with implanted 125I seeds and external beam irradiation can decrease the total dose of the external beam irradiation and, hence, offer the possibility of considerable dose sparing of normal tissues without compromising local tumor control rates. (authors)

2009-01-01

355

Development of esophageal 125I seed irradiated stent and its experiment  

International Nuclear Information System (INIS)

Objective: To investigate the feasibility of developing the esophageal irradiating esophageal stent by placing 125I seed into it, the safety of the irradiative stent esophageal in animal experiments. Methods: (1) Development of esophageal 125I seed irradiated stent: a plastic 'bullet chamber' was moulded which held only one 125I seed. Its distribution and the spot where it was stitched on outside the stents. Thus esophageal intraluminal irradiating stents were developed. (2) Animal experiment: 36 rabbits were randomly assigned to 4 groups according to different irradiated dosage, 9 rabbits in each group. Intraluminal irradiated stents each with two 125I seeds totaling 22.2 MBq (group A), 44.4 MBq (group B) and 66.6 MBq (group C) respectively were placed in the rabbits esophagus and stents without 125I seeds were placed in group D rabbits esophagus which as control group. Three rabbits of each group were killed at the 2th, 4th, or 8th week after insertion of the stents, followed by esophageal contrast exam and CT scan to observe displacement of stents and transposition of 125I seed. The damage and its degree of esophagus and the lung, bronchus and large vessels around it caused by intraluminal irradiated stents were observed macroscopically or under optical and electric microscope. Results: (1) Development of esophageal intraluminal irradiated stents: 125I seed could be stitched on outside the stents firmly. Experiments of filling and releasing seeds in vitro were feasible. Irradiated steats could be easily placed in rabbits esophagus. It was safe for no losing of radioactive source has been found after they have been placed in esophagus for a long-term. (2) Animal experiments: the esophageal wall near 125I seed thickened most distinctly in mental groups during the 8th week[ group A(4.2 ± 0.3)mm,group B(4.3 ± 0.3)mm, group C(4.5 ± 0.3)mm]. There was a significant difference between the experimental group and control group [(3.1 ± 0.1) mm (P0.05). Four weeks after the produce, no other noticeable changes of thickness occurred among the 4 groups except esophageal bore size narrowed progressively along with time, there was no significant difference between the esophageal bore size of experimental groups during the 8th [group A (5.7 ± 0.2) mm, group B (5.6 ± 0.3) mm, group C (5.6 ± 0.3) mm ] and control group (5.6 ± 0.2) mm (P>0.05). The macroscopical observation of lung, trachea and thoracic aortal wall around the stents were consistent with those under optical microscope, however the ultrastructure had mild impairment observed under electric microscope. Conclusion: The design and fabrication of binding esophageal intraluminal irradiated stents have been proven to be feasible. The radioactivity of 125I radioactive seeds commonly used in clinics only causes slight injury to the lung, trachea, large vessels around esophagus in animal experiment, 125I radioactive seed has no obvious effect of inhibition or stimulation on the hyperplastic esophageal mucosa due to the placement of stent. It is possible that